

## Hospital Report

|                 |                |                  |   |                   |                |
|-----------------|----------------|------------------|---|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> |   | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |   |                   |                |
| <b>DOB</b>      | 1979           |                  |   |                   |                |

|                    |                     |              |                                                                    |
|--------------------|---------------------|--------------|--------------------------------------------------------------------|
| Facility Report #: | 2082209832          |              |                                                                    |
| Sent to:           | Taylor, Sinead      | Reported By: | Ridgeway Family Health                                             |
| Collection Date:   | 2022-Dec-22         | Reviewed:    | 2022-Dec-26 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| Message Unique ID: | 2082209832          |              |                                                                    |
| Updated On:        | 2022-Dec-26 4:56 AM |              |                                                                    |

### Flags Results Ref Range

**MEDICAL RECORDS (S)** Electrocardiogram 12 Lead See Below Cedar Specialist Group 4 ; a nearby city, a nearby city 6, ON ; 848 Main Blvd HEART RATE: 59 bpm P-R Interval: 179 ms P Horizontal Axis: 7 deg QRSD Interval: 125 ms QT Interval: 402 ms QTcB: 398 ms QRS Axis: 23 deg T Wave Axis: 23 deg ECG Severity: - ABNORMAL ECG - ECG Impression: Sinus rhythm ECG Impression: Nonspecific intraventricular conduction delay Ordered By: 414 235 249 Taylor, Sinead Electronically Signed By: Taylor, Sinead 10540 Electronically Signed On: 2022-12-19 42:90:90

**Patient:** Mr. Ethan Kang **Appointment Date:** 2022-Dec-19 **Title:** CT Crestwood Medical Group Study Visit Note (Cedar Specialist Group 4) **Provider:** Taylor, Sinead **Referred By:** Taylor, Sinead

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Dec-19.

**Problem History:** Crohn's disease

**Active Medications:** None Recorded

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 168 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: Sinus infection in [REDACTED-DATE], took Amoxicillin 250mg QD for 8 days.

Ongoing Adverse Events: Hypertension, being cared for by his GP

The following changes in medications have occurred since the last study visit: none

**INTERIM HISTORY**

Ethan has been symptomatic since the last study visit.

He has between 4 and 6 bowel movements per day. His stools are always watery. None of his bowel movements are associated with the passage of blood. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports arthritis and fever over 37.8C over the past 7 days.

**On physical examination**, his weight was 134.5 kg, he looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam was normal.

**Assessment and Plan** In summary, Mr. Ethan Kang is a 43 year-old male with Crohn's disease . The patient has mild clinical disease activity.

We will reassess in [REDACTED-DATE] to decide if Ethan will continue on his current treatment or switch to something else.

No changes in the patient's management will be made at this time.

The patient will follow-up according to the clinical trial protocol.

---

# Review

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 12/19/2022                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2022-Dec-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Please finish note and generate letter. Thank you!  |                        |                                                                    |

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2022-Dec-19

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

**Patient:** Mr. Ethan Kang **PHN:** 0748 361 588KT **Birthdate:** 1979 **Phone:** H: (442) 733-2165 C: (442) 733-2165 **Address:** a nearby city a nearby city, ON a nearby city

Dear Dr. Sinead Taylor,

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Dec-19.

**Problem History:** Crohn's disease

**Active Medications:** None Recorded

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 168 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: Sinus infection in [REDACTED-DATE], took Amoxicillin 250mg QD for 8 days.

Ongoing Adverse Events: Hypertension, being cared for by his GP

The following changes in medications have occurred since the last study visit: none

## INTERIM HISTORY

Ethan has been symptomatic since the last study visit.

He has between 4 and 6 bowel movements per day. His stools are always watery. None of his bowel movements are associated with the passage of blood. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports arthritis and fever over 37.8C over the past 7 days.

**On physical examination**, his weight was 134.5 kg, he looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam was normal.

---

**Assessment and Plan** In summary, Mr. Ethan Kang is a 43 year-old male with Crohn's disease . The patient has mild clinical disease activity.

We will reassess in [REDACTED-DATE] to decide if Ethan will continue on his current treatment or switch to something else.

No changes in the patient's management will be made at this time.

The patient will follow-up according to the clinical trial protocol.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

☐ \*--

This task has been completed

|                    |                                                                                                                              |                        |                                                                    |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                                                                                   | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 12/13/2022                                                                                                                   | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                                                                          | <b>Completed</b>       | 2022-Dec-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | - order ECG at appt on Dec 19<br>- Anesthesia needs to review ECG to determine if he can be scoped at Ridgeway Family Health |                        |                                                                    |

☐ REsearch consideration

This task has been completed

|                    |                                                                                                                       |                        |                                                                    |
|--------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                                                                            | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 12/12/2022                                                                                                            | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME],<br>[REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]           | <b>Completed</b>       | 2022-Dec-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Do you think DUET-CD would be a good option? Although his BMI may be too high to do scopes at Ridgeway Family Health? |                        |                                                                    |

|                  |                       |                          |                    |
|------------------|-----------------------|--------------------------|--------------------|
| <b>Patient:</b>  | <b>Mr. Ethan Kang</b> | <b>Appointment Date:</b> | <b>2022-Dec-13</b> |
| <b>Title:</b>    | <b>Phone Log</b>      |                          |                    |
| <b>Provider:</b> | <b>Taylor, Sinead</b> | <b>Referred By:</b>      | <b>None</b>        |

### Phone Conversation Log

Patient: Ethan Kang

Health Card No: 0748 361 588KT

Date: 2022-Dec-18

Time (Approx.): 11:19 AM

Number called: Cell (442) 733-2165

Spoke to: Ethan

Details: Discussion RE DUET-CD Study

Ethan is interested in pursuing DUET-CD study once it becomes available early next year. As his BMI is >35 and he has obstructive sleep apnea, anesthesia has requested a baseline ECG to review to confirm that Ethan can have a colonoscopy done at Ridgeway Family Health.

Plan: Order ECG at appointment on Dec 19 and send to anesthesia to review DUET-CD to start in [REDACTED-DATE]. Filgotinib washout is 4 weeks prior to randomization Continue in Lena Beaulieu

|                  |                                                                               |                          |                       |
|------------------|-------------------------------------------------------------------------------|--------------------------|-----------------------|
| <b>Patient:</b>  | <b>Mr. Ethan Kang</b>                                                         | <b>Appointment Date:</b> | <b>2022-Oct-03</b>    |
| <b>Title:</b>    | <b>CT Crestwood Medical Group Study Visit Note (Cedar Specialist Group 4)</b> |                          |                       |
| <b>Provider:</b> | <b>Taylor, Sinead</b>                                                         | <b>Referred By:</b>      | <b>Taylor, Sinead</b> |

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Oct-03.

**Problem History:** Crohn's disease

**Active Medications:** Filgotinib 200mg PO daily

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 156 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: none

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: none

## INTERIM HISTORY

Ethan has been feeling well since the last study visit.

He has between 4-6 bowel movements per day. His stools are always watery. Few of his bowel movements are associated with the passage of blood. He has no abdominal pain.

---

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports arthritis.

His weight today is 132.1Kg

**On physical examination**, his weight was 132 kg, he looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam was normal

**Assessment and Plan** In summary, Mr. Ethan Kang is a 43 year-old male with Crohn's disease . The patient is in symptomatic remission. He has gained some weight and I have counseled him about this. Although he is doing reasonably well I suspect he has ongoing small bowel disease activity. When he is reviewed in [REDACTED-DATE] we will evaluate whether he should continue to remain in the trial. We could consider a switch to Skyrizi once it is available.

No changes in the patient's management will be made at this time.

The patient will follow-up according to the clinical trial protocol.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2022-Oct-03

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: a nearby city a nearby city, ON a nearby city

Dear Dr. Sinead Taylor,

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Oct-03.

Problem History: Crohn's disease

Active Medications: Filgotinib 200mg PO daily

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 156 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: none

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: none

#### INTERIM HISTORY

Ethan has been feeling well since the last study visit.

He has between 4-6 bowel movements per day. His stools are always watery. Few of his bowel movements are associated with the passage of blood. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports arthritis.

His weight today is 132.1Kg

On physical examination, his weight was 132 kg, he looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam

---

was normal

**Assessment and Plan** In summary, Mr. Ethan Kang is a 43 year-old male with Crohn's disease . The patient is in symptomatic remission. He has gained some weight and I have counseled him about this. Although he is doing reasonably well I suspect he has ongoing small bowel disease activity. When he is reviewed in [REDACTED-DATE] we will evaluate whether he should continue to remain in the trial. We could consider a switch to Skyrizi once it is available.

No changes in the patient's management will be made at this time.

The patient will follow-up according to the clinical trial protocol.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

---

Patient: Mr. Ethan Kang Appointment Date: 2022-Aug-01 Title: Ridgeway Family Health - Clinical Dietitian  
Note Provider: Taylor, Sinead Referred By: None Date/Time: Aug 1, 2022 4:15pm Patient Name: Kang, Ethan Age: 91 suasv Pronoun: He/Him Sex: M Verbal consent received for appt. Privacy and confidentiality considerations noted. Zoom appt

---S/O---

Previous Recommendations:

1. reduce diet coke to 1 can a day. Reduce coffee to 3-4 espressos daily.
2. limit fluids to inbetween meals
3. Boost soluble fibre add banana for B, hummus on sandwich
4. smoothie in am. provided layout;
5. pm snack: suggested almonds and fruit
6. daily multivitamin and omega 3 1000mg (EPA+DHA) daily

Since last visit:

Increase fruit and increase protein.

Checks blood pressure daily - 132/80 average daily. Is his typical average.

BM's frequency improved to 3-5 times per day, less loose.

Hasent reduced coffee amounts, but 1 diet coke a day.

Drinking water in between meals.

Added more calcium to diet - milk in shake and yogurt.

Reported feeling more energy

Client really wants the accountability and support from RD to stay on track.

---A/P---

1. car friendly snacks for the drive home. Preferrably at costco:

Snack list:

RX granola bar: <https://www.costco.ca>

Three Farmers Roasted Chickpeas: <https://www.costco.ca> OR Good Bean Roasted Chickpeas: <https://www.costco.ca>

Unsalted, roasted Almonds (<https://www.costco.ca>) and a banana

Harvest Snaps: Green Pea snack: <https://www.costco.ca>

---

Ensure or PC high protein drink: <https://www.costco.ca> OR <https://www.costco.ca>

2. daily multivitamin (kirkland) and omega 3 1000mg (EPA+DHA) daily
3. Continue 3 espresso per day.
4. Importance of PA and exercise briefly discussed

F/U in 2 months. email dates.

---

#### Hospital Report

|                 |                |                  |   |                   |                |
|-----------------|----------------|------------------|---|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> |   | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |   |                   |                |
| <b>DOB</b>      | 1979           |                  |   |                   |                |

---

|                    |            |  |  |
|--------------------|------------|--|--|
| Facility Report #: | 2082209832 |  |  |
|--------------------|------------|--|--|



|                    |                     |              |                                                                    |
|--------------------|---------------------|--------------|--------------------------------------------------------------------|
| Sent to:           | Taylor, Sinead      | Reported By: | Ridgeway Family Health                                             |
| Collection Date:   | 2022-Jul-25         | Reviewed:    | 2022-Jul-25 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| Message Unique ID: | 2082209832          |              |                                                                    |
| Updated On:        | 2022-Jul-25 8:19 PM |              |                                                                    |

|                            | Flags | Results   | Ref Range |
|----------------------------|-------|-----------|-----------|
| <b>MEDICAL RECORDS (S)</b> |       |           |           |
| Electrocardiogram 12 Lead  |       | See Below |           |

Cedar Specialist Group 4 ; a nearby city, a nearby city 6, ON ; 848 Main Blvd HEART RATE: 62 bpm P-R Interval: 153 ms P Horizontal Axis: 29 deg QRSD Interval: 127 ms QT Interval: 409 ms QTcB: 416 ms QRS Axis: 14 deg T Wave Axis: 17 deg ECG Severity: - ABNORMAL ECG - ECG Impression: Sinus rhythm ECG Impression: Nonspecific intraventricular conduction delay ECG Impression: Early transition ECG Impression: ST elev, probable normal early repol pattern ECG Impression: No change Ordered By: 10540 Taylor, Sinead Electronically Signed By: Taylor, Sinead 10540 Electronically Signed On: 2022-07-10 79:41:39

## [X] Review

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 07/25/2022                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2022-Jul-26 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | do you need this for the clinical study?            |                        |                                                                    |

### Conversations

**Created 2022-Jul-26 8:36 AM**

2022-Jul-26 8:36 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [?] is this for you? [image] Sinead Taylor

2022-Jul-26 9:25 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [?] yes, can you file it? It's for my Lakeshore Specialty Clinic pt [image] Sinead Taylor

# [X] Review

This task has been completed

|             |                                                     |                 |                                                                    |
|-------------|-----------------------------------------------------|-----------------|--------------------------------------------------------------------|
| Patient     | Ethan Kang                                          | Task Created By | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| Date Due    | 07/11/2022                                          | Priority        | Normal                                                             |
| Assigned To | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | Completed       | 2022-Jul-20 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| Notes       | Please complete the note                            |                 |                                                                    |

|           |                                                  |                   |             |
|-----------|--------------------------------------------------|-------------------|-------------|
| Patient:  | Mr. Ethan Kang                                   | Appointment Date: | 2022-Jul-10 |
| Title:    | Ridgeway Family Health - Clinical Dietitian Note |                   |             |
| Provider: | Taylor, Sinead                                   | Referred By:      | None        |

Date/Time: Jul 10, 2022 11:15am Patient Name: Ethan Kang Age: 91 suasv Pronoun: He/Him Sex: M Verbal consent received for appt. Privacy and confidentiality considerations noted. Zoom appt

Reason for Visit: active CD - manage crohns disease with diet and medication and lose weight. reports arthritis

Medical and Surgical History: Crohns disease, stricturing. Hx of bowel resection (5ft ileum) in 2014.

Pertinent Medications: Filgotinib 200mg PO daily

Pertinent Supplements/Vitamins: vit D 2000IU daily, terazyme (digestive enzyme) long life vitality (<https://www.costco.ca>)

Pertinent Lab Data: noted

<u>Anthropometrics</u>

Height: Weight: 127kg BMI: Height:

Physical Activity Level: Subjective Global Assessment Score: N/A

<u>Social History</u>

Work: manager - working season full time - has winters off Housing Environment: Dependents: Food Literacy skill: moderate Sleep: 6 hours a night - has insomnia but manages with marijuana

## <u>Diet Information</u>

Food Allergies: eggplant Food Intolerances: fried foods, caffeine,

Eats a food groups.

Dislikes zucchini and bell peppers, cottage cheese,

Vegetables: some broccoli, spinach, salad, rapini, bokchoy, green beans Protein: pork 90% of time, chicken, fish, beef other 10% of the time. Fruits: apples. melon, berries, raspberries, strawberries Legumes: rarely. Dairy: some cheese, bowl of cereal with milk starches: cereal, bagels, white bread.

24h Diet Recall:

B: bagel with 2-3 slices of cheese

L: sandwich (deli meat),

D: pasta, meat and vegetables, potatoes (fried, mashed), rice, sweet potato

---

HS: peanut butter on white bread

Hydration: - 3L. coffee ( 2-3 cups per day ) +tea Alcohol consumption: rarely.

<u>Bowel Health</u> Bowel Movements: 4-6 times per day. loose. minimal abd pain. Urine Output: no concerns. feels dehydrated still even with 2-3L of water consumption

## <u>Nutrition Plan/Recommendations</u>

1. reduce diet coke to 1 can a day. Reduce coffee to 3-4 espressos daily.
2. limit fluids to inbetween meals
3. Boost soluble fibre add banana for B, hummus on sandwich
4. smoothie in am. provided layout;
5. pm snack: suggested almonds and fruit
6. daily multivitamin and omega 3 1000mg (EPA+DHA) daily .

Follow Up

F/U on August 1st at 4:15pm

|                  |                                                                               |                          |                       |
|------------------|-------------------------------------------------------------------------------|--------------------------|-----------------------|
| <b>Patient:</b>  | <b>Mr. Ethan Kang</b>                                                         | <b>Appointment Date:</b> | <b>2022-Jul-10</b>    |
| <b>Title:</b>    | <b>CT Crestwood Medical Group Study Visit Note (Cedar Specialist Group 4)</b> |                          |                       |
| <b>Provider:</b> | <b>Taylor, Sinead</b>                                                         | <b>Referred By:</b>      | <b>Taylor, Sinead</b> |

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Jul-10.

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 144 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: 1 kidney stone size of 7mm on July 6th. Passed the stone on the same day.

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: Flomax and tylenol for kidney stone.

## INTERIM HISTORY

Ethan has been clinically unchanged since the last study visit.

He has between 4 and 6 bowel movements per day. His stools are always loose. Few of his bowel movements are associated with the passage of blood. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports arthritis.

His weight today is 127.2KG

---

On physical examination, he looks well and nutritionally fit. His abdomen is soft and non tender.

**Assessment and Plan** In summary, Mr. Ethan Kang is a 43 year-old male with Crohn's disease . The patient has mild clinical disease activity. As he is stable, will continue clinical trial. Consider newer therapies once available in the future.

---

Ridgeway Family Health

Dear Patients – PLEASE READ THIS IMPORTANT INFORMATION December 2020

In addition to a clinical practice and research program in digestive diseases at Cedar Specialist Group 4 and the Ridgeway Family Health I have opened the Ridgeway Family Health to further assist patients with digestive health and chronic immune diseases such as inflammatory bowel disease (IBD).

Numerous programs and services are available at Ridgeway Family Health that have been set up to make your care more effective and efficient. These services include: care from a team of expert gastroenterologists, psychologists and mental health professionals, nutritionists and dietitians; access to nurses/physician assistants; on site blood tests, vaccine administration and TB tests; infusion/injection treatment centre and for patients for whom approved treatments are ineffective, rapid access to promising new treatments through clinical trials.

Some of these services require payments that are not covered by OHIP and many of these services generate revenue to pay our expenses and overhead at Ridgeway Family Health. Ridgeway Family Health

is also paid to perform clinical trials although there is no cost to patients to participate in such trials. Dr. Sinead Taylor, Founder of Ridgeway Family Health, is the sole owner of Ridgeway Family Health and may benefit from these revenues.

Please be aware that any private pay services available at Ridgeway Family Health are completely optional. Although you may be offered these services if Ridgeway Family Health staff believe they may be of benefit to your care, you are not required to accept these services and if you choose not to it will in no way affect your medical care at Ridgeway Family Health. You are also under no obligation to receive any services at Ridgeway Family Health, including recommended services covered by OHIP such as endoscopic procedures, and you are welcome to pursue any of these services at a location of your choice or through outside providers. Please inquire with our staff if you have any questions or require clarification or would like a referral for services to be carried out in another location.

[signature]

Jasmin Kaminski, Director and Founder of Ridgeway Family Health

I acknowledge that I have read and understand this document on (Date): 07/06/2022

Name (PRINT): Ethan Kang

Signature: [signature]

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city CANADA t: 993-089-6973 qaa 0534 | f: 993-089-6973 qaa 0534

---

Ridgeway Family Health

### **Consent for Nutritional Counselling**

I hereby request and consent to Sinead Taylor providing Nutrition Counselling to myself or the client for which I am legally responsible. I understand that the consult will provide information and guidance about my diet, nutrition, and lifestyle.

I understand that Sinead Taylor is a Registered Dietitian and he does not dispense medical advice, nor will he diagnose or treat any medical condition. Methods of nutritional evaluation or testing made available to me are not intended to diagnose disease. Rather, these assessments are intended as a guide to enhancing my nutritional health and supporting the achievement of my nutrition goals.

### **Confidentiality and Consent for Web-Based Counselling**

Medical records and personal information and history divulged in session to Sinead Taylor will be kept confidential and only shared with the medical professionals at the Ridgeway Family Health. Further, if I would like nutritional advice provided through web-supported platforms, I understand and accept that Internet associated activities are inherently at risk for a breach of personal information. I understand that if I schedule a web-based session that this implies consent and understanding of these risks.

### **Consent for Personal Information:**

I accept that it will be necessary for Sinead Taylor RD, to collect personal, health and lifestyle information, e.g. home telephone, address, gender identity, way of eating, etc.

## **Use, Disclosure, and Retention of Information**

I understand that only information relevant to the provision of nutritional therapy services will be collected and that this information will be retained in my client health record for ten years following the last date of service (or ten years following my eighteenth birthday, whichever is longer). I give permission for this information to be shared with my primary care physician, if needed.

I understand that I may review the information in my file for accuracy and currency. If I disagree with the information, I accept that either a correction will be made or my disagreement will also be noted.

I understand that I may review the Privacy Policy of Sinead Taylor so I can fully understand how it applies to me. I know that at any time I may ask questions about the Privacy Policy, and have them answered to my satisfaction.

I understand that I may review the information in my file for accuracy and currency. If I disagree with the information, I accept that either a correction will be made or my disagreement will also be noted.

---

Further, I understand that I may withdraw consent for any or all of the above at any time and that I should do so in writing.

All data collected and reported during the sessions will be retained by the Ridgeway Family Health clinic for a minimum of 10 years.

## **Consent for Cost of Services**

### *Individual Sessions*

Individual Consultation \$170.00/hour. I understand and consent that the full payment will be made at the time of the appointment.

Individual Follow-Up \$85.00/ half hour. I understand and consent that the full payment will be made at the time of the appointment.

## **Insurance Reimbursement**

The services of a Registered Dietitian are not covered by Ontario Health Insurance Plan (OHIP). Some private insurance carriers do cover some of the cost. Check your private insurance carrier for details. We do not do direct billing, we can provide you with a receipt with details of your visit; however it is your responsibility for submitting costs to your insurance company. We will provide individual receipts after each session for you to submit to your insurance provider.

## **Tax Reimbursement**

Registered Dietitians in Ontario are classified as "Authorized Medical Practitioner." Retain your receipt and you may be able to claim the fees as non-refundable tax credit for medical expense, from the government. Visit Canada Revenue Agency website for details.

## **Refund Policy:**

We offer 100% refund if you cancel more than 24 hours before your initial appointment for the service/package.

Fees are due at or before each visit and with each service, depending on the package/payment plan chosen. All service fees are **non-refundable** after service is rendered (regardless of the time spent).

**We do NOT issue a refund under these conditions:**

- ◆ After you have completed your appointment and the services are rendered
- ◆ If you cancel or reschedule within less than 24-hours of your appointment

**It is your responsibility to book and keep your appointments. All no shows will be regarded as a completed visit!**

I declare that the information provided is true and accurate at the time of signing and that I have understood and agreed to the above.

Ethan Kang

Name

07/06/2022

Date

[image]

Signature

# Ridgeway Family Health

## Dietitian Intake Form

### Personal Information

|            |           |  |
|------------|-----------|--|
| First name | Last name |  |
| Ethan      | Kang      |  |

|               |      |
|---------------|------|
| Street        | Unit |
| a nearby city |      |

|               |                |               |
|---------------|----------------|---------------|
| City          | State/Province | Postal code   |
| a nearby city | Ontario        | a nearby city |

| Home phone | Mobile phone   | Email address        |
|------------|----------------|----------------------|
|            | (442) 733-2165 | Ngkyqh3528@pyhyr.shn |

| Date of birth |
|---------------|
| Jun 21, 1979  |

| Occupation | Hours per week |
|------------|----------------|
| Manager    | 44             |

| Referred by       |
|-------------------|
| Dr. Sinead Taylor |

**What is your sex assigned at birth?** examples: Male, Female, Intersex... Male

**What is your gender?** examples: cisgender man, cisgender women, transgender man, transgender women, trans, non-binary... (blank)

**What are your pronouns?** example: She/Her/Hers, He/Him/His, They/Them/Theirs, (blank)

---

Ridgeway Family Health Dietitian Intake Form

**List your current health/nutrition concerns in order of importance**

| Health Concerns                             |
|---------------------------------------------|
| Managing Crohn ' s disease and loose weight |
|                                             |
|                                             |

## Family History

### Paternal Family Illnesses

| Paternal Family Member | Illness                                       |
|------------------------|-----------------------------------------------|
| Father                 | Angina, diabetes, prostate cancer, sleep apne |
| Grandfather            | Angina, diabetes                              |
| Grandmother            | Cancer                                        |

### Maternal Family Illnesses

| Maternal Family Member | Illness                                       |
|------------------------|-----------------------------------------------|
| Mother                 | Diabetes                                      |
| Grandfather            | Diabetes, arthritis, lung disease from mining |
| Grandmother            | Leukaemia                                     |



## Personal Health History

### Medical Diagnosis

| Diagnosis           | Current                             | Past                     | Date of Onset |
|---------------------|-------------------------------------|--------------------------|---------------|
| Sleep apnea         | <input checked="" type="checkbox"/> | <input type="checkbox"/> | 2012          |
| Crohn ' s disease   | <input checked="" type="checkbox"/> | <input type="checkbox"/> | 2013          |
| Arthritis           | <input checked="" type="checkbox"/> | <input type="checkbox"/> |               |
| High blood pressure | <input checked="" type="checkbox"/> | <input type="checkbox"/> |               |

Ridgeway Family Health Dietitian Intake Form

### Past Hospitalizations/Surgeries

| Hospitalization/Surgery | Date         | Reason                   |
|-------------------------|--------------|--------------------------|
| Bowel resection         | Jan 12, 2014 | Remove damaged intestine |
| Kidney stone stint      | May 2020     | Remove kidney stone      |
|                         |              |                          |

**Supplements** List all supplements you're currently taking including vitamins, herbs, minerals.

| Supplement         | Dose    | Frequency | Start Date | Reason           |
|--------------------|---------|-----------|------------|------------------|
| Long life vitality |         | Daily     | 2020       | Improve health   |
| Terazyme           |         | Daily     | 2020       | Better digestion |
| Vitamin D          | 2000 mg | Daily     | 2018       | Immune support   |
|                    |         |           |            |                  |
|                    |         |           |            |                  |

**Medications** List all medications you're currently taking.

| Medication | Dose | Frequency | Start Date | Reason        |
|------------|------|-----------|------------|---------------|
| Filgotinib |      | Daily     |            | Manage crohns |
|            |      |           |            |               |
|            |      |           |            |               |
|            |      |           |            |               |

Do you experience digestive difficulties? (i.e. bloating constipation, gas, constipation) (blank)

How often do you have a bowel movement? 4-6 times a day

Do you strain to have a bowel movement? ☐ Yes ☒ No

Are your bowels loose? ☒ Yes ☐ No

Ridgeway Family Health Dietitian Intake Form

**List any food or environmental allergies you experience**

| Food/Environmental Allergies | Reaction                             |
|------------------------------|--------------------------------------|
| Eggplant                     | Burns/numbs my mouth                 |
| Dust                         | Congestion                           |
| Grass                        | Itchiness watery eyes                |
| Cats                         | Itchiness watery eyes and congestion |

**Diet**

**Are you following any specific diets? (i.e. intermittent fasting, Mediterranean, keto, vegetarian, vegan, etc)** (blank)

**How much water do you drink daily?** 3 litres

**Are there any foods you avoid?** Zucchini, sweet bell peppers, eggplant

**Do you experience any symptoms after meals?** Usually need to go to the bathroom within a few minutes of finishing a meal

Do you consume coffee? ☒ Yes ☐ No

Do you consume tea? ☒ Yes ☐ No

Do you consume alcohol? ☐ Yes ☒ No

4

---

Ridgeway Family Health Dietitian Intake Form

**Lifestyle**

**Are you currently working or in school? What's your schedule like?** Working seasonal full time -have winters off

**Do you have trouble falling asleep? Staying asleep? You wake frequently during the night?** Insomnia but I manage it with marijuana at night

**How many hours do you sleep a night?** 6

**How often do you exercise?** Never

**What types of exercise do you do?** (blank)

**Do you smoke cigarettes? If so, how many cigarettes do you smoke per day?** No

**Do you smoke or consume marijuana?** Other names of marijuana include: weed, pot, grass, hash, herb, Yes

**Do you or have you used any other recreational drugs?** ☐ Yes ☒ No

**What do you do to have fun?** Play with my kids

**Describe your relationship with food** Emotional especially stress eater, I feel hungry all the time especially when I frequent the bathroom daily I ' m thirsty all the time

5

---

Ridgeway Family Health Dietitian Intake Form

**What is your level of commitment to improving your health?**

☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☒ 10

*1 = Lowest, 10 = Highest*

**Anything Else You Would Like Me To Know?**

---

a nearby city

a nearby city ON, Canada

a nearby city

**Ridgeway Family Health**

## Fax Cover Sheet

To: Dr. Sinead Taylor

Phone: 994-882-7246

Fax: (442) 733-2165

Date: 2022-Jul-20

From: Dr. Sinead Taylor

Phone: 277-586-4140

Fax: 290 827 5744 ext. 6902

Number of pages including cover: 3

**Confidential: This communication is intended only for the individual or institution to which it is addressed and should not be distributed, copied or disclosed to anyone else. The documents in this communication may contain personal, confidential or privileged information, which may be subject to the Freedom of information and Protection of Privacy Act, the Health Information Act and other legislation. If you have received this communication in error, please notify us immediately and return original transmission to us. Thank you for your co-operation and assistance.**

Re: Ethan Kang

---

**Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Ridgeway Family Health FOR DIGESTIVE DISEASES**

**Dr. Sinead Taylor Keller, FRCPC** Gastroenterologist, Ridgeway Family Health a nearby city, a nearby city 6, Ontario 848 Main Blvd t: 993-089-6973 qaa 0534 f: 993-089-6973 qaa 0534

2022-Jul-10

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

|                   |                                                   |
|-------------------|---------------------------------------------------|
| <b>Patient:</b>   | Mr. Ethan Kang                                    |
| <b>PHN:</b>       | 0748 361 588KT                                    |
| <b>Birthdate:</b> | 1979                                              |
| <b>Phone:</b>     | <b>H:</b> (442) 733-2165 <b>C:</b> (442) 733-2165 |
| <b>Address:</b>   | 412 Marigold Ave                                  |
|                   | a nearby city 6, ON 848 Main Blvd                 |

Dear Dr. Sinead Taylor,

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Jul-10.

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 144 He is currently on open label filgotibnib 200mg.

The following adverse events have occurred since the last study visit: 1 kidney stone size of 7mm on July 6th. Passed the stone on the same day.

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: Flomax and tylenol for kidney stone.

**INTERIM HISTORY**

Ethan has been clinically unchanged since the last study visit.

He has between 4 and 6 bowel movements per day. His stools are always loose. Few of his bowel movements are associated with the passage of blood. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports arthritis.

His weight today is 127.2KG

**On physical examination,** he looks well and nutritionally fit. His abdomen is soft and non tender.

**Assessment and Plan** In summary, Mr. Ethan Kang is a 43 year-old male with Crohn's disease. The patient has mild clinical disease activity. As he is stable, will continue clinical trial. Consider newer therapies once available in the future.

If you have any questions or concerns, please do not hesitate to contact me at

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

(779) 925-5114 ext. 9575.

Sincerely,

**Electronically generated to avoid delay**

**Sinead Taylor, Keller, FRCPC Sinead Taylor Medicine MPC Dominic Vinter; OHIP 10540**

**NEW: Dr Taylor accepts eConsults via OTN service. Register at <https://www.costco.ca>**

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

Lab Results: Manual Entry Generated On 2026-Apr-09

|                 |              |                  |                |                   |                |
|-----------------|--------------|------------------|----------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang   | <b>HomePhone</b> | (442) 733-2165 | <b>WorkPhone</b>  | (442) 733-2165 |
| <b>Health #</b> | 6609604884PP | <b>Sex</b>       | M              | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years     |                  |                |                   |                |
| <b>DOB</b>      | 1979         |                  |                |                   |                |

Ordered By: Taylor, Sinead Collection Date: 2022-Jun-29 Reviewed: 2022-Jun-29 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

|                         | Flags | Results | Ref Range |
|-------------------------|-------|---------|-----------|
| <b>Physical History</b> |       |         |           |
| Weight                  |       | 132     | kg        |

Ordered By: Taylor, Sinead Collection Date: 2022-Jun-29 Reviewed: 2022-Jun-29 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

|                          | Flags | Results | Ref Range |
|--------------------------|-------|---------|-----------|
| <b>OBRI-IBD-PMS-PHYS</b> |       |         |           |
| PMS Assessment Phys      |       | 0       |           |
| PMS BM Freq Phys         |       | 0       |           |
| PMS Rectal Bleeding Phys |       | 0       |           |

|                  | Flags | Results | Ref Range |
|------------------|-------|---------|-----------|
| PMS Total Phys   |       | 0       |           |
| PMS Urgency Phys |       | 1       |           |

Ordered By: Taylor, Sinead Collection Date: 2022-Jun-29 Reviewed: 2022-Jun-29 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

|                           | Flags | Results | Ref Range |
|---------------------------|-------|---------|-----------|
| <b>OBRI-IBD-FU-RATING</b> |       |         |           |
| BM Frequency              |       | 4       |           |
| BM Frequency Normal       |       | 4       |           |

Ordered By: Taylor, Sinead Collection Date: 2022-Jun-29 Reviewed: 2022-Jun-29 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

|                          | Flags | Results | Ref Range |
|--------------------------|-------|---------|-----------|
| <b>OBRI-IBD-HBI-PHYS</b> |       |         |           |
| HBI Overall Phys         |       | 1       |           |
| HBI Abd Pain Phys        |       | 0       |           |
| HBI Arthralgia Phys      |       | 0       |           |
| BM Freq Loose Phys       |       | 4       |           |
| HBI Fever Phys           |       | 0       |           |
| HBI Fistula Phys         |       | 0       |           |
| HBI Total Phys           |       | 5       |           |

Ordered By: Taylor, Sinead Collection Date: 2022-Jun-29 Reviewed: 2022-Jun-29 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

|                            | Flags | Results | Ref Range |
|----------------------------|-------|---------|-----------|
| <b>OBRI-IBD-SYMP-SCORE</b> |       |         |           |
| Overall Wellness Phys      |       | 3       |           |
| Abd Pain Score Phys        |       | 1       |           |

Patient: Mr. Ethan Kang Appointment Date: 2022-Jun-29 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: Taylor, Sinead I saw Ethan Kang today for follow up of his Crohn's disease by telephone.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

Endoscopy Results: 2022-Feb-28 Colonoscopy - Anastomosis widely patent,ulceration at anastomosis. ongoing inflammation in neoTI with moderately significant inflammatory process-small and medium ulcers, >5 ulcers some >1cm. normal colon 2022-Feb-28 Colonoscopy - neoTI: Rutgeert's i4, SES 7, right SES 0, tra SES 0, left SES 0, rec SES 0 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

Active Medications: Filgotinib 200mg PO daily (Clinical Trial OLE)

Current Status

Had an episode of worsening symptoms in [REDACTED-DATE] with diarrhea, chills and abdominal cramps and passed some blood. Stool tests were negative. COVID testing was negative. He has spontaneously resolved and is currently back to baseline.

He probably had a transient infection. He still however has active ileal CD. We have decided to continue on with filgotinib for now and there may be additional trial and commercially available options for him in the fall. He has a clinical trial study visit due on July 11.

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health IBD VISIT FORM SYMPTOM SCORE SHEET OBRI IBD CLINICAL PATIENT REGISTRY

PATIENT DEMOGRAPHICS

Name: Ethan Kang Date of Birth: 1979 Age: 43 Yr Sex: M MRN: 414 235 249 OHIP: 0748 361 588KT

DATE COMPLETED BY PATIENT

Dec 1, 2024

| QUESTIONS                                                                                                                                                                                                                                                                      | PATIENT                        | CLINICIAN                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|
| OVERALL WELL-BEING RATING (HBI/PMS)<br>Rate how you are feeling overall, in relationship to your IBD<br>1 = my IBD is in complete control and is not affecting my well being at all<br>10 = my IBD is as bad as it could possibly be, and is maximally affecting my well-being | (blank)                        | 3                              |
|                                                                                                                                                                                                                                                                                | HBI (Overall) 1<br>PMS (PGA) 1 | HBI (Overall) 1<br>PMS (PGA) 0 |
| ABDOMINAL PAIN RATING (PMS)<br>Rate the severity of your abdominal pain on a scale of 1 to 10<br>1 = absent, no pain at all<br>10 = excruciating, worst pain I could possibly have                                                                                             | 0                              | 1                              |
|                                                                                                                                                                                                                                                                                | HBI (Abd Pain) 0               | HBI (Abd Pain) 0               |

| QUESTIONS                                                                                                                                                                                                            | PATIENT                                   | CLINICIAN                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| <b>BOWEL MOVEMENT FREQUENCY</b>                                                                                                                                                                                      |                                           |                                                                                                                           |
| How many LOOSE/LIQUID BMs/day on average over last week? ( <i>HBI</i> )                                                                                                                                              | <b>4</b>                                  | 4                                                                                                                         |
| How many TOTAL BM/s day on average over the last week? ( <i>PMS</i> )                                                                                                                                                | <b>4</b>                                  | 4                                                                                                                         |
| How many BMs do you have on an average day when you feel well? ( <i>PMS</i> )                                                                                                                                        | <b>4</b>                                  | 4                                                                                                                         |
| How would you rate your URGENCY for needing a BM in the last week<br>(0) I don't have to hurry (2) I have to go Immediately, or I'll have an accident<br>(1) I have to hurry (3) I have had accidents / incontinence | <b>1</b>                                  | <input type="checkbox"/> 0 <input type="checkbox"/> 2<br><input checked="" type="checkbox"/> 1 <input type="checkbox"/> 3 |
|                                                                                                                                                                                                                      | HBI (BM)<br><b>4</b><br>PMS (BM) <b>0</b> | HBI (BM)<br><b>4</b><br>PMS (BM) <b>0</b>                                                                                 |
| <b>RECTAL BLEEDING (PMS)</b><br>Describe the blood in your stool<br>(0) Absent (2) definitely present in stool<br>(1) present in small amounts/streaks (3) bleeding without stool                                    | <b>0</b>                                  | <input checked="" type="checkbox"/> 0 <input type="checkbox"/> 2<br><input type="checkbox"/> 1 <input type="checkbox"/> 3 |
| <b>ARTHROGIA/ARTHRITIS (HBI)</b><br>Are you having any joint swelling or pain that you believe is related to your IBD?<br>(0) = absent (1) = present                                                                 | <b>1</b>                                  | <input checked="" type="checkbox"/> 0 <input type="checkbox"/> 1                                                          |

#### CALCULATED SCORES:

☐ fever > 38.0 ☐ active fistula **0**

Current Weight: 132 kg Current Weight: 136.4 kg on Dec 1, 2024

| HBI           |                 | PMS           |                 |
|---------------|-----------------|---------------|-----------------|
| PATIENT TOTAL | CLINICIAN TOTAL | PATIENT TOTAL | CLINICIAN TOTAL |
| <b>6</b>      | <b>5</b>        | <b>1</b>      | <b>0</b>        |

Version 1.1.0 ☐ CALCULATE

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2022-Jun-29

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

**Patient:** Mr. Ethan Kang **PHN:** 0748 361 588KT **MRN:** 414 235 249 **Birthdate:** 1979 **Phone:** H: (442) 733-2165 C: (442) 733-2165 **Address:** 412 Marigold Ave a nearby city 6, ON 848 Main Blvd



Dear Dr. Sinead Taylor,

I saw Ethan Kang today for follow up of his Crohn's disease by telephone.

**Problem History:** Crohn's disease

**IBD Phenotype:** Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**Endoscopy Results:** 2022-Feb-28 Colonoscopy - Anastomosis widely patent,ulceration at anastomosis. ongoing inflammation in neoTI with moderately significant inflammatory process-small and medium ulcers, >5 ulcers some >1cm. normal colon 2022-Feb-28 Colonoscopy - neoTI: Rutgeert's i4, SES 7, right SES 0, tra SES 0, left SES 0, rec SES 0 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

**Active Medications:** Filgotinib 200mg PO daily (Clinical Trial OLE)

**Current Status**

Had an episode of worsening symptoms in [REDACTED-DATE] with diarrhea, chills and abdominal cramps and passed some blood. Stool tests were negative. COVID testing was negative. He has spontaneously resolved and is currently back to baseline.

He probably had a transient infection. He still however has active ileal CD. We have

---

decided to continue on with filgotinib for now and there may be additional trial and commercially available options for him in the fall. He has a clinical trial study visit due on July 11.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

---

Lab Results: Generated On 2026-Apr-09

|                 |                |                  |                |                   |                |
|-----------------|----------------|------------------|----------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (442) 733-2165 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M              | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                |                   |                |
| <b>DOB</b>      | 1979           |                  |                |                   |                |

---

Accession Id: 2082209832 (Final) Ordered By: Sinead Taylor  
Reported By: Ridgeway Family Health Collection Date: 2022-Jun-15  
Reviewed: 2022-Jun-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service  
Date: 2022-Jun-15 Report Date: 2022-Jun-18 8:30 AM

CC: Sinead Taylor Updated On: 2022-Jun-19 9:41 AM

## MICROBIOLOGY REPORT

| Results                                                                                                  | Flags | Ref Range | Test Loc |
|----------------------------------------------------------------------------------------------------------|-------|-----------|----------|
| SOURCE STOOL                                                                                             |       |           | 10       |
| CULTURE STATUS FINAL                                                                                     |       |           |          |
| CULTURE REPORT Enteric Culture No Salmonella, Shigella, Campylobacter, E. coli O157 or Yersinia isolated |       |           |          |
| COLLECTION DATE Jun 15, 2022                                                                             |       |           |          |
| COLLECTION TIME 10:00                                                                                    |       |           |          |

a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 2082209832 (Final) Ordered By: Sinead Taylor

Reported By: Ridgeway Family Health Collection Date: 2022-Jun-15

Reviewed: 2022-Jun-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2022-Jun-15 Report Date: 2022-Jun-18 8:30 AM

CC: Sinead Taylor Updated On: 2022-Jun-19 9:41 AM

## PARASITOLOGY

| Results                                                                                                                                                                                                                                                                                                                                                             | Flags | Ref Range | Test Loc            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|---------------------|
| SOURCE STOOL                                                                                                                                                                                                                                                                                                                                                        |       |           | 10                  |
| STATUS FINAL                                                                                                                                                                                                                                                                                                                                                        |       |           | 2022-Jun-15 6:14 PM |
| REPORT Parasite PCR No Blastocystis hominis, Giardia lamblia, Entamoeba histolytica, Cryptosporidium species, Dientamoeba fragilis, or Cyclospora cayetanensis detected. If helminthic infestation is suspected, immunocompromised status or for immigration/refugee screening purposes please recollect stool sample in SAF container for microscopic examination. |       |           |                     |
| COLLECTION DATE Jun 15, 2022                                                                                                                                                                                                                                                                                                                                        |       |           |                     |
| COLLECTION TIME 10:00                                                                                                                                                                                                                                                                                                                                               |       |           |                     |

a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 2082209832 (Final) Ordered By: Sinead Taylor

Reported By: Ridgeway Family Health Collection Date: 2022-Jun-15

Reviewed: 2022-Jun-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service  
Date: 2022-Jun-15 Report Date: 2022-Jun-18 8:30 AM

CC: Sinead Taylor Updated On: 2022-Jun-19 9:41 AM

|                    | Results                                                                                                                                                                  | Flags | Ref Range | Test Loc |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|----------|
| REF-OUTS           |                                                                                                                                                                          |       |           |          |
| PUBLIC HEALTH TEST | Specimen referred to: Ridgeway Family Health. Test results will be sent directly to the requesting physician from PHL. For result inquiries, call 993-089-6973 qaa 0534. |       |           | 174      |

174 -

**Ridgeway Family Health | Ridgeway Family Health** Crestwood Medical Group 2 | PARTENAIRES POUR LA SANTÉ

**Ridgeway Family Health** a nearby city 8

**LIMS Report #:** 2082209832 **Fax To:** 676 681 3013 **Provider:** Dr. Sinead Taylor a nearby city 6 Lakeshore Specialty Clinic 338 Marigold St 338 Marigold St a nearby city, ON a nearby city **Phone:**

**Patient:** Ethan Kang a nearby city 8 **Patient Phone:** 993-089-6973 qaa 0534

**HIN:** 0748 361 588KT **Date of Birth:** 1979-06-21 **Gender:** Male

**Report Copied To:** Dr. Sinead Taylor

**Sample #:** 2082209832 (2082209832) **Date Collected:** 2022-06-15 **Source:** Stool (Unpreserved) **Date Received:** 2022-06-16 **Testing Reason:** Diagnostic, Immunocompromised **Date Reported:** 2022-06-16 **Clinical Info:** Other **Patient Setting:** Physician Office/ Clinic **Additional Info:** IBD PATIENT FLARING SYMPTOMS **Acute/Conv:** **Specimen Note:** Test results for C.difficile specimens submitted frozen or greater than 3 days since collection date may be affected and should be interpreted with caution.

| Test                                  | Result       | Date Approved |
|---------------------------------------|--------------|---------------|
| C.difficile GDH Ag by EIA-Screen Test | Not detected | 2022-06-16    |

**Note:** Results do not support the diagnosis of C.difficile. C.difficile toxin testing by enzyme immunoassay (EIA) has been demonstrated to have limited sensitivity. If the initial test is 'not detected' and there is ongoing clinical suspicion, a second specimen for C.difficile testing should be sent.

*The contents of this document are confidential and intended only for the use of the individual named as the "Provider". If you have received this information in error, please notify the Sunnymede Family Practice 4 by telephone at 993-089-6973 qaa 0534 or 993-089-6973 qaa 0534.*

Ridgeway Family Health a nearby city 8

## Final

Ontario Health Santé

T\_SingleSampleOPHL\_rpt **Print Date:** 2022-06-16

Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name: Dr. Sinead Taylor Address: 338 Marigold St a nearby city ON, Canada a nearby city (442) 733-2165

Laboratory Use Only

| <b>Clinician/Practitioner Number</b> | <b>CPSO / Registration No.</b> | <b>Clinician/Practitioner's Contact Number for Urgent Results: 993-089-6973 qaa 0534</b> | <b>Service Date: 1979 / mm / 1979</b> |
|--------------------------------------|--------------------------------|------------------------------------------------------------------------------------------|---------------------------------------|
| Health Number: 0748<br>361 588KT     | Version                        | Sex: <input checked="" type="checkbox"/> M <input type="checkbox"/> F                    | Date of Birth: 1979                   |

Check (☒) one: ☒ OHIP/Insured ☐ Third Party / Uninsured ☐ WSIB

| <b>Province:</b>                                                                                 | <b>Other Provincial Registration Number</b> | <b>Patient's Telephone Contact Number: (442) 733-2165</b> |
|--------------------------------------------------------------------------------------------------|---------------------------------------------|-----------------------------------------------------------|
| Additional Clinical Information (e.g. diagnosis): IBD patient flaring, Stools rule out infection |                                             |                                                           |

Patient's Last Name (as per OHIP Card): Ethan Kang Patient's First & Middle Names (as per OHIP Card): Ethan

☒ Copy to: Clinician/Practitioner Last Name: Dr. Sinead Taylor First Name: (blank) Address: 412 Marigold Ave a nearby city 6 ON, Canada 848 Main Blvd

Patient's Address (including Postal Code): 412 Marigold Ave a nearby city 6 ON, Canada 848 Main Blvd 848 Main Blvd

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Crestwood Medical Group

| <b>x</b>                 | <b>Biochemistry</b>                                                      | <b>x</b>                 | <b>Hematology</b>      | <b>x</b>                 | <b>Viral Hepatitis (check one only)</b> |
|--------------------------|--------------------------------------------------------------------------|--------------------------|------------------------|--------------------------|-----------------------------------------|
| <input type="checkbox"/> | Glucose <input type="checkbox"/> Random <input type="checkbox"/> Fasting | <input type="checkbox"/> | CBC                    | <input type="checkbox"/> | Acute Hepatitis                         |
| <input type="checkbox"/> | HbA1C                                                                    | <input type="checkbox"/> | Prothrombin Time (INR) | <input type="checkbox"/> | Chronic Hepatitis                       |

| <b>x</b> | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b> | <b>Hematology</b>                                                  | <b>x</b> | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [<br>]   | Creatinine (eGFR)                                                                                                                                                                   |          | Immunology                                                         | [ ]      | Immune Status / Previous Exposure                                                                                                                                |
| [<br>]   | Uric Acid                                                                                                                                                                           | [ ]      | Pregnancy Test (Urine)                                             |          | Specify: [ ] Hepatitis A                                                                                                                                         |
| [<br>]   | Sodium                                                                                                                                                                              | [ ]      | Mononucleosis Screen                                               |          | [ ] Hepatitis B                                                                                                                                                  |
| [<br>]   | Potassium                                                                                                                                                                           | [ ]      | Rubella                                                            |          | [ ] Hepatitis C                                                                                                                                                  |
| [<br>]   | ALT                                                                                                                                                                                 | [ ]      | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) |          | or order individual hepatitis tests in the "Other Tests" section below                                                                                           |
| [<br>]   | Alk. Phosphatase                                                                                                                                                                    | [ ]      | Repeat Prenatal Antibodies                                         |          | Prostate Specific Antigen (PSA)                                                                                                                                  |
| [<br>]   | Bilirubin                                                                                                                                                                           |          | Microbiology ID & Sensitivities (if warranted)                     | [ ]      | Total PSA [ ] Free PSA                                                                                                                                           |
| [<br>]   | Albumin                                                                                                                                                                             | [ ]      | Cervical                                                           |          | Specify one below:                                                                                                                                               |
| [<br>]   | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [ ]      | Vaginal                                                            | [ ]      | Insured - Meets OHIP eligibility criteria                                                                                                                        |
| [<br>]   | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | [ ]      | Vaginal / Rectal – Group B Strep                                   | [ ]      | Uninsured – Screening: Patient responsible for payment                                                                                                           |
| [<br>]   | Urinalysis (Chemical)                                                                                                                                                               | [ ]      | Chlamydia (specify source):                                        |          | Vitamin D (25-Hydroxy)                                                                                                                                           |
|          | Neonatal Bilirubin:                                                                                                                                                                 | [ ]      | GC (specify source):                                               | [ ]      | Insured – Meets OHIP eligibility criteria; osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |

|          |                                       |          |                                     |                    |                                             |
|----------|---------------------------------------|----------|-------------------------------------|--------------------|---------------------------------------------|
| <b>x</b> | <b>Biochemistry</b>                   | <b>x</b> | <b>Hematology</b>                   | <b>x</b>           | <b>Viral Hepatitis (check one only)</b>     |
|          | Child's Age: days / hours             | [ ]      | Sputum                              |                    |                                             |
|          | Clinician/Practitioner's tel. no. ( ) | [ ]      | Throat                              | [ ]                | Uninsured – Patient responsible for payment |
|          | Patient's 24 hr telephone no. ( )     | [ ]      | Wound (specify source):             |                    | Other Tests - one test per line             |
| [<br>]   | Therapeutic Drug Monitoring:          | [X]      | Urine                               |                    | C diff stools [X]                           |
|          | Name of Drug #1                       | [X]      | Stool Culture                       |                    | (blank) [ ]                                 |
|          | Name of Drug #2                       | [X]      | Stool Ova & Parasites               |                    | (blank) [ ]                                 |
|          | Time Collected #1: hr. #2: hr.        | [ ]      | Other Swabs / Pus (specify source): |                    | (blank) [ ]                                 |
|          | Time of Last Dose #1: hr. #2: hr.     |          | Specimen Collection                 |                    | (blank) [ ]                                 |
|          | Time of Next Dose #1: hr. #2: hr.     |          | Time: 24 hour clock                 | Date: 1979/mm/1979 |                                             |

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

Fecal Occult Blood Test (FOBT) (check one) [ ] FOBT (non CCC) [ ] ColonCancerCheck FOBT (CCC) no other test can be ordered on this form

[image] Laboratory Use Only

X [signature] 2022-Jun-14 Clinician/Practitioner Signature Date

4422-84 (2013/01) © Queen's Printer for Ontario, 2013 7530-4581

Ridgeway Family Health / Ridgeway Family Health

|                                       |                 |
|---------------------------------------|-----------------|
| <b>Date received 1979 / mm / 1979</b> | <b>PHOL No.</b> |
|---------------------------------------|-----------------|

General Test Requisition ALL Sections of this Form MUST be Completed

1 - Submitter

Courier Code: (blank)

Provide Return Address: Dr. Sinead Taylor 338 Marigold St a nearby city a nearby city

Clinician Initial / Surname and OHIP / CPSO Number: Dr. Sinead Taylor 0748 361 588KT

Tel: 277-586-4140 Fax: 290 827 5744 ext. 6902

cc Doctor Information Name: Dr. Sinead Taylor Lab/Clinic Name: Taylor Laila Yamamoto Address: 412 Marigold Ave

Tel: 994-882-7246 Fax: (442) 733-2165 Postal Code: (blank)

## 2 - Patient Information

|                                  |                     |                                             |
|----------------------------------|---------------------|---------------------------------------------|
| <b>Health No. 0748 361 588KT</b> | <b>Sex: (blank)</b> | <b>Date of Birth: 1979 / mm / 1979 1979</b> |
| Medical Record No. (blank)       |                     |                                             |

Patient's Last Name (per OHIP card): Ethan Kang First Name (per OHIP card): Ethan

Patient Address: 412 Marigold Ave

Postal Code: 848 Main Blvd Patient Phone No. (442) 733-2165

Submitter Lab No. (blank) Public Health Unit Outbreak No. (blank)

Public Health Investigator Information Name: (blank) Health Unit: (blank) Tel: (blank) Fax: (blank)

3 - Test(s) Requested (Please see descriptions on reverse) Test: Enter test descriptions below Rule out C difficile Infection (blank) (blank) (blank) (blank) (blank)

Hepatitis Serology Reason for test (Check ☐ only one box): ☐ Immune status ☐ Acute infection ☐ Chronic infection Indicate specific viruses (Check ☐ all that apply): ☐ Hepatitis A ☐ Hepatitis B ☐ Hepatitis C (testing only available for acute or chronic infection; no test for determining immunity to HCV is currently available)

4 - Specimen Type and Site ☐ blood / serum ☒ faeces ☐ nasopharyngeal ☐ sputum ☐ urine ☐ vaginal smear ☐ urethral ☐ cervix ☐ BAL ☐ other - (specify) (blank)

Patient Setting ☒ physician office/clinic ☐ ER (not admitted) ☐ inpatient (ward) ☐ inpatient (ICU) ☐ institution

## 5 - Reason for Test

☒ diagnostic ☐ immune status ☐ needle stick ☐ follow-up ☐ prenatal ☐ chronic condition ☒ immunocompromised ☐ post-mortem ☐ other - (specify) (blank)

Date Collected: 1979 / mm / 1979 (blank) Onset Date: 1979 / mm / 1979 (blank)

Clinical Information ☐ fever ☒ gastroenteritis ☐ respiratory symptoms ☐ STI ☐ headache / stiff neck ☐ vesicular rash ☐ pregnant ☐ encephalitis / meningitis ☐ maculopapular rash ☐ jaundice ☒ other - (specify) IBD patient - flaring symptoms

☐ influenza high risk - (specify) (blank) ☐ recent travel - (specify location) (blank)

For HIV, please use the HIV serology form. - For referred cultures, please use the reference bacteriology form. To re-order this test requisition contact your local Crestwood Medical Group and ask for form number F-SD-SCG-1000. Current version of Crestwood Medical Group requisitions are available at

<https://www.costco.ca> The personal health information is collected under the authority of the Personal Health Information Protection Act, s.36 (1)(c)(iii) for the purpose of clinical laboratory testing. If you have questions about the collection of this personal health information please contact the PHOL Manager of Customer Service at 993-089-6973 qaa 0534 or toll free 993-089-6973 qaa 0534. F-SD-SCG-1000 (08/2013)

Crestwood Medical Group 2 Ridgeway Family Health

Ridgeway Family Health / Ridgeway Family Health

| Date received 1979 / mm / 1979 | PHOL No. |
|--------------------------------|----------|
|--------------------------------|----------|

General Test Requisition ALL Sections of this Form MUST be Completed

1 - Submitter

Courier Code: (blank)

Provide Return Address: Dr. Sinead Taylor a nearby city a nearby city ON, Canada a nearby city City & Province: ON, Canada Postal Code: a nearby city

Clinician Initial / Surname and OHIP / CPSO Number Sinead Taylor 0748 361 588KT

Tel: 993-089-6973 qaa 0534 Fax: (442) 733-2165

cc Doctor Information Name: Dr. Sinead Taylor Lab/Clinic Name: Taylor Laila Yamamoto Address: 412 Marigold Ave a nearby city 6 ON, Canada Postal Code: 848 Main Blvd Tel: 994-882-7246 Fax: (442) 733-2165

2 - Patient Information

|                            |              |                                      |
|----------------------------|--------------|--------------------------------------|
| Health No. 0748 361 588KT  | Sex: (blank) | Date of Birth: 1979 / mm / 1979 1979 |
| Medical Record No. (blank) |              |                                      |

Patient's Last Name (per OHIP card): Ethan Kang First Name (per OHIP card): Ethan

Patient Address: 412 Marigold Ave a nearby city 6 ON, Canada Postal Code: 848 Main Blvd Patient Phone No. (442) 733-2165

Submitter Lab No. (blank) Public Health Unit Outbreak No. (blank)

Public Health Investigator Information Name: (blank) Health Unit: (blank) Tel: (blank) Fax: (blank)

3 - Test(s) Requested (Please see descriptions on reverse) Test: Enter test descriptions below Ova & Parasites (blank) (blank) (blank) (blank) (blank)

Hepatitis Serology Reason for test (Check ☐ only one box): ☐ Immune status ☐ Acute infection ☐ Chronic infection Indicate specific viruses (Check ☐ all that apply): ☐ Hepatitis A ☐ Hepatitis B ☐ Hepatitis C (testing only available for acute or chronic infection; no test for determining immunity to HCV is currently available)



4 - Specimen Type and Site ☐ blood / serum ☒ faeces ☐ nasopharyngeal ☐ sputum ☐ urine ☐ vaginal smear ☐ urethral ☐ cervix ☐ BAL ☐ other - (specify) (blank)

Patient Setting ☒ physician office/clinic ☐ ER (not admitted) ☐ inpatient (ward) ☐ inpatient (ICU) ☐ institution

#### 5 - Reason for Test

☒ diagnostic ☐ immune status ☐ needle stick ☐ follow-up ☐ prenatal ☐ chronic condition ☒ immunocompromised ☐ post-mortem ☐ other - (specify) (blank)

Date Collected: 1979 / mm / 1979 (blank) Onset Date: 1979 / mm / 1979 (blank)

Clinical Information ☐ fever ☒ gastroenteritis ☐ respiratory symptoms ☐ STI ☐ headache / stiff neck ☐ vesicular rash ☐ pregnant ☐ encephalitis / meningitis ☐ maculopapular rash ☐ jaundice ☒ other - (specify) IBD patient

☐ influenza high risk - (specify) (blank) ☐ recent travel - (specify location) (blank)

For HIV, please use the HIV serology form. - For referred cultures, please use the reference bacteriology form. To re-order this test requisition contact your local Crestwood Medical Group and ask for form number F-SD-SCG-1000. Current version of Crestwood Medical Group requisitions are available at <https://www.costco.ca> The personal health information is collected under the authority of the Personal Health Information Protection Act, s.36 (1)(c)(iii) for the purpose of clinical laboratory testing. If you have questions about the collection of this personal health information please contact the PHOL Manager of Customer Service at 993-089-6973 qaa 0534 or toll free 993-089-6973 qaa 0534. F-SD-SCG-1000 (08/2013)

Crestwood Medical Group 2 Ridgeway Family Health

[image] \*\_\_

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 05/26/2022                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2022-May-31 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |

**Notes** Ethan is interested in consulting with [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] - Please schedule an appointment!

#### Conversations

**Created 2022-May-31 10:49 AM**

2022-May-31 10:49 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [image]  
Spoke with the patient and booked [image] Sinead Taylor

Patient: Mr. Ethan Kang Title: Phone Log Provider: Taylor, Sinead Phone Conversation Log

Appointment Date: 2022-May-25 Referred By: None

Patient: Ethan Kang Date: 2022-May-25 Time (Approx.): 11:14 AM

Number called: Cell (442) 733-2165

Spoke to: Ethan

Call Details: TD called Ethan to notify him of elevated triglycerides (4.92 mmol/L) on lab results from May 10, 2022. He is currently participating in the Lena Beaulieu Clinical Trial (Filgotinib), which may be contributing to hypertriglyceridemia.

From a dietary perspective, Ethan consumes a lot of carbohydrates. No alcohol. He does not exercise regularly.

We had a discussion about lifestyle strategies, including physical activity, weight loss, and healthier eating habits.

Ethan is interested in consulting with a Dietician/Nutritionist. We will arrange this for him.

[X] \* --

This task has been completed

|                    |                                                          |                        |                                                                    |
|--------------------|----------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                               | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 05/18/2022                                               | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]      | <b>Completed</b>       | 2022-Jun-05 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | note triglycerides and HDL...?<br>adverse event required |                        |                                                                    |

[X] Review lab test

This task has been completed

|                 |            |                        |                                                     |
|-----------------|------------|------------------------|-----------------------------------------------------|
| <b>Patient</b>  | Ethan Kang | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Date Due</b> | 05/11/2022 | <b>Priority</b>        | Normal                                              |

|                    |                                                                        |                  |                                                                    |
|--------------------|------------------------------------------------------------------------|------------------|--------------------------------------------------------------------|
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                    | <b>Completed</b> | 2022-May-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Clinical Trial Pt... Please review labs. Elevated triglycerides (4.92) |                  |                                                                    |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 2082209832 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2022-May-10 Reviewed: 2022-May-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]  
Reported Date: 2022-May-11 3:24 AM Updated On: 2022-May-18 12:01 PM

|                                                     | Flags | Results | Ref Range        | Units           |
|-----------------------------------------------------|-------|---------|------------------|-----------------|
| <b>CRP</b>                                          |       |         |                  |                 |
| CRP (F)                                             | N     | 5.8     | < 8.0 mg/L       | mg/L            |
| <b>GLUCOSE SERUM FASTING</b>                        |       |         |                  |                 |
| GLUCOSE SERUM FASTING (F)                           | N     | 5.5     | 3.6 - 6.00       | mmol/L          |
| mmol/L                                              |       |         |                  |                 |
| 3.6 - 6.0 NORMAL FASTING GLUCOSE                    |       |         |                  |                 |
| 6.1 - 6.9 IMPAIRED FASTING GLUCOSE                  |       |         |                  |                 |
| >6.9 PROVISIONAL DIAGNOSIS OF DIABETES MELLITUS     |       |         |                  |                 |
| <b>UREA</b>                                         |       |         |                  |                 |
| UREA (F)                                            | N     | 3.7     | 2.5 - 8.1 mmol/L | mmol/L          |
| <b>CREATININE</b>                                   |       |         |                  |                 |
| CREATININE (F)                                      | N     | 72      | 60 - 110 umol/L  | umol/L          |
| eGFR (F)                                            | N     | 109     | 60. - 99999.99   | mL/min/1.73m**2 |
| >=60. mL/min/1.73m**2                               |       |         |                  |                 |
| eGFR is calculated using the CKD-EPI 2009 equation. |       |         |                  |                 |

|                                                         | Flags | Results | Ref Range          | Units  |
|---------------------------------------------------------|-------|---------|--------------------|--------|
| Normal eGFR.                                            |       |         |                    |        |
| For patients of African descent, the reported eGFR must |       |         |                    |        |
| be multiplied by 1.15.                                  |       |         |                    |        |
| <b>CALCIUM</b>                                          |       |         |                    |        |
| CALCIUM (F)                                             | N     | 2.26    | 2.15 - 2.60 mmol/L | mmol/L |
| <b>PHOSPHORUS</b>                                       |       |         |                    |        |
| PHOSPHORUS (F)                                          | N     | 0.92    | 0.80 - 1.45 mmol/L | mmol/L |
| <b>MAGNESIUM</b>                                        |       |         |                    |        |
| MAGNESIUM (F)                                           | N     | 0.83    | 0.65 - 1.05 mmol/L | mmol/L |
| <b>PROTEIN</b>                                          |       |         |                    |        |
| PROTEIN (F)                                             | N     | 65      | 60 - 80 g/L        | g/L    |
| <b>ALBUMIN</b>                                          |       |         |                    |        |
| ALBUMIN (F)                                             | N     | 41      | 35 - 52 g/L        | g/L    |
| <b>BILIRUBIN TOTAL</b>                                  |       |         |                    |        |
| BILIRUBIN TOTAL (F)                                     | N     | 3       | <23 umol/L         | umol/L |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 2082209832 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2022-May-10 Reviewed: 2022-May-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2022-May-11 4:41 AM Updated On: 2022-May-18 12:01 PM

|                         | Flags | Results | Ref Range | Units  |
|-------------------------|-------|---------|-----------|--------|
| <b>BILIRUBIN DIRECT</b> |       |         |           |        |
| BILIRUBIN DIRECT (F)    | N     | <2.     | <8 umol/L | umol/L |

|                                                                | Flags | Results                                                                  | Ref Range              | Units  |
|----------------------------------------------------------------|-------|--------------------------------------------------------------------------|------------------------|--------|
| <b>HOURS FASTING</b>                                           |       |                                                                          |                        |        |
| HOURS FASTING (F)                                              | N     | 12                                                                       | hours                  | hrs    |
| <b>CHOLESTEROL</b>                                             |       |                                                                          |                        |        |
| CHOLESTEROL (F)                                                | N     | 3.41                                                                     | DESIRED: < 5.20 mmol/L | mmol/L |
| <b>TRIGLYCERIDES</b>                                           |       |                                                                          |                        |        |
| TRIGLYCERIDES (F)                                              | H     | 4.92                                                                     | < 1.70 mmol/L          | mmol/L |
| <b>HDL CHOLESTEROL</b>                                         |       |                                                                          |                        |        |
| HDL CHOLESTEROL (F)                                            | L     | 0.71                                                                     | M: >=1.00 mmol/L       | mmol/L |
| <b>LDL CHOLESTEROL CALC.</b>                                   |       |                                                                          |                        |        |
| LDL CHOLESTEROL CALC. (F)                                      |       | * LDL-cholesterol calculation is invalid at triglycerides >=4.52 mmol/L. |                        |        |
| <b>NON-HDL-CHOLESTEROL(CALC</b>                                |       |                                                                          |                        |        |
| NON-HDL-CHOLESTEROL(CALC (F)                                   | N     | 2.70                                                                     | -4.29                  | mmol/L |
| mmol/L                                                         |       |                                                                          |                        |        |
| Non HDL-cholesterol is calculated from total cholesterol       |       |                                                                          |                        |        |
| and HDL-cholesterol and is not affected by                     |       |                                                                          |                        |        |
| the fasting status of the patient.                             |       |                                                                          |                        |        |
| Treatment thresholds and targets based on 2016 CCS guidelines: |       |                                                                          |                        |        |

| :Category    | :Consider initiating therapy if          | :Treatment target :   |
|--------------|------------------------------------------|-----------------------|
| :Primary     | :High FRS (>=20%); or Intermediate FRS   | :LDL-C <2.00 mmol/L : |
| :prevention: | (10-19%) and: LDL-C >=3.5 mmol/L, or     | :or >50% decrease;:   |
| :            | :non-HDL-C >=4.30 mmol/L, or ApoB        | :or ApoB <0.80 g/L; : |
| :            | :>=1.20 g/L, or men >=50 and women >=60: | :or non-HDL-C <2.60 : |
| :            | :y with >=1 additional CVD risk factor : | :mmol/L :             |
| :Statin      | :Clinical atherosclerosis*;              | :LDL-C <2.00 mmol/L : |
| :indicated   | :abdominal aortic aneurysm; diabetes     | :or >50% decrease; :  |
| :conditions: | mellitus (DM) and age >=40 y or >=30 y:  | :or ApoB <0.80 g/L; : |

| :Category | :Consider initiating therapy if        | :Treatment target :   |
|-----------|----------------------------------------|-----------------------|
| :         | :with 15 years duration (DM1); DM with | :or non-HDL-C <2.60 : |
| :         | :microvascular disease; chronic kidney | :mmol/L :             |
| :         | :disease (age >=50 years) :            | ::                    |
| :Low-risk | :LDL-C >=5.00 mmol/L                   | :LDL-C >50% decrease: |

\*Consider target of LDL-C <1.8 mmol/L for subjects with ACS <=3 months.

|                       | Flags | Results | Ref Range        | Units  |
|-----------------------|-------|---------|------------------|--------|
| <b>TC/HDL-C RATIO</b> |       |         |                  |        |
| TC/HDL-C RATIO (F)    | N     | 4.8     |                  |        |
| <b>SODIUM</b>         |       |         |                  |        |
| SODIUM (F)            | N     | 142     | 136 - 146 mmol/L | mmol/L |
| <b>POTASSIUM</b>      |       |         |                  |        |
| POTASSIUM (F)         | N     | 4.2     | 3.7 - 5.4 mmol/L | mmol/L |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 2082209832 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2022-May-10 Reviewed: 2022-May-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
USERNAME] Reported Date: 2022-May-11 4:41 AM Updated On: 2022-May-18 12:01 PM

|                            | Flags | Results | Ref Range       | Units  |
|----------------------------|-------|---------|-----------------|--------|
| <b>CHLORIDE</b>            |       |         |                 |        |
| CHLORIDE (F)               | N     | 104     | 95 - 108 mmol/L | mmol/L |
| <b>BICARBONATE</b>         |       |         |                 |        |
| BICARBONATE (F)            | N     | 1979    | 20 - 30 mmol/L  | mmol/L |
| <b>ALKALINEPHOSPHATASE</b> |       |         |                 |        |
| ALKALINE PHOSPHATASE (F)   | N     | 74      | 40-129 U/L      | U/L    |
| <b>CK</b>                  |       |         |                 |        |

|                         | Flags | Results | Ref Range           | Units     |
|-------------------------|-------|---------|---------------------|-----------|
| CK (F)                  | N     | 134     | <225 U/L            | U/L       |
| <b>AST</b>              |       |         |                     |           |
| AST (F)                 | N     | 15      | <37 U/L             | U/L       |
| <b>ALT</b>              |       |         |                     |           |
| ALT (F)                 | N     | 21      | <46 U/L             | U/L       |
| <b>HEMOGLOBIN</b>       |       |         |                     |           |
| HEMOGLOBIN (F)          | N     | 133     | 129 - 165 g/L       | g/L       |
| <b>HEMATOCRIT</b>       |       |         |                     |           |
| HEMATOCRIT (F)          | N     | 0.40    | 0.39 - 0.49 l/l     | L/L       |
| <b>RBC</b>              |       |         |                     |           |
| RBC (F)                 | N     | 4.8     | 4.2 - 5.8 x 10E12/L | x 10*12/L |
| <b>RBC INDICES: MCV</b> |       |         |                     |           |
| RBC INDICES: MCV (F)    | N     | 83      | 80 - 98 fl          | fl        |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 2082209832 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2022-May-10 Reviewed: 2022-May-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
USERNAME] Reported Date: 2022-May-11 4:41 AM Updated On: 2022-May-18 12:01 PM

|             | Flags | Results | Ref Range     | Units |
|-------------|-------|---------|---------------|-------|
| <b>MCH</b>  |       |         |               |       |
| MCH (F)     | N     | 28      | 24 - 33 pg    | pg    |
| <b>MCHC</b> |       |         |               |       |
| MCHC (F)    | N     | 335     | 313 - 344 g/L | g/L   |
| <b>RDW</b>  |       |         |               |       |
| RDW (F)     | N     | 16.4    | 12.5 - 17.3   |       |
| <b>WBC</b>  |       |         |               |       |

|                           | Flags | Results | Ref Range          | Units    |
|---------------------------|-------|---------|--------------------|----------|
| WBC (F)                   | N     | 6.0     | 3.2 - 9.4 x 10E9/L | x 10*9/L |
| <b>PLATELETS</b>          |       |         |                    |          |
| PLATELETS (F)             | N     | 240     | 155 - 372 x 10E9/L | x 10*9/L |
| <b>MPV</b>                |       |         |                    |          |
| MPV (F)                   | N     | 9.4     | 4.0 - 14.0 fl      | fL       |
| <b>DIFFERENTIAL WBC'S</b> |       |         |                    |          |
| NEUTROPHILS (F)           | N     | 4.1     | 1.4 -6.3 x10E9/L   | x 10*9/L |
| LYMPHOCYTES (F)           | N     | 1.3     | 1.0 -2.9 x10E9/L   | x 10*9/L |
| MONOCYTES (F)             | N     | 0.5     | 0.2 -0.8 x10E9/L   | x 10*9/L |
| EOSINOPHILS (F)           | N     | 0.1     | 0.0 -0.5 x10E9/L   | x 10*9/L |
| BASOPHILS (F)             | N     | 0.00    | 0.00-0.09x10E9/L   | x 10*9/L |
| <b>INR</b>                |       |         |                    |          |
| INR (F)                   | N     | 0.9     | 0.9 - 1.300        |          |

0.9 - 1.3 GUIDELINES: SUGGESTED INR RANGE:

1. Most clinical conditions indicating 2.0 - 3.0 anticoagulant therapy
2. Patients with mechanical prosthetic 2.5 - 3.5 heart valves

**URINALYSIS CHEMICAL** URINALYSIS CHEMICAL (F) NO SPECIMEN RECEIVED WITH REQUISITION.  
<---

[X] Review

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 04/18/2022                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2022-May-02 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Good to be reviewed                                 |                        |                                                                    |

Patient: Mr. Ethan Kang Appointment Date: 2022-Apr-18 Title: CT Crestwood Medical Group Study Visit Note (Cedar Specialist Group 4) Provider: Taylor, Sinead Referred By: Taylor, Sinead Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Apr-18. He was seen in person at Lakeshore Specialty Clinic.



Problem History: Crohn's disease

Active Medications: None Recorded

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 132 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: COVID-19 infection x2, and kidney stones.

2nd COVID November 2021 (around holidays): lasted less than a week. Kang reported having very mild symptoms (runny nose, sinus congestion). He continued taking the study med. Kang did not take any medication.

3rd COVID January 2022: lasted less than a week, with very mild symptoms (sinus congestion). Kang reported not taking Filgotinib for 5 days. He also did not take any medication.

Kidney stones January 2022: passed on its own. Kang did not take any medication.

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: none

#### INTERIM HISTORY

Ethan has been clinically unchanged since the last study visit.

He has between 4 and 5 bowel movements per day. His stools are always watery. None of his bowel movements are associated with the passage of blood. Kang has very infrequent blood in stool. Last time was a month ago. He has no abdominal pain. .

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

His weight today is 132.3 kg

On physical examination, he looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam was normal

Assessment and Plan In summary, Mr. Ethan Kang is a 42 year-old male with Crohn's disease . The patient is in symptomatic and remission . He will continue on the current medication and FU with us in 3-4m.

The patient will follow-up according to the clinical trial protocol.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2022-May-02

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT WJQ: 158847108 Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Sinead Taylor,

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's Disease on 2022-Apr-18. He was seen in person at Lakeshore Specialty Clinic.

Problem History: Crohn's disease

Active Medications: None Recorded

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 132 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: COVID-19 infection x2, and kidney stones.

2nd COVID November 2021 (around holidays): lasted less than a week. Kang reported having very mild symptoms (runny nose, sinus congestion). He continued taking the study med. Kang did not take any medication.

3rd COVID January 2022: lasted less than a week, with very mild symptoms (sinus congestion). Kang reported not taking Filgotinib for 5 days. He also did not take any medication.

Kidney stones January 2022: passed on its own. Kang did not take any medication.

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: none

#### INTERIM HISTORY

Ethan has been clinically unchanged since the last study visit.

---

He has between 4 and 5 bowel movements per day. His stools are always watery. None of his bowel movements are associated with the passage of blood. Kang has very infrequent blood in stool. Last time was a month ago. He has no abdominal pain. .

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

His weight today is 132.3 kg

**On physical examination**, he looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam was normal

**Assessment and Plan** In summary, Mr. Ethan Kang is a 42 year-old male with Crohn's disease . The patient is in symptomatic and remission . He will continue on the current medication and FU with us in 3-4m.

The patient will follow-up according to the clinical trial protocol.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

[X] \* \_ \_

This task has been completed

|                    |                                                                                                                                                                                       |                        |                                                                    |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                                                                                                                                            | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 04/12/2022                                                                                                                                                                            | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                                                                                                                                   | <b>Completed</b>       | 2022-Apr-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Hi [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME], looks like this patient has a clinical trial visit on April 18th. As such, can cancel the follow-up with me on Apr 27. Thanks |                        |                                                                    |

**Cedar Specialist Group 4**

Cedar Specialist Group 4

**Ridgeway Family Health**

412 Marigold Ave

a nearby city 6, Ontario, Canada 848 Main Blvd

t: 994-882-7246

f: 994-882-7246

|                    |                   |                  |                    |
|--------------------|-------------------|------------------|--------------------|
| Health Card #:     | 1260951398        | Medical Record # | <b>414 235 249</b> |
| Location:          | ENDOSCOPY         | Visit #:         | 2082209832         |
| Room:              |                   |                  |                    |
| Physician:         | Dr. Sinead Taylor | Last Name:       | <b>Ethan Kang</b>  |
| Date of Procedure: | 2022.02.28        | First Name:      | <b>Ethan</b>       |

|                          |                  |                |      |
|--------------------------|------------------|----------------|------|
| Accession Date:          | 2022.02.28       | Date of Birth: | 1979 |
| Date and Time of Report: | 2022.03.03 13:47 | Sex:           | M    |

## FINAL SURGICAL PATHOLOGY REPORT 2082209832

### PATHOLOGY DIAGNOSIS:

1. Neo-terminal ileum, biopsy:

- Chronic inactive ileitis with pyloric metaplasia and including gastric type parietal cells
- Negative for dysplasia

2-5. Colon, right, transverse, left, rectum, biopsies:

- Large bowel mucosa with mild architectural distortion suggestive of prior mucosal injury
- Negative for dysplasia

**Specimen:** (1) TERMINAL ILEUM BIOPSY, NEO (2) COLON BIOPSY RIGHT (3) COLON TRANSVERSE BIOPSY (4) COLON BIOPSY LEFT (5) RECTUM BIOPSY

**Clinical History:** ileal CD

### Gross Description:

1. The specimen container is labelled with the patient's identification only and contains 2 fragments of tan soft tissue measuring 0.3 and 0.2 cm in greatest dimension. - 1 submitted in toto.
2. The specimen container is labelled with the patient's identification only and contains 2 fragments of tan soft tissue measuring 0.3 and 0.2 cm in greatest dimension. - 1 submitted in toto.
3. The specimen container is labelled with the patient's identification only and contains 2 fragments of tan soft tissue measuring 0.3 and 0.2 cm in greatest dimension. - 1 submitted in toto.
4. The specimen container is labelled with the patient's identification only and contains a single fragment of tan soft tissue measuring 0.5 cm in greatest dimension. - 1 submitted in toto.

Printed 2022-03-05 7:81:52 AM

**Cedar Specialist Group 4** Cedar Specialist Group 4

**Ridgeway Family Health**

412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd t: 994-882-7246 f: 994-882-7246

|                |            |                  |                    |
|----------------|------------|------------------|--------------------|
| Health Card #: | 1260951398 | Medical Record # | <b>414 235 249</b> |
| Location:      | ENDOSCOPY  | Visit #:         | 2082209832         |

|                          |                   |                |                   |
|--------------------------|-------------------|----------------|-------------------|
| Room:                    |                   |                |                   |
| Physician:               | Dr. Sinead Taylor | Last Name:     | <b>Ethan Kang</b> |
| Date of Procedure:       | 2022.02.28        | First Name:    | <b>Ethan</b>      |
| Accession Date:          | 2022.02.28        | Date of Birth: | 1979              |
| Date and Time of Report: | 2022.03.03 13:47  | Sex:           | M                 |

## FINAL SURGICAL PATHOLOGY REPORT 2082209832

5. The specimen container is labelled with the patient's identification only and contains a single fragment of tan soft tissue measuring 0.5 cm in greatest dimension. - 1 submitted in toto.

Grossed by: Sinead Taylor, Pathologists' Assistant

**Microscopic Description:** Sinead Taylor PGY-2

Electronically verified by: Sinead Taylor, MD, FRCPath, FRCPC

Printed 2022-03-05 7:81:52 AM

### Hospital Report

|                 |                |                  |   |                   |
|-----------------|----------------|------------------|---|-------------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> |   | <b>WorkPhone</b>  |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M | <b>Patient ID</b> |
| <b>Age</b>      | 46 years       |                  |   |                   |
| <b>DOB</b>      | 1979           |                  |   |                   |

Facility Report #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Sent to: Taylor, Sinead Reported By: Ridgeway Family Health Collection Date: 2022-Feb-27 Reviewed: 2022-Feb-28 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Message Unique ID: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Updated On: 2022-Feb-28 84:71

**Flags Results Ref Range MEDICAL RECORDS (S)** Endoscopy See Below Procedure PowerNote Cedar Specialist Group 4 ; a nearby city, a nearby city 6, ON ; 848 Main Blvd

Patient: Ethan Kang NEP: 566-383-973 FIN: 844 Age: 42 years Sex: Male DOB: 1979 Author: Sinead Taylor

Visit Information PROCEDURE INFORMATION: Procedure : Colonoscopy Date of procedure : 2022-02-28 84:71 Location : Endoscopy Surgeon/Procedure Physician : Sinead Taylor . PROCEDURE INFORMATION: Procedure Provider: Assisted by Sinead Taylor.

Primary Care Provider: Sinead Taylor

INDICATION

COLONOSCOPY CN - Surveillance for colorectal neoplasm (or long term IBD): dysplasia surveillance, inflammatory bowel disease. PRE PROCEDURE DIAGNOSIS: Crohn's disease.

Consultation Information HISTORY and PHYSICAL: 42M on open label Filgotinib 200mg PO daily. He remains clinically well with 4-5 BMs per day that are always watery. He presents for restaging of his disease, particularly his significant ileal inflammatory disease. He has had a prior ICR.. MEDICATIONS: Medication reviewed.

Physical Examination GASTROINTESTINAL: Soft, Non-tender. HEAD AND NECK: No scleral icterus, No conjunctival pallor. RESPIRATORY: Non-labored respirations. CARDIOVASCULAR: Normal rate.

Pre-Procedure INFORMED CONSENT: After discussing the rationale, risks and benefits, and alternatives to this procedure, the patient provided verbal consent for the procedure. ASA GRADE: Mild Systemic Disease (ASA-2). CONFIRMED: Patient, Procedure, With safety procedures followed.

Procedure The patient was positioned starting in the left lateral decubitus position. MEDICATIONS Sedation: Midazolam 4 mg, Fentanyl 50 mcg. See MAR. MONITORING See nursing documentation. COLONOSCOPY

---

ENDOSCOPE Type pediatric colonoscope. DIGITAL RECTAL EXAM Within normal limits. Cecal Intubation No Not applicable: No cecum/Ileocolonic anastomosis.

EXTENT OF EXAMINATION Scope past anastomosis to neoterminal ileum: Photographic documentation obtained.

DIFFICULTY / LIMITATION None. BOWEL PREP QUALITY Qualitative: Very good.

WITHDRAWAL Time exceeded 7 minutes. Rectal retroflexion was performed. FINDINGS - Rectum Normal rectum

FINDINGS - Perianal Normal

FINDINGS Notes: 1. Anastomosis widely patent, ulceration at anastomosis 2. Ongoing inflammation in neoTI with moderately significant inflammatory process - small and medium ulcers, however surrounding mucosa normal, minimal erythema. > 5 ulcers, some larger than 1cm. 3. Normal colon.

BIOPSIES Neo-terminal ileum: Non-polypoid tissue. Ascending colon: Non-polypoid tissue. Transverse colon: Non-polypoid tissue. Descending colon: Non-polypoid tissue. Rectum: Non-polypoid tissue.

SIMPLIFIED ENDOSCOPIC activity SCORE for Crohn's Ileum: presence and size of ulcers: 2, extent of ulcerated surface: 3, extent of affected surface: 2, presence and type of narrowings: 0. Right colon: presence and size of ulcers: 0, extent of ulcerated surface: 0, extent of affected surface: 0, presence and type of narrowings: 0. Transverse colon: presence and size of ulcers: 0, extent of ulcerated surface: 0, extent of affected surface: 0, presence and type of narrowings: 0. Left colon: presence and size of ulcers: 0, extent of ulcerated surface: 0, extent of affected surface: 0, presence and type of narrowings: 0. Rectum: presence and size of ulcers: 0, extent of ulcerated surface: 0, extent of affected surface: 0, presence and type of narrowings: 0. Sum of all variables: ileum score: 7, right colon score: 0, transverse colon score: 0, left colon score: 0, rectum score: 0. Total SES score: 7 .

RUTGEERT`S SCORE (CD Post-operative) Grade: 4 (diffuse inflammation with large ulcer nodules and or narrowing).

Post-Procedure COMPLICATIONS: none.

Impression and Plan IMPRESSION: Abnormal, Stable ileal CD on Filgotinib. PLAN: 1. Follow up biopsies 2. Continue trial medication 3. Clinic follow-up 2- 3months.

Images PROCEDURE IMAGES:

(Images available in source system) Colonoscopy\_0001.jpg (Images available in source system) Colonoscopy\_0002.jpg (Images available in source system)

Colonoscopy\_0003.jpg (Images available in source system) Colonoscopy\_0004.jpg (Images available in source system) Colonoscopy\_0005.jpg (Images available in source system) Colonoscopy\_0006.jpg (Images available in source system) Colonoscopy\_0007.jpg (Images available in source system) Colonoscopy\_0008.jpg (Images available in source system) Colonoscopy\_0009.jpg (Images available in source system) Colonoscopy\_0010.jpg (Images available in source system) Colonoscopy\_0011.jpg (Images available in source system) Colonoscopy\_0012.jpg (Images available in source system) Colonoscopy\_0013.jpg (Images available in source system) Colonoscopy\_0014.jpg (Images available in source system) Colonoscopy\_0015.jpg .

Ordered By: Taylor, Sinead Collection Date: 2022-Feb-28 Reviewed: 2022-Mar-08 by pvarghaei Updated On: 2022-Feb-28 84:71

|                  | Flags | Results | Ref Range |
|------------------|-------|---------|-----------|
| OBRI-IBD: SES-CD |       |         |           |
| Terminal Ileum   |       | 7       |           |
| Right Colon      |       | 0       |           |
| Transverse Colon |       | 0       |           |
| Left Colon       |       | 0       |           |
| Rectum           |       | 0       |           |
| SES-CD Total     |       | 7       |           |
| Rutgeert's Score |       | 4       |           |

[X] \* \_ \_

This task has been completed

|         |            |                 |                                                     |
|---------|------------|-----------------|-----------------------------------------------------|
| Patient | Ethan Kang | Task Created By | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
|---------|------------|-----------------|-----------------------------------------------------|

|                    |                                                                                           |                  |                                                                    |
|--------------------|-------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------|
| <b>Date Due</b>    | 02/28/2022                                                                                | <b>Priority</b>  | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                                       | <b>Completed</b> | 2022-Mar-03 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Ridgeway Family Health f/u with me (Parul) in [REDACTED-DATE], can be in-person that day. |                  |                                                                    |

[X] \* \_ \_

This task has been completed

|                    |                                                       |                        |                                                                    |
|--------------------|-------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                            | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 01/20/2022                                            | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]   | <b>Completed</b>       | 2022-Jan-26 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | book colonoscopy at Lakeshore Specialty Clinic please |                        |                                                                    |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2022-Jan-20 Reviewed: 2022-Jan-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2022-Jan-21 84:71 Updated On: 2022-Jan-23 84:71

|                              | Flags | Results | Ref Range  | Units |
|------------------------------|-------|---------|------------|-------|
| <b>CRP</b>                   |       |         |            |       |
| CRP (F)                      | H     | 8.8     | < 8.0 mg/L | mg/L  |
| <b>GLUCOSE SERUM FASTING</b> |       |         |            |       |



|                                                         | Flags | Results | Ref Range             | Units           |
|---------------------------------------------------------|-------|---------|-----------------------|-----------------|
| GLUCOSE SERUM FASTING (F)                               | N     | 4.5     | 3.6 - 6.00            | mmol/L          |
| mmol/L                                                  |       |         |                       |                 |
| 3.6 - 6.0 NORMAL FASTING GLUCOSE                        |       |         |                       |                 |
| 6.1 - 6.9 IMPAIRED FASTING GLUCOSE                      |       |         |                       |                 |
| >6.9 PROVISIONAL DIAGNOSIS OF DIABETES MELLITUS         |       |         |                       |                 |
| <b>UREA</b>                                             |       |         |                       |                 |
| UREA (F)                                                | N     | 4.4     | 2.5 - 8.1<br>mmol/L   | mmol/L          |
| <b>CREATININE</b>                                       |       |         |                       |                 |
| CREATININE (F)                                          | N     | 79      | 60 - 110 umol/L       | umol/L          |
| eGFR (F)                                                | N     | 105     | 60. - 99999.99        | mL/min/1.73m**2 |
| >=60. mL/min/1.73m**2                                   |       |         |                       |                 |
| eGFR is calculated using the CKD-EPI 2009 equation.     |       |         |                       |                 |
|                                                         |       |         |                       |                 |
| Normal eGFR.                                            |       |         |                       |                 |
| For patients of African descent, the reported eGFR must |       |         |                       |                 |
| be multiplied by 1.15.                                  |       |         |                       |                 |
| <b>CALCIUM</b>                                          |       |         |                       |                 |
| CALCIUM (F)                                             | N     | 2.28    | 2.15 - 2.60<br>mmol/L | mmol/L          |
| <b>PHOSPHORUS</b>                                       |       |         |                       |                 |
| PHOSPHORUS (F)                                          | N     | 1.04    | 0.80 - 1.45<br>mmol/L | mmol/L          |
| <b>MAGNESIUM</b>                                        |       |         |                       |                 |
| MAGNESIUM (F)                                           | N     | 0.83    | 0.65 - 1.05<br>mmol/L | mmol/L          |
| <b>PROTEIN</b>                                          |       |         |                       |                 |
| PROTEIN (F)                                             | N     | 66      | 60 - 80 g/L           | g/L             |
| <b>ALBUMIN</b>                                          |       |         |                       |                 |
| ALBUMIN (F)                                             | N     | 42      | 35 - 52 g/L           | g/L             |
| <b>BILIRUBINTOTAL</b>                                   |       |         |                       |                 |

|                     | Flags | Results | Ref Range  | Units  |
|---------------------|-------|---------|------------|--------|
| BILIRUBIN TOTAL (F) | N     | 4       | <23 umol/L | umol/L |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2022-Jan-20 Reviewed: 2022-Jan-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2022-Jan-21 84:71 Updated On: 2022-Jan-23 84:71

|                                                                                                    | Flags | Results | Ref Range              | Units  |
|----------------------------------------------------------------------------------------------------|-------|---------|------------------------|--------|
| <b>BILIRUBIN DIRECT</b>                                                                            |       |         |                        |        |
| BILIRUBIN DIRECT (F)                                                                               | N     | <2.     | <8 umol/L              | umol/L |
| <b>BILIRUBIN INDIRECT</b>                                                                          |       |         |                        |        |
| BILIRUBIN INDIRECT (F)                                                                             |       |         | <18 umol/L             | umol/L |
| Unable to perform calculation as one or more of the components is outside the limits of detection. |       |         |                        |        |
| <b>HOURSFASTING</b>                                                                                |       |         |                        |        |
| HOURS FASTING (F)                                                                                  | N     | 12      | hours                  | hrs    |
| <b>CHOLESTEROL</b>                                                                                 |       |         |                        |        |
| CHOLESTEROL (F)                                                                                    | N     | 3.18    | DESIRED: < 5.20 mmol/L | mmol/L |
| <b>TRIGLYCERIDES</b>                                                                               |       |         |                        |        |
| TRIGLYCERIDES (F)                                                                                  | H     | 3.78    | < 1.70 mmol/L          | mmol/L |
| <b>HDL CHOLESTEROL</b>                                                                             |       |         |                        |        |
| HDL CHOLESTEROL (F)                                                                                | L     | 0.79    | M: >=1.00 mmol/L       | mmol/L |
| <b>LDL CHOLESTEROL CALC.</b>                                                                       |       |         |                        |        |
| LDL CHOLESTEROL CALC. (F)                                                                          | N     | 0.66    | mmol/L                 | mmol/L |

|                                                                | Flags | Results | Ref Range | Units  |
|----------------------------------------------------------------|-------|---------|-----------|--------|
| <b>NON-HDL-CHOLESTEROL(CALC</b>                                |       |         |           |        |
| NON-HDL-CHOLESTEROL(CALC (F)                                   | N     | 2.39    | -4.29     | mmol/L |
| mmol/L                                                         |       |         |           |        |
| Non HDL-cholesterol is calculated from total cholesterol       |       |         |           |        |
| and HDL-cholesterol and is not affected by                     |       |         |           |        |
| the fasting status of the patient.                             |       |         |           |        |
| Treatment thresholds and targets based on 2016 CCS guidelines: |       |         |           |        |

| :Category    | :Consider initiating therapy if                   | :Treatment target :                |
|--------------|---------------------------------------------------|------------------------------------|
| :Primary     | :High FRS ( $\geq 20\%$ ); or Intermediate FRS    | :LDL-C $< 2.00$ mmol/L :           |
| :prevention: | (10-19%) and: LDL-C $\geq 3.5$ mmol/L, or         | : or $> 50\%$ decrease; :          |
| :            | :non-HDL-C $\geq 4.30$ mmol/L, or ApoB            | :or ApoB $< 0.80$ g/L; :           |
| :            | : $\geq 1.20$ g/L, or men $\geq 50$ and women     | $\geq 60$ :or non-HDL-C $< 2.60$ : |
| :            | :y with $\geq 1$ additional CVD risk factor       | :mmol/L :                          |
|              |                                                   |                                    |
| :Statin      | :Clinical atherosclerosis*;                       | :LDL-C $< 2.00$ mmol/L :           |
| :indicated   | :abdominal aortic aneurysm; diabetes              | :or $> 50\%$ decrease; :           |
| :conditions: | mellitus (DM) and age $\geq 40$ y or $\geq 30$ y: | or ApoB $< 0.80$ g/L; :            |
| :            | :with 15 years duration (DM1); DM with            | :or non-HDL-C $< 2.60$ :           |
| :            | :microvascular disease; chronic kidney            | :mmol/L :                          |
| :            | :disease (age $\geq 50$ years)                    | : :                                |
|              |                                                   |                                    |
| :Low-risk    | :LDL-C $\geq 5.00$ mmol/L                         | :LDL-C $> 50\%$ decrease:          |

\*Consider target of LDL-C  $< 1.8$  mmol/L for subjects with ACS  $\leq 3$  months.

|                       |   |     |                  |        |
|-----------------------|---|-----|------------------|--------|
| <b>TC/HDL-C RATIO</b> |   |     |                  |        |
| TC/HDL-C RATIO (F)    | N | 4.0 |                  |        |
| <b>SODIUM</b>         |   |     |                  |        |
| SODIUM (F)            | N | 139 | 136 - 146 mmol/L | mmol/L |

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2022-Jan-20 Reviewed: 2022-Jan-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2022-Jan-21 84:71 Updated On: 2022-Jan-23 84:71

|                            | Flags | Results | Ref Range           | Units     |
|----------------------------|-------|---------|---------------------|-----------|
| <b>POTASSIUM</b>           |       |         |                     |           |
| POTASSIUM (F)              | N     | 4.6     | 3.7 - 5.4 mmol/L    | mmol/L    |
| <b>CHLORIDE</b>            |       |         |                     |           |
| CHLORIDE (F)               | N     | 103     | 95 - 108 mmol/L     | mmol/L    |
| <b>BICARBONATE</b>         |       |         |                     |           |
| BICARBONATE (F)            | N     | 25      | 20 - 30 mmol/L      | mmol/L    |
| <b>ALKALINEPHOSPHATASE</b> |       |         |                     |           |
| ALKALINE PHOSPHATASE (F)   | N     | 75      | 40-129 U/L          | U/L       |
| <b>CK</b>                  |       |         |                     |           |
| CK (F)                     | H     | 251     | <225 U/L            | U/L       |
| <b>AST</b>                 |       |         |                     |           |
| AST (F)                    | N     | 14      | <37 U/L             | U/L       |
| <b>ALT</b>                 |       |         |                     |           |
| ALT (F)                    | N     | 20      | <46 U/L             | U/L       |
| <b>HEMOGLOBIN</b>          |       |         |                     |           |
| HEMOGLOBIN (F)             | N     | 130     | 129 - 165 g/L       | g/L       |
| <b>HEMATOCRIT</b>          |       |         |                     |           |
| HEMATOCRIT (F)             | N     | 0.40    | 0.39 - 0.49 I/I     | L/L       |
| <b>RBC</b>                 |       |         |                     |           |
| RBC (F)                    | N     | 4.8     | 4.2 - 5.8 x 10E12/L | x 10*12/L |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2022-Jan-20 Reviewed: 2022-Jan-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2022-Jan-21 84:71 Updated On: 2022-Jan-23 84:71

|                           | Flags | Results | Ref Range          | Units    |
|---------------------------|-------|---------|--------------------|----------|
| <b>RBC INDICES: MCV</b>   |       |         |                    |          |
| RBC INDICES: MCV (F)      | N     | 84      | 80 - 98 fL         | fL       |
| <b>MCH</b>                |       |         |                    |          |
| MCH (F)                   | N     | 27      | 24 - 33 pg         | pg       |
| <b>MCHC</b>               |       |         |                    |          |
| MCHC (F)                  | N     | 326     | 313 - 344 g/L      | g/L      |
| <b>RDW</b>                |       |         |                    |          |
| RDW (F)                   | N     | 14.7    | 12.5 - 17.3        |          |
| <b>WBC</b>                |       |         |                    |          |
| WBC (F)                   | N     | 5.4     | 3.2 - 9.4 x 10E9/L | x 10*9/L |
| <b>PLATELETS</b>          |       |         |                    |          |
| PLATELETS (F)             | N     | 245     | 155 - 372 x 10E9/L | x 10*9/L |
| <b>MPV</b>                |       |         |                    |          |
| MPV (F)                   | N     | 9.3     | 4.0 - 14.0 fL      | fL       |
| <b>DIFFERENTIAL WBC'S</b> |       |         |                    |          |
| NEUTROPHILS (F)           | N     | 3.5     | 1.4 -6.3 ×10E9/L   | x 10*9/L |
| LYMPHOCYTES (F)           | N     | 1.2     | 1.0 -2.9 ×10E9/L   | x 10*9/L |
| MONOCYTES (F)             | N     | 0.5     | 0.2 -0.8 ×10E9/L   | x 10*9/L |
| EOSINOPHILS (F)           | N     | 0.1     | 0.0 -0.5 ×10E9/L   | x 10*9/L |
| BASOPHILS (F)             | N     | 0.00    | 0.00-0.09×10E9/L   | x 10*9/L |
| <b>INR</b>                |       |         |                    |          |
| INR (F)                   | N     | 0.9     | 0.9 - 1.300        |          |

0.9 - 1.3 GUIDELINES:

- 1. Most clinical conditions indicating anticoagulant therapy
- 2. Patients with mechanical prosthetic heart valves SUGGESTED INR RANGE: 2.0 - 3.0 2.5 - 3.5

URINALYSIS CHEMICAL URINALYSIS CHEMICAL (F) NO SPECIMEN RECEIVED WITH REQUISITION.  
<---

# Review

This task has been completed

|             |                                                     |                 |                                                                    |
|-------------|-----------------------------------------------------|-----------------|--------------------------------------------------------------------|
| Patient     | Ethan Kang                                          | Task Created By | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| Date Due    | 01/18/2022                                          | Priority        | Normal                                                             |
| Assigned To | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | Completed       | 2022-Jan-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| Notes       | review and generate letter                          |                 |                                                                    |

Patient: Mr. Ethan Kang Appointment Date: 2022-Jan-17 Title: CT Crestwood Medical Group Study Visit Note (Cedar Specialist Group 4) Provider: Taylor, Sinead Referred By: None Ethan Kang was assessed by telephone for his Crohn's Disease on 2022-Jan-17.

Problem History: Crohn's disease

Active Medications: None Recorded

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 120 He is currently on open label filgotibnib 200mg.

The following adverse events have occurred since the last study visit: none

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: none

## INTERIM HISTORY

Ethan has been feeling well since the last study visit.

He has between 4 and 5 bowel movements per day. His stools are always watery. None of his bowel movements are associated with the passage of blood. He did have blood in his stool once last week, which resolved on its own. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

His weight today is 283 lbs

Physical examination was not done as patient was assessed remotely.

Assessment and Plan In summary, Mr. Ethan Kang is a 42 year-old male with Crohn's disease. He remains clinically unchanged. We will continue for now on his current therapy.

No changes in the patient's management will be made at this time.

The following study procedures were modified or not done due to the current COVID-19 pandemic: Vital signs were not done Weight was measured by the patient Physical examination was not done Patient was instructed to head to a local laboratory to complete safety assessments (hematology, chemistry, lipid profile and urinalysis) Urine pregnancy test was not done as subject is male IP was sent to subject using YourWay (courier) The subject was instructed to keep all bottles of IP to return to the site at the next in-person study visit.

The patient will follow-up according to the clinical trial protocol.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2022-Jan-18

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT WJQ: 158847108 Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Sinead Taylor,

Ethan Kang was assessed by telephone for his Crohn's Disease on 2022-Jan-17.

Problem History: Crohn's disease

Active Medications: None Recorded

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 120 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: none

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: none

INTERIM HISTORY

Ethan has been feeling well since the last study visit.

He has between 4 and 5 bowel movements per day. His stools are always watery. None of his bowel movements are associated with the passage of blood. He did have blood in his stool once last week, which resolved on its own. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

His weight today is 283 lbs

Physical examination was not done as patient was assessed remotely.

---

**Assessment and Plan** In summary, Mr. Ethan Kang is a 42 year-old male with Crohn's disease. He remains clinically unchanged. We will continue for now on his current therapy.

No changes in the patient's management will be made at this time.

The following study procedures were modified or not done due to the current COVID-19 pandemic: Vital signs were not done Weight was measured by the patient Physical examination was not done Patient was instructed to head to a local laboratory to complete safety assessments (hematology, chemistry, lipid profile and urinalysis) Urine pregnancy test was not done as subject is male IP was sent to subject using YourWay (courier) The subject was instructed to keep all bottles of IP to return to the site at the next in-person study visit.

The patient will follow-up according to the clinical trial protocol.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

---

! [Ontario logo] Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 412 Marigold Ave a nearby city 6 ON T: 993-089-6973 qaa 0534 F: (442) 733-2165

Clinician/Vivienne Vasquez CPSO / Sofia Bianchi

Check (☐) one: ☒ OHIP/Insured ☐ Third Party / Uninsured ☐ WSIB

Additional Clinical Information (e.g. diagnosis): patient with inflammatory bowel disease. These tests are being ordered by a gastroenterologist

☒ Copy to: Clinician/Practitioner Last Name: Taylor First Name: Sinead Address: 412 Marigold Ave a nearby city 6 848 Main Blvd Fax (442) 733-2165

Laboratory Use Only



Clinician/Practitioner's Contact Number for Urgent Results: (442) 733-2165 Service Date: 1979 / mm / 1979  
 Health Number: 0748 361 588KT Version: (blank) Sex: M Date of Birth: 1979 Province: (blank) Other  
 Provincial Registration Number: (blank) Patient's Telephone Contact Number: (442) 733-2165

Patient's Last Name (as per OHIP Card) Ethan Kang Patient's First & Middle Names (as per OHIP Card)  
 Ethan Kang Patient's Address (including Postal Code) a nearby city 8

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by  
 Crestwood Medical Group

| x   | Biochemistry                                                                                                                                                                        | x   | Hematology                                                         | x   | Viral Hepatitis (check one only)                                       |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|--------------------------------------------------------------------|-----|------------------------------------------------------------------------|
| [X] | Glucose [ ] Random [X] Fasting                                                                                                                                                      | [X] | CBC                                                                | [ ] | Acute Hepatitis                                                        |
| [ ] | HbA1C                                                                                                                                                                               | [X] | Prothrombin Time (INR)                                             | [ ] | Chronic Hepatitis                                                      |
| [X] | Creatinine (eGFR)                                                                                                                                                                   |     | <b>Immunology</b>                                                  | [ ] | Immune Status / Previous Exposure                                      |
| [ ] | Uric Acid                                                                                                                                                                           | [ ] | Pregnancy Test (Urine)                                             |     | Specify: [ ] Hepatitis A [ ] Hepatitis B [ ] Hepatitis C               |
| [X] | Sodium                                                                                                                                                                              | [ ] | Mononucleosis Screen                                               |     | or order individual hepatitis tests in the "Other Tests" section below |
| [X] | Potassium                                                                                                                                                                           | [ ] | Rubella                                                            |     | <b>Prostate Specific Antigen (PSA)</b>                                 |
| [X] | ALT                                                                                                                                                                                 | [ ] | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) | [ ] | Total PSA [ ] Free PSA                                                 |
| [X] | Alk. Phosphatase                                                                                                                                                                    | [ ] | Repeat Prenatal Antibodies                                         |     | Specify one below:                                                     |
| [X] | Bilirubin                                                                                                                                                                           |     | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          | [ ] | Insured – Meets OHIP eligibility criteria                              |
| [X] | Albumin                                                                                                                                                                             | [ ] | Cervical                                                           | [ ] | Uninsured – Screening: Patient responsible for payment                 |
| [X] | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [ ] | Vaginal                                                            |     | <b>Vitamin D (25-Hydroxy)</b>                                          |

| <b>x</b> | <b>Biochemistry</b>                   | <b>x</b> | <b>Hematology</b>                   | <b>x</b> | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
|----------|---------------------------------------|----------|-------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [ ]      | Albumin / Creatinine Ratio, Urine     | [ ]      | Vaginal / Rectal – Group B Strep    | [ ]      | Insured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
| [X]      | Urinalysis (Chemical)                 | [ ]      | Chlamydia (specify source):         | [ ]      | Uninsured – Patient responsible for payment                                                                                                                      |
|          | Neonatal Bilirubin:                   | [ ]      | GC (specify source):                |          | <b>Other Tests - one test per line</b>                                                                                                                           |
|          | Child's Age: days hours               | [ ]      | Sputum                              |          | Direct and indirect bilirubin                                                                                                                                    |
|          | Clinician/Practitioner's tel. no. ( ) | [ ]      | Throat                              |          | total protein                                                                                                                                                    |
|          | Patient's 24 hr telephone no. ( )     | [ ]      | Wound (specify source):             |          | Bicarbonate, BUN and CPK                                                                                                                                         |
|          | Therapeutic Drug Monitoring:          | [ ]      | Urine                               |          | AST                                                                                                                                                              |
|          | Name of Drug #1                       | [ ]      | Stool Culture                       |          | Phosphorus, Mg, Chloride, calcium                                                                                                                                |
|          | Name of Drug #2                       | [ ]      | Stool Ova & Parasites               |          | C-reactive protein                                                                                                                                               |
|          | Time Collected #1 hr. #2 hr.          | [ ]      | Other Swabs / Pus (specify source): |          |                                                                                                                                                                  |
|          | Time of Last Dose #1 hr. #2 hr.       |          |                                     |          |                                                                                                                                                                  |
|          | Time of Next Dose #1 hr. #2 hr.       |          |                                     |          |                                                                                                                                                                  |

Specimen Collection Time: (blank) Date: MM/1979/1979

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

Fecal Occult Blood Test (FOBT) (check one) [ ] FOBT (non CCC) [ ] ColonCancerCheck FOBT (CCC) no other test can be ordered on this form

Laboratory Use Only

[signature] X Clinician/Practitioner Signature

Date: 2022-Jan-05

**Patient: Mr. Ethan Kang Appointment Date: 2022-Jan-04 Title: Ocean: Multiple Notes Provider: None Referred By: None**

*Ocean online questionnaire completed on Jan 3, 2022 8:15 am.* Consent: **Email Consent Given**  
@OBRIEmailConsent: Yes @OptOut :

*Ocean online questionnaire completed on Jan 3, 2022 8:15 am.* Consent: **Communication Consent Given** @permission: "Granted" I, Ethan Kang, confirm that this clinic can communicate with me about research opportunities via EMAIL Yes @email: Yes Is this your preferred email address: sinead.taylor50@brookfieldmedicalcentre.ca Yes I, Ethan Kang, confirm that this clinic can communicate with me about research opportunities via PHONE Yes @phone: "Yes" Can we leave you a message about research opportunities at this phone number? We will not leave any personal health information on a voicemail, or unless we are talking with you directly or someone you have authorized Yes @PhoneMessage: Yes Would you like us to notify you about research opportunities by REGULAR MAIL Yes @OBRIPermToContact: "Granted" @OBRIPermToContactEmail: "Yes" @OBRIPermToContactPhone: "Yes" @OBRIPermToContactMessages: "Yes" @OBRIPermToContactMail: "Yes"

*Ocean online questionnaire completed on Jan 3, 2022 8:15 am.* YES. I want to receive health questionnaires from the Ridgeway Family Health 5 (OPT IN) @OptOut: No

---

Ridgeway Family Health

a nearby city a nearby city ON, Canada a nearby city

## Fax Cover Sheet

To: Dr. Sinead Taylor Phone: 277-586-4140 Fax: 277-586-4140

Date: 2023-Oct-04

From: Dr. Sinead Taylor Phone: 277-586-4140 Fax: 290 827 5744 ext. 6902

Number of pages including cover: 2

**Confidential: This communication is intended only for the individual or institution to which it is addressed and should not be distributed, copied or disclosed to anyone else. The documents in this communication may contain personal, confidential or privileged information, which may be subject to the Freedom of information and Protection of Privacy Act, the Health Information Act and other legislation. If you have received this communication in error, please notify us immediately and return original transmission to us. Thank you for your co-operation and assistance.**

Re: Ethan Kang

[image]

[REDACTED-DATE]

Dr. Taylor;

Our office contacted your patient this afternoon and he is requesting to be seen closer to his home in a nearby city. Pt declined an appt.

Kindly redirect his referral.

No appointment in our office at this time.

Regards,

Dr. Taylor's office

---

[image]

## Ridgeway Family Health

2023-Oct-04

Dr. Sinead Taylor a nearby city 2 a nearby city 2, ON a nearby city 2

**Patient:** Mr. Ethan Kang **PHN:** 1892131832 **Birthdate:** 1979 **Phone:** H: (442) 733-2165 C: (442) 733-2165

**Address:** a nearby city a nearby city, ON a nearby city

Dear Dr. Sinead Taylor,

Please see this 44yo male with low testosterone and adrenal adenoma, many thanks

Sincerely,

Sinead Taylor **Electronically Reviewed to Expedite Delivery**

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 338 Marigold St. 338 Marigold St, a nearby city 6,  
ONTARIO a nearby city CANADA

Patient: Mr. Ethan Kang Appointment Date: 2021-Oct-26 Title: CT Crestwood Medical Group Study Visit Note (Cedar Specialist Group 4) Provider: Taylor, Sinead Referred By: Taylor, Sinead Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's disease on 2021-Oct-26.

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 108 They are currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: Kidney stones

Ongoing Adverse Events: Kidney stones

The following changes in medications have occurred since the last study visit: none

#### INTERIM HISTORY

Ethan has been clinically unchanged since the last study visit.

He has between 3 and 4 bowel movements per day. His stools are always watery. Few of his bowel movements are associated with the passage of blood. He has no significant abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

On physical examination, his weight was 131kg. He looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam was normal.

Assessment and Plan In summary, Mr. Ethan Kang is a 42 year-old male with Crohn's disease . The patient is in symptomatic and remission.

No changes in the patient's management will be made at this time.

The patient will follow-up according to the clinical trial protocol.

---

! [Northview Clinic Logo]

#### AUTHORIZING ORGANIZATION/ PHYSICIAN CONTACT INFO

#### COVID-19 VACCINE 3RD DOSE PHYSICIAN OR HOSPITAL SPECIALTY PROGRAM PATIENT REFERRAL FORM:

##### Important to Note:

- Referral form to be completed ONLY when vaccination administration is unable to be completed intra-organizationally by Physician or Specialty Program responsible for eligible patient care.
- To refer an eligible candidate for a 3rd dose of the COVID-19 vaccine, this form must be COMPLETED IN FULL, signed, and shared with the patient.
- Upon completion, this form may be provided digitally in pdf format to eligible patients.
- Patient MUST present the completed form when attending their vaccination appointment (See page 2 for details).

- This form should NOT be sent to Northview Clinic.

Patient Name: Ethan Kang Date: 2021-Oct-26 Patient Health Card Number: 0748 361 588KT

Based on the recommendation of the Chief Medical Officer of Health and health experts, Ontario is offering third doses of the COVID-19 vaccine to select vulnerable populations which may be required to provide sufficient protection based on a suboptimal or waning immune response to vaccines and increased risk of COVID-19 infection.

**PATIENT ELIGIBILITY:** Please identify the relevant sub-category below of patient eligibility for a 3rd dose of the COVID-19 vaccine: (Note: The Patient must meet one or more of the criteria listed below. Patients with other health conditions/criteria will not be accepted for 3rd doses at this time.) (See page 2 for consensus definitions)

☐ Receiving active treatment for solid tumor and hematologic malignancies ☐ Recipient of a solid-organ transplant and taking immunosuppressive therapy ☐ Recipient of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within two years of transplantation or taking immunosuppression therapy) ☐ Moderate or severe primary immunodeficiency (e.g. DiGeorge syndrome, Wiskott-Aldrich syndrome) ☐ Stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome ☒ Undergoing active treatment with the following categories of immunosuppressive therapies: high-dose systemic corticosteroids, alkylating agents, antimetabolites, tumor-necrosis (TNF) blockers, and anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22)

**PATIENT-SPECIFIC TREATMENT CONSIDERATIONS AND SCHEDULING:** Please Note: 3rd dose vaccinations can be administered no earlier than 8 weeks (or 56 days) after second dose.

**CONDITION-SPECIFIC TREATMENT NEEDS:** ☒ No Treatment Considerations ([REDACTED-DATE] book as appropriate after second dose) ☐ Yes, Treatment must be Considered ☐ Specific Scheduling Requirements: (blank)

**1ST/2ND DOSE VACCINATION SCHEDULE & TYPE(S):** First Dose: Vaccine Type: (blank) Date: (blank)  
Second Dose: Vaccine Type: (blank) Date: (blank)

Physician Name: Sinead Taylor CSPO#: 414 235 249 Signature: [signature image]

I have provided counselling regarding the risks, benefits, and timing of a 3rd dose of COVID-19 vaccine in accordance with provincial guidance. By signing, I confirm the information above to be true and accurate to the best of my knowledge.

---

! [Northview Clinic Logo]

## Consensus Definitions for Currently Eligible Patients

### Active Treatment for Malignant Hematological Conditions includes:

Recipients of stable, active treatment (chemotherapy, targeted therapies, immunotherapy) including:

- All malignant hematology patients who are on treatment or are within 6 months post-treatment (including all CML patients)

- All patients who received an allogenic transplant within the last 3 years or who are on chronic post-transplant immune-suppressive therapy
- All patients who received an autologous transplant within the last two years
- All patients who have received CART-cell therapy

**Also Eligible:**

- Patients who were initially vaccinated during or within 12 months after treatment with anti-CD20 agents (e.g., rituximab, ocrelizumab, ofatumumab)

**Patients must bring this completed form, along with their Ontario Health Card, or appropriate piece of identification, to their appointment.**

- We have made the following arrangement for your vaccine and it is scheduled for:
  - Date (MMM/1979/YY): \_\_\_\_ / \_\_\_\_ / \_\_\_\_
  - Location: \_\_\_\_\_
- For questions/concerns/missed appointments please contact: \_\_\_\_\_

**OR**

- You can access the vaccine through pharmacies participating in the Ontario COVID-19 vaccination program. <https://www.glenmorespecialistcentre.ca>

**OR**

- Vaccinations are available every Tuesday to Saturday from 1 p.m. to 7 p.m. at the following a nearby city 6 City-run vaccine clinics:
  - Northview Clinic, Northview Clinic, Northview Clinic, Northview Clinic and Northview Clinic.
  - For more information about vaccination clinics run by the **City of a nearby city 6** please visit: <https://www.glenmorespecialistcentre.ca> or call **Northview Clinic Hotline** 8:30 a.m. – 8 p.m., 7 days a week **Telephone:** 277-586-4140 **TTY:** 277-586-4140 **Email:** sofia.bianchi24@crestwoodmedicalgroup.ca

PH VERSION 1.3 09/13/2021

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2021-Oct-28

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT WJQ: 158847108 Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Sinead Taylor,

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's disease on 2021-Oct-26.

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 108 They are currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: Kidney stones

Ongoing Adverse Events: Kidney stones

The following changes in medications have occurred since the last study visit: none

#### INTERIM HISTORY

Ethan has been clinically unchanged since the last study visit.

He has between 3 and 4 bowel movements per day. His stools are always watery. Few of his bowel movements are associated with the passage of blood. He has no significant abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

On physical examination, his weight was 131kg. He looks well and nutritionally fit. His abdomen is soft and non-tender with no organomegaly or masses. Remainder of symptom directed exam was normal.

Assessment and Plan In summary, Mr. Ethan Kang is a 42 year-old male with Crohn's disease. The patient is in symptomatic and remission.

No changes in the patient's management will be made at this time.

The patient will follow-up according to the clinical trial protocol.

---

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

---

☐ \* --

**This task has been completed**

|                 |            |                        |                                                     |
|-----------------|------------|------------------------|-----------------------------------------------------|
| <b>Patient</b>  | Ethan Kang | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Date Due</b> | 10/24/2021 | <b>Priority</b>        | Normal                                              |



|                    |                                                     |                  |                                                                    |
|--------------------|-----------------------------------------------------|------------------|--------------------------------------------------------------------|
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b> | 2021-Oct-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
|--------------------|-----------------------------------------------------|------------------|--------------------------------------------------------------------|

**Notes** Please cancel 3:15pm appointment with Dr. Taylor. Pt is booked for a study visit with Mark on the same day morning.

Administration Cedar Specialist Group 4 Ridgeway Family Health a nearby city 8 t: (089) 697-3500 a5345 f: 994-882-7246

## LABORATORY REPORT

### Permanent Chart Copy

Medical Record#: 414 235 249 Case Number: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Last Name: Ethan Kang First Name: Ethan N Date of Birth: 1979 Sex: M Health Card#: 0748 361 588KT Facility: Cedar Specialist Group 4 Location: PRIVATE OUT PATIENT Room: Physician: Taylor, Sinead Copy to: Taylor, Sinead Order#: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 D&T Ordered: 2021. 08. 02 84:71

| Test Name                                               | Results | Flag | Reference | Units |
|---------------------------------------------------------|---------|------|-----------|-------|
| <b>BLOOD CHEMISTRY</b>                                  |         |      |           |       |
| <b>COLLECTED 2021. 08. 02 09: 27</b>                    |         |      |           |       |
| <b>Immunology</b>                                       |         |      |           |       |
| Deamid Gliadin Ab IgA                                   | *<5     |      |           | CU    |
| Deamidated Gliadin Antibody IgA Reference Range:        |         |      |           |       |
| <20 Negative                                            |         |      |           |       |
| 20 - 30 Weakly Positive                                 |         |      |           |       |
| >30 Positive                                            |         |      |           |       |
| False negative results may occur in individuals who are |         |      |           |       |
| IgA deficient.                                          |         |      |           |       |
| Deamid Gliadin Ab IgG                                   | *<3     |      |           | CU    |
| Deamidated Gliadin Antibody IgG Reference Range:        |         |      |           |       |
| <20 Negative                                            |         |      |           |       |
| 20 - 30 Weakly Positive                                 |         |      |           |       |
| >30 Positive                                            |         |      |           |       |
| Tiss Transglut Ab IgA                                   | *<2     |      |           | CU    |
| Tissue Transglutaminase Antibody IgA Reference Range:   |         |      |           |       |
| <20 Negative                                            |         |      |           |       |

| Test Name                                               | Results | Flag | Reference | Units |
|---------------------------------------------------------|---------|------|-----------|-------|
| 20 - 30 Weakly Positive                                 |         |      |           |       |
| >30 Positive                                            |         |      |           |       |
| False negative results may occur in individuals who are |         |      |           |       |
| IgA deficient.                                          |         |      |           |       |
| Tiss Transglut Ab IgG                                   | *<4     |      |           | CU    |
| Tissue Transglutaminase Antibody IgG Reference Range:   |         |      |           |       |
| <20 Negative                                            |         |      |           |       |
| 20 - 30 Weakly Positive                                 |         |      |           |       |
| >30 Positive                                            |         |      |           |       |

- FIRST PRINTING OF THIS RESULT Result Flags: L-LOW, H-HIGH, CL-CRITICAL LOW, CH-CRITICAL HIGH, AB-ABNORMAL, X-ABSURD PRINTED: 2021.08.09 84:71 by SCC to Sav,273381R6-T5V2-324J-H47Q-5P15H6Z30HT6.xOrder#: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Aux#: D&T Ordered: 2021. 08. 02 84:71 h

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

NEP: 566-383-973 Visit #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Patient Name: Ethan Kang  
Address: 412 Marigold Ave a nearby city 6, Ontario 848 Main Blvd Encounter: Ambulatory OP Fin #: 844

412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd t: (492) 417-7743

Date of Birth: 1979 Sex: Male Health Card: 6609604884PP V: 5753727875QP Admit Date: 2021-08-02  
Discharge Date: 2021-08-02

RAD - Cardiology Investigations

Document Type: Electrocardiogram 12 Lead Result Status: Final Performed Information: Signed  
Information:

Electrocardiogram 12 Lead HEART RATE: 65 bpm P-R Interval: 173 ms P Horizontal Axis: 14 deg QRSD  
Interval: 124 ms QT Interval: 393 ms QTcB: 407 ms QRS Axis: 20 deg T Wave Axis: 20 deg ECG Severity: -  
ABNORMAL ECG - ECG Impression: Sinus rhythm ECG Impression: Nonspecific intraventricular  
conduction delay ECG Impression: ST elev, probable normal early repol pattern ECG Impression: No  
change Ordered By: 414 235 249 Taylor, Sinead Electronically Signed By: Taylor, Sinead 273381R6-T5V2-  
324J-H47Q-5P15H6Z30HT6 Electronically Signed On: 2021-08-02 33:43:70

Page 1 of 1 Request ID: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Print Date: 2021-08-03 84:71  
Printed By: System Generated

This information is privileged and contains confidential information intended for specified person(s) for  
limited purposed. Accordingly, this information should be treated as strictly confidential. Any unauthorized  
access, disclosure, copying, other distribution of this information or taking any action on its contents is

strictly prohibited by law. If you have received this information in error, please notify Cedar Specialist Group 4 immediately by contacting Outpatient Services at 277-586-4140.

Administration Cedar Specialist Group 4 Ridgeway Family Health a nearby city 8 t: (089) 697-3500 a5345 f: 994-882-7246

## LABORATORY REPORT

### Permanent Chart Copy

Medical Record#: 414 235 249 Case Number: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Last Name: Ethan Kang First Name: Ethan N Date of Birth: 1979 Sex: M Health Card#: 0748 361 588KT Facility: Cedar Specialist Group 4 Location: PRIVATE OUT PATIENT Room: Physician: Taylor, Sinead Copy to: Taylor, Sinead Order#: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 D&T Ordered: 2021. 08. 02 84:71

| Test Name                                                        | Results | Flag | Reference   | Units |
|------------------------------------------------------------------|---------|------|-------------|-------|
| <b>BLOOD CHEMISTRY</b>                                           |         |      |             |       |
| <b>COLLECTED 2021. 08. 02 09: 27</b>                             |         |      |             |       |
| <b>Proteins</b>                                                  |         |      |             |       |
| C-Reactive Prot Ser                                              | *7. 8   |      |             | mg/L  |
| Unequivocal inflammatory response >10 mg/L.                      |         |      |             |       |
| Cardiovascular Risk Assessment (Circulation 2003; 107: 499-511): |         |      |             |       |
| Average 2 measurements at least 2 weeks apart (omit CRP >10)     |         |      |             |       |
| Risk: Low <1 mg/L, Average 1-2. 9 mg/L, Higher 3-10 mg/L.        |         |      |             |       |
| IgG Immunoglobulin                                               | *10. 4  |      | 6. 0-16. 0  | g/L   |
| IgA Immunoglobulin                                               | *0. 72  |      | 0. 70-4. 00 | g/L   |
| IgM Immunoglobulin                                               | *0. 54  |      | 0. 45-3. 00 | g/L   |

- FIRST PRINTING OF THIS RESULT Result Flags: L-LOW, H-HIGH, CL-CRITICAL LOW, CH-CRITICAL HIGH, AB-ABNORMAL, X-ABSURD PRINTED: 2021.08.03 84:71 by SCC to Sav,273381R6-T5V2-324J-H47Q-5P15H6Z30HT6.xOrder#: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Aux#: Page: 1 of 1 D&T Ordered: 2021. 08. 02 84:71 h

Patient: Mr. Ethan Kang Appointment Date: 2021-Aug-02 Title: CT Crestwood Medical Group Study Visit Note Provider: Taylor, Sinead Referred By: Taylor, Sinead Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's disease on 2021-Aug-02.

Problem History: Crohn's disease

Past Medical History: Hyperlipidemia Nephrolithiasis Past Surgical History: Appendectomy Active Medications: None Recorded Known Allergies: None Recorded

## INFLAMMATORY BOWEL DISEASE PROFILE

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

IBD Extraintestinal Manifestations: Arthritis Nephrolithiasis IBD Diagnostics: 2019-Jun-28 Lab tests - Hb 133, WBC 6.75, plt 274, Alb 45, ALT 15, Alk ph 67, AST 10(L) 2018-Aug-15 Lab tests - vit B12 119 pmol/L (L) 2018-Jun-13 Lab tests - Hb 126 g/L, HS-CRP 40.84 mg/L 2018-Apr-04 Fecal calprotectin - 604 ug/g 2018-Mar-07 Drug level - Vedolizumab: 3.0 ug/ml, ATV 2.4 U/ml (+) Endoscopy Results: 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4, SES 8, colon SES 0 [REDACTED-DATE] Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal. Medical Imaging: 2021-Mar-07 CT Enterography - long segment (30-40 cm ) active inflammation in the distal ileum involve neo TI , more prominent mucosal enhancement with small outpouching likely ulceration in the distal ileum 2019-Jul-11 MRE - recurrent disease involving the neoTI(20 cm) mod degree of mural thickening. There is associated luminal narrowing in conjunction with stricturing. There is angulation of the segment of the diseased ileum with an impression of a fistula between 2 seg of SB 2016-May-17 CT abdomen/pelvis - 10-15 cm dist ileum including neoTI mod activity on background of mild chr granulomatous ileitis

Mr. Ethan Kang is participating in the following clinical trial:Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 96 They are currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: none

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: none

Ethan has been feeling well since the last study visit.

He has between 4 and 5 bowel movements per day. His stools are often soft. None of his bowel movements are associated with the passage of blood.

---

He has no abdominal pain.

IP compliance was 79%. Kang attributes this to COVID-19 he had back in [REDACTED-DATE].

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports arthralgias.

His weight today is 130.1kg

**On physical examination**, he looks [well|unwell] and [nutritionally fit|underweight|malnourished]. His abdomen is soft and [non-tender|tender throughout|tender in the RLQ|tender in both lower quadrants] with no organomegaly or masses. [Remainder of symptom directed exam was normal|Symptom directed physical exam was significant for:]

**Assessment and Plan** In summary, Mr. Ethan Kang is a 42 year-old male with Crohn's disease . The patient [is in symptomatic|remission|null] [has mild clinical disease activity|has moderate clinical disease activity|has severe clinical disease activity|null].

[We will arrange the following clinical investigations:] {Bloodwork| Ultrasound| X-Ray| Pelvic MRI| MR Enterography | Low-dose CT enterography| Fecal calprotectin| Colonoscopy| Upper GI endoscopy| Referral}

[There are no contraindications to the endoscopic procedures. The risks and benefits of the procedure were discussed, including but not limited to the risk of a cardiopulmonary event, bleeding, perforation, or missed lesion. Ample time was available for questions and informed consent was obtained.]null]

[No changes|The following changes] in the patient's management will be made at this time.

The patient will follow-up according to the clinical trial protocol.

---

Cedar Specialist Group 4 Cedar Specialist Group 4

[ ] STAT

Gastroenterology Requisition (GI-IBD) Administration a nearby city 8 (089) 697-3500 a5345

Attending Physician: Dr. Sinead Taylor Cedar Specialist Group 4

CPSO#

FAX: (442) 733-2165

Clinical Comments: r/o celiac

Date Ordered (1979-MM-1979): 2021-08-02

Please imprint clearly, or affix label

Order Number

Ethan Kang DOB: 1979 HC: 0748 361 588KT WJQ: 158847108 SEX: M a nearby city 8 H: (442) 733-2165

## Haematology

[ ] CBC (Complete Blood Count) [ ] Reticulocyte Count Indicated if anaemia is expected or suspected. [ ] PT (Prothrombin Time / INR) [ ] ESR (Erythrocyte Sedimentation Rate) [ ] aPTT (Partial Thromboplastin Time)

## General Chemistry

Glucose: [ ] Fasting [ ] Post-Prandial [ ] Random [ ] Electrolytes (Na<sup>+</sup>, K<sup>+</sup>, Cl<sup>-</sup>) [ ] TCO<sub>2</sub> (Carbon Dioxide, Total) Indicated only if suspecting an acid/base disorder. [ ] Creatinine Bilirubin: Total [ ] Direct [ ] [ ] Ca (Calcium, Total) [ ] PO<sub>4</sub> (Phosphate, Inorganic) [ ] Mg (Magnesium, Total) [ ] Urate (Uric Acid) [ ] NH<sub>3</sub> (Ammonia) Lavender-top tube (EDTA anticoagulant only) — send on ice.

## Enzymes

[ ] Amylase [ ] ALP (Alkaline Phosphatase) [ ] GGT (Gamma-Glutamyl Transferase) [ ] ALT (Alanine Transaminase) [ ] AST (Aspartate Transaminase)

## Proteins

☐ Protein, Total ☐ Albumin ☒ CRP (C-Reactive Protein) ☐ C4 Complement ☐ C3 Complement  
Immunoglobulins: ☐ IgA ☐ IgG ☐ IgM ☐ CEA (Carcinoembryonic Antigen)

## Lipids

☐ Cholesterol, Total ☐ HDLC (High Density Lipoprotein Cholesterol) ☐ Triglycerides, Total Low Density Lipoprotein Cholesterol (LDLC) will be calculated if all of the above lipid tests are ordered.

## Micronutrients

☐ Iron, Transferrin, Iron Saturation ☐ Ferritin ☐ Vitamin B12 (Cobalamin) ☐ 25-Hydroxy-Vitamin D (Calcidiol) ☐ Folate, Erythrocyte As per the [REDACTED-DATE] 2013 OHIP addendum, Folate testing is restricted to patients having anaemia and increased MCV, or a suspected malabsorption disorder, or suspected malnutrition.

## Endocrinology

☐ CG (Choriogonadotropin) ☐ HbA1c (Glycohemoglobin) Lavender-top tube ☐ TSH (Thyrotropin) ☐ FT4 (Thyroxine, Free) ☐ PTH (Parathyrin) ☐ Cortisol ☐ 1,25-Dihydroxy-Cholecalciferol (Calcitriol)

## Gastrointestine-Related Antibodies

☐ Tissue Transglutaminase IgA ☐ Deamidated Gliadin IgG Coeliac auto-antibodies above may be falsely negative if the patient is already eating a gluten-free diet. ☐ Intrinsic Factor Antibodies ☐ Parietal Cell Antibodies ☐ ASCA (Anti-Saccharomyces Cerevisiae Antibodies — IgG and IgA) ☐ Mitochondrial Antibodies ☐ Smooth Muscle Antibodies

## Arthritis Auto-Antibodies

☐ Anti-CCP (Cyclic Citrullinated Peptide) ☐ RF (Rheumatoid Factor) To diagnose or monitor rheumatoid arthritis, anti-CCP is more sensitive and specific than RF.

## Other Auto-Antibodies

☐ ANA (Nuclear Antibodies) ☐ Double-Stranded DNA Antibodies ☐ ANCA (Neutrophil Cytoplasmic Antibodies)

## Thiopurine Immunosuppressants

(Azathioprine, 6-Mercaptopurine, 6-Thioguanine) ☐ TPMT Phenotype (Thiopurine Methyl-Transferase enzyme activity) Indicated only once, before starting a patient on a thiopurine immunosuppressant for the first time. ☐ Thiopurine Metabolites: 6-TG, 6-MMP (6-Thioguanine, 6-Methylmercaptopurine) Indicated only for monitoring patients who are taking a thiopurine immunosuppressant.

Hydrogen Breath Testing

[ ] LTT (Lactose Tolerance Test 25g 3h)

Faecal Testing

[ ] FOB (Faecal Occult Blood)

**Additional Haematology or Biochemistry tests:** (not Microbiology or Serology tests, because they go to a different department)

**IgA, IgG, IgM anti TTG, deamidated gliadin**

**Don't photocopy this form — Laser print clean copies.** Form GI-IBD version 1.28(34), revised 2013-04-09 ILB

Cedar Specialist Group 2 Northview Clinic

Lab Results: Generated On 2026-Apr-09

|                                  |            |                              |                            |
|----------------------------------|------------|------------------------------|----------------------------|
| <b>Patient</b>                   | Ethan Kang | <b>ONTARIO Health Number</b> | <b>Telephone</b>           |
| <b>Date of Birth</b>             | 1979       | 6609604884PP                 | (442) 733-2165             |
| <b>Age (Time of Observation)</b> | 42 years   |                              | (Primary Residence Number) |
| <b>Sex</b>                       | M          |                              |                            |
| <b>Address</b>                   |            |                              |                            |
| 847 Fennimore St                 |            |                              |                            |
| a nearby city 6 ON 848 Main Blvd |            |                              |                            |
| (Home)                           |            |                              |                            |

|                                                         |                                    |                                |
|---------------------------------------------------------|------------------------------------|--------------------------------|
| <b>Lab Order #</b>                                      | <b>Ordering Practitioner</b>       | <b>Primary Performing Lab</b>  |
| 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 (Northview Clinic) | Taylor, Sinead                     | Northview Clinic               |
|                                                         | (Tariq Zimmerman)                  | (Lab 26095)                    |
| <b>Last Updated in OLIS</b>                             |                                    |                                |
| 2021-Jul-14 84:71                                       | <b>Address</b>                     | <b>Address</b>                 |
| <b>Specimen Received Date/Time</b>                      | a nearby city 2                    | 848 Main Blvd                  |
| 2021-07-13 84:71                                        | a nearby city 6 ON a nearby city 2 | 848 Main Blvd 848 Main Blvd ON |

|  |                  |                                |
|--|------------------|--------------------------------|
|  | Northview Clinic | (Firm/Business)                |
|  | (Firm/Business)  |                                |
|  |                  | <b>Primary Reporting Lab</b>   |
|  |                  | Northview Clinic               |
|  |                  | (Lab 26095)                    |
|  |                  |                                |
|  |                  | <b>Address</b>                 |
|  |                  | 848 Main Blvd                  |
|  |                  | 848 Main Blvd 848 Main Blvd ON |
|  |                  | (Firm/Business)                |

## Chemistry

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Serum         | 2021-Jul-13 84:71 | Northview Clinic      |
|               |                   | (Lab 26095)           |

|                                                        | Flags | Results | Reference Range | Units |
|--------------------------------------------------------|-------|---------|-----------------|-------|
| <b>Alkaline Phosphatase</b>                            |       |         |                 |       |
| Alkaline Phosphatase (Reference Range Specific to Sex) | N     | 66.     | 40 - 129        | U/L   |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Serum         | 2021-Jul-13 84:71 | Northview Clinic      |
|               |                   | (Lab 26095)           |

|                                                                  | Flags | Results | Reference Range | Units |
|------------------------------------------------------------------|-------|---------|-----------------|-------|
| <b>Alanine Aminotransaminase</b>                                 |       |         |                 |       |
| Alanine Aminotransferase [ALT] (Reference Range Specific to Sex) | N     | 35.     | < 46            | U/L   |

## Hematology

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |



| Specimen Type | Collection Date | Specimen Collected By |
|---------------|-----------------|-----------------------|
|               |                 | (Lab 26095)           |

|                                                       | Flags | Results | Reference Range | Units                 |
|-------------------------------------------------------|-------|---------|-----------------|-----------------------|
| <b>Erythrocyte Count</b>                              |       |         |                 |                       |
| Erythrocytes; Blood (Reference Range Specific to Sex) | N     | 4.7     | 4.2 - 5.8       | x 10 <sup>12</sup> /L |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |
|               |                   | (Lab 26095)           |

|                                                                | Flags | Results | Reference Range | Units |
|----------------------------------------------------------------|-------|---------|-----------------|-------|
| <b>MCV</b>                                                     |       |         |                 |       |
| Mean Corpuscular Volume; RBC (Reference Range Specific to Sex) | N     | 85.     | 80 - 98         | fL    |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |
|               |                   | (Lab 26095)           |

(Lab 26095)

## MCH

|                                                                    | Flags | Results | Reference Range | Units |
|--------------------------------------------------------------------|-------|---------|-----------------|-------|
| Mean Corpuscular Hemoglobin; RBC (Reference Range Specific to Age) | N     | 28.     | 24 - 33         | pg    |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

# Complete Blood Count

|                                                                       | Flags | Results | Reference Range | Units |
|-----------------------------------------------------------------------|-------|---------|-----------------|-------|
| Erythrocyte Distribution Width; RBC (Reference Range Specific to Age) | N     | 15.8    | 12.5 - 17.3     | %     |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

# Leukocyte Count

|                                                     | Flags | Results | Reference Range | Units                |
|-----------------------------------------------------|-------|---------|-----------------|----------------------|
| Leukocytes; Blood (Reference Range Specific to Age) | N     | 4.8     | 3.2 - 9.4       | x 10 <sup>9</sup> /L |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

# Platelet Count

|                                                    | Flags | Results | Reference Range | Units                |
|----------------------------------------------------|-------|---------|-----------------|----------------------|
| Platelets; Blood (Reference Range Specific to Age) | N     | 186.    | 155 - 372       | x 10 <sup>9</sup> /L |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

# Mean Platelet Volume

|                                                               | Flags | Results | Reference Range | Units |
|---------------------------------------------------------------|-------|---------|-----------------|-------|
| Mean Platelet Volume; Blood (Reference Range Specific to Age) | N     | 9.5     | 4.0 - 14.0      | fL    |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

# WBC Differential

|                                                      | Flags | Results | Reference Range | Units                |
|------------------------------------------------------|-------|---------|-----------------|----------------------|
| Neutrophils; Blood (Reference Range Specific to Age) | N     | 2.7     | 1.4 - 6.3       | x 10 <sup>9</sup> /L |
| Lymphocytes; Blood (Reference Range Specific to Age) | N     | 1.1     | 1.0 - 2.9       | x 10 <sup>9</sup> /L |
| Monocytes; Blood (Reference Range Specific to Age)   | N     | 0.8     | 0.2 - 0.8       | x 10 <sup>9</sup> /L |
| Eosinophils; Blood (Reference Range Specific to Age) | N     | 0.0     | 0.0 - 0.5       | x 10 <sup>9</sup> /L |
| Basophils; Blood (Reference Range Specific to Age)   | N     | 0.00    | 0.00 - 0.09     | x 10 <sup>9</sup> /L |

Cedar Specialist Group 2 Northview Clinic

Lab Results: Generated On 2026-Apr-09

|                           |                                                                |                       |                            |
|---------------------------|----------------------------------------------------------------|-----------------------|----------------------------|
| Patient                   | Ethan Kang                                                     | ONTARIO Health Number | Telephone                  |
| Date of Birth             | 1979                                                           | 6609604884PP          | (442) 733-2165             |
| Age (Time of Observation) | 42 years                                                       |                       | (Primary Residence Number) |
| Sex                       | M                                                              |                       |                            |
| Address                   | 847 Fennimore St<br>a nearby city 6 ON 848 Main Blvd<br>(Home) |                       |                            |

|                                                         |                                    |                                |
|---------------------------------------------------------|------------------------------------|--------------------------------|
| Lab Order #                                             | Ordering Practitioner              | Primary Performing Lab         |
| 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 (Northview Clinic) | Taylor, Sinead                     | Northview Clinic               |
| Last Updated in OLIS                                    | (Tariq Zimmerman)                  | (Lab 26095)                    |
| 2021-Jul-14 84:71                                       | Address                            | Address                        |
| Specimen Received Date/Time                             | a nearby city 2                    | 848 Main Blvd                  |
| 2021-07-13 84:71                                        | a nearby city 6 ON a nearby city 2 | 848 Main Blvd 848 Main Blvd ON |
|                                                         | Northview Clinic                   | (Firm/Business)                |
|                                                         | (Firm/Business)                    | Primary Reporting Lab          |
|                                                         |                                    | Northview Clinic               |
|                                                         |                                    | (Lab 26095)                    |

|  |  |                                |
|--|--|--------------------------------|
|  |  | <b>Address</b>                 |
|  |  | 848 Main Blvd                  |
|  |  | 848 Main Blvd 848 Main Blvd ON |
|  |  | (Firm/Business)                |

## Hematology

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

|                                                     | Flags | Results | Reference Range | Units |
|-----------------------------------------------------|-------|---------|-----------------|-------|
| <b>Hemoglobin</b>                                   |       |         |                 |       |
| Hemoglobin; Blood (Reference Range Specific to Sex) | N     | 132.    | 129 - 165       | g/L   |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

|                                                     | Flags | Results | Reference Range | Units |
|-----------------------------------------------------|-------|---------|-----------------|-------|
| <b>Hematocrit</b>                                   |       |         |                 |       |
| Hematocrit; Blood (Reference Range Specific to Sex) | N     | 0.40    | 0.39 - 0.49     | L/L   |

| Specimen Type | Collection Date   | Specimen Collected By |
|---------------|-------------------|-----------------------|
| Whole blood   | 2021-Jul-13 84:71 | Northview Clinic      |

|                                                                                  | Flags | Results | Reference Range | Units |
|----------------------------------------------------------------------------------|-------|---------|-----------------|-------|
| <b>MCHC</b>                                                                      |       |         |                 |       |
| Mean Corpuscular Hemoglobin Concentration; RBC (Reference Range Specific to Age) | N     | 330.    | 313 - 344       | g/L   |

Patient: Mr. Ethan Kang Appointment Date: 2021-Jun-13 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: Taylor, Sinead I saw Ethan Kang today for follow up of his Crohn's disease.

Problem History: Crohn's disease 2008 , underwent ICR 2014

IBD Phenotype: Montreal: CD Location - L1 - Ileal , Behaviour - B2 - Stricturing Endoscopy Results: 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5

(SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal. Medical Imaging: 2021-Mar-07 CT Enterography - long segment (30-40 cm ) active inflammation in the distal ileum involve neo TI , more prominent mucosal enhancement with small outpouching likely ulceration in the distal ileum 2019-Jul-11 MRE - recurrent disease involving the neoTI(20 cm) mod degree of mural thickening. There is associated luminal narrowing in conjunction with stricturing. There is angulation of the segment of the diseased ileum with an impression of a fistula between 2 seg of SB Active Medications: Filgotinib - open label clinical trial [REDACTED-DATE] Current Status Ethan is feeling relatively well . He has 3-5 soft non bloody BM per day . He denies abdominal pain , N/V or bloating . His weight is table . He has no perianal symptoms . On physical examination, Recent Labs: 2021-May-31 Hgb 137 , WBC 6.1 , Plts 220 , CRP 6.2 ,Ferritin 104

Assessment and Plan Ethan Kang is currently in symptomatic remission but has persistence long segment active inflammation in the distal small bowel . He is on Filgotinib since 2019 after failed with Remicade ,humira and Entyvio . Giving his symptoms improved after he started on Filgotinib trial ,we believe he should continue in the trial and we don't think switching him to Stelara would help especially he failed with multiple biologics . I will see him again in follow up in 4 month in the office.

Report prepared by Dr. Sinead Taylor , advanced IBD Fellow for Dr. Sinead Taylor

---

[X] \* \_\_

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 06/13/2021                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2021-Jun-22 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | office FU 4m                                        |                        |                                                                    |

---

**Dr. Sinead Taylor**

415 Juniper Rd a nearby city 6 ON, Canada 848 Main Blvd

## Fax Cover Sheet

To: Dr. Sinead Taylor Phone: 994-882-7246 Fax: (442) 733-2165

Date: 2021-Jul-01

From: Dr. Sinead Taylor Phone: 993-089-6973 qaa 0534 Fax: (442) 733-2165

Number of pages including cover: 3

**Confidential: This communication is intended only for the individual or institution to which it is addressed and should not be distributed, copied or disclosed to anyone else. The documents in this communication may contain personal, confidential or privileged information, which may be subject to the Freedom of Information and Protection of Privacy Act, the Health Information Act and other legislation. If you have received this communication in error, please notify us immediately and return original transmission to us. Thank you for your co-operation and assistance.**

Re: Ethan Kang

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2021-Jul-01

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT WJQ: 158847108 Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Sinead Taylor,

I saw Ethan Kang today for follow up of his Crohn's disease.

Problem History: Crohn's disease 2008 , underwent ICR 2014

IBD Phenotype: Montreal: CD Location - L1 - Ileal , Behaviour - B2 - Stricturing Endoscopy Results: 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal. Medical Imaging: 2021-Mar-07 CT Enterography - long segment (30-40 cm ) active inflammation in the distal ileum involve neo TI , more prominent mucosal enhancement with small outpouching likely ulceration in the distal ileum 2019-Jul-11 MRE - recurrent disease involving the neoTI(20 cm) mod degree of mural thickening. There is associated luminal narrowing in conjunction with stricturing. There is angulation of the segment of the diseased ileum with an impression of a fistula between 2 seg of SB Active Medications: Filgotinib - open label clinical trial [REDACTED-DATE]

Current Status Ethan is feeling relatively well . He has 3-5 soft non bloody BM per day . He denies abdominal pain , N/V or bloating . His weight is stable . He has no perianal symptoms .

Recent Labs: 2021-May-31 Hgb 137 , WBC 6.1 , Plts 220 , CRP 6.2 , Ferritin 104

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

---

**Assessment and Plan** Ethan Kang is currently in symptomatic remission but has persistence long segment active inflammation in the distal small bowel . He is on Filgotinib since 2019 after failed with Remicade , humira and Entyvio . Giving his symptoms improved after he started on Filgotinib trial , we believe he should continue in the trial and we don't think switching him to Stelara would help especially he failed with multiple biologics . I will see him again in follow up in 4 month in the office.

Report prepared by Dr. Sinead Taylor , advanced IBD Fellow for Dr. Sinead Taylor

Sincerely,

[image]

Riverside Medical Centre Isolda Xiong **Electronically Reviewed to Expedite Delivery**

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

Ontario **Cedar Specialist Group 2** Laboratory Requisition

**Requisitioning Clinician / Practitioner** Name: Dr. Sinead Taylor Address: 412 Marigold Ave a nearby city 6 ON, Canada a nearby city 2 (442) 733-2165 ( ) -

Clinician/Vivienne Vasquez CPSO / Bodhi Sorensen

Check ( ) one: [X] OHIP/Insured [ ] Third Party / Uninsured [ ] WSIB

Additional Clinical Information (e.g. diagnosis) r/o celiac

[X] Copy to: Clinician/Practitioner Last Name: Taylor First Name: Sinead Address: 412 Marigold Ave a nearby city 6 ON, Canada 848 Main Blvd F: (442) 733-2165

**Laboratory Use Only**

Clinician/Practitioner's Contact Number for Urgent Results: 993-089-6973 qaa 0534 Service Date: 2021-Aug-02 Health Number: 0748 361 588KT Version: Sex: M Date of Birth: 1979 Province: ON Other Provincial Registration Number: Patient's Telephone Contact Number: (442) 733-2165 (442) 733-2165 Patient's Last Name (as per OHIP Card): Ethan Kang Patient's First & Middle Names (as per OHIP Card): Ethan Kang Patient's Address (including Postal Code): 412 Marigold Ave a nearby city 6 ON, Canada 848 Main Blvd

**Note: Separate requisitions are required for cytology, histology / pathology, ColonCancerCheck FIT test, and tests performed by Crestwood Medical Group**

| x   | Biochemistry                   | x   | Hematology             | x   | Viral Hepatitis (check one only)                                                           |
|-----|--------------------------------|-----|------------------------|-----|--------------------------------------------------------------------------------------------|
| [ ] | Glucose [ ] Random [ ] Fasting | [X] | CBC                    | [ ] | Acute Hepatitis                                                                            |
| [ ] | HbA1C                          | [ ] | Prothrombin Time (INR) | [ ] | Chronic Hepatitis                                                                          |
| [ ] | Creatinine (eGFR)              |     | <b>Immunology</b>      | [ ] | Immune Status / Previous Exposure Specify: [ ] Hepatitis A [ ] Hepatitis B [ ] Hepatitis C |
| [ ] | Uric Acid                      | [ ] | Pregnancy Test (Urine) |     |                                                                                            |

| x      | Biochemistry                                                                                                                                                                        | x      | Hematology                                                         | x      | Viral Hepatitis (check one only)                                                                                                                                 |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [<br>] | Sodium                                                                                                                                                                              | [<br>] | Mononucleosis Screen                                               |        | or order individual hepatitis tests in the "Other Tests" section below                                                                                           |
| [<br>] | Potassium                                                                                                                                                                           | [<br>] | Rubella                                                            |        | <b>Prostate Specific Antigen (PSA)</b>                                                                                                                           |
| [<br>] | ALT                                                                                                                                                                                 | [<br>] | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) | [<br>] | Total PSA [<br>] Free PSA                                                                                                                                        |
| [<br>] | Alk. Phosphatase                                                                                                                                                                    |        |                                                                    |        | Specify one below:                                                                                                                                               |
| [<br>] | Bilirubin                                                                                                                                                                           | [<br>] | Repeat Prenatal Antibodies                                         | [<br>] | Insured – Meets OHIP eligibility criteria                                                                                                                        |
| [<br>] | Albumin                                                                                                                                                                             |        | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          | [<br>] | Uninsured – Screening: Patient responsible for payment                                                                                                           |
| [<br>] | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [<br>] | Cervical                                                           |        | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                    |
| [<br>] | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | [<br>] | Vaginal                                                            | [<br>] | Insured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
| [<br>] | Urinalysis (Chemical)                                                                                                                                                               | [<br>] | Vaginal / Rectal – Group B Strep                                   | [<br>] | Uninsured - Patient responsible for payment                                                                                                                      |
| [<br>] | Neonatal Bilirubin:                                                                                                                                                                 | [<br>] | Chlamydia (specify source):                                        |        | <b>Other Tests</b> - one test per line                                                                                                                           |
|        | Child's Age: days hours                                                                                                                                                             | [<br>] | GC (specify source):                                               |        | IgA, IgG, IgM                                                                                                                                                    |
|        | Clinician/Practitioner's tel. no.                                                                                                                                                   | [<br>] | Sputum                                                             |        | anti TTG, deamidated gliadin                                                                                                                                     |
|        | Patient's 24 hr telephone no.                                                                                                                                                       | [<br>] | Throat                                                             |        |                                                                                                                                                                  |
|        | Therapeutic Drug Monitoring:                                                                                                                                                        | [<br>] | Wound (specify source):                                            |        |                                                                                                                                                                  |



| <input checked="" type="checkbox"/> | Biochemistry                    | <input checked="" type="checkbox"/> | Hematology                          | <input checked="" type="checkbox"/> | Viral Hepatitis (check one only) |
|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------------------|
| [<br>]                              | Name of Drug #1                 | [ ]                                 | Urine                               |                                     |                                  |
| [<br>]                              | Name of Drug #2                 | [ ]                                 | Stool Culture                       |                                     |                                  |
|                                     | Time Collected #1 hr. #2 hr.    | [ ]                                 | Stool Ova & Parasites               |                                     |                                  |
|                                     | Time of Last Dose #1 hr. #2 hr. | [ ]                                 | Other Swabs / Pus (specify source): |                                     |                                  |
|                                     | Time of Next Dose #1 hr. #2 hr. |                                     |                                     |                                     |                                  |

**I hereby certify the tests ordered are not for registered in or out patients of a hospital.**

**Specimen Collection** Time: Date: MM/1979/1979

**Laboratory Use Only**

[image] Clinician/Practitioner Signature

Date 2021-Aug-02

Ridgeway Family Health

COVID-19 Screening Tool

Patient Name: Ethan Kang

Date of Screening: 2021-May-31

Date of Appointment: 2021-May-31

Instructions: Ask patient the COVID-19 screening questions outlined below.

1. "Do you require an essential visitor to accompany you to your appointment?" [ ] YES [X] NO If yes, complete Pre-Screening form for both patient and essential visitor.

|    |                                                                                                                          |                   |
|----|--------------------------------------------------------------------------------------------------------------------------|-------------------|
| 2. | Do you have currently have a confirmed diagnosis of COVID-19 OR had a confirmed diagnosis of COVID-19 in the past month? | [ ] YES<br>[X] NO |
| 3. | Are you currently self-isolating because you had close contact with a confirmed case of COVID-19?                        | [ ] YES<br>[X] NO |
| 4. | Have you had close contact with a confirmed case of COVID-19 in the past 2 months?                                       | [ ] YES<br>[X] NO |
| 5. | Have you had close contact with anyone with acute respiratory illness?                                                   | [ ] YES<br>[X] NO |

|    |                                                                                                                                                                                                  |                                                                        |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| 6. | Have you travelled outside of Canada in the past 14 days?                                                                                                                                        | <input type="checkbox"/> YES<br><input checked="" type="checkbox"/> NO |
| 7. | Are you experiencing any of the following symptoms?                                                                                                                                              | <input type="checkbox"/> YES<br><input checked="" type="checkbox"/> NO |
|    | <input type="checkbox"/> Fever ( $\geq 37.8$ C) <input type="checkbox"/> Decrease or loss of sense of taste or smell                                                                             |                                                                        |
|    | <input type="checkbox"/> New onset cough <input type="checkbox"/> Headaches                                                                                                                      |                                                                        |
|    | <input type="checkbox"/> Worsening chronic cough <input type="checkbox"/> Unexplained fatigue/malaise/muscle aches                                                                               |                                                                        |
|    | <input type="checkbox"/> Shortness of breath <input type="checkbox"/> Unexplained nausea/vomiting, diarrhea, abdominal pain*                                                                     |                                                                        |
|    | <input type="checkbox"/> Sore throat <input type="checkbox"/> Pink eye (conjunctivitis)                                                                                                          |                                                                        |
|    | <input type="checkbox"/> Difficulty swallowing Runny nose/nasal congestion without other known cause                                                                                             |                                                                        |
|    | <input type="checkbox"/> Chills                                                                                                                                                                  |                                                                        |
| 8. | Are you 70 years of age or older, and experiencing any of the following symptoms: delirium, unexplained or increased number of falls, acute functional decline, or worsening chronic conditions? | <input type="checkbox"/> YES<br><input checked="" type="checkbox"/> NO |

- If present, review with nurse or MD to assess if presence of nausea/vomiting, diarrhea, abdominal pain is expected with their IBD Diagnosis and/or current clinical status.

Current Temperature: 36.3

|                                                       |                       |
|-------------------------------------------------------|-----------------------|
| If response to ALL of the screening questions is NO:  | COVID screen NEGATIVE |
| If response to ANY of the screening questions is YES: | COVID screen POSITIVE |

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave,a nearby city 6, ONTARIO a nearby city

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2021-May-31 Reviewed: 2021-Jun-13 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2021-Jun-01 84:71 Updated On: 2021-Jun-13 84:71

|                                                                                | Flags | Results | Ref Range             | Units          |
|--------------------------------------------------------------------------------|-------|---------|-----------------------|----------------|
| <b>GLUCOSE SERUM RANDOM</b>                                                    |       |         |                       |                |
| GLUCOSE SERUM RANDOM (F)                                                       | N     | 6.6     | 3.6 - 7.70            | mmol/L         |
| mmol/L                                                                         |       |         |                       |                |
| 3.6 - 7.7 Normal random glucose                                                |       |         |                       |                |
| 7.8 - 11.0 Potentially at risk for diabetes; consider repeat fasting           |       |         |                       |                |
| >11.0 Provisional diagnosis of Diabetes Mellitus                               |       |         |                       |                |
| Please note new reference range effective Sep 2, 2019                          |       |         |                       |                |
| <b>UREA</b>                                                                    |       |         |                       |                |
| UREA (F)                                                                       | N     | 4.8     | 2.5 - 8.1<br>mmol/L   | mmol/L         |
| <b>CREATININE</b>                                                              |       |         |                       |                |
| CREATININE (F)                                                                 | N     | 77      | 60 - 110<br>umol/L    | umol/L         |
| eGFR (F)                                                                       | N     | 107     | 60 - 99999.99         | mL/min/1.73m*2 |
| >=60 mL/min/1.73m**2                                                           |       |         |                       |                |
| eGFR is calculated using the CKD-EPI 2009 equation.                            |       |         |                       |                |
| CREATININE (F)                                                                 |       |         |                       |                |
| Normal eGFR.                                                                   |       |         |                       |                |
| For patients of African descent, the reported eGFR must be multiplied by 1.15. |       |         |                       |                |
| <b>CALCIUM</b>                                                                 |       |         |                       |                |
| CALCIUM (F)                                                                    | N     | 2.31    | 2.15 - 2.60<br>mmol/L | mmol/L         |
| <b>PHOSPHORUS</b>                                                              |       |         |                       |                |
| PHOSPHORUS(F)                                                                  | N     | 1.06    | 0.80 - 1.45<br>mmol/L | mmol/L         |
| <b>MAGNESIUM</b>                                                               |       |         |                       |                |
| MAGNESIUM (F)                                                                  | N     | 0.82    | 0.65 - 1.05<br>mmol/L | mmol/L         |
| <b>PROTEIN</b>                                                                 |       |         |                       |                |
| PROTEIN (F)                                                                    | N     | 67      | 60 - 80 g/L           | g/L            |

|                         | Flags | Results | Ref Range   | Units  |
|-------------------------|-------|---------|-------------|--------|
| <b>ALBUMIN</b>          |       |         |             |        |
| ALBUMIN (F)             | N     | 43      | 35 - 52 g/L | g/L    |
| <b>BILIRUBIN TOTAL</b>  |       |         |             |        |
| BILIRUBIN TOTAL (F)     | N     | 3       | <23 umol/L  | umol/L |
| <b>BILIRUBIN DIRECT</b> |       |         |             |        |
| BILIRUBIN DIRECT (F)    | N     | <2      | <8 umol/L   | umol/L |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2021-May-31 Reviewed: 2021-Jun-13 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2021-Jun-01 84:71 Updated On: 2021-Jun-13 84:71

|                           | Flags | Results                                                                                            | Ref Range        | Units  |
|---------------------------|-------|----------------------------------------------------------------------------------------------------|------------------|--------|
| <b>BILIRUBIN INDIRECT</b> |       |                                                                                                    |                  |        |
| BILIRUBIN INDIRECT (F)    |       |                                                                                                    | <18 umol/L       | umol/L |
| BILIRUBIN INDIRECT (F)    |       |                                                                                                    |                  |        |
|                           |       | Unable to perform calculation as one or more of the components is outside the limits of detection. |                  |        |
| <b>SODIUM</b>             |       |                                                                                                    |                  |        |
| SODIUM (F)                | N     | 140                                                                                                | 136 - 146 mmol/L | mmol/L |
| <b>POTASSIUM</b>          |       |                                                                                                    |                  |        |
| POTASSIUM (F)             | N     | 4.2                                                                                                | 3.7 - 5.4 mmol/L | mmol/L |
| <b>CHLORIDE</b>           |       |                                                                                                    |                  |        |

|                            | Flags | Results | Ref Range       | Units  |
|----------------------------|-------|---------|-----------------|--------|
| CHLORIDE (F)               | N     | 102     | 95 - 108 mmol/L | mmol/L |
| <b>BICARBONATE</b>         |       |         |                 |        |
| BICARBONATE (F)            | N     | 1979    | 20 - 30 mmol/L  | mmol/L |
| <b>ALKALINEPHOSPHATASE</b> |       |         |                 |        |
| ALKALINE PHOSPHATASE (F)   | N     | 68      | 40-129 U/L      | U/L    |
| <b>CK</b>                  |       |         |                 |        |
| CK (F)                     | N     | 155     | <225 U/L        | U/L    |
| <b>AST</b>                 |       |         |                 |        |
| AST (F)                    | N     | 18      | <37 U/L         | U/L    |
| <b>ALT</b>                 |       |         |                 |        |
| ALT (F)                    | N     | 1979    | <46 U/L         | U/L    |
| <b>HEMOGLOBIN</b>          |       |         |                 |        |
| HEMOGLOBIN (F)             | N     | 137     | 129 - 165 g/L   | g/L    |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2021-May-31 Reviewed: 2021-Jun-13 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2021-Jun-01 84:71 Updated On: 2021-Jun-13 84:71

|                   | Flags | Results | Ref Range       | Units |
|-------------------|-------|---------|-----------------|-------|
| <b>HEMATOCRIT</b> |       |         |                 |       |
| HEMATOCRIT (F)    | N     | 0.43    | 0.39 - 0.49 I/I | L/L   |
| <b>RBC</b>        |       |         |                 |       |

|                           | Flags | Results | Ref Range           | Units     |
|---------------------------|-------|---------|---------------------|-----------|
| RBC (F)                   | N     | 5.0     | 4.2 - 5.8 x 10E12/L | x 10*12/L |
| <b>RBC INDICES: MCV</b>   |       |         |                     |           |
| RBC INDICES: MCV (F)      | N     | 86      | 80 - 98 fl          | fL        |
| <b>MCH</b>                |       |         |                     |           |
| MCH (F)                   | N     | 28      | 24 - 33 pg          | pg        |
| <b>MCHC</b>               |       |         |                     |           |
| MCHC (F)                  | N     | 322     | 313 - 344 g/L       | g/L       |
| <b>RDW</b>                |       |         |                     |           |
| RDW (F)                   | N     | 15.3    | 12.5 - 17.3         |           |
| <b>WBC</b>                |       |         |                     |           |
| WBC (F)                   | N     | 6.1     | 3.2 - 9.4 x 10E9/L  | x 10*9/L  |
| <b>PLATELETS</b>          |       |         |                     |           |
| PLATELETS (F)             | N     | 220     | 155 - 372 x 10E9/L  | x 10*9/L  |
| <b>MPV</b>                |       |         |                     |           |
| MPV (F)                   | N     | 9.4     | 4.0 - 14.0 fl       | fL        |
| <b>DIFFERENTIAL WBC'S</b> |       |         |                     |           |
| NEUTROPHILS (F)           | N     | 4.4     | 1.4 -6.3 x10E9/L    | x 10*9/L  |
| LYMPHOCYTES (F)           | N     | 1.2     | 1.0 -2.9 x10E9/L    | x 10*9/L  |
| MONOCYTES (F)             | N     | 0.4     | 0.2 -0.8 x10E9/L    | x 10*9/L  |
| EOSINOPHILS (F)           | N     | 0.1     | 0.0 -0.5 x10E9/L    | x 10*9/L  |
| BASOPHILS (F)             | N     | 0.00    | 0.00-0.09x10E9/L    | x 10*9/L  |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 273381R6-T5V2-324J-H47Q-5P15H6Z30HT6 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2021-May-31 Reviewed: 2021-Jun-13 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2021-Jun-01 84:71 Updated On: 2021-Jun-13 84:71

|            | Flags | Results | Ref Range   | Units |
|------------|-------|---------|-------------|-------|
| <b>INR</b> |       |         |             |       |
| INR (F)    | N     | 0.9     | 0.9 - 1.300 |       |
| 0.9 - 1.3  |       |         |             |       |

GUIDELINES: SUGGESTED INR RANGE:

1. Most clinical conditions indicating 2.0 - 3.0 anticoagulant therapy
2. Patients with mechanical prosthetic 2.5 - 3.5 heart valves

## Review

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 05/24/2021                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2021-Jun-05 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | review and generate letter                          |                        |                                                                    |

Patient: Mr. Ethan Kang Appointment Date: 2021-May-16 Title: CT Crestwood Medical Group Study Visit  
Note Provider: Taylor, Sinead Referred By: Taylor, Sinead

Ethan Kang was assessed by virtual visit for his Crohn's disease on 2021-May-16.

Informed verbal consent was obtained from this patient to communicate and provide care using virtual and other telecommunications tools. This patient has been explained the risks related to unauthorized disclosure or interception of personal health information and steps they can take to help protect their information. We have discussed that care provided through video or audio communication cannot replace the need for physical examination or an in person visit for some disorders or urgent problems and patient understands the need to seek urgent care in an Emergency Department as necessary.

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 84 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: COVID-19 recovered on May 9th

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: will re-start filgotinib today

Ethan has been clinically unchanged since the last study visit.

He has roughly 4 bowel movements per day. His stools are often formed. None of his bowel movements are associated with the passage of blood. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

He does not have access to a scale to measure weight today

**Physical examination was not done as patient was assessed remotely.**

**Assessment and Plan** In summary, Mr. Ethan Kang is a 41 year-old male with Crohn's disease.

No changes in the patient's management will be made at this time.

The following study procedures were modified or not done due to the current COVID-19 pandemic: Vital signs were not done Physical examination was not done Subject was instructed to complete safety profile blood work at a local lab (hematology and chemistry) Urine pregnancy test was not done as subject is male IP was sent to subject using YourWay (courier) The subject was instructed to keep all bottles of IP to return to the site at the next in-person study visit.

The patient will follow-up with me on June 16.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2021-Jun-05

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

**Patient:** Mr. Ethan Kang **PHN:** 0748 361 588KT **MRN:** 414 235 249 **Birthdate:** 1979 **Phone:** H: (442) 733-2165 C: (442) 733-2165 **Address:** 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Sinead Taylor,

Ethan Kang was assessed by virtual visit for his Crohn's disease on 2021-May-16.

Informed verbal consent was obtained from this patient to communicate and provide care using virtual and other telecommunications tools. This patient has been explained the risks related to unauthorized disclosure or interception of personal health information and steps they can take to help protect their information. We have discussed that care provided through video or audio communication cannot replace the need for physical examination or an in person visit for some disorders or urgent problems and patient understands the need to seek urgent care in an Emergency Department as necessary.

Mr. Ethan Kang is participating in the following clinical trial:Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 84 He is currently on open label filgotibnib 200mg.

The following adverse events have occurred since the last study visit: COVID-19 recovered on May 9th



Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: will re-start filgotinib today

Ethan has been clinically unchanged since the last study visit.

He has roughly 4 bowel movements per day. His stools are often formed. None of his bowel movements are associated with the passage of blood. He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

He does not have access to a scale to measure weight today

**Physical examination was not done as patient was assessed remotely.**

**Assessment and Plan** In summary, Mr. Ethan Kang is a 41 year-old male with Crohn's disease.

No changes in the patient's management will be made at this time.

The following study procedures were modified or not done due to the current COVID-19 pandemic: Vital signs were not done

---

Physical examination was not done Subject was instructed to complete safety profile blood work at a local lab (hematology and chemistry) Urine pregnancy test was not done as subject is male IP was sent to subject using YourWay (courier) The subject was instructed to keep all bottles of IP to return to the site at the next in-person study visit.

The patient will follow-up with me on June 16.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

---

Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 412 Marigold Ave a nearby city 6 ON T: 993-089-6973 qaa 0534 F: (442) 733-2165

Clinician/Vivienne Vasquez CPSO / Sofia Bianchi

Check (☐) one: ☒ OHIP/Insured ☐ Third Party / Uninsured ☐ WSIB

Additional Clinical Information (e.g. diagnosis) Patient with inflammatory bowel disease. These tests are being ordered by a gastroenterologist

[X] Copy to: Clinician/Practitioner Last Name: Taylor First Name: Sinead Address: 412 Marigold Ave a nearby city 6 848 Main Blvd Fax: (442) 733-2165

Laboratory Use Only

Clinician/Practitioner's Contact Number for Urgent Results (442) 733-2165

Service Date: (blank) 1979 / (blank) mm / (blank) 1979

Health Number: 0748 361 588KT Version: (blank) Sex: M Date of Birth: 1979 Province: (blank) Other  
Provincial Registration Number: (blank) Patient's Telephone Contact Number: (442) 733-2165

Patient's Last Name (as per OHIP Card) Ethan Kang Patient's First & Middle Names (as per OHIP Card)  
Ethan Kang Patient's Address (including Postal Code) a nearby city 8

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by  
Crestwood Medical Group

| x   | Biochemistry                   | x   | Hematology                                                         | x   | Viral Hepatitis (check one only)                                                                                                                                  |
|-----|--------------------------------|-----|--------------------------------------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [X] | Glucose [X] Random [ ] Fasting | [X] | CBC                                                                | [ ] | Acute Hepatitis                                                                                                                                                   |
| [ ] | HbA1C                          | [ ] | Prothrombin Time (INR)                                             | [ ] | Chronic Hepatitis                                                                                                                                                 |
| [X] | Creatinine (eGFR)              |     | <b>Immunology</b>                                                  | [ ] | Immune Status / Previous Exposure Specify: [ ] Hepatitis A [ ] Hepatitis B [ ] Hepatitis C or order individual hepatitis tests in the "Other Tests" section below |
| [ ] | Uric Acid                      | [ ] | Pregnancy Test (Urine)                                             |     |                                                                                                                                                                   |
| [X] | Sodium                         | [ ] | Mononucleosis Screen                                               |     |                                                                                                                                                                   |
| [X] | Potassium                      | [ ] | Rubella                                                            |     |                                                                                                                                                                   |
| [X] | ALT                            | [ ] | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) |     | <b>Prostate Specific Antigen (PSA)</b>                                                                                                                            |
| [ ] | Alk. Phosphatase               | [ ] | Repeat Prenatal Antibodies                                         | [ ] | Total PSA [ ] Free PSA                                                                                                                                            |
| [X] | Bilirubin                      |     | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          |     | Specify one below:                                                                                                                                                |
| [X] | Albumin                        | [ ] | Cervical                                                           | [ ] | Insured - Meets OHIP eligibility criteria                                                                                                                         |

|                          |                                                                                                                                                                                     |                          |                                     |                          |                                                                                                                                                                  |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b>                 | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b>                 | <b>Hematology</b>                   | <b>x</b>                 | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
| <input type="checkbox"/> | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | <input type="checkbox"/> | Vaginal                             | <input type="checkbox"/> | Uninsured – Screening: Patient responsible for payment                                                                                                           |
|                          |                                                                                                                                                                                     | <input type="checkbox"/> | Vaginal / Rectal – Group B Strep    |                          | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                    |
| <input type="checkbox"/> | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | <input type="checkbox"/> | Chlamydia (specify source):         | <input type="checkbox"/> | Insured - Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
| <input type="checkbox"/> | Urinalysis (Chemical)                                                                                                                                                               | <input type="checkbox"/> | GC (specify source):                |                          |                                                                                                                                                                  |
|                          | Neonatal Bilirubin:                                                                                                                                                                 | <input type="checkbox"/> | Sputum                              | <input type="checkbox"/> | Uninsured - Patient responsible for payment                                                                                                                      |
|                          | Child's Age: days hours                                                                                                                                                             | <input type="checkbox"/> | Throat                              |                          | <b>Other Tests - one test per line</b>                                                                                                                           |
|                          | Clinician/Practitioner's tel. no. ( )                                                                                                                                               | <input type="checkbox"/> | Wound (specify source):             |                          | Direct and indirect bilirubin                                                                                                                                    |
|                          | Patient's 24 hr telephone no. ( )                                                                                                                                                   | <input type="checkbox"/> | Urine                               |                          | Total protein                                                                                                                                                    |
|                          | Therapeutic Drug Monitoring:                                                                                                                                                        | <input type="checkbox"/> | Stool Culture                       |                          | bicarbonate, BUN and CPK                                                                                                                                         |
|                          | Name of Drug #1                                                                                                                                                                     | <input type="checkbox"/> | Stool Ova & Parasites               |                          | AST                                                                                                                                                              |
|                          | Name of Drug #2                                                                                                                                                                     | <input type="checkbox"/> | Other Swabs / Pus (specify source): |                          | Phosphorus, Mg, Chloride, Calcium                                                                                                                                |
|                          | Time Collected #1 hr. #2 hr.                                                                                                                                                        |                          |                                     |                          |                                                                                                                                                                  |
|                          | Time of Last Dose #1 hr. #2 hr.                                                                                                                                                     |                          | <b>Specimen Collection</b>          |                          |                                                                                                                                                                  |
|                          | Time of Next Dose #1 hr. #2 hr.                                                                                                                                                     |                          | Time: (blank) Date: MM/1979/1979    |                          |                                                                                                                                                                  |

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

Fecal Occult Blood Test (FOBT) (check one) ☐ FOBT (non CCC) ☐ ColonCancerCheck FOBT (CCC) no other test can be ordered on this form

[image] X: [image] Clinician/Practitioner Signature Date: 2021-May-09

Laboratory Use Only

4422-84 (2013/01) © Queen's Printer for Ontario, 2013 7530-4581

Patient: Mr. Ethan Kang Appointment Date: 2021-Apr-28 Title: Note Provider: Taylor, Sinead Referred By: None SR talked to Ethan to follow-up on his COVID-19 infection. Ethan feels fine - he does not have COVID-19 symptoms anymore. He has been advised by the public health to quarantine until May 4th. In terms of Crohn's: Ethan halted taking filgotinib 200mg as of April 18th. He states that his symptoms are stable. SR will follow-up with the patient in [REDACTED-DATE] for the Crestwood Medical Group study.

Patient: Mr. Ethan Kang Appointment Date: 2021-Apr-18 Title: Note Provider: Taylor, Sinead Referred By: None

Ethan Kang tested positive for COVID 19 on April 16th. His symptoms started on April 11. He received the COVID-19 vaccine on April 9.

He reports common symptoms from cold/flu and loss of taste and smell but has not developed any fevers thus far.

Patient has been advised to temporarily hold filgotinib until the infection clears.

Medical Monitor has been informed.

#### Hospital Report

|                 |                |                  |                        |                   |                |
|-----------------|----------------|------------------|------------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | 290 827 5744 ext. 6902 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                      | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                        |                   |                |
| <b>DOB</b>      | 1979           |                  |                        |                   |                |

|                    |                              |              |                                                                    |
|--------------------|------------------------------|--------------|--------------------------------------------------------------------|
| Facility Report #: | 0748 361 588KT               |              |                                                                    |
| Sent to:           | Taylor, Sinead               | Reported By: | Ridgeway Family Health                                             |
| Collection Date:   | 2021-Mar-04                  | Reviewed:    | 2021-Apr-04 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| Message Unique ID: | 0748 361 588KT               |              |                                                                    |
| Source Author:     | ^Cedar Specialist Group^Ur^^ |              |                                                                    |

|             |                     |  |  |
|-------------|---------------------|--|--|
| Updated On: | 2021-Apr-04 2:14 PM |  |  |
|-------------|---------------------|--|--|

## Flags Results Ref Range

### DIAGNOSTIC IMAGING (S) CT See Below

Cedar Specialist Group 4 Outpatient Services 412 Marigold Ave a nearby city 8 Telephone: 994-882-7246

Patient Name: Ethan Kang Date of Birth: 1979 MRN: Y633528593

REPORT (FINAL 2021-03-07)

CT enterography

Technique: Standard enterography protocol, with intravenous contrast

Comparison examination: Prior noncontrast enhanced CT dated Jun 11, 2019 and prior MR enterography dated May 6, 2019.

**FINDINGS:** Ileocolic anastomosis is seen in the right mid abdomen. There is circumferential mural thickening with avid mucosal enhancement and mural stratification involving the distal 30 - 40 cm of small bowel, most prominent at the neo terminal ileum. Although difficult to compare different imaging modalities, the extent of mural thickening appears similar. There are small, reactive appearing lymph nodes in the adjacent mesentery and proliferation of mesenteric fat, as also seen previously.

There is a thin soft tissue attenuating band between two loops of thickened small bowel (approximately 5 - 10 cm proximal to the ileocolic anastomosis), with no air within this band. This is nonspecific and was also seen on prior MR (series 3, image 199). A fibrosed fistulous tract cannot be excluded. There is mild prominence of the vasa recti at this level (series 3, image 218). There is a small low attenuation outpouching associated with the mesenteric side of the more proximal loop of thickened small bowel, not clearly appreciated on prior MR; mucosal ulceration cannot be excluded (series 3, image 203). No free fluid in the abdomen or pelvis. No organized, drainable fluid collections.

There is mild increased mucosal enhancement of the rectum. A further mild inflamed segment of bowel cannot be excluded. For correlation with endoscopy.

No acute process in the visualized lung bases. No pleural effusions.

There is mild decreased attenuation of the liver parenchyma, perhaps due to fatty infiltration. No abnormal dilatation of the biliary tree. Gallbladder is not distended. Hyperattenuating material in the dependent portion of the gallbladder may represent gallstones and/or sludge. This could be further assessed with sonography, if needed. Pancreas, spleen, adrenal glands, and kidneys are unchanged. No hydronephrosis. No size significant retroperitoneal lymphadenopathy.

Bladder is grossly normal in configuration.

No destructive bone lesion in the region being assessed.

**IMPRESSION:** Redemonstration of circumferential mural thickening, stratification, and increased mucosal enhancement of a long segment of distal small bowel including the neo-terminal ileum. The more prominent

mucosal enhancement is seen distally where there is a small outpouching associated with a loop of small bowel, perhaps due to mucosal ulceration, as described in detail above. Findings likely represent acute on chronic inflammation.

---

No intra-abdominal fluid collections.

FOR PHYSICIAN USE ONLY - Please note that this report was generated using voice recognition software. The Outpatient Services (Outpatient Services) supports a culture of continuous improvement. If you require further clarification or feel there has been an error in this report please contact the Outpatient Services Call Centre from 8am - 8pm Monday to Friday, 8am - 4pm Saturday to Sunday (excludes statutory holidays) at (442) 733-2165.

Ordering Provider: Riverside Medical Centre Copies To: CT Abdomen and Pelvis - 2021-Mar-04 11:38 AM

Principal Author: Cedar Specialist Group

---

Ridgeway Family Health

COVID-19 Screening Tool

Patient Name: Ethan Kang

Date of Screening: 2021-Feb-17

Date of Appointment: 2021-Feb-17

Instructions: Ask patient the COVID-19 screening questions outlined below.

1. "Do you require an essential visitor to accompany you to your appointment?" ☐ YES ☒ NO If yes, complete Pre-Screening form for both patient and essential visitor.

|                                                                                                                             |                              |                                        |
|-----------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------|
| 2. Do you have currently have a confirmed diagnosis of COVID-19 OR had a confirmed diagnosis of COVID-19 in the past month? | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 3. Are you currently self-isolating because you had close contact with a confirmed case of COVID-19?                        | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 4. Have you had close contact with a confirmed case of COVID-19 in the past 2 months?                                       | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 5. Have you had close contact with anyone with acute respiratory illness?                                                   | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 6. Have you travelled outside of Canada in the past 14 days?                                                                | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 7. Are you experiencing any of the following symptoms?                                                                      | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |

☐ Fever ( $\geq 37.8$  C) ☐ New onset cough ☐ Worsening chronic cough ☐ Shortness of breath ☐ Sore throat ☐ Difficulty swallowing ☐ Chills ☐ Decrease or loss or sense of taste or smell ☐ Headaches ☐ Unexplained

fatigue/malaise/muscle aches [ ] Unexplained nausea/vomiting, diarrhea, abdominal pain\* [ ] Pink eye (conjunctivitis) Runny nose/nasal congestion without other known cause

|                                                                                                                                                                                                     |                              |                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------|
| 8. Are you 70 years of age or older, and experiencing any of the following symptoms: delirium, unexplained or increased number of falls, acute functional decline, or worsening chronic conditions? | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------|

- If present, review with nurse or MD to assess if presence of nausea/vomiting, diarrhea, abdominal pain is expected with their IBD Diagnosis and/or current clinical status.

Current Temperature: 35.3

|                                                       |                       |
|-------------------------------------------------------|-----------------------|
| If response to ALL of the screening questions is NO:  | COVID screen NEGATIVE |
| If response to ANY of the screening questions is YES: | COVID screen POSITIVE |

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave,a nearby city 6, ONTARIO a nearby city

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 0748 361 588KT Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2021-Feb-17 Reviewed: 2021-Feb-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2021-Feb-18 6:36 AM Updated On: 2021-Feb-18 8:25 AM

|                                                 | Flags | Results | Ref Range  | Units  |
|-------------------------------------------------|-------|---------|------------|--------|
| <b>GLUCOSE SERUM FASTING</b>                    |       |         |            |        |
| GLUCOSE SERUM FASTING (F)                       | N     | 4.1     | 3.6 - 6.00 | mmol/L |
| mmol/L                                          |       |         |            |        |
| 3.6 - 6.0 NORMAL FASTING GLUCOSE                |       |         |            |        |
| 6.1 - 6.9 IMPAIRED FASTING GLUCOSE              |       |         |            |        |
| >6.9 PROVISIONAL DIAGNOSIS OF DIABETES MELLITUS |       |         |            |        |
| <b>CREATININE</b>                               |       |         |            |        |

|                                                     | Flags | Results | Ref Range          | Units          |
|-----------------------------------------------------|-------|---------|--------------------|----------------|
| CREATININE (F)                                      | N     | 82      | 60 - 110<br>umol/L | umol/L         |
| eGFR (F)                                            | N     | 102     | 60. -<br>99999.99  | mL/min/1.73m*2 |
| >=60. mL/min/1.73m**2                               |       |         |                    |                |
| eGFR is calculated using the CKD-EPI 2009 equation. |       |         |                    |                |
| CREATININE (F)                                      |       |         |                    |                |

Normal eGFR.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

|                         |   |      |                     |           |
|-------------------------|---|------|---------------------|-----------|
| <b>HEMOGLOBIN</b>       |   |      |                     |           |
| HEMOGLOBIN (F)          | N | 136  | 129 - 165 g/L       | g/L       |
| <b>HEMATOCRIT</b>       |   |      |                     |           |
| HEMATOCRIT (F)          | N | 0.41 | 0.39 - 0.49 l/l     | L/L       |
| <b>RBC</b>              |   |      |                     |           |
| RBC (F)                 | N | 4.9  | 4.2 - 5.8 x 10E12/L | x 10*12/L |
| <b>RBC INDICES: MCV</b> |   |      |                     |           |
| RBC INDICES: MCV (F)    | N | 84   | 80 - 98 fl          | fl        |
| <b>MCH</b>              |   |      |                     |           |
| MCH (F)                 | N | 28   | 24 - 33 pg          | pg        |
| <b>MCHC</b>             |   |      |                     |           |
| MCHC (F)                | N | 331  | 313 - 344 g/L       | g/L       |
| <b>RDW</b>              |   |      |                     |           |
| RDW (F)                 | N | 14.9 | 12.5 - 17.3         |           |
| <b>WBC</b>              |   |      |                     |           |
| WBC (F)                 | N | 6.2  | 3.2 - 9.4 x 10E9/L  | x 10*9/L  |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |



|            |      |  |  |  |  |
|------------|------|--|--|--|--|
| <b>DOB</b> | 1979 |  |  |  |  |
|------------|------|--|--|--|--|

Comments: CC copy sent to Sinead Taylor

Lab Order #: 0748 361 588KT Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2021-Feb-17 Reviewed: 2021-Feb-18 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2021-Feb-18 6:36 AM Updated On: 2021-Feb-18 8:25 AM

|                           | Flags | Results | Ref Range          | Units    |
|---------------------------|-------|---------|--------------------|----------|
| <b>PLATELETS</b>          |       |         |                    |          |
| PLATELETS (F)             | N     | 235     | 155 - 372 x 10E9/L | x 10*9/L |
| <b>MPV</b>                |       |         |                    |          |
| MPV (F)                   | N     | 9.4     | 4.0 - 14.0 fl      | fL       |
| <b>DIFFERENTIAL WBC'S</b> |       |         |                    |          |
| NEUTROPHILS (F)           | N     | 4.0     | 1.4 -6.3 x 10E9/L  | x 10*9/L |
| LYMPHOCYTES (F)           | N     | 1.4     | 1.0 -2.9 x 10E9/L  | x 10*9/L |
| MONOCYTES (F)             | N     | 0.6     | 0.2 -0.8 x 10E9/L  | x 10*9/L |
| EOSINOPHILS (F)           | N     | 0.1     | 0.0 -0.5 x 10E9/L  | x 10*9/L |
| BASOPHILS (F)             | N     | 0.00    | 0.00-0.09x10E9/L   | x 10*9/L |
| <b>INR</b>                |       |         |                    |          |
| INR (F)                   | N     | 0.9     | 0.9 - 1.300        |          |
| 0.9 - 1.3                 |       |         |                    |          |

GUIDELINES: SUGGESTED INR RANGE:

1. Most clinical conditions indicating 2.0 - 3.0 anticoagulant therapy
2. Patients with mechanical prosthetic 2.5 - 3.5 heart valves

|            |   |     |            |      |
|------------|---|-----|------------|------|
| <b>CRP</b> |   |     |            |      |
| CRP (F)    | N | 6.2 | < 8.0 mg/L | mg/L |

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

YTYMEKZDF VR. 4310370309

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W72

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical Group Highpark Health Centre Windsor, CA United States Z3C 3T6

Week 72 COLLECTION TIME: 09:15 DATE: Feb 15, 2021 DATE RECEIVED IN LABORATORY: Feb 17, 2021 DATE REPORTED BY LABORATORY: Feb 20, 2021 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: XXXXXXXX DOB: HC 1981

|                                      |        | Ref. Ranges      | Clinically Significant |     |
|--------------------------------------|--------|------------------|------------------------|-----|
|                                      |        |                  | Yes*                   | No  |
| <b>CREATININE CLEARANCE CC&amp;G</b> |        |                  |                        |     |
| Weight                               | 123.6  | kg               |                        |     |
| Creatinine                           | 72     | 40-110 umol/L    |                        |     |
| Creat Clr                            | 3.46 H | 1.42-2.08 mL/sec | [ ]                    | [ ] |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low) =Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

YTYMEKZDF VR. 4310370309

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W72

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical Group Highpark Health Centre Windsor, CA United States Z3C 3T6

Week 72 COLLECTION TIME: 09:15 DATE: Feb 15, 2021 DATE RECEIVED IN LABORATORY: Feb 17, 2021 DATE REPORTED BY LABORATORY: Feb 19, 2021 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: XXXXXXXX DOB: HC 1981

|                        |  | Ref. Ranges | Clinically Significant |    |
|------------------------|--|-------------|------------------------|----|
|                        |  |             | Yes*                   | No |
| <b>CHEMISTRY PANEL</b> |  |             |                        |    |

|            |      | Ref. Ranges      | Clinically Significant |  |
|------------|------|------------------|------------------------|--|
| Total Bili | 5    | 3-21 umol/L      |                        |  |
| Dir Bili   | 2    | <2-7 umol/L      |                        |  |
| Ind Bili   | 3    | 0-21 umol/L      |                        |  |
| Alk Phos   | 66   | 31-129 U/L       |                        |  |
| ALT (SGPT) | 14   | 6-43 U/L         |                        |  |
| AST (SGOT) | 13   | 11-36 U/L        |                        |  |
| Urea       | 3.9  | 1.4-8.6 mmol/L   |                        |  |
| Creatinine | 72   | 40-110 umol/L    |                        |  |
| Glucose    | 4.33 | 3.89-5.55 mmol/L |                        |  |
| Calcium    | 2.35 | 2.07-2.64 mmol/L |                        |  |
| Phosphorus | 1.10 | 0.71-1.65 mmol/L |                        |  |
| Total Prot | 68   | 61-84 g/L        |                        |  |
| Alb BCG    | 46   | 33-49 g/L        |                        |  |
| CK         | 117  | 39-308 U/L       |                        |  |

#### URINE MACRO & MICRO PANEL

Color: Yellow, Ref Rng: Colorless or Yellow Clarity: Hazy, Ref Rng: Clear pH: 5.5, 5.0-8.0 Protein: Negative, Ref Rng: Negative Glucose: Normal, Ref Rng: Normal Urobilin: Normal, Ref Rng: Normal Blood: Negative, Ref Rng: Negative Leuk Est: Negative, Ref Rng: Negative Microscop: Positive

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low) -Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

YTYMEKZDF VR. 4310370309

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
 NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W72

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical  
 Group Highpark Health Centre Windsor, CA United States Z3C 3T6

Week 72 COLLECTION TIME: 09:15 DATE: Feb 15, 2021 DATE RECEIVED IN LABORATORY: Feb 17,  
 2021 DATE REPORTED BY LABORATORY: Feb 19, 2021 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN  
 NUMBER: XXXXXXXX DOB: HC 1981

|                                  |         | Ref. Ranges          |    | Clinically Significant |     |
|----------------------------------|---------|----------------------|----|------------------------|-----|
|                                  |         |                      |    | Yes*                   | No  |
| <b>CRYSTALS</b>                  |         |                      |    |                        |     |
| Ca Ox                            | Present | Ref Rng: Not present |    |                        |     |
| <b>ALT AND T.BILI</b>            |         |                      |    |                        |     |
| ALT TBIL                         | No      |                      |    |                        |     |
| <b>AST AND T.BILI</b>            |         |                      |    |                        |     |
| AST TBIL                         | No      |                      |    |                        |     |
| <b>ALBUMIN CORRECTED CALCIUM</b> |         |                      |    |                        |     |
| Corr Ca                          | 2.35    | 2.07-2.64 mmol/L     |    |                        |     |
| <b>LIPID PANEL</b>               |         |                      |    |                        |     |
| HDL-C                            | 0.83    | 0.70-1.73 mmol/L     |    |                        |     |
| Triglycer                        | 3.94 H  | 0.62-3.69 mmol/L     | G2 | [ ]                    | [ ] |
| Cholest                          | 3.18 L  | 4.19-7.24 mmol/L     |    | [ ]                    | [ ] |
| LDL 3rdGen                       | 1.19    | <3.36 mmol/L         |    |                        |     |
| <b>ELECTROLYTE PANEL</b>         |         |                      |    |                        |     |
| Sodium                           | 139     | 132-147 mmol/L       |    |                        |     |
| Potassium                        | 4.1     | 3.5-5.2 mmol/L       |    |                        |     |
| Bicarb                           | 18.8    | 17.0-30.6 mmol/L     |    |                        |     |
| Chloride                         | 105     | 94-112 mmol/L        |    |                        |     |
| Magnesium                        | 0.77    | 0.66-1.07 mmol/L     |    |                        |     |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low) -Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

YTYMEKZDF VR. 4310370309

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W72

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical  
Group Highpark Health Centre Windsor, CA United States Z3C 3T6

Week 72 COLLECTION TIME: 09:15 DATE: Feb 15, 2021 DATE RECEIVED IN LABORATORY: Feb 17,  
2021 DATE REPORTED BY LABORATORY: Feb 18, 2021 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN  
NUMBER: 0748 361 588KT DOB: HC 1981

|                                     |       | Ref. Ranges    | Clinically Significant |    |
|-------------------------------------|-------|----------------|------------------------|----|
|                                     |       |                | Yes*                   | No |
| <b>TOTAL IG</b>                     |       |                |                        |    |
| Total Ig                            | 10.94 | g/L No Ref Rng |                        |    |
| <b>IMMUNOGLOBULIN A, G, M PANEL</b> |       |                |                        |    |
| IgA                                 | 0.75  | 0.70-4.00 g/L  |                        |    |
| IgG                                 | 9.68  | 5.65-17.65 g/L |                        |    |
| IgM                                 | 0.51  | 0.40-2.30 g/L  |                        |    |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date:

---

H(High) and L(Low) =Values above or below Crestwood Medical Group Reference Ranges 0748 361  
588KT T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1,  
G2, G3, G4: Toxicity Grades

(INV)

---

![Ontario logo] Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 412 Marigold Ave a nearby city 6 ON T: 993-089-6973 qaa 0534 F: (442) 733-2165

| Clinician/Practitioner Number | CPSO / Registration No. | Laboratory Use Only |
|-------------------------------|-------------------------|---------------------|
| 0748 361 588KT                | 414 235 249             |                     |

| Clinician/Practitioner's Contact Number for Urgent Results | Service Date | 1979 | mm | 1979 |
|------------------------------------------------------------|--------------|------|----|------|
| (442) 733-2165                                             |              |      |    |      |

Check (☐) one: ☒ OHIP/Insured ☐ Third Party / Uninsured ☐ WSIB

| Health Number  | Version | Sex | Date of Birth | 1979 | mm | 1979 |
|----------------|---------|-----|---------------|------|----|------|
| 0748 361 588KT |         | M   |               | 1979 | 06 | 1979 |

| Province | Other Provincial Registration Number | Patient's Telephone Contact Number |
|----------|--------------------------------------|------------------------------------|
|          |                                      | (442) 733-2165                     |

Additional Clinical Information (e.g. diagnosis)

Patient's Last Name (as per OHIP Card) Ethan Kang

Patient's First & Middle Names (as per OHIP Card) Ethan Kang

☒ Copy to: Clinician/Practitioner Last Name: Taylor First Name: Sinead Address: 412 Marigold Ave a nearby city 6 848 Main Blvd Fax (442) 733-2165

Patient's Address (including Postal Code) a nearby city 8

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Crestwood Medical Group

| x                                   | Biochemistry                                                                        | x                                   | Hematology             | x                        | Viral Hepatitis (check one only)                                                                                        |
|-------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------|------------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------|
| <input checked="" type="checkbox"/> | Glucose <input type="checkbox"/> Random <input checked="" type="checkbox"/> Fasting | <input checked="" type="checkbox"/> | CBC                    | <input type="checkbox"/> | Acute Hepatitis                                                                                                         |
| <input type="checkbox"/>            | HbA1C                                                                               | <input checked="" type="checkbox"/> | Prothrombin Time (INR) | <input type="checkbox"/> | Chronic Hepatitis                                                                                                       |
| <input checked="" type="checkbox"/> | Creatinine (eGFR)                                                                   |                                     | <b>Immunology</b>      | <input type="checkbox"/> | Immune Status / Previous Exposure                                                                                       |
| <input type="checkbox"/>            | Uric Acid                                                                           | <input type="checkbox"/>            | Pregnancy Test (Urine) |                          | Specify: <input type="checkbox"/> Hepatitis A <input type="checkbox"/> Hepatitis B <input type="checkbox"/> Hepatitis C |
| <input type="checkbox"/>            | Sodium                                                                              | <input type="checkbox"/>            | Mononucleosis Screen   |                          | or order individual hepatitis tests in the "Other Tests" section below                                                  |

|                          |                                                                                                                                                                                     |                          |                                                                    |                          |                                                                                                                                                                  |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b>                 | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b>                 | <b>Hematology</b>                                                  | <b>x</b>                 | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
| <input type="checkbox"/> | Potassium                                                                                                                                                                           | <input type="checkbox"/> | Rubella                                                            |                          | <b>Prostate Specific Antigen (PSA)</b>                                                                                                                           |
| <input type="checkbox"/> | ALT                                                                                                                                                                                 | <input type="checkbox"/> | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) | <input type="checkbox"/> | Total PSA <input type="checkbox"/> Free PSA                                                                                                                      |
| <input type="checkbox"/> | Alk. Phosphatase                                                                                                                                                                    | <input type="checkbox"/> | Repeat Prenatal Antibodies                                         |                          | Specify one below:                                                                                                                                               |
| <input type="checkbox"/> | Bilirubin                                                                                                                                                                           |                          | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          | <input type="checkbox"/> | Insured - Meets OHIP eligibility criteria                                                                                                                        |
| <input type="checkbox"/> | Albumin                                                                                                                                                                             | <input type="checkbox"/> | Cervical                                                           | <input type="checkbox"/> | Uninsured – Screening: Patient responsible for payment                                                                                                           |
| <input type="checkbox"/> | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | <input type="checkbox"/> | Vaginal                                                            |                          | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                    |
| <input type="checkbox"/> | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | <input type="checkbox"/> | Vaginal / Rectal – Group B Strep                                   | <input type="checkbox"/> | Insured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
| <input type="checkbox"/> | Urinalysis (Chemical)                                                                                                                                                               | <input type="checkbox"/> | Chlamydia (specify source):                                        | <input type="checkbox"/> | Uninsured – Patient responsible for payment                                                                                                                      |
|                          | <b>Neonatal Bilirubin:</b>                                                                                                                                                          | <input type="checkbox"/> | GC (specify source):                                               |                          | <b>Other Tests</b> – one test per line                                                                                                                           |
|                          | Child's Age: days hours                                                                                                                                                             | <input type="checkbox"/> | Sputum                                                             |                          | c-reactive protein                                                                                                                                               |
|                          | Clinician/Practitioner's tel. no. ( )                                                                                                                                               | <input type="checkbox"/> | Throat                                                             |                          |                                                                                                                                                                  |
|                          | Patient's 24 hr telephone no. ( )                                                                                                                                                   | <input type="checkbox"/> | Wound (specify source):                                            |                          |                                                                                                                                                                  |
|                          | <b>Therapeutic Drug Monitoring:</b>                                                                                                                                                 | <input type="checkbox"/> | Urine                                                              |                          |                                                                                                                                                                  |
|                          | Name of Drug #1                                                                                                                                                                     | <input type="checkbox"/> | Stool Culture                                                      |                          |                                                                                                                                                                  |
|                          | Name of Drug #2                                                                                                                                                                     | <input type="checkbox"/> | Stool Ova & Parasites                                              |                          |                                                                                                                                                                  |

|          |                                 |                          |                                     |          |                                         |
|----------|---------------------------------|--------------------------|-------------------------------------|----------|-----------------------------------------|
| <b>x</b> | <b>Biochemistry</b>             | <b>x</b>                 | <b>Hematology</b>                   | <b>x</b> | <b>Viral Hepatitis (check one only)</b> |
|          | Time Collected #1 hr. #2 hr.    | <input type="checkbox"/> | Other Swabs / Pus (specify source): |          |                                         |
|          | Time of Last Dose #1 hr. #2 hr. |                          |                                     |          |                                         |
|          | Time of Next Dose #1 hr. #2 hr. |                          |                                     |          |                                         |

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

[signature]

X \_\_\_\_\_ 2021-Feb-15 Clinician/Practitioner Signature Date

|                            |                   |  |
|----------------------------|-------------------|--|
| <b>Specimen Collection</b> |                   |  |
| Time                       | Date MM/1979/1979 |  |

|                                                   |                                                                                                |  |
|---------------------------------------------------|------------------------------------------------------------------------------------------------|--|
| <b>Fecal Occult Blood Test (FOBT) (check one)</b> |                                                                                                |  |
| <input type="checkbox"/> FOBT (non CCC)           | <input type="checkbox"/> ColonCancerCheck FOBT (CCC) no other test can be ordered on this form |  |

Laboratory Use Only

4422-84 (2013/01) © Queen's Printer for Ontario, 2013 7530-4581

! [Ridgeway Family Health logo] a nearby city 6 Harbour Medical Centre — INSTITUTE —

2021-Jan-31

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Sinead Taylor,

I saw Ethan Kang today for follow up of his Crohn's disease. He was seen in person at Ridgeway Family Health. This is a regular clinical assessment and not a clinical trial visit.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

Endoscopy Results: 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4, SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD: 7, colon: normal.

Active Medications: Filgotinib - open label clinical trial



Current Status

Ethan is feeling relatively well. He is having 2-5 BMs/day. Variable calibre and consistency. No blood in his stool. No systemic symptoms. He is still overweight and feels his stool pattern corresponds to his dietary intake.

On physical examination, he looks well and nutritionally fit. He has no lymphadenopathy. His abdomen is soft, non-tender with no organomegaly or masses.

Assessment and Plan Ethan Kang currently has mildly active disease. For now he would like to continue to stay in the trial but we will restage his small bowel disease with a CT enterography.

I discussed with Ethan moving his clinical trial visits to Ridgeway Family Health in the future and he was ok with this. I will see him again in follow up in 3-4m.

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city CANADA

Sincerely,

! [Signature]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city CANADA

☐ \*--

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | [REDACTED-DATE]                                     | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2021-Feb-01 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | office FU 3-4m after CT done                        |                        |                                                                    |

☐ \*--

This task has been completed

|                |            |                        |                                                     |
|----------------|------------|------------------------|-----------------------------------------------------|
| <b>Patient</b> | Ethan Kang | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
|----------------|------------|------------------------|-----------------------------------------------------|

|                    |                                                                                                                                        |                  |                                                                    |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------|
| <b>Date Due</b>    | [REDACTED-DATE]                                                                                                                        | <b>Priority</b>  | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                                                                                    | <b>Completed</b> | 2021-Feb-01 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | ok to move clinical trial visits to Ridgeway Family Health.<br>send him disclosure (rrtpvfjgm has updated one) to sign when time comes |                  |                                                                    |

☐ \*--

This task has been completed

|                    |                                                                                                                                        |                        |                                                     |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                                                                                             | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Date Due</b>    | [REDACTED-DATE]                                                                                                                        | <b>Priority</b>        | Normal                                              |
| <b>Assigned To</b> | rrtpvfjgm, rrtpvfjgm                                                                                                                   | <b>Completed</b>       | 2021-Feb-02 by rrtpvfjgm                            |
| <b>Notes</b>       | arrange dietitian assessment with [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]<br><br>crohn's - ileal and obesity. no stricture |                        |                                                     |

## Conversations

**Created 2021-Feb-02 10:43 AM**

2021-Feb-02 10:43 AM rrtpvfjgm

[ ] pt contacted and info sent

[image] Dr. Sinead Taylor

Cedar Specialist Group 4 Cedar Specialist Group 4 412 Marigold Ave, a nearby city 6, Ontario, Canada 848 Main Blvd C13 (Rev. 11.2011)

CT Requisition Form

**MODALITY** CT Request Form **SITE AND LOCATION** 5th Floor Medical Imaging - Main Reception Desk  
TELEPHONE 290 827 5744 ext. 6902 FAX (442) 733-2165

Clearly imprint patient identification card Ethan Kang M 1979 0748 361 588KT 412 Marigold Ave ON, Canada 848 Main Blvd

Please fax a copy of appointment details to 290 827 5744 ext. 6902

**PATIENT INFORMATION: INCOMPLETE REQUISITIONS WILL BE RETURNED**

|                       |                                    |
|-----------------------|------------------------------------|
| <b>BIRTHDATE 1979</b> | <b>HOSPITAL MEDICAL RECORD NO.</b> |
| 1979                  | 414 235 249                        |

|                |                   |
|----------------|-------------------|
| <b>SURNAME</b> | <b>GIVEN NAME</b> |
| Ethan Kang     | Ethan             |

ADDRESS (Street, Apt #) 412 Marigold Ave

|                        |           |                      |
|------------------------|-----------|----------------------|
| <b>a nearby city 6</b> | <b>ON</b> | <b>848 Main Blvd</b> |
| CITY/TOWN              | PROVINCE  | POSTAL CODE          |

|                             |                       |
|-----------------------------|-----------------------|
| <b>(442) 733-2165</b>       | <b>(442) 733-2165</b> |
| TELEPHONE (Area Code & No.) | (442) 733-2165        |

|                           |                     |
|---------------------------|---------------------|
| <b>Health Card Number</b> | <b>Version Code</b> |
| 0748 361 588KT            | 5753727875QP        |

**The following MUST be completed by the referring physician: (Please check)**

1. Does the patient have a history of Kidney disease? Yes ☐ No ☐ (eg. 1 kidney, renal failure, dialysis)
2. Is the patient diabetic? Yes ☐ No ☐
3. Previous reaction to IV contrast? Yes ☐ No ☐
4. Does the patient have a pelvic/ileoanal pouch? Yes ☐ No ☐

If YES to question #1 or #2, please provide blood work (must be within the last 3 months) Creatinine \_\_\_\_\_ eGFR \_\_\_\_\_

List Diabetic Medications:

Known Allergies:

**EXAMINATION(S):** CT enterography

**Clinical History and Indications:** Small bowel crohn's. assess disease activity and compare to prior MRE

**IF THE PATIENT HAS A KNOWN CONTRAST ALLERGY, THE REQUESTING PHYSICIAN IS RESPONSIBLE FOR ORGANIZING THE PRE-MEDICATION PRIOR TO THE PATIENTS SCAN.**

**PLEASE FOLLOW THE PRE-MEDICATION INSTRUCTIONS BELOW:** PREDNISONE 50mg P.O 13 HOURS AND 1 HOUR PRE-EXAMINATION PLUS BENADRYL 50mg P.O 1 HOUR PRE-EXAMINATION. NOTE: BENADRYL CAN CAUSE DROWSINESS. PATIENTS SHOULD MAKE ARRANGEMENTS TO BE DRIVEN TO AND FROM THE EXAMINATION.

## REFERRING PHYSICIAN INFORMATION

**Name and Initials (Print):** Dr. Sinead Taylor **Telephone #:** 993-089-6973 qaa 0534 **Requested Appointment Date (if applicable):** 1979-MMM-1979 **Mailing Address:**

**Doctor's Signature:** X [signature] **Fax #:** 290 827 5744 ext. 6902 **CPSO #** 414 235 249

|                                 |                               |                  |
|---------------------------------|-------------------------------|------------------|
| <b>MEDICAL IMAGING USE ONLY</b> | <b>RADIOLOGIST SIGNATURE:</b> | <b>PROTOCOL:</b> |
|                                 | RADIOLOGIST NAME (PRINT):     |                  |

|                                 |                                |                                               |
|---------------------------------|--------------------------------|-----------------------------------------------|
| <b>MEDICAL IMAGING USE ONLY</b> | <b>APPOINTMENT DATE (1979)</b> | <b>APPOINTMENT TIME (24 hr clock) (HH:MM)</b> |
|---------------------------------|--------------------------------|-----------------------------------------------|

Ridgeway Family Health

COVID-19 Screening Tool

Patient Name: Ethan Kang

Date of Screening: 2021-Jan-31

Date of Appointment: 2021-Jan-31

Instructions: Ask patient the COVID-19 screening questions outlined below.

1. "Do you require an essential visitor to accompany you to your appointment?" ☐ YES ☒ NO If yes, complete Pre-Screening form for both patient and essential visitor.

|                                                                                                                             |                              |                                        |
|-----------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------|
| 2. Do you have currently have a confirmed diagnosis of COVID-19 OR had a confirmed diagnosis of COVID-19 in the past month? | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 3. Are you currently self-isolating because you had close contact with a confirmed case of COVID-19?                        | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 4. Have you had close contact with a confirmed case of COVID-19 in the past 2 months?                                       | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 5. Have you had close contact with anyone with acute respiratory illness?                                                   | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 6. Have you travelled outside of Canada in the past 14 days?                                                                | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 7. Are you experiencing any of the following symptoms?                                                                      | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |

☐ Fever ( $\geq 37.8$  C) ☐ New onset cough ☐ Worsening chronic cough ☐ Shortness of breath ☐ Sore throat ☐ Difficulty swallowing ☐ Chills ☐ Decrease or loss or sense of taste or smell ☐ Headaches ☐ Unexplained fatigue/malaise/muscle aches ☐ Unexplained nausea/vomiting, diarrhea, abdominal pain\* ☐ Pink eye (conjunctivitis) Runny nose/nasal congestion without other known cause

|                                                                                                                                                                                                     |                              |                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------|
| 8. Are you 70 years of age or older, and experiencing any of the following symptoms: delirium, unexplained or increased number of falls, acute functional decline, or worsening chronic conditions? | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------|

- If present, review with nurse or MD to assess if presence of nausea/vomiting, diarrhea, abdominal pain is expected with their IBD Diagnosis and/or current clinical status.

Current Temperature: 35.5

|                                                       |                       |
|-------------------------------------------------------|-----------------------|
| If response to ALL of the screening questions is NO:  | COVID screen NEGATIVE |
| If response to ANY of the screening questions is YES: | COVID screen POSITIVE |

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city

Patient: Mr. Ethan Kang Appointment Date: 2021-Jan-31 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: None I saw Ethan Kang today for follow up of his Crohn's disease. He was seen in person at Ridgeway Family Health. This is a regular clinical assessment and not a clinical trial visit.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

Endoscopy Results: 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4, SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

Active Medications: Filgotinib - open label clinical trial

Current Status

Ethan is feeling relatively well. He is having 2-5 BMs/day. Variable calibre and consistency. No blood in his stool. No systemic symptoms. He is still overweight and feels his stool pattern corresponds to his dietary intake.

On physical examination, he looks well and nutritionally fit. He has no lymphadenopathy. His abdomen is soft, non-tender with no organomegaly or masses.

Assessment and Plan Ethan Kang currently has mildly active disease. For now he would like to continue to stay in the trial but we will restage his small bowel disease with a CT enterography.

I discussed with Ethan moving his clinical trial visits to Ridgeway Family Health in the future and he was ok with this. I will see him again in follow up in 3-4m.

[X] \* --

This task has been completed

|                    |            |                        |                          |
|--------------------|------------|------------------------|--------------------------|
| <b>Patient</b>     | Ethan Kang | <b>Task Created By</b> | rrtpvfjgm                |
| <b>Date Due</b>    | 01/24/2021 | <b>Priority</b>        | Normal                   |
| <b>Assigned To</b> | rrtpvfjgm  | <b>Completed</b>       | 2021-Jan-24 by rrtpvfjgm |

**Notes** Ethan wants to know if there are instructions for his in-person visit on Feb 1st (i.e. fasting for blood work) or anything else. Thank you.

## Conversations

**Created 2021-Jan-24 11:1979 AM**

---

2021-Jan-24 11:1979 AM rrtpvfjgm

[image] no there are no instructions

[image] rrtpvfjgm

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

HXREMJDHQD ES. 6609604884

Page 1 of 1 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: 0748 361 588KT Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W60 a nearby city 6, ON Canada 848 Main Blvd Week 60 SPONSOR REPORT TO: COLLECTION TIME:09:55 DATE:Nov 23, 2020 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Nov 24, 2020 c/o Fairlight Medical Centre DATE REPORTED BY LABORATORY: Nov 27, 2020 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 46 Highpark Health Centre SCREEN NUMBER: 0748 361 588KT Windsor, CA United States 94404DOB: HC 1981

|                           |       | Ref. Ranges      | Clinically Significant |
|---------------------------|-------|------------------|------------------------|
|                           |       |                  | Yes* No                |
| <b>RETICULOCYTE COUNT</b> |       |                  |                        |
| Retic %                   | 1.7   | 0.6-2.5 %        |                        |
| Retic Abs                 | 0.079 | 0.030-0.130 TI/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades (INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

HXREMJBHQD ES. 6609604884

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: 0748 361 588KT Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W60 a nearby city 6, ON Canada 848 Main Blvd Week 60 SPONSOR REPORT TO: COLLECTION TIME: 09:55 DATE: Nov 23, 2020 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Nov 24, 2020 c/o Fairlight Medical Centre DATE REPORTED BY LABORATORY: Nov 24, 2020 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 46 Highpark Health Centre SCREEN NUMBER: 0748 361 588KT Windsor, CA United States Z3C 3T6 DOB: HC 1981

|                                  |      | Ref. Ranges      | Clinically Significant |
|----------------------------------|------|------------------|------------------------|
|                                  |      |                  | Yes* No                |
| <b>CHEMISTRY PANEL</b>           |      |                  |                        |
| Total Bili                       | 5    | 3-21 umol/L      |                        |
| Dir Bili                         | 2    | <2-7 umol/L      |                        |
| Ind Bili                         | 3    | 0-21 umol/L      |                        |
| Alk Phos                         | 62   | 31-129 U/L       |                        |
| ALT (SGPT)                       | 17   | 6-43 U/L         |                        |
| AST (SGOT)                       | 17   | 11-36 U/L        |                        |
| Urea                             | 5.4  | 1.4-8.6 mmol/L   |                        |
| Creatinine                       | 75   | 40-110 umol/L    |                        |
| Glucose                          | 4.61 | 3.89-5.55 mmol/L |                        |
| Calcium                          | 2.35 | 2.07-2.64 mmol/L |                        |
| Phosphorus                       | 1.23 | 0.71-1.65 mmol/L |                        |
| Total Prot                       | 67   | 61-84 g/L        |                        |
| Alb BCG                          | 44   | 33-49 g/L        |                        |
| CK                               | 192  | 39-308 U/L       |                        |
| <b>ALT AND T.BILI</b>            |      |                  |                        |
| ALT TBIL                         | No   |                  |                        |
| <b>AST AND T.BILI</b>            |      |                  |                        |
| AST TBIL                         | No   |                  |                        |
| <b>ALBUMIN CORRECTED CALCIUM</b> |      |                  |                        |

|         |      | Ref. Ranges      | Clinically Significant |
|---------|------|------------------|------------------------|
| Corr Ca | 2.35 | 2.07-2.64 mmol/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades (INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

HXREMJDH ES. 6609604884

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical  
Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: 0748  
361 588KT Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W60  
a nearby city 6, ON Canada 848 Main Blvd Week 60 SPONSOR REPORT TO: COLLECTION TIME: 09:55  
DATE: Nov 23, 2020 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Nov 24, 2020 c/o  
Fairlight Medical Centre DATE REPORTED BY LABORATORY: Nov 24, 2020 Crestwood Medical Group  
SEX: M BIRTHDATE: 1979 AGE: 46 Highpark Health Centre SCREEN NUMBER: 0748 361 588KT  
Windsor, CA United States Z3C 3T6 DOB: HC 1981

|                          |      | Ref. Ranges      | Clinically Significant |
|--------------------------|------|------------------|------------------------|
|                          |      |                  | Yes* No                |
| <b>ELECTROLYTE PANEL</b> |      |                  |                        |
| Sodium                   | 139  | 132-147 mmol/L   |                        |
| Potassium                | 4.6  | 3.5-5.2 mmol/L   |                        |
| Bicarb                   | 20.3 | 17.0-30.6 mmol/L |                        |
| Chloride                 | 104  | 94-112 mmol/L    |                        |
| Magnesium                | 0.79 | 0.66-1.07 mmol/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades (INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT



HXREMJDHQD ES. 6609604884

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: XXXXXXXXXXXXXXXXXXXX Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W60 a nearby city 6, ON Canada 848 Main Blvd Week 60 SPONSOR REPORT TO: COLLECTION TIME: 09:55 DATE: Nov 23, 2020 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Nov 24, 2020 c/o Fairlight Medical Centre DATE REPORTED BY LABORATORY: Nov 24, 2020 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 46 Highpark Health Centre SCREEN NUMBER: 0748 361 588KT Windsor, CA United States Z3C 3T6 DOB: HC 1981

|||| Ref. Ranges | Clinically Significant ||| :--- | :--- | :--- | :--- | :--- | :--- | :--- ||||| Yes\* | No ||  
**CREATININE CLEARANCE CC&G** ||||| Weight | 127.5 | | kg ||||| Creatinine | 75 | | 40-110 umol/L ||  
||| Creat Clr | 3.44 | H | 1.42-2.08 mL/sec | [ ] [ ] |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades (INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

HXREMJDHQD ES. 6609604884

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: XXXXXXXXXXXXXXXXXXXX Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W60 a nearby city 6, ON Canada 848 Main Blvd Week 60 SPONSOR REPORT TO: COLLECTION TIME: 09:55 DATE: Nov 23, 2020 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Nov 24, 2020 c/o Fairlight Medical Centre DATE REPORTED BY LABORATORY: Nov 24, 2020 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 46 Highpark Health Centre SCREEN NUMBER: 0748 361 588KT Windsor, CA United States Z3C 3T6 DOB: HC 1981

|                                       |    |  | Ref. Ranges | Clinically Significant |    |
|---------------------------------------|----|--|-------------|------------------------|----|
|                                       |    |  |             | Yes*                   | No |
| <b>SUBJECT AGE AT TIME OF COLLECT</b> |    |  |             |                        |    |
| Subj.age                              | 41 |  | years       |                        |    |
| <b>IS SUBJECT FASTING?</b>            |    |  |             |                        |    |
| Fasting?                              | No |  |             |                        |    |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades (INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

HXREMJDH ES. 6609604884

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical  
Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER:  
XXXXXXXXXXXXXXXXX Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold  
Ave VISIT: W60 a nearby city 6, ON Canada 848 Main Blvd Week 60 SPONSOR REPORT TO:  
COLLECTION TIME: 09:55 DATE: Nov 23, 2020 Glenmore Specialist Centre DATE RECEIVED IN  
LABORATORY: Nov 24, 2020 c/o Fairlight Medical Centre DATE REPORTED BY LABORATORY: Nov 24,  
2020 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 46 Highpark Health Centre SCREEN  
NUMBER: 0748 361 588KT Windsor, CA United States Z3C 3T6 DOB: HC 1981

|                                              |                       | Ref. Ranges        | Clinically<br>Significant |    |
|----------------------------------------------|-----------------------|--------------------|---------------------------|----|
|                                              |                       |                    | Yes*                      | No |
| <b>HEMATOLOGY&amp;DIFFERENTIAL<br/>PANEL</b> |                       |                    |                           |    |
| HGB                                          | 134                   | 127-181 g/L        |                           |    |
| HCT                                          | 0.39                  | 0.39-0.54          |                           |    |
| RBC                                          | 4.7                   | 4.5-6.4 TI/L       |                           |    |
| RBC Morph                                    | No Review<br>Required |                    |                           |    |
| MCV                                          | 82                    | 79-96 fL           |                           |    |
| WBC                                          | 7.13                  | 3.80-10.70<br>GI/L |                           |    |
| Neutrophil                                   | 4.87                  | 1.96-7.23 GI/L     |                           |    |
| Lymphocyte                                   | 1.62                  | 0.91-4.28 GI/L     |                           |    |
| Monocytes                                    | 0.52                  | 0.12-0.92 GI/L     |                           |    |
| Eosinophil                                   | 0.09                  | 0.00-0.57 GI/L     |                           |    |
| Basophils                                    | 0.03                  | 0.00-0.20 GI/L     |                           |    |
| Neutrophil                                   | 68.3                  | 40.5-75.0 %        |                           |    |
| Lymphocyte                                   | 1979.7                | 15.4-48.5 %        |                           |    |
| Monocytes                                    | 7.3                   | 2.6-10.1 %         |                           |    |
| Eosinophil                                   | 1.3                   | 0.0-6.8 %          |                           |    |

|           |     | Ref. Ranges  | Clinically Significant |  |
|-----------|-----|--------------|------------------------|--|
| Basophils | 0.4 | 0.0-2.0 %    |                        |  |
| Platelets | 249 | 140-400 GI/L |                        |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades (INV)

Patient: Mr. Ethan Kang Appointment Date: 2020-Nov-23 Title: MS IBD Follow up Provider: Taylor, Sinead  
Referred By: Taylor, Sinead I saw Ethan Kang today for follow up of his Crohn's disease in person at Lakeshore Specialty Clinic.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Strictureing

Endoscopy Results: 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03  
Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7,  
colon:normal.

Active Medications: Filgotinib - open label extension clinical trial (since [REDACTED-DATE])

#### Current Status

Feels well. No changes to his health. Feels that the medication is working. 3-5 semi-formed stools per day. No abdominal pain. No change to his energy level, appetite and weight. No infections or overt side effects related to study med.

On physical examination, he looks well and nutritionally fit. He has no lymphadenopathy. Chest is clear. Heart sounds normal. His abdomen is soft, non-tender with no organomegaly or masses. Skin exam is normal.

Assessment and Plan Ethan Kang is currently in symptomatic remission but likely continues to have active endoscopic disease. We discussed whether to stay on the study med or discontinue but as he has limited options regarding future treatments he prefers to stay on it for the time being. I don't think this is unreasonable.

I will see him again in follow up in 6 months in the office.

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

HXREMJHQD ES. 6609604884

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical Group Highpark Health Centre Windsor, CA United States Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W60

Week 60 COLLECTION TIME: 09:55 DATE: Nov 23, 2020 DATE RECEIVED IN LABORATORY: Nov 24, 2020 DATE REPORTED BY LABORATORY: Nov 27, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                           |       | Ref. Ranges      | Clinically Significant |
|---------------------------|-------|------------------|------------------------|
|                           |       |                  | Yes* No                |
| <b>RETICULOCYTE COUNT</b> |       |                  |                        |
| Retic %                   | 1.7   | 0.6-2.5 %        |                        |
| Retic Abs                 | 0.079 | 0.030-0.130 TI/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades (INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

HXREMJDH ES. 6609604884

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical Group Highpark Health Centre Windsor, CA United States Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W60

Week 60 COLLECTION TIME: 09:55 DATE: Nov 23, 2020 DATE RECEIVED IN LABORATORY: Nov 24, 2020 DATE REPORTED BY LABORATORY: Nov 24, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|  |  | Ref. Ranges | Clinically Significant |
|--|--|-------------|------------------------|
|  |  |             | Yes* No                |

|                        |      | Ref. Ranges      | Clinically Significant |
|------------------------|------|------------------|------------------------|
| <b>CHEMISTRY PANEL</b> |      |                  |                        |
| Total Bili             | 5    | 3-21 umol/L      |                        |
| Dir Bili               | 2    | <2-7 umol/L      |                        |
| Ind Bili               | 3    | 0-21 umol/L      |                        |
| Alk Phos               | 62   | 31-129 U/L       |                        |
| ALT (SGPT)             | 17   | 6-43 U/L         |                        |
| AST (SGOT)             | 17   | 11-36 U/L        |                        |
| Urea                   | 5.4  | 1.4-8.6 mmol/L   |                        |
| Creatinine             | 75   | 40-110 umol/L    |                        |
| Glucose                | 4.61 | 3.89-5.55 mmol/L |                        |
| Calcium                | 2.35 | 2.07-2.64 mmol/L |                        |
| Phosphorus             | 1.23 | 0.71-1.65 mmol/L |                        |
| Total Prot             | 67   | 61-84 g/L        |                        |
| Alb BCG                | 44   | 33-49 g/L        |                        |
| CK                     | 192  | 39-308 U/L       |                        |

**ALT AND T.BILI** ALT TBIL No

**AST AND T.BILI** AST TBIL No

**ALBUMIN CORRECTED CALCIUM** Corr Ca 2.35 2.07-2.64 mmol/L

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades (INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

HXREMJHQD ES. 6609604884

GS US-450-437-5094 INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W60

Week 60 SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical Group Highpark Health Centre Windsor, CA United States Z3C 3T6

COLLECTION TIME:09:55 DATE:Nov 23, 2020 DATE RECEIVED IN LABORATORY: Nov 24, 2020 DATE REPORTED BY LABORATORY: Nov 24, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                          |      | Ref. Ranges      | Clinically Significant |
|--------------------------|------|------------------|------------------------|
|                          |      |                  | Yes* No                |
| <b>ELECTROLYTE PANEL</b> |      |                  |                        |
| Sodium                   | 139  | 132-147 mmol/L   |                        |
| Potassium                | 4.6  | 3.5-5.2 mmol/L   |                        |
| Bicarb                   | 20.3 | 17.0-30.6 mmol/L |                        |
| Chloride                 | 104  | 94-112 mmol/L    |                        |
| Magnesium                | 0.79 | 0.66-1.07 mmol/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

HXREMJHQD ES. 6609604884

0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W60

Week 60 SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical Group Highpark Health Centre Windsor, CA United States Z3C 3T6

COLLECTION TIME: 09:55 DATE: Nov 23, 2020 DATE RECEIVED IN LABORATORY: Nov 24, 2020 DATE REPORTED BY LABORATORY: Nov 24, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|  |  | Ref. Ranges | Clinically Significant |
|--|--|-------------|------------------------|
|  |  |             | Yes* No                |

|                                      |        | Ref. Ranges      | Clinically Significant |
|--------------------------------------|--------|------------------|------------------------|
| <b>CREATININE CLEARANCE CC&amp;G</b> |        |                  |                        |
| Weight                               | 127.5  | kg               |                        |
| Creatinine                           | 75     | 40-110 umol/L    |                        |
| Creat Clr                            | 3.44 H | 1.42-2.08 mL/sec | [[[]                   |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

HXREMJHQD ES. 6609604884

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W60

Week 60

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Fairlight Medical Centre Crestwood Medical  
Group Highpark Health Centre Windsor, CA United States Z3C 3T6

COLLECTION TIME: 09:55 DATE: Nov 23, 2020 DATE RECEIVED IN LABORATORY: Nov 24, 2020 DATE  
REPORTED BY LABORATORY: Nov 24, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER:  
0748 361 588KT DOB: HC 1981

|                                          |      | Ref. Ranges  | Clinically Significant |
|------------------------------------------|------|--------------|------------------------|
|                                          |      |              | Yes* No                |
| <b>HEMATOLOGY&amp;DIFFERENTIAL PANEL</b> |      |              |                        |
| HGB                                      | 134  | 127-181 g/L  |                        |
| HCT                                      | 0.39 | 0.39-0.54    |                        |
| RBC                                      | 4.7  | 4.5-6.4 TI/L |                        |

|            |                    | Ref. Ranges     | Clinically Significant |
|------------|--------------------|-----------------|------------------------|
| RBC Morph  | No Review Required |                 |                        |
| MCV        | 82                 | 79-96 fL        |                        |
| WBC        | 7.13               | 3.80-10.70 GI/L |                        |
| Neutrophil | 4.87               | 1.96-7.23 GI/L  |                        |
| Lymphocyte | 1.62               | 0.91-4.28 GI/L  |                        |
| Monocytes  | 0.52               | 0.12-0.92 GI/L  |                        |
| Eosinophil | 0.09               | 0.00-0.57 GI/L  |                        |
| Basophils  | 0.03               | 0.00-0.20 GI/L  |                        |
| Neutrophil | 68.3               | 40.5-75.0 %     |                        |
| Lymphocyte | 1979.7             | 15.4-48.5%      |                        |
| Monocytes  | 7.3                | 2.6-10.1 %      |                        |
| Eosinophil | 1.3                | 0.0-6.8 %       |                        |
| Basophils  | 0.4                | 0.0-2.0 %       |                        |
| Platelets  | 249                | 140-400 GI/L    |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 2

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: [illegible] PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48



SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: [illegible] DOB: HC 1981

|                        |      | Ref. Ranges      | Clinically Significant |
|------------------------|------|------------------|------------------------|
|                        |      |                  | Yes* No                |
| <b>CHEMISTRY PANEL</b> |      |                  |                        |
| Total Bili             | 5    | 3-21 umol/L      |                        |
| Dir Bili               | 2    | <2-7 umol/L      |                        |
| Ind Bili               | 3    | 0-21 umol/L      |                        |
| Alk Phos               | 59   | 31-129 U/L       |                        |
| ALT (SGPT)             | 18   | 6-43 U/L         |                        |
| AST (SGOT)             | 16   | 11-36 U/L        |                        |
| Urea                   | 5.0  | 1.4-8.6 mmol/L   |                        |
| Creatinine             | 84   | 40-110 umol/L    |                        |
| Glucose                | 4.55 | 3.89-5.55 mmol/L |                        |
| Calcium                | 2.35 | 2.07-2.64 mmol/L |                        |
| Phosphorus             | 1.26 | 0.71-1.65 mmol/L |                        |
| Total Prot             | 68   | 61-84 g/L        |                        |
| Alb BCG                | 44   | 33-49 g/L        |                        |
| CK                     | 172  | 39-308 U/L       |                        |

#### URINE MACRO & MICRO PANEL

|           |          |                              |
|-----------|----------|------------------------------|
| Color     | Yellow   | Ref Rng: Colorless or Yellow |
| Clarity   | Hazy     | Ref Rng: Clear               |
| pH        | 5.0      | 5.0-8.0                      |
| Protein   | Negative | Ref Rng: Negative            |
| Glucose   | Normal   | Ref Rng: Normal              |
| Urobilin  | Normal   | Ref Rng: Normal              |
| Blood     | Negative | Ref Rng: Negative            |
| Leuk Est  | Negative | Ref Rng: Negative            |
| Microscop | Positive |                              |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

CSUFTRPUU YE. 4957518921 Page 2 of 2

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: [illegible] PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE  
REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER:  
[illegible] DOB: HC 1981

|                                  |         | Ref. Ranges          | Clinically Significant |
|----------------------------------|---------|----------------------|------------------------|
|                                  |         |                      | Yes* No                |
| <b>CELLULAR ELEMENTS</b>         |         |                      |                        |
| RBC                              | 1       | 0-3 /HPF             |                        |
| <b>CRYSTALS</b>                  |         |                      |                        |
| Ca Ox                            | Present | Ref Rng: Not present |                        |
| <b>ALT AND T.BILI</b>            |         |                      |                        |
| ALT TBIL                         | No      |                      |                        |
| <b>AST AND T.BILI</b>            |         |                      |                        |
| AST TBIL                         | No      |                      |                        |
| <b>ALBUMIN CORRECTED CALCIUM</b> |         |                      |                        |
| Corr Ca                          | 2.35    | 2.07-2.64 mmol/L     |                        |
| <b>LIPID PANEL</b>               |         |                      |                        |

|                          |        | Ref. Ranges      | Clinically Significant |
|--------------------------|--------|------------------|------------------------|
| HDL-C                    | 0.88   | 0.70-1.73 mmol/L |                        |
| Triglycer                | 3.29   | 0.62-3.69 mmol/L | G1 [ ] [ ]             |
| Cholest                  | 3.23 L | 4.19-7.24 mmol/L | [ ] [ ]                |
| LDL 3rdGen               | 1.42   | <3.36 mmol/L     |                        |
| <b>ELECTROLYTE PANEL</b> |        |                  |                        |
| Sodium                   | 140    | 132-147 mmol/L   |                        |
| Potassium                | 4.5    | 3.5-5.2 mmol/L   |                        |
| Bicarb                   | 19.8   | 17.0-30.6 mmol/L |                        |
| Chloride                 | 104    | 94-112 mmol/L    |                        |
| Magnesium                | 0.80   | 0.66-1.07 mmol/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 1

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: [illegible] PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1,  
2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN  
NUMBER: [illegible] DOB: HC 1981

|                                      |  | Ref. Ranges | Clinically Significant |
|--------------------------------------|--|-------------|------------------------|
|                                      |  |             | Yes* No                |
| <b>CREATININE CLEARANCE CC&amp;G</b> |  |             |                        |

|            |        | Ref. Ranges      | Clinically Significant |
|------------|--------|------------------|------------------------|
| Weight     | 128.4  | kg               |                        |
| Creatinine | 84     | 40-110 umol/L    |                        |
| Creat Clr  | 3.10 H | 1.42-2.08 mL/sec | [[[]                   |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 1

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME:10:08 DATE:Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1,  
2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN  
NUMBER: 0748 361 588KT DOB: HC 1981

|                           |       | Ref. Ranges      | Clinically Significant |
|---------------------------|-------|------------------|------------------------|
|                           |       |                  | Yes* No                |
| <b>RETICULOCYTE COUNT</b> |       |                  |                        |
| Retic %                   | 1.8   | 0.6-2.5 %        |                        |
| Retic Abs                 | 0.085 | 0.030-0.130 TI/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 1

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME:10:08 DATE:Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER XXXXXXXX906XXXX DOB: HC 1981

|                                     |       | Ref. Ranges    | Clinically Significant |
|-------------------------------------|-------|----------------|------------------------|
|                                     |       |                | Yes* No                |
| <b>TOTAL IG</b>                     |       |                |                        |
| Total Ig                            | 11.97 | g/L No Ref Rng |                        |
|                                     |       |                |                        |
| <b>IMMUNOGLOBULIN A, G, M PANEL</b> |       |                |                        |
| IgA                                 | 0.78  | 0.70-4.00 g/L  |                        |
| IgG                                 | 10.70 | 5.65-17.65 g/L |                        |
| IgM                                 | 0.49  | 0.40-2.30 g/L  |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 1 INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME:10:08 DATE:Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: XXXXXXXX906XXXX DOB: HC 1981

|                                          |                    | Ref. Ranges     | Clinically Significant |
|------------------------------------------|--------------------|-----------------|------------------------|
|                                          |                    |                 | Yes* No                |
| <b>HEMATOLOGY&amp;DIFFERENTIAL PANEL</b> |                    |                 |                        |
| HGB                                      | 132                | 127-181 g/L     |                        |
| HCT                                      | 0.39               | 0.39-0.54       |                        |
| RBC                                      | 4.7                | 4.5-6.4 TI/L    |                        |
| RBC Morph                                | No Review Required |                 |                        |
| MCV                                      | 82                 | 79-96 fL        |                        |
| WBC                                      | 6.97               | 3.80-10.70 GI/L |                        |
| Neutrophil                               | 4.86               | 1.96-7.23 GI/L  |                        |
| Lymphocyte                               | 1.42               | 0.91-4.28 GI/L  |                        |
| Monocytes                                | 0.55               | 0.12-0.92 GI/L  |                        |
| Eosinophil                               | 0.10               | 0.00-0.57 GI/L  |                        |
| Basophils                                | 0.03               | 0.00-0.20 GI/L  |                        |
| Neutrophil                               | 69.8               | 40.5-75.0 %     |                        |
| Lymphocyte                               | 20.5               | 15.4-48.5%      |                        |
| Monocytes                                | 7.8                | 2.6-10.1 %      |                        |
| Eosinophil                               | 1.4                | 0.0-6.8 %       |                        |
| Basophils                                | 0.5                | 0.0-2.0 %       |                        |
| Platelets                                | 252                | 140-400 GI/L    |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

CSUFTRPUU YE. 4957518921

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1,  
2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN  
NUMBER: 0748 361 588KT DOB: HC 1981

|  |  | Ref. Ranges | Clinically Significant |
|--|--|-------------|------------------------|
|  |  |             | Yes* No                |

**SUBJECT AGE AT TIME OF COLLECT** Subj. age 46 years

**IS SUBJECT FASTING?** Fasting? Yes

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

CSUFTRPUU YE. 4957518921

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|  |  | Ref. Ranges | Clinically Significant |
|--|--|-------------|------------------------|
|  |  |             | Yes* No                |

**CHEMISTRY PANEL** Total Bili 5 3-21 umol/L Dir Bili 2 <2-7 umol/L Ind Bili 3 0-21 umol/L Alk Phos 59 31-129 U/L ALT (SGPT) 18 6-43 U/L AST (SGOT) 16 11-36 U/L Urea 5.0 1.4-8.6 mmol/L Creatinine 84 40-110 umol/L Glucose 4.55 3.89-5.55 mmol/L Calcium 2.35 2.07-2.64 mmol/L Phosphorus 1.26 0.71-1.65 mmol/L Total Prot 68 61-84 g/L Alb BCG 44 33-49 g/L CK 172 39-308 U/L

**URINE MACRO & MICRO PANEL** Color Yellow Ref Rng: Colorless or Yellow Clarity Hazy Ref Rng: Clear pH 5.0 5.0-8.0 Protein Negative Ref Rng: Negative Glucose Normal Ref Rng: Normal Urobilin Normal Ref Rng: Normal Blood Negative Ref Rng: Negative Leuk Est Negative Ref Rng: Negative Microscop Positive

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981



|  |  |                    |                               |
|--|--|--------------------|-------------------------------|
|  |  | <b>Ref. Ranges</b> | <b>Clinically Significant</b> |
|  |  |                    | Yes* No                       |

**CELLULAR ELEMENTS** RBC 1 0-3 /HPF

**CRYSTALS** Ca Ox Present Ref Rng: Not present

**ALT AND T.BILI** ALT TBIL No

**AST AND T.BILI** AST TBIL No

**ALBUMIN CORRECTED CALCIUM** Corr Ca 2.35 2.07-2.64 mmol/L

**LIPID PANEL** HDL-C 0.88 0.70-1.73 mmol/L Triglycer 3.29 0.62-3.69 mmol/L G1 [ ] [ ] Cholest 3.23 L 4.19-7.24 mmol/L [ ] [ ] LDL 3rdGen 1.42 <3.36 mmol/L

**ELECTROLYTE PANEL** Sodium 318 322-645 mmol/L Potassium 4.5 3.5-5.2 mmol/L Bicarb 19.8 17.0-30.6 mmol/L Chloride 104 94-112 mmol/L Magnesium 0.80 0.66-1.07 mmol/L

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 1

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

Week 48 COLLECTION TIME:10:08 DATE:Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|  |  |                    |                               |
|--|--|--------------------|-------------------------------|
|  |  | <b>Ref. Ranges</b> | <b>Clinically Significant</b> |
|  |  |                    | Yes* No                       |

**CREATININE CLEARANCE CC&G** Weight 128.4 kg Creatinine 84 40-110 umol/L Creat Clr 3.10 H 1.42-2.08 mL/sec [ ] [ ]

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921 INVESTIGATOR: (0748 361 588KT) 0748 361 588KT Riverside Medical Centre PROTOCOL 0748 361 588KT c/o Brookfield Medical Centre INVESTIGATOR NO.: 0748 361 588KT Cedar Specialist Group 4 SUBJECT NUMBER: 0748 361 588KT 412 Marigold Ave PATIENT INITIALS NOT COLLECTED: a nearby city 6, ON Canada 848 Main Blvd Week 48 VISIT: W48 SPONSOR REPORT TO: COLLECTION TIME:10:08 DATE:Aug 31, 2020 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Sep 1, 2020 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY: Sep 2, 2020 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 46 412 Marigold Ave SCREEN NUMBER: 0748 361 588KT Brockville, United Kingdom UB11 1AFDOB: HC 1981

Ref. Ranges Clinically Significant Yes\* No

RETICULOCYTE COUNT Retic % 1.8 0.6-2.5 % Retic Abs 0.085 0.030-0.130 TI/L

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX, KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 1

INVESTIGATOR: (0748 361 588KT) 0748 361 588KT Riverside Medical Centre PROTOCOL 0748 361 588KT c/o Brookfield Medical Centre INVESTIGATOR NO.: 0748 361 588KT Cedar Specialist Group 4 SUBJECT NUMBER: 0748 361 588KT 412 Marigold Ave PATIENT INITIALS NOT COLLECTED: a nearby city 6, ON Canada 848 Main Blvd Week 48 VISIT: W48 SPONSOR REPORT TO: COLLECTION TIME:10:08 DATE:Aug 31, 2020 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Sep 1, 2020 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY: Sep 2, 2020 Crestwood

Medical Group SEX: M BIRTHDATE: 1979 AGE: 46 412 Marigold Ave SCREEN NUMBER: 0748 361  
588KT Brockville, United Kingdom UB11 1AFDOB: HC 1981

|  |  |             |                        |
|--|--|-------------|------------------------|
|  |  | Ref. Ranges | Clinically Significant |
|  |  |             | Yes* No                |

TOTAL IG Total Ig 11.97 g/L No Ref Rng

IMMUNOGLOBULIN A, G, M PANEL IgA 0.78 0.70-4.00 g/L IgG 10.70 5.65-17.65 g/L IgM 0.49 0.40-2.30 g/L

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

CSUFTRPUU YE. 4957518921 Page 1 of 1

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W48

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

Week 48 COLLECTION TIME:10:08 DATE:Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 1, 2020 DATE REPORTED BY LABORATORY: Sep 2, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|  |  | Ref. Ranges | Clinically Significant |    |
|--|--|-------------|------------------------|----|
|  |  |             | Yes*                   | No |

HEMATOLOGY&DIFFERENTIAL PANEL

| Analyte    | Value              | Ref. Ranges     |  |  |
|------------|--------------------|-----------------|--|--|
| HGB        | 132                | 127-181 g/L     |  |  |
| HCT        | 0.39               | 0.39-0.54       |  |  |
| RBC        | 4.7                | 4.5-6.4 TI/L    |  |  |
| RBC Morph  | No Review Required |                 |  |  |
| MCV        | 82                 | 79-96 fL        |  |  |
| WBC        | 6.97               | 3.80-10.70 GI/L |  |  |
| Neutrophil | 4.86               | 1.96-7.23 GI/L  |  |  |
| Lymphocyte | 1.42               | 0.91-4.28 GI/L  |  |  |
| Monocytes  | 0.55               | 0.12-0.92 GI/L  |  |  |
| Eosinophil | 0.10               | 0.00-0.57 GI/L  |  |  |
| Basophils  | 0.03               | 0.00-0.20 GI/L  |  |  |
| Neutrophil | 69.8               | 40.5-75.0 %     |  |  |
| Lymphocyte | 20.5               | 15.4-48.5%      |  |  |
| Monocytes  | 7.8                | 2.6-10.1 %      |  |  |
| Eosinophil | 1.4                | 0.0-6.8 %       |  |  |
| Basophils  | 0.5                | 0.0-2.0 %       |  |  |

| Analyte   | Value | Ref. Ranges  |  |  |
|-----------|-------|--------------|--|--|
| Platelets | 252   | 140-400 GI/L |  |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges T=Telephoned  
P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity  
Grades

0748 361 588KT

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

EPNQRJVKX UJ. 0188855763 INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o  
Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848  
Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: [illegible] PATIENT INITIALS NOT COLLECTED: VISIT: TB-W48

TB Assessment COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep  
2, 2020 DATE REPORTED BY LABORATORY: Sep 3, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN  
NUMBER: [illegible] DOB: HC 1981

|  | Ref. Ranges | Clinically Significant |    |
|--|-------------|------------------------|----|
|  |             | Yes*                   | No |

QUANTIFERON GOLD TB2

| Analyte | Value | Units | Ref. Ranges |
|---------|-------|-------|-------------|
| QFT-TB2 | 0.09  | IU/mL | No Ref Rng  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges T=Telephoned  
P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity  
Grades

0748 361 588KT

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

EPNQRJVKX UJ. 0188855763 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: TB-W48

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

TB Assessment COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 2, 2020 DATE REPORTED BY LABORATORY: Sep 3, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: ZSNJZVNLN55QGJ DOB: HC 1981

| Ref. Ranges | Clinically Significant |    |
|-------------|------------------------|----|
|             | Yes*                   | No |

QUANTIFERON GOLD NIL QFTNil 0.08 IU/mL No Ref Rng

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

0748 361 588KT

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

EPNQRJVKX UJ. 0188855763 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: TB-W48

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

TB Assessment COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 2, 2020 DATE REPORTED BY LABORATORY: Sep 3, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: ZSNJZVNLN55QGJ DOB: HC 1981

|  | Ref. Ranges | Clinically Significant |    |
|--|-------------|------------------------|----|
|  |             | Yes*                   | No |

QUANTIFERON GOLD TB1 QFT-TB1 0.07 IU/mL No Ref Rng

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

0748 361 588KT

(INV)

---

Sunnymede Family Practice 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

EPNQRJVKX UJ. 0188855763

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL NG-KV-806-2528 INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: TB-W48

TB Assessment COLLECTION TIME: 10:08 DATE: Aug 31, 2020 DATE RECEIVED IN LABORATORY: Sep 2, 2020 DATE REPORTED BY LABORATORY: Sep 3, 2020 SEX: M BIRTHDATE: 1979 AGE: 46 SCREEN NUMBER: ZSNJZVNLN55QGJ DOB: HC 1981

|  | Ref. Ranges | Clinically Significant |    |
|--|-------------|------------------------|----|
|  |             | Yes*                   | No |

QUANTIFERON GOLD MITOGEN/INTER QFT-Mit >10.00 IU/mL No Ref Rng \*1 QFTInt Negative Normal=Negative

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

\_\_\_\_\_

Conversation Report (Generated on 2026-Apr-09)

Sign Up for Medeo to Send Secure Emails to Your Provider

Creator: Dr. Sinead Taylor

Patient: First Name: Ethan Last Name: Ethan Kang DOB: 1979 Gender: Male PHN: 6609604884PP (ON)

Status: Closed

Dr. Sinead Taylor - 2020-Aug-17 6:20 PM Dear Patients. Please download this app if you wish to communicate with our office electronically and securely. We can send you lab reqs, reports and other information directly through your Medeo account. Dr. Sinead Taylor

\_\_\_\_\_

![[logo]

# a nearby city 6 Harbour Medical Centre

## INSTITUTE

2020-Aug-16

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

|                   |                                                   |
|-------------------|---------------------------------------------------|
| <b>Patient:</b>   | Mr. Ethan Kang                                    |
| <b>PHN:</b>       | 0748 361 588KT                                    |
| <b>MRN:</b>       | 414 235 249                                       |
| <b>Birthdate:</b> | 1979                                              |
| <b>Phone:</b>     | <b>H:</b> (442) 733-2165 <b>C:</b> (442) 733-2165 |
| <b>Address:</b>   | 412 Marigold Ave                                  |
|                   | a nearby city 6, ON 848 Main Blvd                 |

Dear Dr. Herrera,

I saw Ethan Kang today for follow up of his Crohn's disease in person at Ridgeway Family Health. This was a regularly scheduled follow up and not part of the clinical trial assessments.



## Problem History:

Crohn's disease

## IBD Phenotype:

Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

## Endoscopy Results:

2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

## Active Medications:

Filgotinib - open label extension clinical trial (since [REDACTED-DATE])

## Current Status

Feels ok. Has added some supplements that he has ordered online which he is taking over the counter. One is a digestive enzyme. This is the second month and he feels it is helping him with decreased stool frequency. 2-4 BMs/day. More formed since starting the supplements. No abdominal pain. No change to his energy level, appetite and weight. No infections or overt side effects related to study med.

On physical examination, he looks well and nutritionally fit. He has no lymphadenopathy. His abdomen is soft, non-tender with no organomegaly or masses.

## Assessment and Plan

Ethan Kang is currently in symptomatic remission but likely continues to have active endoscopic disease. We discussed whether to stay on the study med or discontinue but as he has limited options regarding future treatments he prefers to

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city CANADA

---

stay on it for the time being. I don't think this is unreasonable.

I will see him again in follow up in 6 months in the office.

Sincerely,

![signature]

Riverside Medical Centre Isolde Xiong Electronically Reviewed to Expedite Delivery

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city CANADA

---

**Patient:** Mr. Ethan Kang **Appointment Date:** 2020-Aug-16 **Title:** MS IBD Follow up **Provider:** Taylor, Sinead **Referred By:** None

I saw Ethan Kang today for follow up of his Crohn's disease in person at Ridgeway Family Health. This was a regularly scheduled follow up and not part of the clinical trial assessments.

**Problem History:** Crohn's disease

**IBD Phenotype:** Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**Endoscopy Results:** 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4, SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

**Active Medications:** Filgotinib - open label extension clinical trial (since [REDACTED-DATE])

### Current Status

Feels ok. Has added some supplements that he has ordered online which he is taking over the counter. One is a digestive enzyme. This is the second month and he feels it is helping him with decreased stool frequency. 2-4 BMs/day. More formed since starting the supplements. No abdominal pain. No change to his energy level, appetite and weight. No infections or overt side effects related to study med.

**On physical examination,** he looks well and nutritionally fit. He has no lymphadenopathy. His abdomen is soft, non-tender with no organomegaly or masses.

**Assessment and Plan** Ethan Kang is currently in symptomatic remission but likely continues to have active endoscopic disease. We discussed whether to stay on the study med or discontinue but as he has limited options regarding future treatments he prefers to stay on it for the time being. I don't think this is unreasonable.

I will see him again in follow up in 6 months in the office.

---

Ridgeway Family Health

COVID-19 Screening Tool

Patient Name: Ethan Kang Date of Screening: 2020-Aug-12 Date of Appointment:

Instructions: Ask patient the COVID-19 screening questions outlined below.

1. "Do you require an essential visitor to accompany you to your appointment?" ☐ YES ☒ NO If yes, complete Pre-Screening form for both patient and essential visitor.

|                                                                                                      |                              |                                        |
|------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------|
| 2. Do you have currently have a confirmed diagnosis of COVID-19?                                     | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |
| 3. Are you currently self-isolating because you had close contact with a confirmed case of COVID-19? | <input type="checkbox"/> YES | <input checked="" type="checkbox"/> NO |

|                                                                           |                                 |                                           |
|---------------------------------------------------------------------------|---------------------------------|-------------------------------------------|
| 4. Have you had close contact with anyone with acute respiratory illness? | <input type="checkbox"/><br>YES | <input checked="" type="checkbox"/><br>NO |
| 5. Have you travelled outside of Canada in the past 14 days?              | <input type="checkbox"/><br>YES | <input checked="" type="checkbox"/><br>NO |
| 6. Are you experiencing any of the following symptoms?                    | <input type="checkbox"/><br>YES | <input checked="" type="checkbox"/><br>NO |

☐ Fever ( $\geq 37.8$  C) ☐ New onset cough ☐ Worsening chronic cough ☐ Shortness of breath ☐ Sore throat ☐ Difficulty swallowing ☐ Chills ☐ Decrease or loss of sense of taste or smell ☐ Headaches ☐ Unexplained fatigue/malaise/muscle aches ☐ Unexplained nausea/vomiting, diarrhea, abdominal pain\* ☐ Pink eye (conjunctivitis) Runny nose/nasal congestion without other known cause

|                                                                                                                                                                                                     |                                 |                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------------------|
| 7. Are you 70 years of age or older, and experiencing any of the following symptoms: delirium, unexplained or increased number of falls, acute functional decline, or worsening chronic conditions? | <input type="checkbox"/><br>YES | <input checked="" type="checkbox"/><br>NO |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-------------------------------------------|

- If present, review with nurse or MD to assess if presence of nausea/vomiting, diarrhea, abdominal pain is expected with their IBD Diagnosis and/or current clinical status.

#### Screening Results:

|                                                       |                       |                                     |
|-------------------------------------------------------|-----------------------|-------------------------------------|
| If response to ALL of the screening questions is NO:  | COVID screen NEGATIVE | <input checked="" type="checkbox"/> |
| If response to ANY of the screening questions is YES: | COVID screen POSITIVE | <input type="checkbox"/>            |

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city

#### Ridgeway Family Health

Ngkyqh3528@pyhyr.shn | <https://www.costco.ca> | 412 Marigold Ave, a nearby city 6, ONTARIO a nearby city

#### Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

| Patient  | Ethan Kang     | HomePhone | (089) 697-3500 a5345 | WorkPhone  |                |
|----------|----------------|-----------|----------------------|------------|----------------|
| Health # | 0748 361 588KT | Sex       | M                    | Patient ID | 0748 361 588KT |
| Age      | 46 years       |           |                      |            |                |
| DOB      | 1979           |           |                      |            |                |

Comments: FASTING CC copy sent to Sinead Taylor

Lab Order #: Sunnymede Family Practice 2 Ordered By: Sinead Taylor Collection Date: 2020-Jun-02  
Reported Date: 2020-Jun-03 1:27 AM Updated On: 2020-Jun-19 10:20 AM Reported By: Ridgeway Family

|                                                                      | Flags | Results                                                                        | Ref Range          | Units          |
|----------------------------------------------------------------------|-------|--------------------------------------------------------------------------------|--------------------|----------------|
| <b>GLUCOSE SERUM RANDOM</b>                                          |       |                                                                                |                    |                |
| GLUCOSE SERUM RANDOM (F)                                             | N     | 4.1                                                                            | 3.6 - 7.70         | mmol/L         |
| mmol/L                                                               |       |                                                                                |                    |                |
| 3.6 - 7.7 Normal random glucose                                      |       |                                                                                |                    |                |
| 7.8 - 11.0 Potentially at risk for diabetes; consider repeat fasting |       |                                                                                |                    |                |
| >11.0 Provisional diagnosis of Diabetes Mellitus                     |       |                                                                                |                    |                |
| Please note new reference range effective Sep 2, 2019                |       |                                                                                |                    |                |
| <b>UREA</b>                                                          |       |                                                                                |                    |                |
| UREA (F)                                                             | N     | 4.8                                                                            | 2.5 - 8.1 mmol/L   | mmol/L         |
| <b>CREATININE</b>                                                    |       |                                                                                |                    |                |
| CREATININE (F)                                                       | N     | 85                                                                             | 60 - 110 umol/L    | umol/L         |
| eGFR (F)                                                             | N     | 98                                                                             | 60. - 99999.99     | mL/min/1.73m*2 |
| >=60. mL/min/1.73m**2                                                |       |                                                                                |                    |                |
| eGFR is calculated using the CKD-EPI 2009 equation.                  |       |                                                                                |                    |                |
| CREATININE (F)                                                       |       |                                                                                |                    |                |
|                                                                      |       | Normal eGFR.                                                                   |                    |                |
|                                                                      |       | For patients of African descent, the reported eGFR must be multiplied by 1.15. |                    |                |
| <b>CALCIUM</b>                                                       |       |                                                                                |                    |                |
| CALCIUM (F)                                                          | N     | 2.45                                                                           | 2.15 - 2.60 mmol/L | mmol/L         |
| <b>PHOSPHORUS</b>                                                    |       |                                                                                |                    |                |
| PHOSPHORUS(F)                                                        | N     | 1.12                                                                           | 0.80 - 1.45 mmol/L | mmol/L         |

|                         | Flags | Results | Ref Range          | Units  |
|-------------------------|-------|---------|--------------------|--------|
| <b>MAGNESIUM</b>        |       |         |                    |        |
| MAGNESIUM (F)           | N     | 0.89    | 0.65 - 1.05 mmol/L | mmol/L |
| <b>PROTEIN</b>          |       |         |                    |        |
| PROTEIN (F)             | N     | 71      | 60 - 80 g/L        | g/L    |
| <b>ALBUMIN</b>          |       |         |                    |        |
| ALBUMIN (F)             | N     | 46      | 35 - 52 g/L        | g/L    |
| <b>BILIRUBIN TOTAL</b>  |       |         |                    |        |
| BILIRUBIN TOTAL (F)     | N     | 7       | <23 umol/L         | umol/L |
| <b>BILIRUBIN DIRECT</b> |       |         |                    |        |
| BILIRUBIN DIRECT (F)    | N     | 2       | <8 umol/L          | umol/L |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                |                   |                  |                             |                  |                |
|----------------|-------------------|------------------|-----------------------------|------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>HomePhone</b> | <b>(089) 697-3500 a5345</b> | <b>WorkPhone</b> |                |
| Health #       | 0748 361 588KT    | Sex              | M                           | Patient ID       | 0748 361 588KT |
| Age            | 46 years          |                  |                             |                  |                |
| DOB            | 1979              |                  |                             |                  |                |

Comments: FASTING CC copy sent to Sinead Taylor

Lab Order #: Sunnymede Family Practice 2 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2020-Jun-02 Reviewed: 2020-Jun-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2020-Jun-03 1:27 AM Updated On: 2020-Jun-19 10:20 AM

|                           | Flags | Results | Ref Range        | Units  |
|---------------------------|-------|---------|------------------|--------|
| <b>BILIRUBIN INDIRECT</b> |       |         |                  |        |
| BILIRUBIN INDIRECT (F)    | N     | 5       | <18 umol/L       | umol/L |
| <b>SODIUM</b>             |       |         |                  |        |
| SODIUM (F)                | N     | 141     | 136 - 146 mmol/L | mmol/L |
| <b>POTASSIUM</b>          |       |         |                  |        |
| POTASSIUM (F)             | N     | 4.8     | 3.7 - 5.4 mmol/L | mmol/L |
| <b>CHLORIDE</b>           |       |         |                  |        |
| CHLORIDE (F)              | N     | 102     | 95 - 108 mmol/L  | mmol/L |
| <b>BICARBONATE</b>        |       |         |                  |        |

|                             | Flags | Results | Ref Range      | Units  |
|-----------------------------|-------|---------|----------------|--------|
| BICARBONATE (F)             | N     | 25      | 20 - 30 mmol/L | mmol/L |
| <b>ALKALINE PHOSPHATASE</b> |       |         |                |        |
| ALKALINE PHOSPHATASE (F)    | N     | 68      | 40-129 U/L     | U/L    |
| <b>CK</b>                   |       |         |                |        |
| CK (F)                      | N     | 148     | <225 U/L       | U/L    |
| <b>AST</b>                  |       |         |                |        |
| AST (F)                     | N     | 15      | <37 U/L        | U/L    |
| <b>ALT</b>                  |       |         |                |        |
| ALT (F)                     | N     | 21      | <46 U/L        | U/L    |
| <b>HEMOGLOBIN</b>           |       |         |                |        |
| HEMOGLOBIN (F)              | N     | 139     | 129 - 165 g/L  | g/L    |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                |                   |                  |                             |                  |                |
|----------------|-------------------|------------------|-----------------------------|------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>HomePhone</b> | <b>(089) 697-3500 a5345</b> | <b>WorkPhone</b> |                |
| Health #       | 0748 361 588KT    | Sex              | M                           | Patient ID       | 0748 361 588KT |
| Age            | 46 years          |                  |                             |                  |                |
| DOB            | 1979              |                  |                             |                  |                |

Comments: FASTING CC copy sent to Sinead Taylor

Lab Order #: Sunnymede Family Practice 2 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2020-Jun-02 Reviewed: 2020-Jun-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2020-Jun-03 1:27 AM Updated On: 2020-Jun-19 10:20 AM

|                         | Flags | Results | Ref Range           | Units     |
|-------------------------|-------|---------|---------------------|-----------|
| <b>HEMATOCRIT</b>       |       |         |                     |           |
| HEMATOCRIT (F)          | N     | 0.44    | 0.39 - 0.49 I/I     | L/L       |
| <b>RBC</b>              |       |         |                     |           |
| RBC (F)                 | N     | 5.2     | 4.2 - 5.8 x 10E12/L | x 10*12/L |
| <b>RBC INDICES: MCV</b> |       |         |                     |           |
| RBC INDICES: MCV (F)    | N     | 85      | 80 - 98 fl          | fL        |
| <b>MCH</b>              |       |         |                     |           |
| MCH (F)                 | N     | 27      | 24 - 33 pg          | pg        |
| <b>MCHC</b>             |       |         |                     |           |

|                           | Flags | Results | Ref Range          | Units    |
|---------------------------|-------|---------|--------------------|----------|
| MCHC (F)                  | N     | 318     | 313 - 344 g/L      | g/L      |
| <b>RDW</b>                |       |         |                    |          |
| RDW (F)                   | N     | 16.0    | 12.5 - 17.3        |          |
| <b>WBC</b>                |       |         |                    |          |
| WBC (F)                   | N     | 7.6     | 3.2 - 9.4 x 10E9/L | x 10*9/L |
| <b>PLATELETS</b>          |       |         |                    |          |
| PLATELETS (F)             | N     | 263     | 155 - 372 x 10E9/L | x 10*9/L |
| <b>MPV</b>                |       |         |                    |          |
| MPV (F)                   | N     | 9.4     | 4.0 - 14.0 fl      | fL       |
| <b>DIFFERENTIAL WBC'S</b> |       |         |                    |          |
| NEUTROPHILS (F)           | N     | 4.8     | 1.4 - 6.3 x10E9/L  | x 10*9/L |
| LYMPHOCYTES (F)           | N     | 1.7     | 1.0 - 2.9 x10E9/L  | x 10*9/L |
| MONOCYTES (F)             | H     | 0.9     | 0.2 - 0.8 x10E9/L  | x 10*9/L |
| EOSINOPHILS (F)           | N     | 0.1     | 0.0 - 0.5 x10E9/L  | x 10*9/L |
| BASOPHILS (F)             | N     | 0.00    | 0.00-0.09x10E9/L   | x 10*9/L |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                |                   |                  |                             |                  |                |
|----------------|-------------------|------------------|-----------------------------|------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>HomePhone</b> | <b>(089) 697-3500 a5345</b> | <b>WorkPhone</b> |                |
| Health #       | 0748 361 588KT    | Sex              | M                           | Patient ID       | 0748 361 588KT |
| Age            | 46 years          |                  |                             |                  |                |
| DOB            | 1979              |                  |                             |                  |                |

Comments: FASTING CC copy sent to Sinead Taylor

Lab Order #: Sunnymede Family Practice 2 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2020-Jun-02 Reviewed: 2020-Jun-19 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2020-Jun-03 1:27 AM Updated On: 2020-Jun-19 10:20 AM

|            | Flags | Results | Ref Range   | Units |
|------------|-------|---------|-------------|-------|
| <b>INR</b> |       |         |             |       |
| INR (F)    | N     | 0.9     | 0.9 - 1.300 |       |

0.9 - 1.3 GUIDELINES: SUGGESTED INR RANGE:

1. Most clinical conditions indicating 2.0 - 3.0 anticoagulant therapy
2. Patients with mechanical prosthetic 2.5 - 3.5 heart valves

---

Patient: Mr. Ethan Kang Appointment Date: 2020-Jun-02 Title: CT Crestwood Medical Group Study Visit  
Note Provider: Taylor, Sinead Referred By: Taylor, Sinead Ethan Kang was assessed by telephone for his Crohn's disease on 2020-Jun-02.

Informed verbal consent was obtained from this patient to communicate and provide care using virtual and other telecommunications tools. This patient has been explained the risks related to unauthorized disclosure or interception of personal health information and steps they can take to help protect their information. We have discussed that care provided through video or audio communication cannot replace the need for physical examination or an in person visit for some disorders or urgent problems and patient understands the need to seek urgent care in an Emergency Department as necessary.

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 36 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: none

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: Ethan reported taking one pill of Lansoprazole for a heart burn about 2 weeks ago. He reported that it went away shortly after taking the pill

Ethan has been clinically unchanged since the last study visit.

He has between 3 and 4 bowel movements per day. His stools are always loose. He reported having blood with a bowel movement occur once last week.

He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

He does not have access to a scale to measure weight today. However, he reports his weight has not changed much since the last in-person visit in March.

He reports no perianal drainage.

Physical examination was not done as patient was assessed remotely.

Assessment and Plan

No changes in the patient's management will be made at this time.

The following study procedures were modified or not done due to the current COVID-19 pandemic: Vital signs were not done Physical examination was not done Laboratory samples (hematology and chemistry) were done at a local lab Urine pregnancy test was not done as subject is male IP was sent to subject using YourWay (courier) The subject was instructed to keep all bottles of IP to return to the site at the next in-person study visit. IP accountability was reviewed with the subject. Subject IP compliance is 96 % Re-consent was done remotely. A copy of the consent form was emailed to the patient prior to the appointment



and reviewed over the phone with the CRC. The subject provided a copy of signed consent form to SR by email.

The patient will follow-up according to the clinical trial protocol.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2020-Jun-07

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT WJQ: 158847108 Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Herrera,

Ethan Kang was assessed by telephone for his Crohn's disease on 2020-Jun-02.

Informed verbal consent was obtained from this patient to communicate and provide care using virtual and other telecommunications tools. This patient has been explained the risks related to unauthorized disclosure or interception of personal health information and steps they can take to help protect their information. We have discussed that care provided through video or audio communication cannot replace the need for physical examination or an in person visit for some disorders or urgent problems and patient understands the need to seek urgent care in an Emergency Department as necessary.

Mr. Ethan Kang is participating in the following clinical trial: Lena Beaulieu (filgotinib in Crohn's Disease).

Study Visit timepoint: Week 36 He is currently on open label filgotinib 200mg.

The following adverse events have occurred since the last study visit: none

Ongoing Adverse Events: none

The following changes in medications have occurred since the last study visit: Ethan reported taking one pill of Lansoprazole for a heart burn about 2 weeks ago. He reported that it went away shortly after taking the pill

Ethan has been clinically unchanged since the last study visit.

He has between 3 and 4 bowel movements per day. His stools are always loose. He reported having blood with a bowel movement occur once last week.

He has no abdominal pain.

He denies use of diphenoxylate or loperamide or other opiate for diarrhea over the last 7 days.

He reports no extraintestinal manifestations of IBD.

He does not have access to a scale to measure weight today. However, he reports his weight has not changed much since the last in-person visit in March.

He reports no perianal drainage.

Physical examination was not done as patient was assessed remotely.

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

Assessment and Plan

No changes in the patient's management will be made at this time.

The following study procedures were modified or not done due to the current COVID-19 pandemic: Vital signs were not done Physical examination was not done Laboratory samples (hematology and chemistry) were done at a local lab Urine pregnancy test was not done as subject is male IP was sent to subject using YourWay (courier) The subject was instructed to keep all bottles of IP to return to the site at the next in-person study visit. IP accountability was reviewed with the subject. Subject IP compliance is 96 % Re-consent was done remotely. A copy of the consent form was emailed to the patient prior to the appointment and reviewed over the phone with the CRC. The subject provided a copy of signed consent form to SR by email.

The patient will follow-up according to the clinical trial protocol.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

! [Ontario Logo]

Cedar Specialist Group 2 Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 412 Marigold Ave a nearby city 6 ON T: 993-089-6973 qaa 0534 F: (442) 733-2165

| Clinician/Practitioner Number | CPSO / Registration No. |
|-------------------------------|-------------------------|
| 0748 361 588KT                | 414 235 249             |

Check ( ) one: [X] OHIP/Insured [ ] Third Party / Uninsured [ ] WSIB

Additional Clinical Information (e.g. diagnosis) Patient with inflammatory bowel disease, These tests are being ordered by a gastroenterologist

[X] Copy to: Clinician/Practitioner Last Name First Name Sinead Taylor Address 412 Marigold Ave a nearby city 6 848 Main Blvd Fax (442) 733-2165

Laboratory Use Only

Clinician/Practitioner's Contact Number for Urgent Results (442) 733-2165

| Service Date | 1979 | mm | 1979 |
|--------------|------|----|------|
| (blank)      |      |    |      |

Health Number: 0748 361 588KT Version: (blank) Sex: M

Date of Birth: 1979 1979 mm 06 1979 1979

Province: (blank) Other Provincial Registration Number: (blank)

Patient's Telephone Contact Number: (442) 733-2165

Patient's Last Name (as per OHIP Card): Ethan Kang

Patient's First & Middle Names (as per OHIP Card): Ethan Kang

Patient's Address (including Postal Code): a nearby city 8

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Crestwood Medical Group

| x   | Biochemistry                   | x   | Hematology                                                         | x   | Viral Hepatitis (check one only)                                                           |
|-----|--------------------------------|-----|--------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------------|
| [X] | Glucose [X] Random [ ] Fasting | [X] | CBC                                                                | [ ] | Acute Hepatitis                                                                            |
| [ ] | HbA1C                          | [X] | Prothrombin Time (INR)                                             | [ ] | Chronic Hepatitis                                                                          |
| [X] | Creatinine (eGFR)              |     | <b>Immunology</b>                                                  | [ ] | Immune Status / Previous Exposure Specify: [ ] Hepatitis A [ ] Hepatitis B [ ] Hepatitis C |
| [ ] | Uric Acid                      | [ ] | Pregnancy Test (Urine)                                             |     |                                                                                            |
| [X] | Sodium                         | [ ] | Mononucleosis Screen                                               |     |                                                                                            |
| [X] | Potassium                      | [ ] | Rubella                                                            |     | or order individual hepatitis tests in the "Other Tests" section below                     |
| [X] | ALT                            | [ ] | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) |     | <b>Prostate Specific Antigen (PSA)</b>                                                     |

|          |                                                                                                                                                                                     |          |                                                           |          |                                                                                                                                                                  |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|-----------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b> | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b> | <b>Hematology</b>                                         | <b>x</b> | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
| [X]      | Alk. Phosphatase                                                                                                                                                                    | [ ]      | Repeat Prenatal Antibodies                                | [ ]      | Total PSA [ ] Free PSA                                                                                                                                           |
| [X]      | Bilirubin                                                                                                                                                                           |          | <b>Microbiology ID &amp; Sensitivities (if warranted)</b> |          | Specify one below:                                                                                                                                               |
| [X]      | Albumin                                                                                                                                                                             | [ ]      | Cervical                                                  | [ ]      | Insured - Meets OHIP eligibility criteria                                                                                                                        |
| [ ]      | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [ ]      | Vaginal                                                   | [ ]      | Uninsured - Screening: Patient responsible for payment                                                                                                           |
| [ ]      | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | [ ]      | Vaginal / Rectal - Group B Strep                          |          | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                    |
| [ ]      | Urinalysis (Chemical)                                                                                                                                                               | [ ]      | Chlamydia (specify source):                               | [ ]      | Insured - Meets OHIP eligibility criteria; osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
|          | Neonatal Bilirubin: Child's Age: days hours                                                                                                                                         | [ ]      | GC (specify source):                                      |          |                                                                                                                                                                  |
| [ ]      | Clinician/Practitioner's tel. no. ( )                                                                                                                                               | [ ]      | Sputum                                                    | [ ]      | Uninsured - Patient responsible for payment                                                                                                                      |
| [ ]      | Patient's 24 hr telephone no. ( )                                                                                                                                                   | [ ]      | Throat                                                    |          | <b>Other Tests</b> - one test per line                                                                                                                           |
|          | Therapeutic Drug Monitoring:                                                                                                                                                        | [ ]      | Wound (specify source):                                   |          | Direct and indirect bilirubin                                                                                                                                    |
|          | Name of Drug #1                                                                                                                                                                     | [ ]      | Urine                                                     |          | Total protein                                                                                                                                                    |
|          | Name of Drug #2                                                                                                                                                                     | [ ]      | Stool Culture                                             |          | bicarbonate, BUN, and CPK                                                                                                                                        |
|          | Time Collected #1 hr. #2 hr.                                                                                                                                                        | [ ]      | Stool Ova & Parasites                                     |          | AST                                                                                                                                                              |
|          | Time of Last Dose #1 hr. #2 hr.                                                                                                                                                     | [ ]      | Other Swabs / Pus (specify source):                       |          | Phosphorus, Mg, Chloride, Calcium                                                                                                                                |
|          | Time of Next Dose #1 hr. #2 hr.                                                                                                                                                     |          |                                                           |          |                                                                                                                                                                  |

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

Specimen Collection Time: (blank) Date: MM/1979/1979 (blank)

Fecal Occult Blood Test (FOBT) (check one) ☐ FOBT (non CCC) ☐ ColonCancerCheck FOBT (CCC) no other test can be ordered on this form

Laboratory Use Only

[signature] X Clinician/Practitioner Signature

Date: 2020-May-28

4422-84 (2013/01) © Queen's Printer for Ontario, 2013 7530-4581

---

## **Cedar Specialist Group 4** Cedar Specialist Group 4 Ridgeway Family Health

412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd t: (492) 417-7743

NEP: 566-383-973 Visit #: [REDACTED-VISIT-ENCOUNTER-ID] Encounter: Day Surgery Fin #:  
[REDACTED-VISIT-ENCOUNTER-ID] Patient Name: Ethan Kang Address: 412 Marigold Ave a nearby city 6, Ontario 848 Main Blvd

Date of Birth: 1979 Sex: Male Health Card: 6609604884PP V: 5753727875QP Admit Date: 2020-03-05  
Discharge Date: 2020-03-05

---

## **HRS Transcribed Reports**

Document Type: Endoscopy Report Result Status: Transcribed Performed Information: Sinead Taylor  
(2020-04-17 16:24) Signed Information:

### **Endoscopy Report**

Visit ID:[REDACTED-VISIT-ENCOUNTER-ID] Procedure Date:2020-03-05

PROCEDURE: Endoscopy.

STAFF SURGEON: Dr. Sinead Taylor.

ASSISTANT: None.

INDICATION: This patient is a 40-year-old man with Crohn's disease who is presently in a clinical trial evaluating the use of a filgotinib for small bowel Crohn's disease. Endoscopy was undertaken today to evaluate his current disease extent and severity.

PROCEDURE: Written informed consent was obtained from the patient after the risks and benefits were explained to him. He was sedated with 4 mg of IV Versed and 50 mcg of IV fentanyl. His digital rectal exam was normal with no evidence of perianal disease. A variable tension adult colonoscope was inserted from the anus and passed to the neoterminal ileum. The entire colon was well visualized and was normal with SES of zero in each segment. The anastomosis was widely patent. The neoterminal ileum continued to be involved with a moderately significant inflammatory process consisting of small and medium sized ulcers and diffuse inflammatory changes with erythema. The SES score was 8 in the neoterminal ileum with 3 for

affected surface, 3 for ulcerated surface, and 2 for ulcer size. The Rutgeerts score is 4. The scope was withdrawn and no samples were taken.

IMPRESSION: There continues to be significant ileal inflammatory disease. I will meet with him in the office in a few weeks' time to discuss next steps. Sinead Taylor

Request ID: [REDACTED-VISIT-ENCOUNTER-ID] Print Date: 2020-04-17 17:06 Printed By: System Generated

---

This information is privileged and contains confidential information intended for specified person(s) for limited purposes. Accordingly, this information should be treated as strictly confidential. Any unauthorized access, disclosure, copying, other distribution of this information or taking any action on its contents is strictly prohibited by law. If you have received this information in error, please notify Cedar Specialist Group 4 immediately by contacting Outpatient Services at 277-586-4140.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, Ontario 848 Main Blvd

NEP: 566-383-973 Visit #: [REDACTED-VISIT-ENCOUNTER-ID] Fin #: [REDACTED-VISIT-ENCOUNTER-ID] Patient Name: Ethan Kang

---

## HRS Transcribed Reports

---

Authenticated 10 days after distribution date

Dictated By: Sinead Taylor Dictated: 2020-04-17 39:93:34 PM Transcribed: 2020-04-17 72:05:12 PM Distributed: 2020-04-17 72:05:12 PM

Job #: [REDACTED-VISIT-ENCOUNTER-ID] [REDACTED-VISIT-ENCOUNTER-ID]

cc: Sinead Taylor (Fax: (442) 733-2165) Sinead Taylor

Request ID: [REDACTED-VISIT-ENCOUNTER-ID] Print Date: 2020-04-17 17:06 Printed By: System Generated

---

This information is privileged and contains confidential information intended for specified person(s) for limited purposes. Accordingly, this information should be treated as strictly confidential. Any unauthorized access, disclosure, copying, other distribution of this information or taking any action on its contents is strictly prohibited by law. If you have received this information in error, please notify Cedar Specialist Group 4 immediately by contacting Outpatient Services at 277-586-4140.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2020-Apr-06

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

**Patient:** Mr. Ethan Kang **PHN:** 0748 361 588KT **MRN:** 414 235 249 **Birthdate:** 1979 **Phone: H:** (442) 733-2165 **C:** (442) 733-2165 **Address:** 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Herrera,

I saw Ethan Kang today for follow up of his Crohn's disease by telephone.

**Problem History:** Crohn's disease

**IBD Phenotype:** Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**Endoscopy Results:** 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

**Active Medications:** Study medication - open label Filgotinib

**Current Status**

Having 3-4 BMs/day. Loose. No blood. No abdominal pain. Weight, energy and appetite are all stable.

**Assessment and Plan** Ethan Kang currently has mildly active disease but is marginally better than prior to the study both clinically and endoscopically. I don't have a lot of options for him right now so we are going to stay the course for the time being. He is tolerating it well.

I will see him again in follow up in 4 months in the office.

Sincerely,

[signature]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

---

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

---

[X] \* \_ \_

This task has been completed

|                 |                 |                        |                                                     |
|-----------------|-----------------|------------------------|-----------------------------------------------------|
| <b>Patient</b>  | Ethan Kang      | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Date Due</b> | [REDACTED-DATE] | <b>Priority</b>        | Normal                                              |

|                    |                                                     |                  |                                                                    |
|--------------------|-----------------------------------------------------|------------------|--------------------------------------------------------------------|
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b> | 2020-Apr-06 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | office FU 4m                                        |                  |                                                                    |

Patient: Mr. Ethan Kang Appointment Date: 2020-Apr-06 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: None I saw Ethan Kang today for follow up of his Crohn's disease by telephone.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

Endoscopy Results: 2020-Mar-05 Colonoscopy - neoTI : Rutgeert's i4,SES 8, colon SES 0 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

Active Medications: Study medication - open label Filgotinib

Current Status

Having 3-4 BMs/day. Loose. No blood. No abdominal pain. Weight, energy and appetite are all stable.

Assessment and Plan Ethan Kang currently has mildly active disease but is marginally better than prior to the study both clinically and endoscopically. I don't have a lot of options for him right now so we are going to stay the course for the time being. He is tolerating it well.

I will see him again in follow up in 4 months in the office.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

To whom it may concern:

Re: Ethan Kang

Ethan is under my care for a chronic inflammatory illness and is on immunosuppressant medications. There is a potential increased risk of this person contracting infections, and a potential risk of a more severe illness from the infection, than a person who does not have the chronic illness or who is not on the medication. Please consider adjusting their work duties and allowing them to work remotely from their home during the COVID-19 time period.

Please do not hesitate to contact me at (894) 794-5469 ext. 1391

Sincerely

Sincerely,



[image]

Riverside Medical Centre Isolde Xiong Electronically Reviewed to Expedite Delivery

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

|                 |                       |                          |                    |
|-----------------|-----------------------|--------------------------|--------------------|
| <b>Patient:</b> | <b>Mr. Ethan Kang</b> | <b>Appointment Date:</b> | <b>2020-Mar-24</b> |
| Title:          | COVID - work note     | Referred By:             | None               |
| Provider:       | Taylor, Sinead        |                          |                    |

To whom it may concern:

Re: Ethan Kang

Ethan is under my care for a chronic inflammatory illness and is on immunosuppressant medications. There is a potential increased risk of this person contracting infections, and a potential risk of a more severe illness from the infection, than a person who does not have the chronic illness or who is not on the medication. Please consider adjusting their work duties and allowing them to work remotely from their home during the COVID-19 time period.

Please do not hesitate to contact me at (894) 794-5469 ext. 1391

Sincerely

☐ \* --

This task has been completed

|                    |                                                                                           |                        |                                                                    |
|--------------------|-------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                                                | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | [REDACTED-DATE]                                                                           | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                                       | <b>Completed</b>       | 2020-Mar-26 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | check with Bypejz Vhn when is next study visit...otherwise need to see in FU in next 4-6w |                        |                                                                    |

**Conversations**

**Created 2020-Mar-18 12:54 PM**

2020-Mar-18 12:54 PM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

[ ] When is next study visit..

[ ] Sinead Taylor

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

Colonoscopy Record

412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd

Clearly imprint patient identification card

414 235 249 [REDACTED-VISIT-ENCOUNTER-ID] DAYPT Ethan Kang 1979 M 40 Y 994-882-7246 ON 2479844273 2020-Mar-05 10:51 412 Marigold Ave a nearby city 6, ONTARIO a nearby city 7

MS 21 (Rev 02 2016) Page 1 of 1 Date: (1979) MAR 5, 2020 Time: (HH:MM) Requested by Performed by MS

Pre-operative Diagnosis: Crohn's Final Diagnosis: CD

| SES-CD                | 0          | 1                         | 2                    | 3                               |
|-----------------------|------------|---------------------------|----------------------|---------------------------------|
| Ulcer Size (cm)       | None       | Aphthous ulcers (0.1-0.5) | Large ulcers (0.5-2) | Very large ulcers (more than 2) |
| (%) Ulcerated surface | None       | Less than 10              | 10-30                | More than 30                    |
| (%) Affected surface  | Unaffected | Less than 50              | 50-75                | More than 75                    |
| Narrowings?           | None       | Single, can pass          | Multiple, can pass   | Cannot pass                     |

|   | *Mayo Score UC/IC                                                        |
|---|--------------------------------------------------------------------------|
| 0 | Normal / Inactive                                                        |
| 1 | Mild (erythema, decreased vascular pattern, mild friability)             |
| 2 | Moderate (marked erythema, absent vascular pattern, friability, erosion) |
| 3 | Severe (spontaneous bleeding, ulceration)                                |

| Grade | Rutgeert's Score (CD Post-operative)                           |
|-------|----------------------------------------------------------------|
| 0     | Normal                                                         |
| 1     | 5 aphthous ulcers or less                                      |
| 2     | more than 5 aphthous ulcers with normal mucosa                 |
| 3     | Diffuse aphthous ileitis with diffusely inflamed mucosa        |
| 4     | Diffuse inflammation with large ulcer/nodules and/or narrowing |

Total Sedation Required: 50 [ ] Midazolam \_\_\_\_ mg IV [X] Fentanyl 50 mcg [ ] Propofol \_\_\_\_ mg IV [ ] Other:  
 \_\_\_\_

Bowel Preparation: [X] Adequate sludge [ ] Inadequate Time to reach Cecum: \_\_\_\_ min. Terminal ileum  
 intubated: [X] Yes [ ] No \_\_\_\_ cm. Retroflexion in Rectum: [ ] Yes [X] No Withdrawal time (Cecum to Anus):  
 \_\_\_\_ min.

| ASCENDING             | Score |
|-----------------------|-------|
| *Mayo-UC/IC           |       |
| *SES-CD:              | 0     |
| Ulcer Size (cm)       |       |
| (%) Ulcerated surface |       |
| (%) Affected surface  |       |
| Narrowings?           |       |

| ASCENDING          | # of polyps |
|--------------------|-------------|
| Removed            |             |
| Retrieved          |             |
| Partially removed  |             |
| Size               |             |
| Tattoo             |             |
| Number of Biopsies |             |

| TERMINAL ILEUM        | Score |
|-----------------------|-------|
| SES-CD:               | 8     |
| Ulcer Size (cm)       | 3     |
| (%) Ulcerated surface | 2     |
| (%) Affected surface  | 3     |
| Narrowings?           | 0     |
| Rutgeert's Score      | i2a   |

| TRANSVERSE            | Score |
|-----------------------|-------|
| *Mayo-UC/IC           |       |
| *SES-CD:              | 0     |
| Ulcer Size (cm)       |       |
| (%) Ulcerated surface |       |
| (%) Affected surface  |       |

| <b>TRANSVERSE</b> | <b>Score</b> |
|-------------------|--------------|
| Narrowings?       |              |

| <b>TRANSVERSE</b>  | <b># of polyps</b> |
|--------------------|--------------------|
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

[Diagram of colon with handwritten notes: "Cecal patch", "4", "No Bx"]

| <b>DESCENDING</b>     | <b>Score</b> |
|-----------------------|--------------|
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |
| Narrowings?           |              |

| <b>DESCENDING</b>  | <b># of polyps</b> |
|--------------------|--------------------|
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

| <b>RECTUM</b>         | <b>Score</b> |
|-----------------------|--------------|
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |

|               |              |
|---------------|--------------|
| <b>RECTUM</b> | <b>Score</b> |
| Narrowings?   |              |

|                    |                    |
|--------------------|--------------------|
| <b>RECTUM</b>      | <b># of polyps</b> |
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

PERIANAL ☐ Hemorrhoid ☐ ☐ Fissure ☐ Abscess ☐ Fistula ☐ Skin Tag

Date: (1979) Time: (HH : MM) Print Name Signatures: [signature], M.D.

[image]

[image]

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

XKAMJGSJY UD. 4995064053 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W24 Week 24

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

COLLECTION TIME:11:50 DATE:Mar 5, 2020 DATE RECEIVED IN LABORATORY: Mar 6, 2020 DATE REPORTED BY LABORATORY: Mar 6, 2020 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                           |       |    | <b>Ref. Ranges</b> | <b>Clinically Significant</b> |
|---------------------------|-------|----|--------------------|-------------------------------|
|                           |       |    |                    | Yes* No                       |
| CREATININE CLEARANCE CC&G |       |    |                    |                               |
| Weight                    | 126.1 | kg |                    |                               |
| Creatinine                | 70    |    | 40-110 umol/L      |                               |

|           |      |   | Ref. Ranges      | Clinically Significant |
|-----------|------|---|------------------|------------------------|
| Creat Clr | 3.70 | H | 1.42-2.08 mL/sec | [ ] [ ]                |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XKAMJGSJY UD. 4995064053 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical  
Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON  
Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER:  
ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W24 Week 24

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

COLLECTION TIME: 11:50 DATE: Mar 5, 2020 DATE RECEIVED IN LABORATORY: Mar 6, 2020 DATE  
REPORTED BY LABORATORY: Mar 6, 2020 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER:  
0748 361 588KT DOB: HC 1981

|                                  |                       | Ref. Ranges        | Clinically Significant |
|----------------------------------|-----------------------|--------------------|------------------------|
|                                  |                       |                    | Yes* No                |
| HEMATOLOGY&DIFFERENTIAL<br>PANEL |                       |                    |                        |
| HGB                              | 133                   | 127-181 g/L        |                        |
| HCT                              | 0.40                  | 0.39-0.54          |                        |
| RBC                              | 4.9                   | 4.5-6.4 TI/L       |                        |
| RBC Morph                        | No Review<br>Required |                    |                        |
| MCV                              | 81                    | 79-96 fL           |                        |
| WBC                              | 7.39                  | 3.80-10.70<br>GI/L |                        |
| Neutrophil                       | 5.30                  | 1.96-7.23 GI/L     |                        |

|            |      | <b>Ref. Ranges</b> | <b>Clinically Significant</b> |
|------------|------|--------------------|-------------------------------|
| Lymphocyte | 1.42 | 0.91-4.28 GI/L     |                               |
| Monocytes  | 0.49 | 0.12-0.92 GI/L     |                               |
| Eosinophil | 0.11 | 0.00-0.57 GI/L     |                               |
| Basophils  | 0.08 | 0.00-0.20 GI/L     |                               |
| Neutrophil | 71.6 | 40.5-75.0 %        |                               |
| Lymphocyte | 19.1 | 15.4-48.5 %        |                               |
| Monocytes  | 6.6  | 2.6-10.1 %         |                               |
| Eosinophil | 1.5  | 0.0-6.8 %          |                               |
| Basophils  | 1.1  | 0.0-2.0 %          |                               |
| Platelets  | 268  | 140-400 GI/L       |                               |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

XKAMJGSJY UD. 4995064053 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W24 Week 24

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

COLLECTION TIME: 11:50 DATE: Mar 5, 2020 DATE RECEIVED IN LABORATORY: Mar 6, 2020 DATE REPORTED BY LABORATORY: Mar 6, 2020 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                 |  | <b>Ref. Ranges</b> | <b>Clinically Significant</b> |
|-----------------|--|--------------------|-------------------------------|
|                 |  |                    | Yes* No                       |
| CHEMISTRY PANEL |  |                    |                               |

|            |      | Ref. Ranges      | Clinically Significant |
|------------|------|------------------|------------------------|
| Total Bili | 7    | 3-21 umol/L      |                        |
| Dir Bili   | 2    | <2-7 umol/L      |                        |
| Ind Bili   | 5    | 0-21 umol/L      |                        |
| Alk Phos   | 66   | 31-129 U/L       |                        |
| ALT (SGPT) | 19   | 6-43 U/L         |                        |
| AST (SGOT) | 16   | 11-36 U/L        |                        |
| Urea       | 2.9  | 1.4-8.6 mmol/L   |                        |
| Creatinine | 70   | 40-110 umol/L    |                        |
| Glucose    | 4.39 | 3.89-5.55 mmol/L |                        |
| Calcium    | 2.37 | 2.07-2.64 mmol/L |                        |
| Phosphorus | 0.97 | 0.71-1.65 mmol/L |                        |
| Total Prot | 68   | 61-84 g/L        |                        |
| Alb BCG    | 45   | 33-49 g/L        |                        |
| CK         | 215  | 39-308 U/L       |                        |

URINE MACRO & MICRO PANEL Color Yellow Ref Rng: Colorless or Yellow Clarity Clear Ref Rng: Clear pH 5.0 5.0-8.0 Protein Negative Ref Rng: Negative Glucose Normal Ref Rng: Normal Urobilin Normal Ref Rng: Normal Blood Negative Ref Rng: Negative Leuk Est Negative Ref Rng: Negative Microscop Positive

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)-Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

XKAMJGSJY UD. 4995064053 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W24 Week 24 SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6 COLLECTION TIME: 11:50 DATE: Mar 5, 2020 DATE RECEIVED IN LABORATORY: Mar 6, 2020 DATE REPORTED BY LABORATORY: Mar 6, 2020 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981



|                           |        | Ref. Ranges      | Clinically Significant |
|---------------------------|--------|------------------|------------------------|
|                           |        |                  | Yes* No                |
| CELLULAR ELEMENTS         |        |                  |                        |
| WBC                       | 1      | 0-5 /HPF         |                        |
| ALT AND T.BILI            |        |                  |                        |
| ALT TBIL                  | No     |                  |                        |
| AST AND T.BILI            |        |                  |                        |
| AST TBIL                  | No     |                  |                        |
| ALBUMIN CORRECTED CALCIUM |        |                  |                        |
| Corr Ca                   | 2.37   | 2.07-2.64 mmol/L |                        |
| LIPID PANEL               |        |                  |                        |
| HDL-C                     | 0.83   | 0.70-1.73 mmol/L |                        |
| Triglycer                 | 2.79   | 0.62-3.69 mmol/L | G1 [ ] [ ]             |
| Cholest                   | 3.36 L | 4.19-7.24 mmol/L | [ ] [ ]                |
| LDL 3rdGen                | 1.68   | <3.36 mmol/L     |                        |
| ELECTROLYTE PANEL         |        |                  |                        |
| Sodium                    | 139    | 132-147 mmol/L   |                        |
| Potassium                 | 4.4    | 3.5-5.2 mmol/L   |                        |
| Bicarb                    | 21.4   | 17.0-30.6 mmol/L |                        |
| Chloride                  | 103    | 94-112 mmol/L    |                        |
| Magnesium                 | 0.95   | 0.66-1.07 mmol/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)-Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XKAMJGSJY UD. 4995064053 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical  
Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON  
Canada 848 Main Blvd PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W24 Week 24 SPONSOR

REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group  
 412 Marigold Ave Brockville, United Kingdom Z3C 3T6 COLLECTION TIME: 11:50 DATE: Mar 5, 2020  
 DATE RECEIVED IN LABORATORY: Mar 6, 2020 DATE REPORTED BY LABORATORY: Mar 6, 2020  
 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                    |       | Ref. Ranges      | Clinically Significant |
|--------------------|-------|------------------|------------------------|
|                    |       |                  | Yes* No                |
| RETICULOCYTE COUNT |       |                  |                        |
| Retic %            | 1.8   | 0.6-2.5 %        |                        |
| Retic Abs          | 0.087 | 0.030-0.130 TI/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
 T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
 G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
 REPORT

XKAMJGSJY UD. 4995064053 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical  
 Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON  
 Canada 848 Main Blvd PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
 NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W24 Week 24 SPONSOR  
 REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group  
 412 Marigold Ave Brockville, United Kingdom Z3C 3T6 COLLECTION TIME: 11:50 DATE: Mar 5, 2020  
 DATE RECEIVED IN LABORATORY: Mar 6, 2020 DATE REPORTED BY LABORATORY: Mar 8, 2020  
 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                              |       | Ref. Ranges    | Clinically Significant |
|------------------------------|-------|----------------|------------------------|
|                              |       |                | Yes* No                |
| TOTAL IG                     |       |                |                        |
| Total Ig                     | 13.60 | g/L No Ref Rng |                        |
| IMMUNOGLOBULIN A, G, M PANEL |       |                |                        |
| IgA                          | 0.85  | 0.70-4.00 g/L  |                        |
| IgG                          | 12.10 | 5.65-17.65 g/L |                        |
| IgM                          | 0.65  | 0.40-2.30 g/L  |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

QQBYRALVX LP. 5723538960 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical  
Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON  
Canada 848 Main Blvd PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W12 Week 12 SPONSOR  
REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group  
412 Marigold Ave Brockville, United Kingdom Z3C 3T6 COLLECTION TIME: 10:15 DATE: Dec 16, 2019  
DATE RECEIVED IN LABORATORY: Dec 17, 2019 DATE REPORTED BY LABORATORY: Dec 17, 2019  
SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                           |       |   | Ref. Ranges      | Clinically Significant |
|---------------------------|-------|---|------------------|------------------------|
|                           |       |   |                  | Yes* No                |
| CREATININE CLEARANCE CC&G |       |   |                  |                        |
| Weight                    | 128.6 |   | kg               |                        |
| Creatinine                | 79    |   | 40-110 umol/L    |                        |
| Creat Clr                 | 3.35  | H | 1.42-2.08 mL/sec | [[[]]                  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

QQBYRALVX LP. 5723538960 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical  
Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON  
Canada 848 Main Blvd PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W12 Week 12 SPONSOR  
REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group  
412 Marigold Ave Brockville, United Kingdom Z3C 3T6 COLLECTION TIME: 10:15 DATE: Dec 16, 2019

DATE RECEIVED IN LABORATORY: Dec 17, 2019 DATE REPORTED BY LABORATORY: Dec 17, 2019  
 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                               |                    | Ref. Ranges     | Clinically Significant |
|-------------------------------|--------------------|-----------------|------------------------|
|                               |                    |                 | Yes* No                |
| HEMATOLOGY&DIFFERENTIAL PANEL |                    |                 |                        |
| HGB                           | 134                | 127-181 g/L     |                        |
| HCT                           | 0.41               | 0.39-0.54       |                        |
| RBC                           | 5.0                | 4.5-6.4 TI/L    |                        |
| RBC Morph                     | No Review Required |                 |                        |
| MCV                           | 83                 | 79-96 fL        |                        |
| WBC                           | 6.85               | 3.80-10.70 GI/L |                        |
| Neutrophil                    | 4.29               | 1.96-7.23 GI/L  |                        |
| Lymphocyte                    | 1.98               | 0.91-4.28 GI/L  |                        |
| Monocytes                     | 0.46               | 0.12-0.92 GI/L  |                        |
| Eosinophil                    | 0.08               | 0.00-0.57 GI/L  |                        |
| Basophils                     | 0.03               | 0.00-0.20 GI/L  |                        |
| Neutrophil                    | 62.7               | 40.5-75.0 %     |                        |
| Lymphocyte                    | 29.0               | 15.4-48.5 %     |                        |
| Monocytes                     | 6.7                | 2.6-10.1 %      |                        |
| Eosinophil                    | 1.2                | 0.0-6.8 %       |                        |
| Basophils                     | 0.4                | 0.0-2.0 %       |                        |
| Platelets                     | 291                | 140-400 GI/L    |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
 T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

QQBYRALVX LP. 5723538960 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W12 Week 12 SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6 COLLECTION TIME: 10:15 DATE: Dec 16, 2019 DATE RECEIVED IN LABORATORY: Dec 17, 2019 DATE REPORTED BY LABORATORY: Dec 17, 2019 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                 |      | Ref. Ranges      | Clinically Significant |
|-----------------|------|------------------|------------------------|
|                 |      |                  | Yes* No                |
| CHEMISTRY PANEL |      |                  |                        |
| #1 Total Bili   | 3    | 3-21 umol/L      |                        |
| Dir Bili        | <2   | <2-7 umol/L      |                        |
| Ind Bili        | <3   | 0-21 umol/L      |                        |
| Alk Phos        | 70   | 31-129 U/L       |                        |
| ALT (SGPT)      | 21   | 6-43 U/L         |                        |
| AST (SGOT)      | 17   | 11-36 U/L        |                        |
| Urea            | 3.2  | 1.4-8.6 mmol/L   |                        |
| Creatinine      | 79   | 40-110 umol/L    |                        |
| Glucose         | 5.11 | 3.89-5.55 mmol/L |                        |
| Calcium         | 2.42 | 2.07-2.64 mmol/L |                        |
| Phosphorus      | 1.10 | 0.71-1.65 mmol/L |                        |
| Total Prot      | 70   | 61-84 g/L        |                        |
| Alb BCG         | 47   | 33-49 g/L        |                        |
| CK              | 169  | 39-308 U/L       |                        |

ALT AND T.BILI ALT TBIL No

AST AND T.BILI AST TBIL No

ALBUMIN CORRECTED CALCIUM Corr Ca 2.42 2.07-2.64 mmol/L

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,

G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

QQBYRALVX LP. 5723538960 0748 361 588KT INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W12 Week 12 SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6 COLLECTION TIME: 10:15 DATE: Dec 16, 2019 DATE RECEIVED IN LABORATORY: Dec 17, 2019 DATE REPORTED BY LABORATORY: Dec 17, 2019 SEX: M BIRTHDATE: 1979 AGE: 40y SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                   |      | Ref. Ranges      | Clinically Significant |
|-------------------|------|------------------|------------------------|
|                   |      |                  | Yes* No                |
| ELECTROLYTE PANEL |      |                  |                        |
| Sodium            | 140  | 132-147 mmol/L   |                        |
| Potassium         | 4.7  | 3.5-5.2 mmol/L   |                        |
| Bicarb            | 23.0 | 17.0-30.6 mmol/L |                        |
| Chloride          | 103  | 94-112 mmol/L    |                        |
| Magnesium         | 0.86 | 0.66-1.07 mmol/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

QQBYRALVX LP. 5723538960 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: 0748 361 588KT Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W12 a nearby city 6, ON Canada 848 Main Blvd Week 12 SPONSOR REPORT TO: COLLECTION TIME: 10:15 DATE: Dec 16, 2019 Glenmore Specialist Centre DATE RECEIVED IN

LABORATORY: Dec 17, 2019 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY:  
Dec 18, 2019 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 40y 412 Marigold Ave SCREEN  
NUMBER: 0748 361 588KT Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                    |       | Ref. Ranges      | Clinically Significant |
|--------------------|-------|------------------|------------------------|
|                    |       |                  | Yes* No                |
| RETICULOCYTE COUNT |       |                  |                        |
| Retic %            | 1.6   | 0.6-2.5 %        |                        |
| Retic Abs          | 0.081 | 0.030-0.130 TI/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

DXYGDJEWH GF. 6456247984 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748  
361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre  
SUBJECT NUMBER: 0748 361 588KT Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED:  
412 Marigold Ave VISIT: W4 a nearby city 6, ON Canada 848 Main Blvd Week 4 SPONSOR REPORT TO:  
COLLECTION TIME:10:15 DATE:Oct 28, 2019 Glenmore Specialist Centre DATE RECEIVED IN  
LABORATORY: Oct 29, 2019 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY:  
Oct 31, 2019 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN  
NUMBER: 0748 361 588KT Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                           |        | Ref. Ranges      | Clinically Significant |
|---------------------------|--------|------------------|------------------------|
|                           |        |                  | Yes* No                |
| CREATININE CLEARANCE CC&G |        |                  |                        |
| Weight                    | 129.6  | kg               |                        |
| Creatinine                | 85     | 40-110 umol/L    |                        |
| Creat Clr                 | 3.13 H | 1.42-2.08 mL/sec | [[[]]]                 |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,

## G4: Toxicity Grades

(INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

DXYGDJEWH GF. 6456247984 Page 1 of 1 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: 0748 361 588KT Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W4 a nearby city 6, ON Canada 848 Main Blvd Week 4 SPONSOR REPORT TO: COLLECTION TIME:10:15 DATE:Oct 28, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 29, 2019 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY: Oct 31, 2019 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER: 0748 361 588KT Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                               |                    | Ref. Ranges     | Clinically Significant |
|-------------------------------|--------------------|-----------------|------------------------|
|                               |                    |                 | Yes* No                |
| HEMATOLOGY&DIFFERENTIAL PANEL |                    |                 |                        |
| HGB                           | 128                | 127-181 g/L     |                        |
| HCT                           | 0.40               | 0.39-0.54       |                        |
| RBC                           | 4.9                | 4.5-6.4 TI/L    |                        |
| RBC Morph                     | No Review Required |                 |                        |
| MCV                           | 82                 | 79-96 fL        |                        |
| WBC                           | 7.86               | 3.80-10.70 GI/L |                        |
| Neutrophil                    | 5.43               | 1.96-7.23 GI/L  |                        |
| Lymphocyte                    | 1.70               | 0.91-4.28 GI/L  |                        |
| Monocytes                     | 0.59               | 0.12-0.92 GI/L  |                        |
| Eosinophil                    | 0.09               | 0.00-0.57 GI/L  |                        |
| Basophils                     | 0.04               | 0.00-0.20 GI/L  |                        |
| Neutrophil                    | 69.1               | 40.5-75.0 %     |                        |
| Lymphocyte                    | 21.6               | 15.4-48.5%      |                        |
| Monocytes                     | 7.6                | 2.6-10.1 %      |                        |
| Eosinophil                    | 1.2                | 0.0-6.8 %       |                        |



|           |     | <b>Ref. Ranges</b> | <b>Clinically Significant</b> |
|-----------|-----|--------------------|-------------------------------|
| Basophils | 0.5 | 0.0-2.0 %          |                               |
| Platelets | 249 | 140-400 GI/L       |                               |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

DXYGDJEWH GF. 6456247984 Page 1 of 2 INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W4

Week 4 COLLECTION TIME:10:15 DATE:Oct 28, 2019 DATE RECEIVED IN LABORATORY: Oct 29, 2019 DATE REPORTED BY LABORATORY: Nov 1, 2019 SEX: M BIRTHDATE: 1979 AGE: 40 SCREEN NUMBER: 0748 361 588KT DOB: HC 1981

|                 |     | <b>Ref. Ranges</b> | <b>Clinically Significant</b> |
|-----------------|-----|--------------------|-------------------------------|
|                 |     |                    | Yes* No                       |
| CHEMISTRY PANEL |     |                    |                               |
| Total Bili      | 5   | 3-21 umol/L        |                               |
| Dir Bili        | <2  | <2-7 umol/L        |                               |
| Ind Bili        | <5  | 0-21 umol/L        |                               |
| Alk Phos        | 67  | 31-129 U/L         |                               |
| ALT (SGPT)      | 17  | 6-43 U/L           |                               |
| AST (SGOT)      | 17  | 11-36 U/L          |                               |
| Urea            | 5.0 | 1.4-8.6 mmol/L     |                               |
| Creatinine      | 85  | 40-110 umol/L      |                               |

|            |        | Ref. Ranges      | Clinically Significant |
|------------|--------|------------------|------------------------|
| Glucose    | 3.50 L | 3.89-5.55 mmol/L | G1 [ ] [ ]             |
| Calcium    | 2.42   | 2.07-2.64 mmol/L |                        |
| Phosphorus | 1.26   | 0.71-1.65 mmol/L |                        |
| Total Prot | 69     | 61-84 g/L        |                        |
| Alb BCG    | 45     | 33-49 g/L        |                        |
| CK         | 194    | 39-308 U/L       |                        |

ALT AND T.BILI ALT TBIL No

AST AND T.BILI AST TBIL No

ALBUMIN CORRECTED CALCIUM Corr Ca 2.42 2.07-2.64 mmol/L

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

DXYGDJEWH GF. 6456247984 Page 1 of 1 INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre  
c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848  
Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: [illegible] PATIENT INITIALS NOT COLLECTED: VISIT: W4

Week 4 COLLECTION TIME: 10:15 DATE: Oct 28, 2019 DATE RECEIVED IN LABORATORY: Oct 29,  
2019 DATE REPORTED BY LABORATORY: Oct 31, 2019 SEX: M BIRTHDATE: 1979 AGE: 40 SCREEN  
NUMBER: [illegible] DOB: HC 1981

|                    |     | Ref. Ranges | Clinically Significant |
|--------------------|-----|-------------|------------------------|
|                    |     |             | Yes* No                |
| RETICULOCYTE COUNT |     |             |                        |
| Retic %            | 1.9 | 0.6-2.5 %   |                        |

|           |       | Ref. Ranges      | Clinically Significant |
|-----------|-------|------------------|------------------------|
| Retic Abs | 0.093 | 0.030-0.130 TI/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

DXYGDJEWH GF. 6456247984

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar  
Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood  
Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT  
NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W4

Week 4 COLLECTION TIME: 10:15 DATE: Oct 28, 2019 DATE RECEIVED IN LABORATORY: Oct 29,  
2019 DATE REPORTED BY LABORATORY: Nov 1, 2019 SEX: M BIRTHDATE: 1979 AGE: 40 SCREEN  
NUMBER: ZSNJZVNLN55QGJ DOB: HC 1981

|                   |      | Ref. Ranges      | Clinically Significant |
|-------------------|------|------------------|------------------------|
|                   |      |                  | Yes* No                |
| ELECTROLYTE PANEL |      |                  |                        |
| Sodium            | 141  | 132-147 mmol/L   |                        |
| Potassium         | 4.8  | 3.5-5.2 mmol/L   |                        |
| Bicarb            | 21.8 | 17.0-30.6 mmol/L |                        |
| Chloride          | 102  | 94-112 mmol/L    |                        |
| Magnesium         | 0.86 | 0.66-1.07 mmol/L |                        |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)-Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,

G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

LJHMUQNPE NH. 6930376088

INVESTIGATOR: (0748 361 588KT) Riverside Medical Centre c/o Brookfield Medical Centre Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, ON Canada 848 Main Blvd

SPONSOR REPORT TO: Glenmore Specialist Centre c/o Westbrook Medical Associates Crestwood Medical Group 412 Marigold Ave Brockville, United Kingdom Z3C 3T6

0748 361 588KT PROTOCOL 0748 361 588KT INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: ZSNJZVNLN55QGJ PATIENT INITIALS NOT COLLECTED: VISIT: W2

Week 2 COLLECTION TIME: 10:30 DATE: Oct 21, 2019 DATE RECEIVED IN LABORATORY: Oct 22, 2019 DATE REPORTED BY LABORATORY: Oct 25, 2019 SEX: M BIRTHDATE: 1979 AGE: 40 SCREEN NUMBER: ZSNJZVNLN55QGJ DOB: HC 1981

|                           |        | Ref. Ranges      | Clinically Significant |
|---------------------------|--------|------------------|------------------------|
|                           |        |                  | Yes* No                |
| CREATININE CLEARANCE CC&G |        |                  |                        |
| Weight                    | 127.5  | kg               |                        |
| Creatinine                | 78     | 40-110 umol/L    |                        |
| Creat Clr                 | 3.35 H | 1.42-2.08 mL/sec | [ ] [ ]                |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)-Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

LJHMUQNPE NH. 6930376088

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave

VISIT: W2 a nearby city 6, ON Canada 848 Main Blvd Week 2 SPONSOR REPORT TO: COLLECTION  
 TIME: 10:30 DATE: Oct 21, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 22,  
 2019 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY: Oct 24, 2019 Crestwood  
 Medical Group SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
 ZSNJZVNLN55QGJ Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                               |                    |   | Ref. Ranges     | Clinically Significant |     |     |
|-------------------------------|--------------------|---|-----------------|------------------------|-----|-----|
|                               |                    |   |                 | Yes*                   | No  |     |
| HEMATOLOGY&DIFFERENTIAL PANEL |                    |   |                 |                        |     |     |
| HGB                           | 126                | L | 127-181 g/L     | G1                     | [ ] | [ ] |
| HCT                           | 0.39               |   | 0.39-0.54       |                        |     |     |
| RBC                           | 4.8                |   | 4.5-6.4 TI/L    |                        |     |     |
| RBC Morph                     | No Review Required |   |                 |                        |     |     |
| MCV                           | 81                 |   | 79-96 fL        |                        |     |     |
| WBC                           | 7.79               |   | 3.80-10.70 GI/L |                        |     |     |
| Neutrophil                    | 5.45               |   | 1.96-7.23 GI/L  |                        |     |     |
| Lymphocyte                    | 1.72               |   | 0.91-4.28 GI/L  |                        |     |     |
| Monocytes                     | 0.47               |   | 0.12-0.92 GI/L  |                        |     |     |
| Eosinophil                    | 0.10               |   | 0.00-0.57 GI/L  |                        |     |     |
| Basophils                     | 0.05               |   | 0.00-0.20 GI/L  |                        |     |     |
| Neutrophil                    | 70.0               |   | 40.5-75.0 %     |                        |     |     |
| Lymphocyte                    | 1979.1             |   | 15.4-48.5%      |                        |     |     |
| Monocytes                     | 6.0                |   | 2.6-10.1 %      |                        |     |     |
| Eosinophil                    | 1.3                |   | 0.0-6.8 %       |                        |     |     |
| Basophils                     | 0.6                |   | 0.0-2.0 %       |                        |     |     |
| Platelets                     | 272                |   | 140-400 GI/L    |                        |     |     |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)-Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

LJHMQNP NH. 6930376088

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical  
Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER:  
ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave  
VISIT: W2 a nearby city 6, ON Canada 848 Main Blvd Week 2 SPONSOR REPORT TO: COLLECTION  
TIME: 10:30 DATE: Oct 21, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 22,  
2019 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY: Oct 25, 2019 Crestwood  
Medical Group SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
ZSNJZVNLN55QGJ Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                 |      | Ref. Ranges      | Clinically Significant |    |  |
|-----------------|------|------------------|------------------------|----|--|
|                 |      |                  | Yes*                   | No |  |
| CHEMISTRY PANEL |      |                  |                        |    |  |
| Total Bili      | 3    | 3-21 umol/L      |                        |    |  |
| Dir Bili        | <2   | <2-7 umol/L      |                        |    |  |
| Ind Bili        | <3   | 0-21 umol/L      |                        |    |  |
| Alk Phos        | 66   | 31-129 U/L       |                        |    |  |
| ALT (SGPT)      | 17   | 6-43 U/L         |                        |    |  |
| AST (SGOT)      | 14   | 11-36 U/L        |                        |    |  |
| Urea            | 4.3  | 1.4-8.6 mmol/L   |                        |    |  |
| Creatinine      | 78   | 40-110 umol/L    |                        |    |  |
| Glucose         | 4.61 | 3.89-5.55 mmol/L |                        |    |  |
| Calcium         | 2.42 | 2.07-2.64 mmol/L |                        |    |  |
| Phosphorus      | 1.26 | 0.71-1.65 mmol/L |                        |    |  |
| Total Prot      | 69   | 61-84 g/L        |                        |    |  |
| Alb BCG         | 45   | 33-49 g/L        |                        |    |  |
| CK              | 214  | 39-308 U/L       |                        |    |  |

ALT AND T.BILI ALT TBIL No

AST AND T.BILI AST TBIL No

ALBUMIN CORRECTED CALCIUM Corr Ca 2.42 2.07-2.64 mmol/L

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

LJHMUQNPE NH. 6930376088

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical  
Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER:  
ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave  
VISIT: W2 a nearby city 6, ON Canada 848 Main Blvd Week 2 SPONSOR REPORT TO: COLLECTION  
TIME: 10:30 DATE: Oct 21, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 22,  
2019 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY: Oct 24, 2019 Crestwood  
Medical Group SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
ZSNJZVNLN55QGJ Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                    |       | Ref. Ranges      | Clinically Significant |    |  |
|--------------------|-------|------------------|------------------------|----|--|
|                    |       |                  | Yes*                   | No |  |
| RETICULOCYTE COUNT |       |                  |                        |    |  |
| Retic %            | 2.1   | 0.6-2.5 %        |                        |    |  |
| Retic Abs          | 0.102 | 0.030-0.130 TI/L |                        |    |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

LJHMUQNPE NH. 6930376088

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: W2 a nearby city 6, ON Canada 848 Main Blvd Week 2 SPONSOR REPORT TO: COLLECTION TIME: 10:30 DATE: Oct 21, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 22, 2019 c/o Westbrook Medical Associates DATE REPORTED BY LABORATORY: Oct 25, 2019 Crestwood Medical Group SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER: ZSNJZVNLN55QGJ Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                 |      | Ref. Ranges      | Clinically Significant |    |  |
|-----------------|------|------------------|------------------------|----|--|
|                 |      |                  | Yes*                   | No |  |
| ELECTROTE PANEL |      |                  |                        |    |  |
| Sodium          | 142  | 132-147 mmol/L   |                        |    |  |
| Potassium       | 4.5  | 3.5-5.2 mmol/L   |                        |    |  |
| Bicarb          | 20.1 | 17.0-30.6 mmol/L |                        |    |  |
| Chloride        | 105  | 94-112 mmol/L    |                        |    |  |
| Magnesium       | 0.86 | 0.66-1.07 mmol/L |                        |    |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

VKTCBXUWC QG. 1400767262

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: TB-D1 a nearby city 6, ON Canada 848 Main Blvd TB Assessment SPONSOR REPORT TO: COLLECTION TIME: 10:25 DATE: Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 4, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 7, 2019 Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER: ZSNJZVNLN55QGJ Brockville, United Kingdom Z3C 3T6 DOB: HC 1981



|                      |      | Ref. Ranges      | Clinically Significant |    |  |
|----------------------|------|------------------|------------------------|----|--|
|                      |      |                  | Yes*                   | No |  |
| QUANTIFERON GOLD NIL |      |                  |                        |    |  |
| QFTNil               | 0.10 | IU/mL No Ref Rng |                        |    |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

VKTCBXUWC QG. 1400767262

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical  
Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER:  
ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave  
VISIT: TB-D1 a nearby city 6, ON Canada 848 Main Blvd TB Assessment SPONSOR REPORT TO:  
COLLECTION TIME: 10:25 DATE: Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN  
LABORATORY: Oct 4, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 7, 2019  
Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
ZSNJZVNLN55QGJ Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                      |      | Ref. Ranges      | Clinically Significant |    |  |
|----------------------|------|------------------|------------------------|----|--|
|                      |      |                  | Yes*                   | No |  |
| QUANTIFERON GOLD TB1 |      |                  |                        |    |  |
| QFT-TB1              | 0.13 | IU/mL No Ref Rng |                        |    |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

VKTCBXUWC QG. 1400767262

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: TB-D1 a nearby city 6, ON Canada 848 Main Blvd TB Assessment SPONSOR REPORT TO: COLLECTION TIME: 10:25 DATE: Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 4, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 7, 2019 Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER: 0748 361 588KT Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                      |      | Ref. Ranges      | Clinically Significant |    |  |
|----------------------|------|------------------|------------------------|----|--|
|                      |      |                  | Yes*                   | No |  |
| QUANTIFERON GOLD TB2 |      |                  |                        |    |  |
| QFT-TB2              | 0.08 | IU/mL No Ref Rng |                        |    |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3, G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

VKTCBXUWC QG. 1400767262

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER: ZSNJZVNLN55QGJ Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT: TB-D1 a nearby city 6, ON Canada 848 Main Blvd TB Assessment SPONSOR REPORT TO: COLLECTION TIME: 10:25 DATE: Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 4, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 7, 2019 Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER: 0748 361 588KT Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                                |          | Ref. Ranges      | Clinically Significant |    |  |
|--------------------------------|----------|------------------|------------------------|----|--|
|                                |          |                  | Yes*                   | No |  |
| QUANTIFERON GOLD MITOGEN/INTER |          |                  |                        |    |  |
| QFT-Mit                        | 9.95     | IU/mL No Ref Rng |                        |    |  |
| *1 QFTInt                      | Negative | Normal=Negative  |                        |    |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XPNTRHHGH WC. 9295863416

0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748 361 588KT Riverside Medical  
Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre SUBJECT NUMBER:  
YJFHYKC53857 Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED: 412 Marigold Ave VISIT:  
D1 a nearby city 6, ON Canada 848 Main Blvd Day 1 SPONSOR REPORT TO: COLLECTION TIME: 10:25  
DATE: Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN LABORATORY: Oct 3, 2019 c/o Enzo  
Campbell DATE REPORTED BY LABORATORY: Oct 3, 2019 Birchwood Care Clinic SEX: M BIRTHDATE:  
1979 AGE: 40 412 Marigold Ave SCREEN NUMBER: YJFHYKC53857 Brockville, United Kingdom Z3C  
3T6 DOB: HC 1981

|                           |        | Ref. Ranges      | Clinically Significant |     |  |
|---------------------------|--------|------------------|------------------------|-----|--|
|                           |        |                  | Yes*                   | No  |  |
| CREATININE CLEARANCE CC&G |        |                  |                        |     |  |
| Weight                    | 130.4  | kg               |                        |     |  |
| Creatinine                | 72     | 40-110 umol/L    |                        |     |  |
| Creat Clr                 | 3.73 H | 1.42-2.08 mL/sec | [ ]                    | [ ] |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XPNTRHHGH WC. 9295863416 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748  
361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre  
SUBJECT NUMBER: YJFHYKC53857 Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED:

412 Marigold Ave VISIT: D1 a nearby city 6, ON Canada 848 Main Blvd Day 1 SPONSOR REPORT TO:  
 COLLECTION TIME: 10:25 DATE: Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN  
 LABORATORY: Oct 3, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 3, 2019  
 Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
 YJFHYKC53857 Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                               |                    | Ref. Ranges     | Clinically Significant |    |  |
|-------------------------------|--------------------|-----------------|------------------------|----|--|
|                               |                    |                 | Yes*                   | No |  |
| HEMATOLOGY&DIFFERENTIAL PANEL |                    |                 |                        |    |  |
| HGB                           | 136                | 127-181 g/L     |                        |    |  |
| HCT                           | 0.40               | 0.39-0.54       |                        |    |  |
| RBC                           | 5.1                | 4.5-6.4 TI/L    |                        |    |  |
| RBC Morph                     | No Review Required |                 |                        |    |  |
| MCV                           | 79                 | 79-96 fL        |                        |    |  |
| WBC                           | 7.23               | 3.80-10.70 GI/L |                        |    |  |
| Neutrophil                    | 4.53               | 1.96-7.23 GI/L  |                        |    |  |
| Lymphocyte                    | 2.00               | 0.91-4.28 GI/L  |                        |    |  |
| Monocytes                     | 0.55               | 0.12-0.92 GI/L  |                        |    |  |
| Eosinophil                    | 0.10               | 0.00-0.57 GI/L  |                        |    |  |
| Basophils                     | 0.05               | 0.00-0.20 GI/L  |                        |    |  |
| Neutrophil                    | 62.6               | 40.5-75.0 %     |                        |    |  |
| Lymphocyte                    | 27.6               | 15.4-48.5 %     |                        |    |  |
| Monocytes                     | 7.6                | 2.6-10.1 %      |                        |    |  |
| Eosinophil                    | 1.4                | 0.0-6.8 %       |                        |    |  |
| Basophils                     | 0.7                | 0.0-2.0 %       |                        |    |  |
| Platelets                     | 298                | 140-400 GI/L    |                        |    |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XPNTRHHGH WC. 9295863416 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748  
361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre  
SUBJECT NUMBER: YJFHYKC53857 Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED:  
412 Marigold Ave VISIT: D1 a nearby city 6, ON Canada 848 Main Blvd Day 1 SPONSOR REPORT TO:  
COLLECTION TIME: 10:25 DATE: Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN  
LABORATORY: Oct 3, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 4, 2019  
Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
YJFHYKC53857 Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                              |       | Ref. Ranges    | Clinically Significant |    |
|------------------------------|-------|----------------|------------------------|----|
|                              |       |                | Yes*                   | No |
| TOTAL IG                     |       |                |                        |    |
| Total Ig                     | 12.67 | g/L No Ref Rng |                        |    |
| IMMUNOGLOBULIN A, G, M PANEL |       |                |                        |    |
| IgA                          | 0.85  | 0.70-4.00 g/L  |                        |    |
| IgG                          | 11.20 | 5.65-17.65 g/L |                        |    |
| IgM                          | 0.62  | 0.40-2.30 g/L  |                        |    |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XPNTRHHGH WC. 9295863416 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748  
361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre  
SUBJECT NUMBER: YJFHYKC53857 Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED:  
412 Marigold Ave VISIT: D1 a nearby city 6, ON Canada 848 Main Blvd Day 1 SPONSOR REPORT TO:

COLLECTION TIME:10:25 DATE:Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN  
 LABORATORY: Oct 3, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 4, 2019  
 Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
 YJFHYKC53857 Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                        |      | Ref. Ranges      | Clinically Significant |    |
|------------------------|------|------------------|------------------------|----|
|                        |      |                  | Yes*                   | No |
| <b>CHEMISTRY PANEL</b> |      |                  |                        |    |
| #1 Total Bili          | 3    | 3-21 umol/L      |                        |    |
| Dir Bili               | <2   | <2-7 umol/L      |                        |    |
| Ind Bili               | <3   | 0-21 umol/L      |                        |    |
| Alk Phos               | 70   | 31-129 U/L       |                        |    |
| ALT (SGPT)             | 16   | 6-43 U/L         |                        |    |
| AST (SGOT)             | 15   | 11-36 U/L        |                        |    |
| Urea                   | 3.2  | 1.4-8.6 mmol/L   |                        |    |
| Creatinine             | 72   | 40-110 umol/L    |                        |    |
| Glucose                | 5.00 | 3.89-5.55 mmol/L |                        |    |
| Calcium                | 2.42 | 2.07-2.64 mmol/L |                        |    |
| Phosphorus             | 0.94 | 0.71-1.65 mmol/L |                        |    |
| Total Prot             | 73   | 61-84 g/L        |                        |    |
| Alb BCG                | 46   | 33-49 g/L        |                        |    |
| CK                     | 196  | 39-308 U/L       |                        |    |

|                                      |          |                              |  |  |
|--------------------------------------|----------|------------------------------|--|--|
| <b>URINE MACRO &amp; MICRO PANEL</b> |          |                              |  |  |
| Color                                | Yellow   | Ref Rng: Colorless or Yellow |  |  |
| Clarity                              | Cloudy   | Ref Rng:Clear                |  |  |
| pH                                   | 5.0      | 5.0-8.0                      |  |  |
| Protein                              | Negative | Ref Rng:Negative             |  |  |
| Glucose                              | Normal   | Ref Rng:Normal               |  |  |
| Urobilin                             | Normal   | Ref Rng:Normal               |  |  |
| Blood                                | Negative | Ref Rng:Negative             |  |  |
| Leuk Est                             | Negative | Ref Rng:Negative             |  |  |
| Microscop                            | Positive |                              |  |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XPNTRHHGH WC. 9295863416 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748  
361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre  
SUBJECT NUMBER: YJFHYKC53857 Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED:  
412 Marigold Ave VISIT: D1 a nearby city 6, ON Canada 848 Main Blvd Day 1 SPONSOR REPORT TO:  
COLLECTION TIME:10:25 DATE:Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN  
LABORATORY: Oct 3, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 4, 2019  
Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
YJFHYKC53857 Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                                  |         | Ref. Ranges         | Clinically Significant |    |
|----------------------------------|---------|---------------------|------------------------|----|
|                                  |         |                     | Yes*                   | No |
| <b>CELLULAR ELEMENTS</b>         |         |                     |                        |    |
| WBC                              | 1       | 0-5 /HPF            |                        |    |
| <b>CASTS</b>                     |         |                     |                        |    |
| Hyal Casts                       | 3       | 0 /LPF              |                        |    |
| <b>CRYSTALS</b>                  |         |                     |                        |    |
| Ca Ox                            | Present | Ref Rng:Not present |                        |    |
| <b>MISCELLANEOUS ELEMENTS</b>    |         |                     |                        |    |
| Mucous                           | Present | Ref Rng:Not present |                        |    |
| <b>ALT AND T.BILI</b>            |         |                     |                        |    |
| ALT TBIL                         | No      |                     |                        |    |
| <b>AST AND T.BILI</b>            |         |                     |                        |    |
| AST TBIL                         | No      |                     |                        |    |
| <b>ALBUMIN CORRECTED CALCIUM</b> |         |                     |                        |    |
| Corr Ca                          | 2.42    | 2.07-2.64 mmol/L    |                        |    |
| <b>ELECTROLYTE PANEL</b>         |         |                     |                        |    |
| Sodium                           | 139     | 132-147 mmol/L      |                        |    |
| Potassium                        | 4.3     | 3.5-5.2 mmol/L      |                        |    |

|           |      | Ref. Ranges      | Clinically Significant |  |
|-----------|------|------------------|------------------------|--|
| Bicarb    | 19.5 | 17.0-30.6 mmol/L |                        |  |
| Chloride  | 104  | 94-112 mmol/L    |                        |  |
| Magnesium | 0.77 | 0.66-1.07 mmol/L |                        |  |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY  
REPORT

XPNTRHHGH WC. 9295863416 0748 361 588KT INVESTIGATOR: (0748 361 588KT) PROTOCOL 0748  
361 588KT Riverside Medical Centre INVESTIGATOR NO.: 0748 361 588KT c/o Brookfield Medical Centre  
SUBJECT NUMBER: YJFHYKC53857 Cedar Specialist Group 4 PATIENT INITIALS NOT COLLECTED:  
412 Marigold Ave VISIT: D1 a nearby city 6, ON Canada 848 Main Blvd Day 1 SPONSOR REPORT TO:  
COLLECTION TIME:10:25 DATE:Oct 2, 2019 Glenmore Specialist Centre DATE RECEIVED IN  
LABORATORY: Oct 3, 2019 c/o Enzo Campbell DATE REPORTED BY LABORATORY: Oct 4, 2019  
Birchwood Care Clinic SEX: M BIRTHDATE: 1979 AGE: 40 412 Marigold Ave SCREEN NUMBER:  
YJFHYKC53857 Brockville, United Kingdom Z3C 3T6 DOB: HC 1981

|                           |       | Ref. Ranges      | Clinically Significant |    |
|---------------------------|-------|------------------|------------------------|----|
|                           |       |                  | Yes*                   | No |
| <b>RETICULOCYTE COUNT</b> |       |                  |                        |    |
| Retic %                   | 1.4   | 0.6-2.5 %        |                        |    |
| Retic Abs                 | 0.072 | 0.030-0.130 TI/L |                        |    |

\*If abnormality is clinically Significant, comment on Patient contract Form in Case Book.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) and L(Low)=Values above or below Crestwood Medical Group Reference Ranges 0748 361 588KT  
T=Telephoned P="Panic" EX=Exclusion Flag, JX,KX and VX=Sponsor Flag SX=Sponsor Flag G1, G2, G3,  
G4: Toxicity Grades

(INV)

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Tel: (442) 733-2165 Fax: (442) 733-2165



Cedar Specialist Group 4 Tel: (442) 733-2165 Fax: (442) 733-2165

Highpark Health Centre 2 Health care for women REVOLUTIONIZED Tel: (442) 733-2165 Fax: (442) 733-2165

## MRI REQUEST

**Patient Information** Medical Record No.: 414 235 249 Health Card No.: 0748 361 588KT Name: Ethan Kang DOB: 1979 Sex: [X] M [ ] F Address: 412 Marigold Ave City: a nearby city 6 Prov.: ON Postal Code: 848 Main Blvd Home Tel.: (442) 733-2165 Cell: (442) 733-2165 Business Tel.: (442) 733-2165 Mobility Status: [X] Walking [ ] Wheelchair [ ] Stretcher [ ] Ambulance Additional Info.: Billing Information: [X] OHIP [ ] WSIB [ ] Non Resident/Other Claim Number/Insurance No.: (blank) (include attachments if necessary)

For MRI Use Only | Booking Date: | Location:

**To be completed by Patient** FOR PATIENT SAFETY THESE QUESTIONS MUST BE ANSWERED:

| YES                      | NO                       |                                                                                                       | Do you have any of the following? (include reports for each implant device) | Have you ever had surgery on your? (check all that apply) |
|--------------------------|--------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> | Have you had a previous MRI?                                                                          | YES NO                                                                      | <input type="checkbox"/> Abdomen/Pelvis                   |
| <input type="checkbox"/> | <input type="checkbox"/> | Has metal ever gone into your eye?                                                                    | <input type="checkbox"/> <input type="checkbox"/> Aneurysm Clips            | <input type="checkbox"/> Arms/Legs                        |
| <input type="checkbox"/> | <input type="checkbox"/> | Do you have any kidney disease?                                                                       | <input type="checkbox"/> <input type="checkbox"/> Artificial Cardiac Valve  | <input type="checkbox"/> Chest                            |
| <input type="checkbox"/> | <input type="checkbox"/> | Are you on dialysis?                                                                                  | <input type="checkbox"/> <input type="checkbox"/> Cardiac Pacemaker         | <input type="checkbox"/> Head                             |
| <input type="checkbox"/> | <input type="checkbox"/> | Could you be pregnant?                                                                                | <input type="checkbox"/> <input type="checkbox"/> Cochlear Implants         | <input type="checkbox"/> Neck                             |
|                          |                          | Date of last Menstrual Period: (blank) 1979/MM/1979                                                   | <input type="checkbox"/> <input type="checkbox"/> Coils / Stents            | <input type="checkbox"/> Spine                            |
|                          |                          | What is your current Weight: (blank) (maximum allowable weight 550lbs./250kg, but dependent on girth) | <input type="checkbox"/> <input type="checkbox"/> Neurostimulator           |                                                           |
|                          |                          | What is your current Height: (blank)                                                                  | <input type="checkbox"/> <input type="checkbox"/> Retained Pacing Wires     |                                                           |
|                          |                          |                                                                                                       | <input type="checkbox"/> <input type="checkbox"/> Shrapnel / Bullets        |                                                           |
|                          |                          |                                                                                                       | Other Implanted Devices: (blank)                                            |                                                           |

Name all surgeries and approximate year of surgery: (blank) 1979/MM/1979 (blank) 1979/MM/1979 (blank) 1979/MM/1979 (blank) 1979/MM/1979 (blank) 1979/MM/1979 (blank) 1979/MM/1979

Patient's Signature: X \_\_\_\_\_

**Referring Physician Information** Physician's Name: Dr. Sinead Taylor Address: 415 Juniper Rd a nearby city 6 ON Postal Code: 848 Main Blvd Phone: (442) 733-2165 Fax: (442) 733-2165

**Exam Information Area to be Scanned (be specific): MR SMALL BOWEL Clinical Information / Working Diagnosis:**

- 
- 
- 
- 

**Completed Tests and Associated Results** Sites: ☐ Cedar Specialist Group 4 ☐ Cedar Specialist Group 3 ☐ Cedar Specialist Group 3 ☐ Cedar Specialist Group 3 ☐ Highpark Health Centre 2 ☐ Outside Hospital/Clinic (if from outside hospital, attach outside report) Tests: Does the patient require an interpreter? ☐ Yes ☒ No If yes, what language? (blank)

**IMPORTANT INSTRUCTIONS for Referring Physicians** If the patient has impaired renal function, you must submit a serum creatinine done within 3 months of the MRI appointment. For many implanted devices it is absolutely critical TO LIST THE MANUFACTURER AND MODEL NUMBER to ensure that the patient is not harmed in the magnet. Submit all surgical reports available. Physician's Signature: X [signature] Date: 16/09/2019

INCOMPLETE/ILLEGIBLE REQUESTS WILL BE RETURNED/FAXED BACK WITHOUT AN APPOINTMENT FORM MUST BE COMPLETE, INCLUDING PATIENT AND PHYSICIAN SIGNATURES Form 2766 (Rev. 24/11/2011)

414 235 249 Ethan Kang Jul 24, 2019 70:72:05 AM DOB: 1979 40 Years Male Cedar Specialist Group 4 (100) Sunnymede Family Practice 3 (10000) All ECGs (00)

|      |     |                                                 |           |         |  |
|------|-----|-------------------------------------------------|-----------|---------|--|
| HR   | 69  | . Sinus rhythm                                  | Oper:     | CCRXC9R |  |
| RR   | 872 | . Nonspecific intraventricular conduction delay | Location: | OP      |  |
| PR   | 164 | . ST elev, probable normal early repol pattern  |           |         |  |
| QRSD | 117 |                                                 | Comments: | STUDY   |  |
| QT   | 383 |                                                 |           |         |  |
| QTc  | 410 |                                                 |           |         |  |

-- AXIS -- P 12 QRS 14 T 17

- ABNORMAL ECG -
- PREVIOUS:Apr 23, 2019 12:99:79 - Otherwise Normal Confirmed Requested By: Sinead Taylor 12 Lead; Standard Placement CONFIRMED ON BEHALF OF: Taylor, Sinead Jul 29, 2019 41:39:12

[image]

Device: ECG62701 Speed: 25 mm/sec Limb: 10 mm/mV Chest: 10 mm/mV F 60~ 0.5-150 Hz W PH110C  
bCL P?

☐ \* \_\_\_\_

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 07/13/2019                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2019-Jul-14 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |

**Notes** ask Bordeaux if this MR was part of his study protocol and when is the next study visit

Cedar Specialist Group 4 Outpatient Services

412 Marigold Ave a nearby city 6, Ontario 848 Main Blvd Tel: (442) 733-2165

Riverside Medical Centre 415 Juniper Rd a nearby city 6 ON Canada a nearby city 11

|                     |                          |                             |             |
|---------------------|--------------------------|-----------------------------|-------------|
| <b>Patient:</b>     | Ethan Kang               | <b>MRN:</b>                 | Y633528593  |
| <b>Location:</b>    | DI                       | <b>Birth Date:</b>          | 1979        |
| <b>A#:</b>          | 8581636123               | <b>Procedures:</b>          |             |
| <b>Visit #:</b>     | 8581636123               | RESEARCH MRI Abdomen/Pelvis | May 6, 2019 |
| <b>Ordering MD:</b> | Riverside Medical Centre |                             |             |

#### **Report - RESEARCH MRI Abdomen/Pelvis (Final - Jul 11, 2019 11:55)**

Research MRI enterography

Clinical indication history of Crohn disease.

Prior ileocolic resection. JK-QC-684-3264 JK-QC-684-3264

Technique multiplanar, multisequence acquisitions on a 1.5 Tesla magnet as per the routine recent MR protocol.

The background hepatic parenchyma is of normal signal intensity. There are a few tiny punctate hyperintense lesions present for instance in segment 2/3 image 17 series 6 most likely benign entities such as cysts.

Gallbladder contracted. No bile duct dilatation. The pancreas, spleen and adrenals are unremarkable. The kidneys demonstrate no evidence of hydronephrosis.

Urinary bladder unremarkable in configuration. Prostate and seminal vesicles unremarkable. Fat containing left inguinal hernia. No bowel content. No ascites within the abdomen or pelvis.

On this limited evaluation the interrogated large bowel appears grossly unremarkable. Some apparent thickening of the rectosigmoid colon is likely on the basis of underdistension but should be correlated with the patient's endoscopic findings.

There is evidence of recurrent disease involving the neoterminal ileum. This spans at least a 20 cm length of ileum and is seen in conjunction with a moderate degree of mural thickening. There is at least 1 penetrating aphthous ulcer image 42 series 9.

There is associated luminal narrowing in conjunction with stricturing.

*The report may contain PRIVILEGED AND CONFIDENTIAL INFORMATION only for use of the Addressee(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, please be aware that any dissemination or copying of this report is strictly prohibited. If you have received this report in error, please immediately notify the sender to arrange for the return or destruction of this document. Thank you for your cooperation.*

---

The diseased bowel wall is of T2 intermediate signal intensity. There is no evidence of any proximal distension or obstruction. There is regional fibrofatty proliferation with small volume nodes in the adjacent mesentery. No associated mesenteric vascular hyperaemia is seen.

Dynamic acquisitions are confounded by wrap artifact somewhat limiting the sensitivity of the examination however the dynamic acquisitions continue to demonstrate some mild mucosal hyperenhancement however the bowel wall demonstrates a uniform homogeneous pattern of enhancement.

There is angulation of the segment of the diseased ileum with an impression of a fistulous communication image 131 series 16 between 2 associated segments of diseased small bowel.

No extraluminal air or collections are seen.

#### Impression

Recurrent disease involving the neoterminal ileum. Although there are some mild active features present there are chronic changes as evidenced by the uniform enhancement within the bowel wall.

There are imaging features compatible early penetrating disease with a fistulous communication as described.

Initial Interpretation By: Adeyemi, Rhys Verified By: Adeyemi, Rhys

\*\*\*\*\* END OF REPORT \*\*\*\*\*

#### ATTENTION

---

FOR PHYSICIAN USE ONLY - Please note that this report was generated using voice recognition software. The Outpatient Services (Outpatient Services) supports a culture of continuous improvement. If you require further clarification or feel there has been an error in this report please contact the Outpatient Services Call

Centre from 8am - 8pm Monday to Friday, 8am - 4pm Saturday to Sunday (excludes statutory holidays) at (442) 733-2165.

(Medical Imaging Report for Patient: Ethan Kang; MRN: Y633528593)

*The report may contain PRIVILEGED AND CONFIDENTIAL INFORMATION only for use of the Addressee(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, please be aware that any dissemination or copying of this report is strictly prohibited. If you have received this report in error, please immediately notify the sender to arrange for the return or destruction of this document. Thank you for your cooperation.*

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

YPASLBHXX RE. 4336116660 JK-QC-684-3264 INVESTIGATOR: (Farrow) Riverside Medical Centre c/o Brookfield Medical Centre Radiology Brookfield Medical Centre 2 821 Glenarm Ave a nearby city 6, ON Canada 848 Main Blvd PROTOCOL JK-QC-684-3264 INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W6

Week 6 SPONSOR REPORT TO: Gunnar Maloney c/o Sponsor eSite Access Maple Health Clinic 2 412 Marigold Ave Calgary, IN United States a nearby city 3 COLLECTION TIME:10:20 DATE:Jun 26, 2019 DATE RECEIVED IN LABORATORY: Jun 27, 2019 DATE REPORTED BY LABORATORY: Jun 28, 2019 SEX: M BIRTHDATE: 1979 AGE: 39 SCREEN NUMBER: 0748 361 588KT DOB FORMAT: HC 1981

|                        |      | Ref. Ranges      | Clinical Significance | Comments |
|------------------------|------|------------------|-----------------------|----------|
|                        |      |                  | Yes* No               |          |
| <b>CHEMISTRY PANEL</b> |      |                  |                       |          |
| Total Bili             | 5    | 3-21 umol/L      |                       |          |
| Dir Bili               | <2   | <2-7 umol/L      |                       |          |
| Ind Bili               | <5   | 0-21 umol/L      |                       |          |
| Alk Phos               | 67   | 31-129 U/L       |                       |          |
| ALT (SGPT)             | 15   | 6-43 U/L         |                       |          |
| AST (SGOT)             | 10 L | 11-36 U/L        | [[[]                  | _____    |
| Urea                   | 5.4  | 1.4-8.6 mmol/L   |                       |          |
| Creatinine             | 78   | 40-110 umol/L    |                       |          |
| Glucose                | 5.11 | 3.89-5.55 mmol/L |                       |          |
| Calcium                | 2.42 | 2.07-2.64 mmol/L |                       |          |
| Phosphorus             | 1.26 | 0.71-1.65 mmol/L |                       |          |
| Total Prot             | 73   | 61-84 g/L        |                       |          |
| Alb BCG                | 45   | 33-49 g/L        |                       |          |

|    |     | Ref. Ranges | Clinical Significance | Comments |
|----|-----|-------------|-----------------------|----------|
| CK | 107 | 39-308 U/L  |                       |          |

**ALT AND T.BILI** ALT TBIL No

**AST AND T.BILI** AST TBIL No

\*If clinically significant, comment is required.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) or L(Low)=Values above or below Crestwood Medical Group reference range Farrow  
T=Telephoned P="Panic" EX=Exclusion-as specified by the sponsor JX, KX, VX = Sponsor Flag G1, G2, G3, G4 = Toxicity Grades (INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

YPASLBHXX RE. 4336116660 JK-QC-684-3264 INVESTIGATOR: (Farrow) Riverside Medical Centre c/o Brookfield Medical Centre Radiology Brookfield Medical Centre 2 821 Glenarm Ave a nearby city 6, ON Canada 848 Main Blvd PROTOCOL JK-QC-684-3264 INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W6

Week 6 SPONSOR REPORT TO: Gunnar Maloney c/o Sponsor eSite Access Maple Health Clinic 2 412 Marigold Ave Calgary, IN United States a nearby city 3 COLLECTION TIME:10:20 DATE:Jun 26, 2019 DATE RECEIVED IN LABORATORY: Jun 27, 2019 DATE REPORTED BY LABORATORY: Jun 28, 2019 SEX: M BIRTHDATE: 1979 AGE: 39 SCREEN NUMBER: 0748 361 588KT DOB FORMAT: HC 1981

|                                  |      | Ref. Ranges      | Clinical Significance | Comments |
|----------------------------------|------|------------------|-----------------------|----------|
|                                  |      |                  | Yes* No               |          |
| <b>ELECTROLYTE PANEL</b>         |      |                  |                       |          |
| Sodium                           | 140  | 132-147 mmol/L   |                       |          |
| Potassium                        | 4.5  | 3.5-5.2 mmol/L   |                       |          |
| Bicarb                           | 20.6 | 17.0-30.6 mmol/L |                       |          |
| Chloride                         | 103  | 94-112 mmol/L    |                       |          |
| Magnesium                        | 0.77 | 0.66-1.07 mmol/L |                       |          |
| <b>ALBUMIN CORRECTED CALCIUM</b> |      |                  |                       |          |
| Corr Ca                          | 2.42 | 2.07-2.64 mmol/L |                       |          |

\*If clinically significant, comment is required.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) or L(Low)=Values above or below Crestwood Medical Group reference range Farrow  
T=Telephoned P="Panic" EX=Exclusion-as specified by the sponsor JX, KX, VX = Sponsor Flag G1, G2, G3, G4 = Toxicity Grades (INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

YPASLBHXX RE. 4336116660 JK-QC-684-3264 INVESTIGATOR: (Farrow) Riverside Medical Centre c/o Brookfield Medical Centre Radiology Brookfield Medical Centre 2 821 Glenarm Ave a nearby city 6, ON Canada 848 Main Blvd PROTOCOL JK-QC-684-3264 INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W6

Week 6 SPONSOR REPORT TO: Gunnar Maloney c/o Sponsor eSite Access Maple Health Clinic 2 412 Marigold Ave Calgary, IN United States a nearby city 3 COLLECTION TIME:10:20 DATE:Jun 26, 2019 DATE RECEIVED IN LABORATORY: Jun 27, 2019 DATE REPORTED BY LABORATORY: Jun 28, 2019 SEX: M BIRTHDATE: 1979 AGE: 39 SCREEN NUMBER: 0748 361 588KT DOB FORMAT: HC 1981

|                                          |                    | Ref. Ranges    | Clinical Significance | Comments |
|------------------------------------------|--------------------|----------------|-----------------------|----------|
|                                          |                    |                | Yes* No               |          |
| <b>HEMATOLOGY&amp;DIFFERENTIAL PANEL</b> |                    |                |                       |          |
| #1 HGB                                   | 133                | 127-181 g/L    |                       |          |
| #1 HCT                                   | 0.42               | 0.39-0.54      |                       |          |
| #1 RBC                                   | 5.3                | 4.5-6.4 TI/L   |                       |          |
| RBC Morph                                | No Review Required |                |                       |          |
| #1 MCV                                   | 78 L               | 79-96 fL       | [[[]]                 | _____    |
| #1 WBC                                   | 6.75               | 3.80-10.70 G/L |                       |          |
| #1 Neutrophil                            | 4.66               | 1.96-7.23 G/L  |                       |          |
| Lymphocyte                               | 1.44               | 0.91-4.28 G/L  |                       |          |
| #1 Monocytes                             | 0.50               | 0.12-0.92 G/L  |                       |          |
| #1 Eosinophil                            | 0.11               | 0.00-0.57 G/L  |                       |          |
| #1 Basophils                             | 0.04               | 0.00-0.20 G/L  |                       |          |
| #1 Neutrophil                            | 69.0               | 40.5-75.0 %    |                       |          |

|               |      | <b>Ref.<br/>Ranges</b> | <b>Clinical<br/>Significance</b> | <b>Comments</b> |
|---------------|------|------------------------|----------------------------------|-----------------|
| #1 Lymphocyte | 21.4 | 15.4-48.5 %            |                                  |                 |
| #1 Monocytes  | 7.4  | 2.6-10.1 %             |                                  |                 |
| #1 Eosinophil | 1.7  | 0.0-6.8 %              |                                  |                 |
| #1 Basophils  | 0.6  | 0.0-2.0 %              |                                  |                 |
| #1 Platelets  | 274  | 140-400<br>GI/L        |                                  |                 |

\*If clinically significant, comment is required.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) or L(Low)=Values above or below Crestwood Medical Group reference range Farrow  
T=Telephoned P="Panic" EX=Exclusion-as specified by the sponsor JX, KX, VX = Sponsor Flag G1, G2, G3, G4 = Toxicity Grades (INV)

Sinead Taylor, Director 412 Marigold Ave - Calgary, IN Z3C 3T6 Tel. (442) 733-2165 LABORATORY REPORT

YPASLBHXX RE. 4336116660 Page 4 of 4 INVESTIGATOR: (Farrow) Riverside Medical Centre c/o Brookfield Medical Centre Radiology Brookfield Medical Centre 2 821 Glenarm Ave a nearby city 6, ON Canada 848 Main Blvd JK-QC-684-3264 PROTOCOL JK-QC-684-3264 INVESTIGATOR NO.: 0748 361 588KT SUBJECT NUMBER: 0748 361 588KT PATIENT INITIALS NOT COLLECTED: VISIT: W6 Week 6 SPONSOR REPORT TO: Gunnar Maloney c/o Sponsor eSite Access Maple Health Clinic 2 412 Marigold Ave Calgary, IN United States a nearby city 3 COLLECTION TIME:10:20 DATE:Jun 26, 2019 DATE RECEIVED IN LABORATORY: Jun 27, 2019 DATE REPORTED BY LABORATORY: Jun 28, 2019 SEX: M BIRTHDATE: 1979 AGE: 39 SCREEN NUMBER: 0748 361 588KT DOB FORMAT: HC 1981

Note #1 - Result verified by repeat analysis

\*If clinically significant, comment is required.

Investigator's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

H(High) or L(Low)=Values above or below Crestwood Medical Group reference range Farrow  
T=Telephoned P="Panic" EX=Exclusion-as specified by the sponsor JX, KX, VX = Sponsor Flag G1, G2, G3, G4 = Toxicity Grades (INV)

Fairlight Medical Centre 2 HealthWATCH™

Prescription Refill Reauthorization Request

Ridgeway Family Health 3#: 0990 368 Fennimore St a nearby city 4,ON a nearby city 4 CANADA Phone: (442) 733-2165 Fax: (442) 733-2165 Printed: 2019-06-19



|                                  |                            |                              |
|----------------------------------|----------------------------|------------------------------|
| <b>Patient: Ethan Kang</b>       | <b>PHN: 0748 361 588KT</b> | <b>BirthDate: 1979-06-21</b> |
| <b>Address: 847 Fennimore St</b> |                            | <b>Phone: (442) 733-2165</b> |

| <b>Medication</b>                                                                                                 | <b>Last Fill</b>                                                 | <b>Directions</b>                | <b>Reauthorization</b>        |
|-------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------|-------------------------------|
| <b>ENTOCORT</b><br><b>3MG&lt;br&gt;BUDESONIDE</b><br><b>3MG&lt;br&gt;Qty: 180 CAP&lt;br&gt;Days</b><br>Supply: 60 | 2019-04-11<br>Days<br>Since: 69<br>Rx:<br>8936651<br>Tx: 8936651 | TAKE 3<br>CAPSULES<br>ONCE DAILY | <b>Approved: [X]</b>          |
|                                                                                                                   |                                                                  |                                  | <b>Additional Refills: +1</b> |

Notes:

Prescriber: Dr. Sinead Taylor Rumi Wozniak Phone: (442) 733-2165 Patient's PHN: 0748 361 588KT Fax: (442) 733-2165

[image: signature] Prescriber Signature

[REDACTED-DATE] Date

||||| FA6340809056135

**Please fax completed form to: (442) 733-2165**

This telecopy is confidential and is intended to be received by the addressee only. If the reader is not the intended recipient thereof you are advised that any dissemination, distribution or copying of this facsimile is strictly prohibited. Each prescription represents the original of the prescription drug order. The pharmacy addressee noted above is the only intended recipient and there are not others. The original prescription have been invalidated and securely filed and will not be transmitted elsewhere at another time.

Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 415 Juniper Rd a nearby city 6 ON T: (451) 963-7889 ext. 5189 F: (442) 733-2165

| <b>Clinician/Practitioner Number</b> | <b>CPSO / Registration No.</b> | <b>Health Number</b> | <b>Version</b> | <b>Sex</b> | <b>Service Date</b> | <b>Date of Birth</b> |
|--------------------------------------|--------------------------------|----------------------|----------------|------------|---------------------|----------------------|
| 0748 361 588KT                       | 414 235 249                    | 0748 361 588KT       |                | M          | 1979 / mm / 1979    | 1979                 |

Check (☐) one: [X] OHIP/Insured [ ] Third Party / Uninsured [ ] WSIB

Province: [blank] Other Provincial Registration Number: [blank] Patient's Telephone Contact Number: (442) 733-2165

Additional Clinical Information (e.g. diagnosis): [blank]

Patient's Last Name (as per OHIP Card): Ethan Kang Patient's First & Middle Names (as per OHIP Card):  
Ethan Kang Patient's Address (including Postal Code): a nearby city 8

[X] Copy to: Clinician/Practitioner Last Name: Taylor First Name: Sinead Address: 412 Marigold Ave a  
nearby city 6 ON, Canada 848 Main Blvd F: (442) 733-2165

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by  
Crestwood Medical Group

| <b>x</b> | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b> | <b>Hematology</b>                                                  | <b>x</b> | <b>Viral Hepatitis (check one only)</b>                                                          |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------|----------|--------------------------------------------------------------------------------------------------|
| [ ]      | Glucose [X] Random [ ] Fasting                                                                                                                                                      | [X]      | CBC                                                                | [ ]      | Acute Hepatitis                                                                                  |
| [ ]      | HbA1C                                                                                                                                                                               | [ ]      | Prothrombin Time (INR)                                             | [ ]      | Chronic Hepatitis                                                                                |
| [X]      | Creatinine (eGFR)                                                                                                                                                                   |          | <b>Immunology</b>                                                  | [ ]      | Immune Status / Previous Exposure Specify: [ ]<br>Hepatitis A [ ] Hepatitis B [ ]<br>Hepatitis C |
| [ ]      | Uric Acid                                                                                                                                                                           | [ ]      | Pregnancy Test (Urine)                                             |          |                                                                                                  |
| [X]      | Sodium                                                                                                                                                                              | [ ]      | Mononucleosis Screen                                               |          |                                                                                                  |
| [X]      | Potassium                                                                                                                                                                           | [ ]      | Rubella                                                            |          | or order individual hepatitis tests in the "Other Tests" section below                           |
| [X]      | ALT                                                                                                                                                                                 | [ ]      | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) |          | <b>Prostate Specific Antigen (PSA)</b>                                                           |
| [X]      | Alk. Phosphatase                                                                                                                                                                    | [ ]      | Repeat Prenatal Antibodies                                         | [ ]      | Total PSA [ ] Free PSA                                                                           |
| [X]      | Bilirubin                                                                                                                                                                           |          | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          |          | Specify one below:                                                                               |
| [X]      | Albumin                                                                                                                                                                             | [ ]      | Cervical                                                           | [ ]      | Insured – Meets OHIP eligibility criteria                                                        |
| [ ]      | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [ ]      | Vaginal                                                            | [ ]      | Uninsured – Screening: Patient responsible for payment                                           |

|                          |                                                 |                          |                                     |                          |                                                                                                                                                                  |
|--------------------------|-------------------------------------------------|--------------------------|-------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b>                 | <b>Biochemistry</b>                             | <b>x</b>                 | <b>Hematology</b>                   | <b>x</b>                 | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
| <input type="checkbox"/> | Albumin / Creatinine Ratio, Urine               | <input type="checkbox"/> | Vaginal / Rectal – Group B Strep    |                          | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                    |
| <input type="checkbox"/> | Urinalysis (Chemical)                           | <input type="checkbox"/> | Chlamydia (specify source):         | <input type="checkbox"/> | Insured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
|                          | <b>Neonatal Bilirubin:</b>                      | <input type="checkbox"/> | GC (specify source):                |                          |                                                                                                                                                                  |
|                          | Child's Age: [blank] days [blank] hours         | <input type="checkbox"/> | Sputum                              | <input type="checkbox"/> | Uninsured - Patient responsible for payment                                                                                                                      |
|                          | Clinician/Practitioner's tel. no. ( )           | <input type="checkbox"/> | Throat                              |                          | <b>Other Tests</b> - one test per line                                                                                                                           |
|                          | Patient's 24 hr telephone no. ( )               | <input type="checkbox"/> | Wound (specify source):             |                          | Ferritin                                                                                                                                                         |
|                          | <b>Therapeutic Drug Monitoring:</b>             | <input type="checkbox"/> | Urine                               |                          | Vitamin B12                                                                                                                                                      |
|                          | Name of Drug #1 [blank]                         | <input type="checkbox"/> | Stool Culture                       |                          | c-reactive protein                                                                                                                                               |
|                          | Name of Drug #2 [blank]                         | <input type="checkbox"/> | Stool Ova & Parasites               |                          |                                                                                                                                                                  |
|                          | Time Collected #1 [blank] hr. #2 [blank] hr.    | <input type="checkbox"/> | Other Swabs / Pus (specify source): |                          |                                                                                                                                                                  |
|                          | Time of Last Dose #1 [blank] hr. #2 [blank] hr. |                          |                                     |                          |                                                                                                                                                                  |
|                          | Time of Next Dose #1 [blank] hr. #2 [blank] hr. |                          |                                     |                          |                                                                                                                                                                  |

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

Specimen Collection Time: [blank] Date: MM/1979/1979

Fecal Occult Blood Test (FOBT) (check one) ☐ FOBT (non CCC) ☐ ColonCancerCheck FOBT (CCC) no other test can be ordered on this form

[image: signature] X Clinician/Practitioner Signature

Date: 2019-Jun-23

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6,  
Ontario 848 Main Blvd t: (442) 733-2165 f: (442) 733-2165

### **Patient Consent for E-Mail Communication**

**RISKS OF USING E-MAIL** Dr. Taylor's office offers patients the opportunity to communicate by e-mail. Transmitting patient information poses several risks of which the patient should be aware.

- The privacy and security of e-mail communication cannot be guaranteed
- E-mail messages are not encrypted on the hospital email system
- Employers and online services may have a legal right to inspect and keep e-mails that pass through their systems
- E-mail is easier to falsify than handwritten or signed hard copies. In addition, it is impossible to verify the true identity of the sender, or to ensure only the recipient can read the e-mail once it has been sent
- E-mail can be forwarded, intercepted, circulated, stored or even changed without the knowledge or permission of the physician or the patient
- E-mail senders can easily misaddress an e-mail, resulting in it being sent to unintended recipients

### **CONDITIONS OF USING E-MAIL**

- E-mails to or from the patient concerning diagnosis or treatment may be printed in full and made part of the patient's medical record. Because they are part of the medical record, other individuals authorized to access the medical record, such as staff and billing personnel, will have access to those e-mails
- The physician may forward e-mails internally to the physician's staff and to those involved, as necessary, for diagnoses, treatment, reimbursement, health care operations, and other handling. The physician will not, however, forward e-mails to independent third parties without the patient's written consent, except as authorized or required by law
- Although the physician's office will endeavor to read and respond promptly to an e-mail from the patient, the physician cannot guarantee that any particular e-mail will be read and responded to within any particular time period. Thus, the patient should not use e-mail for medical emergencies or other time-sensitive matters
- E-mail communication is not an appropriate substitute for clinical examinations. The patient is responsible for following up on the physician's e-mail and to attend scheduled appointments

**PATIENT ACKNOWLEDGEMENT AND AGREEMENT** I acknowledge that I have read and fully understand this consent form. I understand the risks associated with communication of e-mail between the Dr. Taylor's office and me, and consent to the conditions outlined herein, as well as any other instructions that the physician may communicate with patients by e-mail. I acknowledge the physician's right to, upon the provisions of written notice, withdraw the option of e-mail communication. I agree to inform Dr. Taylor's office in writing if I no longer wish to communicate by e-mail. I understand that my care and treatment will not be affected in any way whether I choose or refuse to consent to being contacted by email for purposes that are not directly related to my care.

---

I additionally consent to Dr. Taylor's office contacting me by e-mail for:

- Highpark Health Centre 4 related fundraising: ☐ yes ☒ no
- Approved Research Opportunities: ☒ yes ☐ no
- General news: ☒ yes ☐ no

E-mail: sinead.taylor50@brookfieldmedicalcentre.ca

Ethan Kang [image: signature] Patient's Name Printed/Signature

[REDACTED-DATE] Date

414 235 249 Ethan Kang Apr 23, 2019 12:99:79 PM DOB: 1979 39 Years Male Cedar Specialist Group 4 (100) Sunnymede Family Practice 3 (10000) All ECGs (00)

HR 75 . Sinus rhythm RR 796 \* Early transition with minimal ST elevation, anterior leads, similar to 25 Oct PR 157 2017 QRSD 114 \* Interpret in clinical context QT 359 QTc 402

-- AXIS -- P 36 - OTHERWISE NORMAL ECG - QRS 8 T 17

Oper: CCRXG9R Location: OP

Comments: STUDY

Edited Requested By: Sinead Taylor PREVIOUS: Oct 24, 2017 45:62:47 - Abnormal Confirmed  
CONFIRMED ON BEHALF OF: Taylor, Sinead Apr 25, 2019 98:44:27 12 Lead; Standard Placement

[image: ECG Tracings for leads I, II, III, aVR, aVL, aVF, V1, V2, V3, V4, V5, V6, and rhythm strip II]

Device: ECG62701 Speed: 25 mm/sec Limb: 10 mm/mV Chest: 10 mm/mV F 60~ 0.5-150 Hz W PH110C  
bCL P?

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6,  
Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2019-Apr-23

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

**Patient:** Mr. Ethan Kang **PHN:** 0748 361 588KT **MRN:** 414 235 249 **Birthdate:** 1979 **Phone: H:** (442) 733-2165 **C:** (442) 733-2165 **Address:** 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Herrera,

I saw Ethan Kang today for follow up of his Crohn's disease.

**Problem History:** Crohn's disease

**IBD Phenotype:** Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**Endoscopy Results:** 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05  
Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

**Active Medications:** ENTOCORT DR/ER 3 MG CAPSULE 3 Capsule(s) QD X 60 Day(s)

### Current Status

Ethan remains symptomatic on Budesonide. He is having 8-10 loose BMs/day. No blood. No abdominal pain. He has been losing weight intentionally. He is also having some lower back and knee pain which is worth at rest and better with activity consistent with possibly inflammatory arthralgia. His previous nasal lesions cleared within a few days and were typical of HSV1 infection. He gets this periodically when he is ill.

**On physical examination,** he looks well and nutritionally fit. He has no lymphadenopathy except for a few mobile, small bilateral submandibular nodes. Skin is normal. Neurologic screen is normal. Head and neck normal. Chest is clear. Heart sounds normal. His abdomen is soft, non-tender with no organomegaly or masses. Perianal examination was normal.

**Assessment and Plan** Ethan Kang currently has moderately active disease despite budesonide. He is being considered for randomization into the filgotinib small bowel clinical trial.

Sincerely,

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

---

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

---

Cedar Specialist Group 4 Outpatient Services

412 Marigold Ave a nearby city 6, Ontario 848 Main Blvd Tel: (442) 733-2165

Riverside Medical Centre 415 Juniper Rd a nearby city 6 ON Canada a nearby city 11

|                     |                          |                           |              |
|---------------------|--------------------------|---------------------------|--------------|
| <b>Patient:</b>     | Ethan Kang               | <b>MRN:</b>               | Y633528593   |
| <b>Location:</b>    | DI                       | <b>Birth Date:</b>        | 1979         |
| <b>A#:</b>          | 8581636123               | <b>Procedures:</b>        |              |
| <b>Visit #:</b>     | 8581636123               | RESEARCH XR Chest Routine | Apr 23, 2019 |
| <b>Ordering MD:</b> | Riverside Medical Centre |                           |              |

**Report - RESEARCH XR Chest Routine (Final - Apr 23, 2019 15:49)**

Frontal and lateral views of the chest show normal heart size.

The lungs are clear.

There is some accentuated kyphosis in the lower thoracic spine with some loss of height of lower thoracic vertebral bodies.

Remainder of examination normal.

Initial Interpretation By: Vance, Kian Verified By: Vance, Kian

\*\*\*\*\* END OF REPORT \*\*\*\*\*

ATTENTION

---

FOR PHYSICIAN USE ONLY - Please note that this report was generated using voice recognition software. The Outpatient Services (Outpatient Services) supports a culture of continuous improvement. If you require

further clarification or feel there has been an error in this report please contact the Outpatient Services Call Centre from 8am - 8pm Monday to Friday, 8am - 4pm Saturday to Sunday (excludes statutory holidays) at (442) 733-2165.

---

(Medical Imaging Report for Patient: Ethan Kang; MRN: Y633528593)

The report may contain PRIVILEGED AND CONFIDENTIAL INFORMATION only for use of the Addressee(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, please be aware that any dissemination or copying of this report is strictly prohibited. If you have received this report in error, please immediately notify the sender to arrange for the return or destruction of this document. Thank you for your cooperation.

---

Please fax a copy of appointment details to: ( ) -

Cedar Specialist Group 4 Cedar Specialist Group 4 Tel: (442) 733-2165 Fax: (442) 733-2165

Cedar Specialist Group 4 Tel: 918-476-6993 Fax: (442) 733-2165

Highpark Health Centre 2 Health care for women REVOLUTIONIZED Tel: (442) 733-2165 Fax: (442) 733-2165

#### MRI REQUEST

Patient Information Medical Record No.: 414 235 249 Health Card No.: 0748 361 588KT Name: Ethan Kang DOB: 1979 Sex: [X] M [ ] F (First Name) (Last Name) 1979 mm 1979 Address: 412 Marigold Ave City: a nearby city 6 Prov.: ON Postal Code: 848 Main Blvd Home Tel.: (442) 733-2165 Cell: (442) 733-2165 Business Tel.: (442) 733-2165 Mobility Status: [ ] Walking [ ] Wheelchair [ ] Stretcher [ ] Ambulance Additional Info.: Billing Information: [X] OHIP [ ] WSIB [ ] Non Resident/Other Claim Number/Insurance No.: (blank) (include attachments if necessary)

To be completed by Patient FOR PATIENT SAFETY THESE QUESTIONS MUST BE ANSWERED:

| YES                      | NO                       |                                    | Do you have any of the following? (include reports for each implant device) | Have you ever had surgery on your? (check all that apply)                                   |
|--------------------------|--------------------------|------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> | Have you had a previous MRI?       | YES NO                                                                      | <input type="checkbox"/> Abdomen/Pelvis Name all surgeries and approximate year of surgery: |
| <input type="checkbox"/> | <input type="checkbox"/> | Has metal ever gone into your eye? | <input type="checkbox"/> <input type="checkbox"/> Aneurysm Clips            | <input type="checkbox"/> Arms/Legs                                                          |
| <input type="checkbox"/> | <input type="checkbox"/> | Do you have any kidney disease?    | <input type="checkbox"/> <input type="checkbox"/> Artificial Cardiac Valve  | <input type="checkbox"/> Chest _____<br>1979/MM/1979                                        |
| <input type="checkbox"/> | <input type="checkbox"/> | Are you on dialysis?               | <input type="checkbox"/> <input type="checkbox"/> Cardiac Pacemaker         | <input type="checkbox"/> Head _____<br>1979/MM/1979                                         |
| <input type="checkbox"/> | <input type="checkbox"/> | Could you be pregnant?             | <input type="checkbox"/> <input type="checkbox"/> Cochlear Implants         | <input type="checkbox"/> Neck _____<br>1979/MM/1979                                         |



| YES | NO |                                                                  | Do you have any of the following? (include reports for each implant device) | Have you ever had surgery on your? (check all that apply) |
|-----|----|------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------|
|     |    |                                                                  | <input type="checkbox"/> <input type="checkbox"/> Coils / Stents            | <input type="checkbox"/> Spine _____<br>1979/MM/1979      |
|     |    | Date of last Menstrual Period: 1979/MM/1979                      | <input type="checkbox"/> <input type="checkbox"/> Neurostimulator           |                                                           |
|     |    |                                                                  | <input type="checkbox"/> <input type="checkbox"/> Retained Pacing Wires     |                                                           |
|     |    | What is your current Weight: _____                               | <input type="checkbox"/> <input type="checkbox"/> Shrapnel / Bullets        |                                                           |
|     |    | (maximum allowable weight 550lbs./250kg, but dependent on girth) | Other Implanted Devices:                                                    |                                                           |
|     |    | What is your current Height: _____                               |                                                                             |                                                           |

Patient's Signature: X \_\_\_\_\_

Referring Physician Information Physician's Name: Dr. Sinead Taylor Address: 412 Marigold Ave a nearby city 6 ON Postal Code: a nearby city Phone: (442) 733-2165 Fax: ( ) -

Exam Information Area to be Scanned (be specific): MR SMALL BOWEL Clinical Information /Working  
Diagnosis: JK-QC-684-3264

Completed Tests and Associated Results Sites: ☐ Cedar Specialist Group 4 ☐ Cedar Specialist Group 3 ☐ Cedar Specialist Group 3 ☐ Cedar Specialist Group 3 ☐ Highpark Health Centre 2 ☐ Outside Hospital/Clinic (if from outside hospital, attach outside report) Tests:

\_\_\_\_\_ Does the patient require an interpreter? ☐ Yes ☐ No If yes, what language? \_\_\_\_\_

**IMPORTANT INSTRUCTIONS for Referring Physicians** If the patient has impaired renal function, you must submit a serum creatinine done within 3 months of the MRI appointment. For many implanted devices it is absolutely critical TO LIST THE MANUFACTURER AND MODEL NUMBER to ensure that the patient is not harmed in the magnet. Submit all surgical reports available.

Physician's Signature: X [signature] Date: 23/04/2019

INCOMPLETE/ILLEGIBLE REQUESTS WILL BE RETURNED/FAXED BACK WITHOUT AN APPOINTMENT FORM MUST BE COMPLETE, INCLUDING PATIENT AND PHYSICIAN SIGNATURES

Form 2766 (Rev. 24/11/2011)

Cedar Specialist Group 4 Medical Imaging Request Form Cedar Specialist Group 4 412 Marigold Ave, a nearby city 6, Ontario, Canada 848 Main Blvd Form MS 275 (Rev. 03.2012)

Clearly imprint patient identification card

Please fax a copy of appointment details to: ( ) -

Bring this form, your Ontario Health Card and your Cedar Specialist Group 4 Card to your Medical imaging examination.

If you don't have a Hospital Card then first go to the main floor Admitting Department to obtain your own card.

| <input type="checkbox"/> | Modality                                                                 | Floor or Location                                        | Telephone      | Fax            |
|--------------------------|--------------------------------------------------------------------------|----------------------------------------------------------|----------------|----------------|
| [X]                      | X-Ray (General Imaging)                                                  | 5th floor                                                | 994-882-7246   | (442) 733-2165 |
| [ ]                      | Angiography, Gastrointestinal, Interventional                            | 5th floor                                                | (442) 733-2165 | (442) 733-2165 |
| [ ]                      | Breast Imaging (Mammography)                                             | Outpatient Services, 12th floor                          | (442) 733-2165 | (442) 733-2165 |
| [ ]                      | Nuclear Medicine                                                         | 6th floor, Room 6-201                                    | (442) 733-2165 | (442) 733-2165 |
| [ ]                      | Ultrasound                                                               | 5th floor                                                | (442) 733-2165 | (442) 733-2165 |
| [ ]                      | Ultrasound SCENT FREE AREA                                               | Outpatient Services 821 Glenarm Ave, 6th floor           | (442) 733-2165 | (442) 733-2165 |
|                          | For Obstetric Ultrasound use the CEOU (Outpatient Services) request form | Lakeshore Specialty Clinic 2 273 Lakeview Ave, 3rd floor | (442) 733-2165 | (442) 733-2165 |
|                          | For MRI use the Magnetic Resonance Imaging request form                  | 821 Glenarm Ave & 5th floor                              | (442) 733-2165 | (442) 733-2165 |
|                          | For CT use the Computed Tomography Imaging request form                  | 5th floor                                                | (442) 733-2165 | (442) 733-2165 |

PATIENT INFORMATION: INCOMPLETE REQUISITIONS WILL BE RETURNED

| BIRTHDATE 1979 | HOSPITAL MEDICAL RECORD NO. | Exam Requested Chest PA and Lateral |
|----------------|-----------------------------|-------------------------------------|
| 1979           | 414 235 249                 |                                     |

| SURNAME Ethan Kang                         | GIVEN NAME Ethan          | Date of Request 2019-Apr-23                                                  |
|--------------------------------------------|---------------------------|------------------------------------------------------------------------------|
| ADDRESS (Street, Apt #) 412 Marigold Ave   |                           | Clinical History and Indication pre-biologic workup for study REB# 18-0049-A |
| a nearby city 6 City/Town                  | ON PROVINCE               | 848 Main Blvd POSTAL CODE                                                    |
| (442) 733-2165 TELEPHONE (Area Code & No.) |                           | Allergies [ ] Yes [ ] No If YES, specify _                                   |
| Health Card Number 0748 361 588KT          | Version Code 5753727875QP | Diabetic [ ] Yes [ ] No                                                      |

REFERRING PHYSICIAN INFORMATION Name and Initials (Print): Dr. Sinead Taylor Doctor's Signature: [signature] Telephone #: (442) 733-2165 Fax #: ( ) - Requested Appointment MM/1979/1979 Date (if applicable): Billing & Nora Fournier 414 235 249 Mailing Address: 412 Marigold Ave a nearby city 6 a nearby city

MEDICAL IMAGING USE ONLY

|                               |                                        |                  |
|-------------------------------|----------------------------------------|------------------|
| <b>RADIOLOGIST SIGNATURE:</b> | <b>APPOINTMENT DATE (1979)</b>         | <b>PROTOCOL:</b> |
| RADIOLOGIST NAME (PRINT):     | APPOINTMENT TIME (24 hr clock) (HH:MM) |                  |

Patient: Mr. Ethan Kang Appointment Date: 2019-Apr-23 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: None I saw Ethan Kang today for follow up of his Crohn's disease.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

Endoscopy Results: 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

Active Medications: ENTOCORT DR/ER 3 MG CAPSULE 3 Capsule(s) QD X 60 Day(s)

Current Status

Ethan remains symptomatic on Budesonide. He is having 8-10 loose BMs/day. No blood. No abdominal pain. He has been losing weight intentionally. He is also having some lower back and knee pain which is worth at rest and better with activity consistent with possibly inflammatory arthralgia. His previous nasal lesions cleared within a few days and were typical of HSV1 infection. He gets this periodically when he is ill.

On physical examination, he looks well and nutritionally fit. He has no lymphadenopathy except for a few mobile, small bilateral submandibular nodes. Skin is normal. Neurologic screen is normal. Head and neck normal. Chest is clear. Heart sounds normal. His abdomen is soft, non-tender with no organomegaly or masses. Perianal examination was normal.

Assessment and Plan Ethan Kang currently has moderately active disease despite budesonide. He is being considered for randomization into the filgotinib small bowel clinical trial.

ADDENDUM - Apr 24, 2019

Based on patient's history and information from prior eye examinations there is no evidence that he has ever had ocular HZV/shingles infection.

! [Cedar Specialist Group 4 Logo] Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2019-Apr-24

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

**Patient:** Mr. Ethan Kang **PHN:** 0748 361 588KT **MRN:** 414 235 249 **Birthdate:** 1979 **Phone:** H: (442) 733-2165 C: (442) 733-2165 **Address:** 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Herrera,

I saw Ethan Kang today for follow up of his Crohn's disease.

**Problem History:** Crohn's disease

**IBD Phenotype:** Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**Endoscopy Results:** 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

**Active Medications:** ENTOCORT DR/ER 3 MG CAPSULE 3 Capsule(s) QD X 60 Day(s)

#### **Current Status**

Ethan remains symptomatic on Budesonide. He is having 8-10 loose BMs/day. No blood. No abdominal pain. He has been losing weight intentionally. He is also having some lower back and knee pain which is worth at rest and better with activity consistent with possibly inflammatory arthralgia. His previous nasal lesions cleared within a few days and were typical of HSV1 infection. He gets this periodically when he is ill.

**On physical examination**, he looks well and nutritionally fit. He has no lymphadenopathy except for a few mobile, small bilateral submandibular nodes. Skin is normal. Neurologic screen is normal. Head and neck normal. Chest is clear. Heart sounds normal. His abdomen is soft, non-tender with no organomegaly or masses. Perianal examination was normal.

**Assessment and Plan** Ethan Kang currently has moderately active disease despite budesonide. He is being considered for randomization into the filgotinib small bowel clinical trial.

#### **ADDENDUM - Apr 24, 2019**

Patient Ethan Kang PHN 0748 361 588KT DOB 1979

---

Based on patient's history and information from prior eye examinations there is no evidence that he has ever had ocular HZV/shingles infection.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong Electronically Reviewed to Expedite Delivery

Patient Ethan Kang PHN 0748 361 588KT DOB 1979

---

Northview Clinic 5 Protocol: JK-QC-684-3264

Site Patient Treatment Allocation Table

| Subject ID Number | Planned Treatment Arm    | Actual Treatment Arm                  |
|-------------------|--------------------------|---------------------------------------|
| YJFHYKC53857      | Placebo                  | Placebo/Placebo                       |
| YJFHYKC53857      | GED 160/GED 160 4 WK ALT | GED 160/GED 160 4 WK ALT - Ethan Kang |
| YJFHYKC53857      | Placebo                  | Placebo/Placebo                       |
| YJFHYKC53857      | Placebo                  | Placebo/Placebo                       |

Program Path: www.crestwoodmedicalgroup.ca Run date: [REDACTED-DATE] Data Extraction Date: [REDACTED-DATE]:45:52:49

! [Northview Clinic 5 Logo]

## **SUMMARY OF CLINICAL TRIAL RESULTS FOR A STUDY THAT MEASURED THE EFFECTS OF GED-0301 IN PATIENTS WITH CROHN'S DISEASE**

**THANK YOU** for participating in the clinical trial for the investigational drug **GED-0301**. The clinical trial took place between **November 2015 and December 2017**. At the time of this study, GED-0301 was considered an “investigational” drug which means it had not been approved by the Food and Drug Administration (FDA) or other regulatory agencies for use in any disease.

As a clinical trial patient volunteer (“patient”), you belong to a large community of volunteers around the world. You help researchers answer important health questions and help them discover new medical treatments.

Northview Clinic 5, the sponsor of this clinical trial, has prepared this summary of results from the clinical trial in which you participated. If you have any questions about the results, please speak with the doctor or staff at the study center where you participated in the clinical trial.

|                                               |                                                                                                                                                                                                            |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Date Clinical Trial Summary Finalized:</b> | <b>Nov 19, 2018</b>                                                                                                                                                                                        |
| <b>Clinical Trial Sponsor:</b>                | <b>Northview Clinic 5</b>                                                                                                                                                                                  |
| <b>Drug(s) Studied:</b>                       | <b>Mongersen (GED-0301)</b>                                                                                                                                                                                |
| <b>Clinical Trial Title:</b>                  | <b>A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects with Active Crohn's Disease</b> |
| <b>Protocol Number:</b>                       | <b>GED-0301-CD-002</b>                                                                                                                                                                                     |
| <b>Clinical Trial Start Date:</b>             | <b>November 2015</b>                                                                                                                                                                                       |
| <b>Trial Completion Date:</b>                 | <b>December 2017</b>                                                                                                                                                                                       |

|                                            |                       |
|--------------------------------------------|-----------------------|
| <b>National Clinical Trial Identifier:</b> | <b>JK-QC-684-3264</b> |
| <b>EudraCT Number:</b>                     | <b>JK-QC-684-3264</b> |

FORM-GWP-DSD-003B\_20Nov2018

---

![[Northview Clinic 5 Logo]

## 1. WHY WAS THE RESEARCH NEEDED?

Researchers are looking for new medical treatments for patients with Crohn's disease (CD). CD is a chronic (occurring again and again for a long time) disease that causes inflammation (irritation or swelling) of any part of the digestive tract. Although there are different treatments available, there is a medical need for additional treatment options.

The main goal of the study was to test if the study drug (called -GED-0301-) had an effect on the symptoms and on healing sores (ulcers) in the lining of patients' intestines.

The study helped answer the following questions:

- *Did GED-0301 have an effect on CD symptoms as measured by CDAI (explained in Section 4) after 12 weeks of study treatment? If so, what was the percentage of patients?*
- *Did patients experience any side effects during treatment with GED-0301?*

## 2. WHO PARTICIPATED?

This study took two years and included 701 patients (355 males, 346 females) with Crohn's disease, at 417 study sites in 34 countries worldwide. The average age of patients was about 39 years old.

To qualify for the study, patients must have been 18 years old or older at the time they entered the study. Prior to joining the study, patients must have been diagnosed with CD for at least 3 months, have symptoms of CD and inflammation and/or ulcers in the lining of their intestines.

Some medicines were approved to take before and during the study, and some patients did take them.

## 3. WHAT HAPPENED DURING THE CLINICAL TRIAL?

Patients were assigned by chance, like pulling numbers from a hat, to one of four groups (see table on next page). Patients were three times more likely to receive GED-0301 than placebo.

The study had two phases: a study treatment phase and a follow-up phase.

FORM-GWP-DSD-003B\_20Nov2018

---

![[Northview Clinic 5 Logo]

The study was "double-blind" which means the study doctor, the patient and the researchers who conducted the study did not know which study treatment the patient received. This helps make sure that

the study results are not influenced in any way.

| Group          | Description                                                                                                                                                                                                |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Group 1</b> | GED-0301 160 mg once daily by mouth for 12 weeks, then<br>Placebo daily by mouth for 4 weeks, then<br>Alternating GED-0301 160 mg once daily for 4 weeks, then placebo daily for 4 weeks until Week 52     |
| <b>Group 2</b> | GED-0301 160 mg once daily by mouth for 12 weeks, then<br>Placebo daily by mouth for 4 weeks, then<br>Alternating GED-0301 40 mg once daily for 4 weeks, then placebo once daily for 4 weeks until Week 52 |
| <b>Group 3</b> | GED-0301 160 mg once daily by mouth for 12 weeks, then<br>GED-0301 40 mg daily until Week 52                                                                                                               |
| <b>Group 4</b> | Placebo daily by mouth until week 52                                                                                                                                                                       |

Northview Clinic 5 provided the study drug and the placebo (a pill that looks exactly like the study drug, but without any medicine in it).

## Study Treatment

Patients continued with their assigned treatment (Group 1, 2, 3 or 4).

- After 12 weeks of treatment, if patients did not get better, they could transfer to an optional long-term study in which all patients received GED-0301.
- If patients stayed in the study for 52 weeks, they could enter the optional long-term study.

Patients could stop the study at any time if they wanted to, and some patients did.

All patients were followed for 28 days after taking their last dose of the study drug or placebo. Patients who completed the study treatment and patients who stopped the study early, entered the Follow-up Phase.

## Follow-up Phase

During the follow-up phase, patients repeated some of the tests that were previously completed throughout the study. This phase lasted 4 weeks. Patients did not take the study drug or the placebo during this phase.

FORM-GWP-DSD-003B\_20Nov2018

---

! [Northview Clinic 5 Logo]

## 4. WHAT WERE THE CLINICAL TRIAL RESULTS?

In CD, patients experience symptoms such as diarrhea, pain, and sores (ulcers) in the lining of their intestines. This study looked at whether GED-0301 had an effect on symptoms of CD and on the healing of the sores in the intestinal lining.

Study doctors used different ways to study symptoms and healing in patients with CD. The most common way to measure CD, which was used in this study, is a scoring system called the *Crohn's Disease Activity*

Index or CDAI. CDAI is a questionnaire and the responses are scored by numbers. For example:

- A score of **less than 150**: very mild or no symptoms of CD
- A score of **150 to 220**: mild symptoms of CD

Researchers wanted to know the percentage of patients who achieved "clinical remission" after 12 weeks of study treatment. In this study, clinical remission meant patients' CDAI score was less than 150 at Week 12.

***Did GED-0301 have an effect on CD symptoms as measured by CDAI after 12 weeks of study treatment? If so, what was the percentage of patients?***

- In the GED-0301 groups, **1979.8%** of the patients achieved clinical remission at Week 12.
- In the placebo group, **25%** of the patients achieved clinical remission at Week 12.

The results did not show a meaningful difference between the patients in the GED-0301 treatment groups and patients in the placebo group. This means researchers could not tell if the changes were due to the effects of GED-0301 or if the changes happened by chance.

FORM-GWP-DSD-003B\_20Nov2018

! [Northview Clinic 5 Logo]

**5. WHAT ADVERSE REACTIONS (SIDE EFFECTS) DID PATIENTS HAVE?**

Adverse reactions are side effects that happened during the study treatment, which may or may not be related to taking the study drug. When drugs are being studied, doctors keep track of side effects that patients have.

***Did patients experience any side effects during treatment with GED-0301?***

During the study, the most common side effects in 5% or more patients were:

| Side Effect (in 5% or more patients) | Placebo Group (out of 174 patients) | GED Groups Combined (out of 527 patients) |
|--------------------------------------|-------------------------------------|-------------------------------------------|
| Abdominal pain                       | 1979 patients (12.6%)               | 50 patients (9.5%)                        |
| Crohn's Disease                      | 17 patients (9.8%)                  | 60 patients (11.4%)                       |
| Nausea                               | 12 patients (6.9%)                  | 29 patients (5.5%)                        |
| Fever                                | 10 patients (5.7%)                  | 33 patients (6.3%)                        |

A side effect is considered serious if it results in death, is life-threatening, results in hospitalization or keeps a patient in the hospital for a longer time, causes a disability or a birth defect, or could cause long-term negative health effects.

During this study, 81 out of 701 patients recorded (seen by the study doctor or reported by patients) serious side effects:

- Placebo group: 16 out of 174 patients (9.2%) had serious side effects



- All GED-0301 groups (combined): 65 out of 527 patients (12.3%) had serious side effects

The most common serious side effect reported by more than 3 patients in any treatment group was Crohn's disease.

There were two deaths reported in this study, both from GED-0301 treatment groups:

- One patient stopped the study due to a bowel blockage. The patient died 41 days later.
- One patient stopped the study due to pneumonia and kidney failure. The patient died 1 day later.

The study doctors did not consider the deaths related to the study drug.

FORM-GWP-DSD-003B\_20Nov2018 Page 5 of 6

---

! [Northview Clinic 5 Logo]

## 6. WERE THERE ANY SIGNIFICANT ISSUES WITH THIS CLINICAL TRIAL?

In September 2017, Northview Clinic 5 stopped the study early as patients' Crohn's disease did not significantly benefit from the study treatment. Because the study ended early, not all patients finished the study treatment. The study did not end due to safety concerns.

## 7. WHERE CAN I LEARN MORE?

If you have questions about the results, please speak with the doctor or staff at your study site, or contact Northview Clinic 5 at the email address: [sinead.taylor50@brookfieldmedicalcentre.ca](mailto:sinead.taylor50@brookfieldmedicalcentre.ca). Additional information can be found at [www.crestwoodmedicalgroup.ca](http://www.crestwoodmedicalgroup.ca) or [www.crestwoodmedicalgroup.ca](http://www.crestwoodmedicalgroup.ca)

*Please note: The information presented in this document is representative of this single clinical trial and is accurate as of the time of the review of the clinical trial results by the sponsor. The information may not reflect other research or approved product information.*

*This information represents the overall results of the study and may not be representative of your individual result. You should consult the doctor or staff at the study center where you participated in the clinical trial for further information about your specific results.*

FORM-GWP-DSD-003B\_20Nov2018

---

Patient: Mr. Ethan Kang Appointment Date: 2019-Jan-23 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: Taylor, Sinead I saw Ethan Kang today for follow up of his Crohn's disease.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

Endoscopy Results: 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

Active Medications: ENTOCORT DR/ER 3 MG CAPSULE 3 Capsule(s) QD X 60 Day(s)

## Current Status

Ethan remains unchanged with ongoing clinically active Crohn's disease that is partially controlled on Entocort. He came today to be screened for entry into the Filgotinib CD trial. However, he indicated that he just recently had a mild outbreak of nasal and perioral ulcers with a recent mild illness. He was given oral and topical anti viral therapy. Symptoms only lasted a few days and the lesions are crusting over. He has a history of these in the past and they have not ever been significant even while on anti TNF therapy. He is systemically well.

On physical examination, he looks well and nutritionally fit. There were crusted over scabs around the nostrils which were quite small and looked to be healing.

Assessment and Plan Ethan Kang currently has moderately active disease. There were some mix ups today about whether the nasal lesions exclude him from participation in the clinical trial and this does seem to be the case. We were initially given the go ahead verbally so started screening him but then shortly thereafter we were told he needs to wait 12 weeks. For now Ethan would like to try and wait to participate in the study but if he deteriorates he will let us know.

I will see him again in follow up in 3 months in the office.

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2019-Jan-23

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 0748 361 588KT WJQ: 158847108 Birthdate: 1979 Phone: H: (442) 733-2165 C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Herrera,

I saw Ethan Kang today for follow up of his Crohn's disease.

Problem History: Crohn's disease

IBD Phenotype: Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

Endoscopy Results: 2018-Dec-03 Colonoscopy - neo TI i5 (SES 9); colon normal 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

Active Medications: ENTOCORT DR/ER 3 MG CAPSULE 3 Capsule(s) QD X 60 Day(s)

## Current Status

Ethan remains unchanged with ongoing clinically active Crohn's disease that is partially controlled on Entocort. He came today to be screened for entry into the Filgotinib CD trial. However, he indicated that he just recently had a mild outbreak of nasal and perioral ulcers with a recent mild illness. He was given oral and topical anti viral therapy. Symptoms only lasted a few days and the lesions are crusting over. He has a

history of these in the past and they have not ever been significant even while on anti TNF therapy. He is systemically well.

On physical examination, he looks well and nutritionally fit. There were crusted over scabs around the nostrils which were quite small and looked to be healing.

Assessment and Plan Ethan Kang currently has moderately active disease. There were some mix ups today about whether the nasal lesions exclude him from participation in the clinical trial and this does seem to be the case. We were initially given the go ahead verbally so started screening him but then shortly thereafter we were told he needs to wait 12 weeks. For now Ethan would like to try and wait to participate in the study but if he deteriorates he will let us know.

Patient Ethan Kang PHN 0748 361 588KT DOB 1979

I will see him again in follow up in 3 months in the office.

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong Electronically Reviewed to Expedite Delivery

Patient Ethan Kang PHN 0748 361 588KT DOB 1979

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 8581636123 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2019-Jan-10 Reviewed: 2019-Jan-14 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
USERNAME] Reported Date: 2019-Jan-12 10:55 AM Updated On: 2019-Jan-14 12:01 PM

|                      | Flags | Results                                                             | Ref Range | Units |
|----------------------|-------|---------------------------------------------------------------------|-----------|-------|
| <b>STOOL CULTURE</b> |       |                                                                     |           |       |
| STOOL CULTURE (F)    |       | -----                                                               |           |       |
|                      |       | No Salmonella, Shigella, Yersinia, Campylobacter or E.coli 0157:H7. |           |       |

Lab Order #: 8581636123 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
 Date: 2019-Jan-09 Reviewed: 2019-Jan-14 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
 USERNAME] Reported Date: 2019-Jan-10 3:23 AM Updated On: 2019-Jan-23 12:12 PM

|                                                        | Flags | Results                                                                                    | Ref Range          | Units          |
|--------------------------------------------------------|-------|--------------------------------------------------------------------------------------------|--------------------|----------------|
| <b>CRP</b>                                             |       |                                                                                            |                    |                |
| CRP (F)                                                | H     | 40.3                                                                                       | < 8.0 mg/L         | mg/L           |
| <b>CREATININE</b>                                      |       |                                                                                            |                    |                |
| CREATININE (F)                                         | N     | 73                                                                                         | 60 - 110<br>umol/L | umol/L         |
| eGFR (F)                                               | N     | 111                                                                                        | 60. -<br>99999.99  | mL/min/1.73m*2 |
| >=60. mL/min/1.73m**2                                  |       |                                                                                            |                    |                |
| eGFR is calculated using the CKD-EPI<br>2009 equation. |       |                                                                                            |                    |                |
| CREATININE (F)                                         |       |                                                                                            |                    |                |
|                                                        |       | Normal eGFR.                                                                               |                    |                |
|                                                        |       | For patients of<br>African descent, the<br>reported eGFR must<br>be multiplied by<br>1.15. |                    |                |
| <b>ALBUMIN</b>                                         |       |                                                                                            |                    |                |
| ALBUMIN (F)                                            | N     | 42                                                                                         | 35 - 52<br>g/L     | g/L            |
| <b>BILIRUBINTOTAL</b>                                  |       |                                                                                            |                    |                |
| BILIRUBIN TOTAL (F)                                    | N     | 4                                                                                          | <23<br>umol/L      | umol/L         |
| <b>VITAMINB12</b>                                      |       |                                                                                            |                    |                |
| VITAMIN B12 (F)                                        | N     | >1475.                                                                                     | 221.-              | pmol/L         |
| pmol/L                                                 |       |                                                                                            |                    |                |
| DEFICIENCY: < 148 pmol/L                               |       |                                                                                            |                    |                |
| INSUFFICIENCY: 148 - 220 pmol/L                        |       |                                                                                            |                    |                |
| SUFFICIENCY: > 220 pmol/L                              |       |                                                                                            |                    |                |

|                                                                                                                     | Flags | Results | Ref Range        | Units  |
|---------------------------------------------------------------------------------------------------------------------|-------|---------|------------------|--------|
| 60% OF SYMPTOMATIC PATIENTS HAVE A HEMATOLOGIC OR NEUROLOGIC RESPONSE TO B12 SUPPLEMENTATION AT A LEVEL <148 pmol/L |       |         |                  |        |
| <b>FERRITIN</b>                                                                                                     |       |         |                  |        |
| FERRITIN (F)                                                                                                        | N     | 104     | 24 - 453 ug/L    | ug/L   |
| <b>SODIUM</b>                                                                                                       |       |         |                  |        |
| SODIUM (F)                                                                                                          | N     | 142     | 136 - 146 mmol/L | mmol/L |
| <b>POTASSIUM</b>                                                                                                    |       |         |                  |        |
| POTASSIUM (F)                                                                                                       | N     | 4.2     | 3.7 - 5.4 mmol/L | mmol/L |
| <b>AMYLASE</b>                                                                                                      |       |         |                  |        |
| AMYLASE (F)                                                                                                         | H     | 118     | 30 - 110 U/L     | U/L    |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 8581636123 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2019-Jan-09 Reviewed: 2019-Jan-14 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]  
Reported Date: 2019-Jan-10 4:44 AM Updated On: 2019-Jan-14 12:01 PM

|                            | Flags | Results | Ref Range  | Units |
|----------------------------|-------|---------|------------|-------|
| <b>ALKALINEPHOSPHATASE</b> |       |         |            |       |
| ALKALINE PHOSPHATASE (F)   | N     | 60      | 40-129 U/L | U/L   |
| <b>GGT</b>                 |       |         |            |       |
| GGT (F)                    | N     | 23      | < 60 U/L   | U/L   |

|                         | Flags | Results | Ref Range           | Units     |
|-------------------------|-------|---------|---------------------|-----------|
| <b>ALT</b>              |       |         |                     |           |
| ALT (F)                 | N     | 24      | <46 U/L             | U/L       |
| <b>HEMOGLOBIN</b>       |       |         |                     |           |
| HEMOGLOBIN (F)          | L     | 128     | 129 - 165 g/L       | g/L       |
| <b>HEMATOCRIT</b>       |       |         |                     |           |
| HEMATOCRIT (F)          | N     | 0.40    | 0.39 - 0.49 l/l     | L/L       |
| <b>RBC</b>              |       |         |                     |           |
| RBC (F)                 | N     | 4.8     | 4.2 - 5.8 x 10E12/L | x 10*12/L |
| <b>RBC INDICES: MCV</b> |       |         |                     |           |
| RBC INDICES: MCV (F)    | N     | 85      | 80 - 98 fl          | fL        |
| <b>MCH</b>              |       |         |                     |           |
| MCH (F)                 | N     | 27      | 24 - 33 pg          | pg        |
| <b>MCHC</b>             |       |         |                     |           |
| MCHC (F)                | N     | 317     | 313 - 344 g/L       | g/L       |
| <b>RDW</b>              |       |         |                     |           |
| RDW (F)                 | N     | 15.3    | 12.5 - 17.3         |           |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 8581636123 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2019-Jan-09 Reviewed: 2019-Jan-14 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
USERNAME] Reported Date: 2019-Jan-10 4:44 AM Updated On: 2019-Jan-14 12:01 PM

|            | Flags | Results | Ref Range          | Units    |
|------------|-------|---------|--------------------|----------|
| <b>WBC</b> |       |         |                    |          |
| WBC (F)    | N     | 5.4     | 3.2 - 9.4 x 10E9/L | x 10*9/L |

|                               | Flags | Results                                   | Ref Range             | Units       |
|-------------------------------|-------|-------------------------------------------|-----------------------|-------------|
| <b>PLATELETS</b>              |       |                                           |                       |             |
| PLATELETS (F)                 | N     | 225                                       | 155 - 372 x<br>10E9/L | x<br>10*9/L |
| <b>MPV</b>                    |       |                                           |                       |             |
| MPV (F)                       | N     | 9.8                                       | 4.0 - 14.0 fl         | fL          |
| <b>DIFFERENTIAL<br/>WBC'S</b> |       |                                           |                       |             |
| NEUTROPHILS (F)               | N     | 3.3                                       | 1.4 -6.3 x10E9/L      | x<br>10*9/L |
| LYMPHOCYTES (F)               | N     | 1.0                                       | 1.0 -2.9 x10E9/L      | x<br>10*9/L |
| MONOCYTES (F)                 | H     | 0.9                                       | 0.2 -0.8 x10E9/L      | x<br>10*9/L |
| EOSINOPHILS (F)               | N     | 0.1                                       | 0.0 -0.5 x10E9/L      | x<br>10*9/L |
| BASOPHILS (F)                 | N     | 0.00                                      | 0.00-<br>0.09x10E9/L  | x<br>10*9/L |
| <b>STOOL CULTURE</b>          |       |                                           |                       |             |
| STOOL CULTURE (F)             |       | NO SPECIMEN RECEIVED WITH<br>REQUISITION. | <---                  |             |

Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 415 Juniper Rd a nearby city 6 ON T: 993-089-6973 qaa 0534 F: (442) 733-2165

Clinician/Vivienne Vasquez CPSO / Sofia Bianchi

Laboratory Use Only

Clinician/Practitioner's Contact Number for Urgent Results: (442) 733-2165 Service Date: 1979 / mm / 1979

Health Number: 0679930896 XV Version: (blank) Sex: M Date of Birth: 1979 1979 mm 06 1979 1979  
Province: (blank) Other Provincial Registration Number: (blank) Patient's Telephone Contact Number: (442) 733-2165

Patient's Last Name (as per OHIP Card) Ethan Kang Patient's First & Middle Names (as per OHIP Card)  
Ethan Kang Patient's Address (including Postal Code) a nearby city 8

Check (☐) one: [☒] OHIP/Insured [☐] Third Party / Uninsured [☐] WSIB Additional Clinical Information (e.g. diagnosis)

[X] Copy to: Clinician/Practitioner Last Name: Taylor First Name: Sinead Address: 412 Marigold Ave a nearby city 6 ON, Canada Fax: (442) 733-2165

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Crestwood Medical Group

|          |                                                                                                                                                                                     |          |                                                                    |          |                                                                                                                                                                   |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b> | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b> | <b>Hematology</b>                                                  | <b>x</b> | <b>Viral Hepatitis (check one only)</b>                                                                                                                           |
| [ ]      | Glucose [X] Random [ ] Fasting                                                                                                                                                      | [X]      | CBC                                                                | [ ]      | Acute Hepatitis                                                                                                                                                   |
| [ ]      | HbA1C                                                                                                                                                                               | [ ]      | Prothrombin Time (INR)                                             | [ ]      | Chronic Hepatitis                                                                                                                                                 |
| [X]      | Creatinine (eGFR)                                                                                                                                                                   |          | <b>Immunology</b>                                                  | [ ]      | Immune Status / Previous Exposure Specify: [ ] Hepatitis A [ ] Hepatitis B [ ] Hepatitis C or order individual hepatitis tests in the "Other Tests" section below |
| [ ]      | Uric Acid                                                                                                                                                                           | [ ]      | Pregnancy Test (Urine)                                             |          |                                                                                                                                                                   |
| [X]      | Sodium                                                                                                                                                                              | [ ]      | Mononucleosis Screen                                               |          |                                                                                                                                                                   |
| [X]      | Potassium                                                                                                                                                                           | [ ]      | Rubella                                                            |          |                                                                                                                                                                   |
| [X]      | ALT                                                                                                                                                                                 | [ ]      | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) |          | <b>Prostate Specific Antigen (PSA)</b>                                                                                                                            |
| [X]      | Alk. Phosphatase                                                                                                                                                                    | [ ]      | Repeat Prenatal Antibodies                                         | [ ]      | Total PSA [ ] Free PSA                                                                                                                                            |
| [X]      | Bilirubin                                                                                                                                                                           |          | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          |          | Specify one below:                                                                                                                                                |
| [X]      | Albumin                                                                                                                                                                             | [ ]      | Cervical                                                           | [ ]      | Insured – Meets OHIP eligibility criteria                                                                                                                         |
| [ ]      | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [ ]      | Vaginal                                                            | [ ]      | Uninsured – Screening: Patient responsible for payment                                                                                                            |
| [ ]      | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | [ ]      | Vaginal / Rectal - Group B Strep                                   |          | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                     |



|                          |                                                              |                                     |                                     |                          |                                                                                                                                                                  |
|--------------------------|--------------------------------------------------------------|-------------------------------------|-------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b>                 | <b>Biochemistry</b>                                          | <b>x</b>                            | <b>Hematology</b>                   | <b>x</b>                 | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
| <input type="checkbox"/> | Urinalysis (Chemical)                                        | <input type="checkbox"/>            | Chlamydia (specify source):         | <input type="checkbox"/> | Insured – Meets OHIP eligibility criteria; osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
|                          | Neonatal Bilirubin: Child's Age: days hours                  | <input type="checkbox"/>            | GC (specify source):                |                          |                                                                                                                                                                  |
|                          | Clinician/Practitioner's tel. no. ( )                        | <input type="checkbox"/>            | Sputum                              | <input type="checkbox"/> | Uninsured - Patient responsible for payment                                                                                                                      |
|                          | Patient's 24 hr telephone no. ( )                            | <input type="checkbox"/>            | Throat                              |                          | <b>Other Tests</b> - one test per line                                                                                                                           |
|                          | Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 | <input type="checkbox"/>            | Wound (specify source):             |                          | Ferritin Vitamin B12 c-reactive protein Amylase GGT                                                                                                              |
|                          | Time Collected #1 hr. #2 hr.                                 | <input type="checkbox"/>            | Urine                               |                          |                                                                                                                                                                  |
|                          | Time of Last Dose #1 hr. #2 hr.                              | <input checked="" type="checkbox"/> | Stool Culture                       |                          |                                                                                                                                                                  |
|                          | Time of Next Dose #1 hr. #2 hr.                              | <input type="checkbox"/>            | Stool Ova & Parasites               |                          |                                                                                                                                                                  |
|                          |                                                              | <input type="checkbox"/>            | Other Swabs / Pus (specify source): |                          |                                                                                                                                                                  |

Specimen Collection Time: (blank) Date: MM/1979/1979

Fecal Occult Blood Test (FOBT) (check one) ☐ FOBT (non CCC) ☐ ColonCancerCheck FOBT (CCC) no other test can be ordered on this form Laboratory Use Only

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

(Signature)

X \_\_\_\_\_ 2019-Jan-08 Clinician/Practitioner Signature Date

4422-84 (2013/01) © Queen's Printer for Ontario, 2013 7530-4581

Fairlight Medical Centre 2 HealthWATCH

Prescription Refill Reauthorization Request

Ridgeway Family Health 3#: 0990 368 Fennimore St a nearby city 4, ON a nearby city 4 CANADA Phone: (442) 733-2165 Fax: (442) 733-2165

| Medication      | Last Fill      | Directions                 | Reauthorization                    |
|-----------------|----------------|----------------------------|------------------------------------|
| ENTOCORT 3MG    | 2018-09-17     | TAKE 3 CAPSULES ONCE DAILY | Approved: <input type="checkbox"/> |
| BUDESONIDE 3MG  | Days Since: 90 |                            | Additional Refills: 2              |
| Qty: 180 CAP    | Rx: 8936651    |                            |                                    |
| Days Supply: 60 | Tx: 8936651    |                            |                                    |

Notes:

Prescriber: Dr. Sinead Taylor Rumi Wozniak Phone: (442) 733-2165 Patient's PHN: (blank) Fax: (442) 733-2165

[signature] Prescriber Signature

[REDACTED-DATE] Date

||||| FA6340809056135

Please fax completed form to: (442) 733-2165

This telecopy is confidential and is intended to be received by the addressee only. If the reader is not the intended recipient thereof you are advised that any dissemination, distribution or copying of this facsimile is strictly prohibited. Each prescription represents the original of the prescription drug order. The pharmacy addressee noted above is the only intended recipient and there are not others. The original prescription have been invalidated and securely filed and will not be transmitted elsewhere at another time.

Ethan Kang

Age 39 yr YJFHYKC53857 Page 1/1

Jan 2, 2014 KR Fever on Dec 29th --x 24hr then vesicles to lip and nose. resolved symptoms. some sinus pressure --entirely frontal (sinuses). Off Humira x since Dec 14th. No signif neuropathic pain. ROS neg. <O> lesions look consistent with HZ opthalmicus Called Dr. Rahman URGENTLY for slit lamp exam <AP> Herpes Zoster eruption start Famvir urgent eye exam.

PS Suite® EMR report Printed on behalf of KR on Dec 10, 2018 17:40 This document contains personal identifiable information that must be treated confidentially. Any unauthorized use or disclosure is prohibited.

Westbrook Medical Associates 4 Optometrists

Dr. Samir Rahman AND ASSOCIATES 224 Harlow Ave a nearby city 6, ON a nearby city 4 Ph: (442) 733-2165 Fax: (442) 733-2165 sinead.taylor50@brookfieldmedicalcentre.ca

Date: Dec 10, 2018 Dear Dr. Taylor Re Patient: Ethan Kang DOB 06/21/1979.

Reason for Consultation: Presented [REDACTED-DATE] - Rash x 3-4 day facial hx herpes Cold sore saw GP was given Famvir wanted to check if any corneal lesions. Medical History: Crohn's Medications: Humara will be having Bowel surgery.

Vision (OD) 20/20 Best Corrected (OD) Uncorrected/or (With Present Glasses) (OS) 20/20 (OS) Intraocular Pressure: (OD) \_\_\_\_ mm Hg (OS) \_\_\_\_ mm Hg External, Pupils: Clear no Stain No Corneal involvement Anterior Segment: Clear Fundus: Diagnosis and Recommendations: Has Herpes Zoster was given Famvir from family DR. was told to continue his meds + see his family DR. Was also referred for hi IOP's -> seen in 2013 No glaucoma Was being Monitored. Next Appointment:

Thank - you for referring this patient for evaluation. [signature] Yours sincerely, Dr. Samir Rahman CC:

---

Ethan Kang 39 M DOB:1979-06-21

Tel:(442) 733-2165 Date of Visit: 2013-10-15 Signed Provider: RFR: repeat VF, OCT Ref:Rahman, Samir [REDACTED-DATE]...LASER CONSULT????

Medical/Past Surgical History Jul 10, 2013:Crohns/low Iron

Allergic to Codeine

Page 1 of 3 2018-12-10

---

Ethan Kang 39 M DOB:1979-06-21

Tel:(442) 733-2165 Date of Visit: 2013-10-15 Signed Provider:Gunnar Herrera RFR: repeat VF, OCT [REDACTED-DATE]...LASER CONSULT???? Ref:Rahman, Samir

## Current History

Oct 15, 2013:3 mths repeat VF/OCT/off PF since [REDACTED-DATE]/D OU @ 1:1979

## Medical/Past Surgical History

Jul 10, 2013:Crohns/low Iron

Allergic to Codeine

## Other Medications

Oct 15, 2013:Prednisone 25mg/day-stopped Humera 40mg/wk Iron meds, B12 inj

## Ocular Examination

VISION ASSESSMENT: Distance vision (cc) OD 20/25; OS 20/20-2;

INTRAOCULAR PRESSURE: Applanation OD 15; OS 15; (13:25).

## **Impression/Plan: (Oct 15, 2013)**

has discontinued pred, VF OCT stable OMH more normal --- RTO PRN [Signed on Oct 15, 2013 14:01 by Gunnar Herrera]

Page 2 of 3 2018-12-10

---

Ethan Kang 39 M DOB:1979-06-21

Tel:(442) 733-2165

Date of Visit: 2013-07-10 Signed Provider:Gunnar Herrera

RFR:NP-HIGH IOPS

Ref:Rahman, Samir

## **Current History**

Jul 10, 2013:Ref: IOP Assymetry/high IOP L forgot to bring gls Vf/OCT done M1 OU@10:33

## **Medical/Past Surgical History**

Jul 10, 2013:Crohns/low Iron

Allergic to Codeine

## **Diagnostic Notes**

Jul 10, 2013:Pachymetry r-586(-3)/L-587(-3)

## **Ocular Examination**

VISION ASSESSMENT: Distance vision (sc) OD 20/100-1;OS 20/200;

VISION MEASUREMENT: Manifest distance OD -3.25 +0.75 x 124 (20/20); OS -4.00 +1.25 x62 (20/25);

INTRAOCULAR PRESSURE: Applanation OD 16; OS 16; (10:34).

ANTERIOR SEGMENT: Cornea OD clear; OS clear. Conjunctiva/Sclera OD white; OS white. Anterior chamber OD deep and quiet; OS deep and quiet. Angle OD open; OS open; Iris OD normal; OS normal. Lens OD clear; OS clear.

POSTERIOR SEGMENT: Optic disc OD normal; OS normal. C/D ratio OD .1; OS .1. Macula OD normal; OS normal. Retina OD normal; OS normal. Vitreous OD clear; OS clear.

## **Impression/Plan: (Jul 10, 2013)**

VF WNL,OCT, ONH slightly swollen = side effect to systemic prednisone --- reassess when stops pred--- reassess then [Signed on Jul 10, 2013 11:11 by Gunnar Herrera]

2018-12-10

---

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

Patient: Ethan Kang HomePhone: (442) 733-2165 WorkPhone: Health #: 0748 361 588KT Sex: M Patient ID: 0748 361 588KT Age: 46 DOB: 1979

Comments: CC copy sent to Sinead Taylor

Lab Order #: 0044 552496 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2018-Dec-10 Reviewed: 2018-Dec-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2018-Dec-10 11:45 PM Updated On: 2018-Dec-15 8:51 AM

|                                                     | Flags | Results | Ref Range          | Units           |
|-----------------------------------------------------|-------|---------|--------------------|-----------------|
| <b>CRP</b>                                          |       |         |                    |                 |
| CRP (F)                                             | N     | 3.4     | < 8.0 mg/L         | mg/L            |
| <b>GLUCOSE SERUM RANDOM</b>                         |       |         |                    |                 |
| GLUCOSE SERUM RANDOM (F)                            | N     | 5.3     | 3.6 - 7.00         | mmol/L          |
| mmol/L                                              |       |         |                    |                 |
| 3.6 - 7.0 NORMAL RANDOM GLUCOSE                     |       |         |                    |                 |
| 7.1 - 11.0 POTENTIALLY AT RISK FOR DIABETES;        |       |         |                    |                 |
| CONSIDER REPEAT FASTING                             |       |         |                    |                 |
| >11.0 PROVISIONAL DIAGNOSIS OF DIABETES MELLITUS    |       |         |                    |                 |
| <b>CREATININE</b>                                   |       |         |                    |                 |
| CREATININE (F)                                      | N     | 76      | 60 - 110<br>umol/L | umol/L          |
| eGFR (F)                                            | N     | 109     | 60. -<br>99999.99  | mL/min/1.73m**2 |
| >=60. mL/min/1.73m**2                               |       |         |                    |                 |
| eGFR is calculated using the CKD-EPI 2009 equation. |       |         |                    |                 |
| CREATININE (F)                                      |       |         |                    |                 |

Normal eGFR. For patients of African descent, the reported eGFR must be multiplied by 1.15.

|                        | Flags | Results | Ref Range   | Units  |
|------------------------|-------|---------|-------------|--------|
| <b>ALBUMIN</b>         |       |         |             |        |
| ALBUMIN (F)            | N     | 47      | 35 - 52 g/L | g/L    |
| <b>BILIRUBIN TOTAL</b> |       |         |             |        |
| BILIRUBIN TOTAL (F)    | N     | 4       | <23 umol/L  | umol/L |

|                                       | Flags | Results | Ref Range        | Units  |
|---------------------------------------|-------|---------|------------------|--------|
| <b>VITAMIN B12</b>                    |       |         |                  |        |
| VITAMIN B12 (F)                       | N     | 251     | 221.-            | pmol/L |
| pmol/L                                |       |         |                  |        |
| DEFICIENCY: < 148 pmol/L              |       |         |                  |        |
| INSUFFICIENCY: 148 - 220 pmol/L       |       |         |                  |        |
| SUFFICIENCY: > 220 pmol/L             |       |         |                  |        |
| 60% OF SYMPTOMATIC PATIENTS HAVE A    |       |         |                  |        |
| HEMATOLOGIC OR NEUROLOGIC RESPONSE TO |       |         |                  |        |
| B12 SUPPLEMENTATION AT A LEVEL        |       |         |                  |        |
| <148 pmol/L                           |       |         |                  |        |
| <b>FERRITIN</b>                       |       |         |                  |        |
| Ferritin (F)                          | N     | 44      | 24 - 453 ug/L    | ug/L   |
| <b>SODIUM</b>                         |       |         |                  |        |
| SODIUM (F)                            | N     | 144     | 136 - 146 mmol/L | mmol/L |
| <b>POTASSIUM</b>                      |       |         |                  |        |
| POTASSIUM (F)                         | N     | 4.8     | 3.7 - 5.4 mmol/L | mmol/L |
| <b>AMYLASE</b>                        |       |         |                  |        |
| AMYLASE (F)                           | N     | 81      | 30 - 110 U/L     | U/L    |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                |                   |                  |                       |                  |                |
|----------------|-------------------|------------------|-----------------------|------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>HomePhone</b> | <b>(442) 733-2165</b> | <b>WorkPhone</b> |                |
| Health #       | 0748 361 588KT    | Sex              | M                     | Patient ID       | 0748 361 588KT |
| Age            | 46 years          |                  |                       |                  |                |
| DOB            | 1979              |                  |                       |                  |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 0044 552496 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2018-Dec-10 Reviewed: 2018-Dec-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
USERNAME] Reported Date: 2018-Dec-10 11:53 PM Updated On: 2018-Dec-15 8:51 AM

|                            | Flags | Results | Ref Range  | Units |
|----------------------------|-------|---------|------------|-------|
| <b>ALKALINEPHOSPHATASE</b> |       |         |            |       |
| ALKALINE PHOSPHATASE (F)   | N     | 66      | 40-129 U/L | U/L   |

|                         | Flags | Results | Ref Range           | Units     |
|-------------------------|-------|---------|---------------------|-----------|
| <b>GGT</b>              |       |         |                     |           |
| GGT (F)                 | N     | 23      | < 60 U/L            | U/L       |
| <b>ALT</b>              |       |         |                     |           |
| ALT (F)                 | N     | 27      | <46 U/L             | U/L       |
| <b>HEMOGLOBIN</b>       |       |         |                     |           |
| HEMOGLOBIN (F)          | N     | 135     | 129 - 165 g/L       | g/L       |
| <b>HEMATOCRIT</b>       |       |         |                     |           |
| HEMATOCRIT (F)          | N     | 0.43    | 0.39 - 0.49 l/l     | L/L       |
| <b>RBC</b>              |       |         |                     |           |
| RBC (F)                 | N     | 5.0     | 4.2 - 5.8 x 10E12/L | x 10*12/L |
| <b>RBC INDICES: MCV</b> |       |         |                     |           |
| RBC INDICES: MCV (F)    | N     | 86      | 80 - 98 fl          | fL        |
| <b>MCH</b>              |       |         |                     |           |
| MCH (F)                 | N     | 27      | 24 - 33 pg          | pg        |
| <b>MCHC</b>             |       |         |                     |           |
| MCHC (F)                | N     | 315     | 313 - 344 g/L       | g/L       |
| <b>RDW</b>              |       |         |                     |           |
| RDW (F)                 | N     | 15.4    | 12.5 - 17.3         |           |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                |                   |                   |                       |                   |                |
|----------------|-------------------|-------------------|-----------------------|-------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>Home Phone</b> | <b>(442) 733-2165</b> | <b>Work Phone</b> |                |
| Health #       | 0748 361 588KT    | Sex               | M                     | Patient ID        | 0748 361 588KT |
| Age            | 46 years          |                   |                       |                   |                |
| DOB            | 1979              |                   |                       |                   |                |

Comments: CC copy sent to Sinead Taylor

Lab Order #: 0044 552496 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2018-Dec-10 Reviewed: 2018-Dec-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
USERNAME] Reported Date: 2018-Dec-10 11:53 PM Updated On: 2018-Dec-15 8:51 AM

|            | Flags | Results | Ref Range          | Units    |
|------------|-------|---------|--------------------|----------|
| <b>WBC</b> |       |         |                    |          |
| WBC (F)    | N     | 6.4     | 3.2 - 9.4 x 10E9/L | x 10*9/L |

|                           | Flags | Results | Ref Range          | Units    |
|---------------------------|-------|---------|--------------------|----------|
| <b>PLATELETS</b>          |       |         |                    |          |
| PLATELETS (F)             | N     | 204     | 155 - 372 x 10E9/L | x 10*9/L |
| <b>MPV</b>                |       |         |                    |          |
| MPV (F)                   | N     | 10.2    | 4.0 - 14.0 fl      | fL       |
| <b>DIFFERENTIAL WBC'S</b> |       |         |                    |          |
| NEUTROPHILS (F)           | N     | 4.2     | 1.4 -6.3 x 10E9/L  | x 10*9/L |
| LYMPHOCYTES (F)           | N     | 1.5     | 1.0 -2.9 x 10E9/L  | x 10*9/L |
| MONOCYTES (F)             | N     | 0.5     | 0.2 -0.8 x 10E9/L  | x 10*9/L |
| EOSINOPHILS (F)           | N     | 0.1     | 0.0 -0.5 x 10E9/L  | x 10*9/L |
| BASOPHILS (F)             | N     | 0.00    | 0.00-0.09x10E9/L   | x 10*9/L |

Dr. Sinead Taylor # 414 235 249 671 Juniper Rd a nearby city 6 ONTARIO 848 Main Blvd TEL: 425-756-3322 FAX : 425-756-3322

Dec 9, 2018

Dr. Sinead Taylor 671 Juniper Rd a nearby city 6, ON a nearby city 11 Phone: 290 827 5744 ext. 6902 Fax: (442) 733-2165

Dear Dr. Sinead Taylor:

**Re: Ethan Kang Jun 21, 1979 Age: 39 yr HN: 2479844273** (442) 733-2165 (H) (442) 733-2165 (M preferred)

(442) 733-2165.

Received your letter dated December 6th. He was diagnosed on January 2nd, 2014 and was treated.

thank you

Sinead Taylor

Yours truly,

[image]

Dr. Gunnar Herrera

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

Friday Dec 6, 2018



Dr. Gunnar Herrera 412 Marigold Ave a nearby city 6, ON 848 Main Blvd Phone: 425-756-3322 Fax: 425-756-3322

RE: Ethan Kang (DOB: 1979)

Dear Dr. Herrera,

I saw our mutual patient Ethan Kang recently, and spoke with him about the possibility of enrolling him into a clinical trials for Filgotinib. During a preliminary screening of his medical history, our study coordinated noted that Dr. Herrera (endocrinologist) noted a medical history of Herpes Zoster ophthalmicus. I've attached a copy of the note in question, with the condition listed under surgical/medical history on the second page.

For consideration in the trial, we will require further information about his Herpes Zoster ophthalmicus diagnosis. Can you please provide details about when Ethan was diagnosed, and what treatment was initiated?

Please fax back to our office: (442) 733-2165.

Thank you.

Yours Sincerely,

[image]

Adaeze Cousineau

---

## Cedar Specialist Group 4

Dr. Sinead Taylor, a nearby city 8 Phone: 994-882-7246 Fax: 994-882-7246

**Patient** Name: Ethan Kang DOB: 1979 HCN: 414 235 249 Address: a nearby city 8

**Referring physician** Name: Dr. Herrera Address: a nearby city 8 Tel: 994-882-7246 Fax: (442) 733-2165

**Appointment details** Date: 2018-May-15 Location: Cedar Specialist Group 4

Dear Dr. Herrera;

Ethan Kang was seen in follow-up today for high triglycerides.

## SUBJECTIVE:

### HPI:

#### Pertinent Medical History

He informs me that another physician has changed some of his medications since his last visit. These changes were made and reflected in his current medication record, as best as he can recall the names and

the doses. He did not get a chance to go for the blood work I had requested him to do before today's appointment.

He has lost 5.2 kg since his last appointment.

He was started on Entivyo in [REDACTED-DATE] for his Crohn's disease.

This office appointment was performed in the presence of, and with the aid of, the clinical assistant Gunnar Herrera.

## **HIGH TRIGLYCERIDES**

He is currently not on any anti-hyperglycemic medications.

He walks for 30 minutes every day.

He is currently on no blood pressure lowering medications. He has checked his blood pressure elsewhere, and when he does he finds that his systolics are 130s and diastolics in the 70s. He checks his blood pressure at home.

He is currently not on any lipid modifying medications.

His work entails some walking.

Page 1 of 3

---

## **HYPOGONADISM**

He is currently on no medications for this condition.

Problem History: HYPERTRIGLYCERIDEMIA {Inactive} HYPOGONADISM [resolved]

Active Medications: None Recorded

External Medications: cyanocobalamin (vitamin B-12) 1,000 mcg/ml Injection Vial (mL) [1.0 qbiweekly]

Surgical/Medical History: Endocrinology, Other - Vitamin B12 deficiency Medical, Other - Insomnia Back pain - chronic Anemia, Other OSA (Obstructive Sleep Apnea) - using CPAP Kidney Stone Surgery, Other - Lipoma- 2015 (removed) Medical, Other - Herniated disc GI, Other - Crohn's disease Eye Disease - Herpes Zoster ophthalmicus Surgery, Other - 2014 - Ileocolic resection Dyslipidemia - Hypertriglyceridemia (in chylomicrons)

Known Allergies: CODEINE 15MG TABLET - Opioids - Morphine Analogues (Drug Allergy)

Current Medical Providers: Family Doctor - Dr. Sinead Taylor Gastroenterologist - Dr. Sinead Taylor - for Crohn's disease Optometrist - Dr. Rahman

Immunization History: Hepatitis B - February 1996 MMR - Aug 1996 Fluviral - Sep 2013 Vaxigrip - Sep 2014 Fluviral - Nov 2015

# OBJECTIVE:

## Vitals:

Ht: 178 cm; Wt: 133.7 kg; BMI: 42.7 BP: 135 / 94; HR: 73 bpm

## Physical Exam:

CARDIOVASCULAR: no systolic murmur, no diastolic murmur, normal rate, normal rhythm, normal S1, and normal S2. RESPIRATORY: there were no inspiratory wheezes, there were no expiratory wheezes, and there were no crackles.

## Lab/Test Results:

HbA1c: 5.3 % (2017-Oct-30) creatinine: 80 umol/L; Normal eGFR. For patients of African descent, the reported eGFR must be multiplied by 1.15. (2017-Oct-30) fasting glucose: 4.9 mmol/L (2017-Oct-30) random glucose: 7.7 mmol/L (2016-Nov-01)

Page 2 of 3

---

U alb:creat: 0.3 mg/mmol creat ( 2017-Oct-30 ) Tot Chol: 3.16 mmol/L ( 2017-Oct-30 ) TG: 4.89 mmol/L ( 2017-Oct-30 ) HDL: 0.62 mmol/L ( 2017-Oct-30 ) LDL: \* LDL-cholesterol calculation is invalid at triglycerides  $\geq 4.52$  mmol/L. ( 2017-Oct-30 ) TSH: 3.21 mIU/L ( 2017-Oct-30 ) FT4: 17 pmol/L ( 2017-Oct-30 ) FT3: 5.4 pmol/L ( 2017-Oct-30 )

# ASSESSMENT:

## HIGH TRIGLYCERIDES

BLOOD PRESSURE: The blood pressure is elevated and not at target. Although his blood pressure is elevated today, it is fine when he checks it elsewhere. He checks his blood pressure at home. As his blood pressure is only mildly increased, I plan to just monitor it for now and then re-assess depending on his future readings. LIPIDS: His Framingham risk score puts him in the low risk category ( < 10% ) for cardiovascular complications in the next 10 years. His triglycerides are increased. His HDL is low. Although the drug of choice for an elevated triglyceride level is fibrates, at best they decrease the triglycerides by 20 - 30%. The TREATMENT of choice is through lifestyle changes with reduction of carbohydrate intake in the diet ( including rice, bread, pasta, potatoes, fruits, etc ), reduction or preferably elimination of alcohol, a regular exercise routine and optimization of diabetes control ( if diabetes is present ). The best way to improve a low HDL is to engage in a regular exercise routine as well as to optimize diabetes control ( if diabetes is present ). This will increase the HDL by 10 - 20%, on average. The lipid profile and urine albumin:creatinine ratio are due to be repeated again in with the next blood work.

# PLAN:

LABORATORY: Diabetic blood work ( including HbA1C and fasting lipid profile ), and this is to be done before the next appointment. Bloodwork to evaluate static pituitary function, and this is to be done before the next appointment. TESTS: No tests have been requested at this point in time. REFERRALS: No referrals have been initiated at this point in time. NEW MEDICATION(S): He was not started on any new medications. DISCONTINUED MEDICATION(S): None of his medications were stopped. CHANGED MEDICATIONS:The dose of none of his medications were changed. FOLLOW-UP: Schedule a follow-up in 1 month(s).

I previously reviewed his lipid profiles dating back to 2011. I think his TG are mainly in chylomicrons which is not a risk factor for CAD, despite his family history.

Letter Generated by: Gunnar Herrera

Sincerely,

[image]

Gunnar Herrera Electronically Reviewed to Expedite Delivery cc: Sinead Taylor

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

|                |               |
|----------------|---------------|
| MSID #:        | 414 235 249   |
| Last Name:     | Ethan Kang    |
| First Name:    | Ethan         |
| Date of Birth: | 1979          |
| Sex:           | M             |
| Visit ID #:    | 0044 552496   |
| Visit Type:    | DS            |
| Room #:        |               |
| Atten. MD:     | Sinead Taylor |

Visit ID: 0044 552496 Procedure Date: 2018-12-03 Physician: Sinead Taylor, Gunnar Herrera (Fellow)  
Assistant: Anaesthetic: Midazolam 4 mg, fentanyl 50 mcg

Diagnosis:

Procedure: Colonoscopy.

Background: Mr. Ethan Kang has a history of Crohn's disease with previous resection. He has previously been on infliximab and adalimumab, to which he had secondary loss of response. More recently, he was on Entyvio but failed to respond despite dose escalation to every four weeks. He is not currently on therapy and is quite symptomatic with bloody diarrhea and urgency.

Procedure Note: DRE was normal. There was no evidence of perianal Crohn's disease. The variable-stiffness adult colonoscope was advanced to the neoterminal ileum. The colon looked entirely healthy; however, the neoterminal ileum was diffusely inflamed. There were numerous large ulcers with some measuring over 2 cm, and intervening mucosa was also diffusely inflamed. SES-CD in the neoterminal ileum was 9, and Rutgeerts score was 4. SES-CD in each colonic segment was 0. No biopsies were taken. The procedure was well tolerated. The prep was a little suboptimal in areas, however, was adequate with washing.

Mr. Ethan Kang will need to be on new medical therapy for his active small bowel Crohn's disease. Options at this point include Stelara or enrollment in the filgotinib trial.

Page 1 of 2

CONFIDENTIAL INFORMATION

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

|                |               |
|----------------|---------------|
| MSID #:        | 414 235 249   |
| Last Name:     | Ethan Kang    |
| First Name:    | Ethan         |
| Date of Birth: | 1979          |
| Sex:           | M             |
| Visit ID #:    | 0044 552496   |
| Visit Type:    | DS            |
| Room #:        |               |
| Atten. MD:     | Sinead Taylor |

We will discuss options with him today.

Sinead Taylor

Authenticated 10 days after distribution date

Dictated by: Gunnar Herrera (Fellow) Dictated: 2018-12-03 10:11 Transcribed: 2018-12-04 23:13

Distributed: 2018-12-05 11:05 Revised 2018-12-05 11:05 Job #: 0044 552496 br-MM cc: (HRM) Sinead

Taylor 671 Juniper Rd , a nearby city 6, ON 848 Main Blvd, Primary Care Provider (dictated fax 9933433437)

CONFIDENTIAL INFORMATION

[X] \* --

This task has been completed

|                    |                                                                                                                           |                        |                                                                    |
|--------------------|---------------------------------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                                                                                | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 12/03/2018                                                                                                                | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                                                                       | <b>Completed</b>       | 2018-Dec-04 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | send routine lab req and speak with Bordeaux about next FU - planning for small bowel Filgotinib study in [REDACTED-DATE] |                        |                                                                    |

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

Colonoscopy Record

412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd

Clearly imprint patient identification card

**414 235 249 0044 552496** DAYPT **Ethan Kang** 1979 M 994-882-7246 ON 2479844273 2018/DEC/04 412 Marigold Ave a nearby city 6, ONTARIO a nearby city 7

MS 21 (Rev. 02.2016) Page 1 of 1 Date: (1979) DEC 3, 2018 Time: (HH:MM) 9:45 Halima Castellano  
Performed by Gunnar Herrera

Pre-operative Diagnosis: Crohn's Final Diagnosis: Crohn's

| <b>SES-CD</b>         | <b>0</b>   | <b>1</b>                  | <b>2</b>             | <b>3</b>                        |
|-----------------------|------------|---------------------------|----------------------|---------------------------------|
| Ulcer Size (cm)       | None       | Aphthous ulcers (0.1-0.5) | Large ulcers (0.5-2) | Very large ulcers (more than 2) |
| (%) Ulcerated surface | None       | Less than 10              | 10-30                | More than 30                    |
| (%) Affected surface  | Unaffected | Less than 50              | 50-75                | More than 75                    |

| SES-CD      | 0    | 1                | 2                  | 3           |
|-------------|------|------------------|--------------------|-------------|
| Narrowings? | None | Single, can pass | Multiple, can pass | Cannot pass |

| *Mayo Score UC/IC |                                                                          |
|-------------------|--------------------------------------------------------------------------|
| 0                 | Normal / Inactive                                                        |
| 1                 | Mild (erythema, decreased vascular pattern, mild friability)             |
| 2                 | Moderate (marked erythema, absent vascular pattern, friability, erosion) |
| 3                 | Severe (spontaneous bleeding, ulceration)                                |

| Grade | Rutgeert's Score (CD Post-operative)                           |
|-------|----------------------------------------------------------------|
| 0     | Normal                                                         |
| 1     | 5 aphthous ulcers or less                                      |
| 2     | more than 5 aphthous ulcers with normal mucosa                 |
| 3     | Diffuse aphthous ileitis with diffusely inflamed mucosa        |
| 4     | Diffuse inflammation with large ulcer/nodules and/or narrowing |

Total Sedation Required: ☐ Midazolam \_\_\_\_\_ mg IV ☐ Propofol \_\_\_\_\_ mg IV ☐ Fentanyl \_\_\_\_\_ mcg ☐ Other: \_\_\_\_\_

Bowel Preparation: ☐ Adequate ☐ Inadequate Time to reach Cecum: \_\_\_\_\_ min. Terminal ileum intubated: ☐ Yes \_\_\_\_\_ cm. ☐ No Retroflexion in Rectum: ☐ Yes ☐ No Withdrawal time (Cecum to Anus): \_\_\_\_\_ min.

| ASCENDING             | Score |
|-----------------------|-------|
| *Mayo-UC/IC           |       |
| *SES-CD:              | 0     |
| Ulcer Size (cm)       |       |
| (%) Ulcerated surface |       |
| (%) Affected surface  |       |
| Narrowings?           |       |

| ASCENDING         | # of polyps |
|-------------------|-------------|
| Removed           |             |
| Retrieved         |             |
| Partially removed |             |
| Size              |             |
| Tattoo            |             |

|                    |                    |
|--------------------|--------------------|
| <b>ASCENDING</b>   | <b># of polyps</b> |
| Number of Biopsies |                    |

|                       |              |
|-----------------------|--------------|
| <b>TERMINAL ILEUM</b> | <b>Score</b> |
| SES-CD:               | 9            |
| Ulcer Size (cm)       | 3            |
| (%) Ulcerated surface | 3            |
| (%) Affected surface  | 3            |
| Narrowings?           |              |
| Rutgeert's Score      | 4            |

|                       |              |
|-----------------------|--------------|
| <b>TRANSVERSE</b>     | <b>Score</b> |
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |
| Narrowings?           |              |

|                    |                    |
|--------------------|--------------------|
| <b>TRANSVERSE</b>  | <b># of polyps</b> |
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

[image]

|                       |              |
|-----------------------|--------------|
| <b>DESCENDING</b>     | <b>Score</b> |
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |



| DESCENDING  | Score |
|-------------|-------|
| Narrowings? |       |

| DESCENDING         | # of polyps |
|--------------------|-------------|
| Removed            |             |
| Retrieved          |             |
| Partially removed  |             |
| Size               |             |
| Tattoo             |             |
| Number of Biopsies |             |

| RECTUM                | Score |
|-----------------------|-------|
| *Mayo-UC/IC           |       |
| *SES-CD:              | 0     |
| Ulcer Size (cm)       |       |
| (%) Ulcerated surface |       |
| (%) Affected surface  |       |
| Narrowings?           |       |

| RECTUM             | # of polyps |
|--------------------|-------------|
| Removed            |             |
| Retrieved          |             |
| Partially removed  |             |
| Size               |             |
| Tattoo             |             |
| Number of Biopsies |             |

PERIANAL [illegible] ☐ Hemorrhoid ☐ Fissure ☐ Fistula ☐ Abscess ☐ Skin Tag

Date: 2018-12-03 (1979) Time: 10:05 (HH:MM) Print Name: Herrera Signatures: Gunnar Herrera

[image]

[image]

Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 415 Juniper Rd a nearby city 6 ON T: 993-089-6973 qaa 0534 F: (442) 733-2165

| Clinician/Practitioner Number | CPSO / Registration No. |
|-------------------------------|-------------------------|
| 0748 361 588KT                | 414 235 249             |

Check (☐) one: ☒ OHIP/Insured ☐ Third Party / Uninsured ☐ WSIB

Additional Clinical Information (e.g. diagnosis) (blank)

☒ Copy to: Clinician/Practitioner Last Name: Taylor First Name: Taylor Address: 415 Juniper Rd a nearby city 6 ON, Canada Fax: (442) 733-2165

Laboratory Use Only (blank)

Clinician/Practitioner's Contact Number for Urgent Results (442) 733-2165

Service Date 1979 = (blank) mm = (blank) 1979 = (blank)

Health Number: 0748 361 588KT Version: 5753727875QP Sex: M Date of Birth: 1979 = 1979 mm = 06 1979 = 1979

Province: (blank) Other Provincial Registration Number: (blank) Patient's Telephone Contact Number: (442) 733-2165

Patient's Last Name (as per OHIP Card) Ethan Kang Patient's First & Middle Names (as per OHIP Card) Ethan Kang Patient's Address (including Postal Code) a nearby city 8

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Crestwood Medical Group

| x                                   | Biochemistry                                                                        | x                                   | Hematology             | x                        | Viral Hepatitis (check one only)                                                                                                                          |
|-------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------|------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/>            | Glucose <input checked="" type="checkbox"/> Random <input type="checkbox"/> Fasting | <input checked="" type="checkbox"/> | CBC                    | <input type="checkbox"/> | Acute Hepatitis                                                                                                                                           |
| <input type="checkbox"/>            | HbA1C                                                                               | <input type="checkbox"/>            | Prothrombin Time (INR) | <input type="checkbox"/> | Chronic Hepatitis                                                                                                                                         |
| <input checked="" type="checkbox"/> | Creatinine (eGFR)                                                                   |                                     | <b>Immunology</b>      | <input type="checkbox"/> | Immune Status / Previous Exposure Specify: <input type="checkbox"/> Hepatitis A <input type="checkbox"/> Hepatitis B <input type="checkbox"/> Hepatitis C |
| <input type="checkbox"/>            | Uric Acid                                                                           | <input type="checkbox"/>            | Pregnancy Test (Urine) |                          |                                                                                                                                                           |
| <input checked="" type="checkbox"/> | Sodium                                                                              | <input type="checkbox"/>            | Mononucleosis Screen   |                          | or order individual hepatitis tests in the "Other Tests" section below                                                                                    |
| <input checked="" type="checkbox"/> | Potassium                                                                           | <input type="checkbox"/>            | Rubella                |                          |                                                                                                                                                           |

|          |                                                                                                                                                                                     |          |                                                                    |          |                                                                                                                                                                  |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b> | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b> | <b>Hematology</b>                                                  | <b>x</b> | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
| [X]      | ALT                                                                                                                                                                                 | [ ]      | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) |          | <b>Prostate Specific Antigen (PSA)</b>                                                                                                                           |
| [X]      | Alk. Phosphatase                                                                                                                                                                    | [ ]      | Repeat Prenatal Antibodies                                         | [ ]      | Total PSA [ ] Free PSA                                                                                                                                           |
| [X]      | Bilirubin                                                                                                                                                                           |          | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          |          | Specify one below:                                                                                                                                               |
| [X]      | Albumin                                                                                                                                                                             | [ ]      | Cervical                                                           | [ ]      | Insured – Meets OHIP eligibility criteria                                                                                                                        |
| [ ]      | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [ ]      | Vaginal                                                            | [ ]      | Uninsured – Screening: Patient responsible for payment                                                                                                           |
| [ ]      | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | [ ]      | Vaginal / Rectal – Group B Strep                                   |          | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                    |
| [ ]      | Urinalysis (Chemical)                                                                                                                                                               | [ ]      | Chlamydia (specify source):                                        | [ ]      | Insured – Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
|          | Neonatal Bilirubin:                                                                                                                                                                 | [ ]      | GC (specify source):                                               |          |                                                                                                                                                                  |
|          | Child's Age: days = (blank) hours = (blank)                                                                                                                                         | [ ]      | Sputum                                                             | [ ]      | Uninsured - Patient responsible for payment                                                                                                                      |
|          | Clinician/Practitioner's tel. no. ( )                                                                                                                                               | [ ]      | Throat                                                             |          | <b>Other Tests</b> - one test per line                                                                                                                           |
|          | Patient's 24 hr telephone no. ( )                                                                                                                                                   | [ ]      | Wound (specify source):                                            |          | Ferritin                                                                                                                                                         |
|          | <b>Therapeutic Drug Monitoring:</b>                                                                                                                                                 | [ ]      | Urine                                                              |          | Vitamin B12                                                                                                                                                      |
|          | Name of Drug #1                                                                                                                                                                     | [ ]      | Stool Culture                                                      |          | c-reactive protein                                                                                                                                               |
|          | Name of Drug #2                                                                                                                                                                     | [ ]      | Stool Ova & Parasites                                              |          | Amylase                                                                                                                                                          |

|          |                                 |          |                                     |          |                                         |
|----------|---------------------------------|----------|-------------------------------------|----------|-----------------------------------------|
| <b>x</b> | <b>Biochemistry</b>             | <b>x</b> | <b>Hematology</b>                   | <b>x</b> | <b>Viral Hepatitis (check one only)</b> |
|          | Time Collected #1 hr. #2 hr.    | [ ]      | Other Swabs / Pus (specify source): |          | GGT                                     |
|          | Time of Last Dose #1 hr. #2 hr. |          |                                     |          |                                         |
|          | Time of Next Dose #1 hr. #2 hr. |          |                                     |          |                                         |

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

[signature image] X 2018-Dec-03 Clinician/Practitioner Signature Date

Specimen Collection Time: (blank) Date: MM/1979/1979 (blank)

Fecal Occult Blood Test (FOBT) (check one) [ ] FOBT (non CCC) [ ] ColonCancerCheck FOBT (CCC) no other test can be ordered on this form

Laboratory Use Only (blank)

4422-84 (2013/01) © Queen's Printer for Ontario, 2013 7530-4581

☐ \*--

This task has been completed

|                    |                                                                                                    |                        |                                                                    |
|--------------------|----------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                                                         | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 09/18/2018                                                                                         | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                                                | <b>Completed</b>       | 2018-Sep-20 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Please review with Bordeaux if Ethan is eligible for the Crestwood Medical Group small bowel study |                        |                                                                    |

PHYSICIAN STATUS REPORT Westbrook Medical Associates 5™ DESIGNED FOR YOU

|                                                       |                                      |
|-------------------------------------------------------|--------------------------------------|
| <b>TO: Dr. Sinead Taylor, (442) 733-2165</b>          | <b>Date: Sep 17, 2018</b>            |
| <b>FROM: Gunnar Herrera; Ridgeway Family Health 5</b> | <b>Page: &lt;Number of Page&gt;</b>  |
| <b>Patient Name: Ethan Kang</b>                       | <b>Patient ID#: Y633528593, 1979</b> |

## Section 1

**Program Services Requested** [X] Medical Clarification Required

## Section 2: PROGRAM COMMENTS/UPDATES

Hi Dr. Taylor,

I received a phone call from the patient advising that he will no longer be on Entyvion due to the antibodies he has built up against the medication. Please advise so I can discontinue this file, thank you

### **Patient will be stopping and switching to different therapy**

If you have any questions about Ridgeway Family Health 5 and/or about your patient's status, please call 867.739.5528.

Sincerely,

### **Ridgeway Family Health 5**

- The independent service provider is subject to change without notice. Westbrook Medical Associates 5 is a trademark of Ridgeway Family Health 5

**Ridgeway Family Health 5** Telephone: 867.739.5528 Fax: 867.739.5528 Email: [mason.sandoval49@northviewclinic.ca](mailto:mason.sandoval49@northviewclinic.ca)

|                 |                       |                          |                    |
|-----------------|-----------------------|--------------------------|--------------------|
| <b>Patient:</b> | <b>Mr. Ethan Kang</b> | <b>Appointment Date:</b> | <b>2018-Sep-16</b> |
| Title:          | MS IBD Follow up      |                          |                    |
| Provider:       | Taylor, Sinead        | Referred By:             | None               |

Sep 16, 2018

### **Re. Ethan Kang, DOB 1979 ZFY 796591380**

I saw Ethan Kang today for follow up of his Crohn's disease.

**Problem History:** Crohn's disease

**IBD Phenotype:** Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**Endoscopy Results:** 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

**Active Medications:** methotrexate 2.5 mg Oral Tablet 10 Tablet(s) 1x/week X 60 Day(s) ENTYVIO 300 MG VIAL

### **Current Status**

Ethan still has approx 6 BM/day -liquid stool. He denies abdominal pain. He has significant urgency, but no incontinence. He has intermittent blood in his stool (<50% of the time). He feels no significant improvement on entyvio. -Levels in March showed low drug level & low level antibodies. Dosing interval changed to

q4/52 at that time. No symptomatic improvement following same. Ethan was previously on infliximab & adalimumab -secondary loss of response to both.

**On physical examination, he looks well and nutritionally fit.**

### **Assessment and Plan**

Ethan has ongoing active Crohn's. He has failed anti-TNFs and has now failed to respond to entyvio. Drug antibody formation may be an important mechanism of lack/loss of drug response for him.

We plan to enrol Ethan in a clinical trial for filgotinib (JAK inhibitor) -he will first need an 8 week entyvio washout. He can stop entyvio from now. He hope to enrol him in [REDACTED-DATE].

In the meantime, he can commence entocort 9mg od

If filgotinib doesn't work, ustekinumab (Stelara) would be considered the next therapeutic option.

**Dictated by Dr. Gunnar Herrera IBD fellow on behalf of Dr. Adaeze Cousineau.**

---

**Dr. Sinead Taylor**

415 Juniper Rd a nearby city 6 ON, Canada 848 Main Blvd

## **Fax Cover Sheet**

To: Dr. Sinead Taylor Phone: 994-882-7246 Fax: (442) 733-2165

Date: 2018-Sep-17

From: Dr. Sinead Taylor Phone: 993-089-6973 qaa 0534 Fax: (442) 733-2165

Number of pages including cover: 3

**Confidential: This communication is intended only for the individual or institution to which it is addressed and should not be distributed, copied or disclosed to anyone else. The documents in this communication may contain personal, confidential or privileged information, which may be subject to the Freedom of information and Protection of Privacy Act, the Health Information Act and other legislation. If you have received this communication in error, please notify us immediately and return original transmission to us. Thank you for your co-operation and assistance.**

Re: Ethan Kang

---

![[Cedar Specialist Group 4 Logo] **Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Ridgeway Family Health FOR DIGESTIVE DISEASES**

**Dr. Jasmin Kaminski** Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

Sep 16, 2018

**Re. Ethan Kang, DOB 1979 ZFY 796591380**

I saw Ethan Kang today for follow up of his Crohn's disease.

**Problem History:** Crohn's disease

**IBD Phenotype:** Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**Endoscopy Results:** 2017-Feb-05 Colonoscopy - neoTI Rutgeert's i3, SES-CD:7, colon:normal.

**Active Medications:** methotrexate 2.5 mg Oral Tablet 10 Tablet(s) 1x/week X 60 Day(s) ENTYVIO 300 MG VIAL

**Current Status**

Ethan still has approx 6 BM/day -liquid stool. He denies abdominal pain. He has significant urgency, but no incontinence. He has intermittent blood in his stool (<50% of the time). He feels no significant improvement on entyvio. -Levels in March showed low drug level & low level antibodies. Dosing interval changed to q4/52 at that time. No symptomatic improvement following same. Ethan was previously on infliximab & adalimumab -secondary loss of response to both.

**On physical examination, he looks well and nutritionally fit.**

**Assessment and Plan**

Ethan has ongoing active Crohn's. He has failed anti-TNFs and has now failed to respond to entyvio. Drug antibody formation may be an important mechanism of lack/loss of drug response for him.

We plan to enrol Ethan in a clinical trial for filgotinib (JAK inhibitor) -he will first need an 8 week entyvio washout. He can stop entyvio from now. He hope to enrol him in [REDACTED-DATE].

In the meantime, he can commence entocort 9mg od

If filgotinib doesn't work, ustekinumab (Stelara) would be considered the next therapeutic option.

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

---

**Dictated by Dr. Gunnar Herrera IBD fellow on behalf of Dr. Sinead Taylor.**

Sincerely,

![signature]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

Patient: Ethan Kang PHN: 0748 361 588KT DOB: 1979

---

Lab Results: Generated On 2026-Apr-09

|                |            |                   |                      |                   |  |
|----------------|------------|-------------------|----------------------|-------------------|--|
| <b>Patient</b> | Ethan Kang | <b>Home Phone</b> | (089) 697-3500 a5345 | <b>Work Phone</b> |  |
|----------------|------------|-------------------|----------------------|-------------------|--|

|                 |                |            |   |                   |                |
|-----------------|----------------|------------|---|-------------------|----------------|
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b> | M | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |            |   |                   |                |
| <b>DOB</b>      | 1979           |            |   |                   |                |

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM

| <b>ROUTINE CHEMISTRY I</b> | <b>Results</b> | <b>Flags</b> | <b>Ref Range</b> |        | <b>Test Loc</b> |
|----------------------------|----------------|--------------|------------------|--------|-----------------|
| CREATININE                 | 71             |              | 67 - 117         | umol/L | KL              |
| eGFR                       | 112            |              |                  |        |                 |

Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

Effective May 3, 2015, eGFR is calculated using the CKD-EPI 2009 equation.

KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.

|                            | <b>Results</b> | <b>Flags</b> | <b>Ref Range</b> |        |  |
|----------------------------|----------------|--------------|------------------|--------|--|
| SODIUM                     | 142            |              | 135 - 145        | mmol/L |  |
| POTASSIUM                  | 4.3            |              | 3.5 - 5.2        | mmol/L |  |
| CHLORIDE                   | 102            |              | 98 - 108         | mmol/L |  |
| TOTAL BILIRUBIN            | 5              |              | < 20             | umol/L |  |
| ALANINE TRANSAMINASE (ALT) | 27             |              | < 50             | U/L    |  |
| ALKALINE PHOSPHATASE       | 73             |              | 40 - 129         | U/L    |  |
| GAMMA-GLUTAMYLTRANSFERASE  | 18             |              | 14 - 62          | U/L    |  |

KL - a nearby city 8 (089) 697-3500 a5345

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM



| ROUTINE CHEMISTRY II | Results | Flags | Ref Range |     | Test Loc |
|----------------------|---------|-------|-----------|-----|----------|
| ALBUMIN              | 44      |       | 35 - 52   | g/L | KL       |

KL - a nearby city 8 (089) 697-3500 a5345

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM

|  | Results | Flags | Ref Range |  | Test Loc |
|--|---------|-------|-----------|--|----------|
|--|---------|-------|-----------|--|----------|

| SPECIAL CHEMISTRY II | Results | Flags | Ref Range |        | Test Loc |
|----------------------|---------|-------|-----------|--------|----------|
| VITAMIN B12          | 203     |       | 138 - 652 | pmol/L | KL       |

KL - a nearby city 8 (089) 697-3500 a5345

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM

|           | Results | Flags | Ref Range  |      | Test Loc |
|-----------|---------|-------|------------|------|----------|
| CHEMISTRY |         |       |            |      |          |
| FERRITIN  | 49      |       | 1979 - 275 | ug/L | KL       |

KL - a nearby city 8 (089) 697-3500 a5345

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM

|              | Results | Flags | Ref Range   |         | Test Loc |
|--------------|---------|-------|-------------|---------|----------|
| HEMATOLOGY I |         |       |             |         |          |
| WBC          | 4.7     |       | 4.0 - 11.0  | x E9/L  | 10       |
| RBC          | 4.98    |       | 4.50 - 6.00 | x E12/L |          |
| HEMOGLOBIN   | 134     | LO    | 135 - 175   | g/L     |          |

|                | Results | Flags | Ref Range            |        | Test Loc |
|----------------|---------|-------|----------------------|--------|----------|
| HEMATOCRIT     | 0.405   |       | 0.400 - 0.500        | L/L    |          |
| MCV            | 81      |       | 80 - 100             | fL     |          |
| MCH            | 26.9    | LO    | 27.5 - 33.0          | pg     |          |
| MCHC           | 331     |       | 0748 361 588KT - 360 | g/L    |          |
| RDW            | 14.2    |       | 11.5 - 14.5          | %      |          |
| PLATELET COUNT | 229     |       | 150 - 400            | x E9/L |          |

a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM

|                       | Results | Flags | Ref Range |          | Test Loc |
|-----------------------|---------|-------|-----------|----------|----------|
| <b>HEMATOLOGY II</b>  |         |       |           |          |          |
| NEUTROPHILS           | 3.0     |       | 2.0 - 7.5 | x E9/L   | 10       |
| LYMPHOCYTES           | 1.2     |       | 1.0 - 3.5 | x E9/L   |          |
| MONOCYTES             | 0.4     |       | 0.2 - 1.0 | x E9/L   |          |
| EOSINOPHILS           | 0.1     |       | 0.0 - 0.5 | x E9/L   |          |
| BASOPHILS             | 0.0     |       | 0.0 - 0.2 | x E9/L   |          |
| IMMATURE GRANULOCYTES | 0.0     |       | 0.0 - 0.1 | x E9/L   |          |
| NRBC                  | 0       |       |           | /100 WBC |          |

Ridgeway Family Health is now reporting five new CBC parameters

- Reticulocyte Hgb, IRF, IPF, NRBC, and IG. All parameters will be automatically reported when applicable. For more information please visit [www.stonebridgehealthclinic.ca](http://www.stonebridgehealthclinic.ca), click on "Healthcare Providers" and refer to an article called "New Hematology Instrumentation and Parameters" under the "News and Notices" section.

a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM

|                          | Results | Flags | Ref Range |     | Test Loc |
|--------------------------|---------|-------|-----------|-----|----------|
| <b>SPECIAL/ROUTINE I</b> |         |       |           |     |          |
| AMYLASE                  | 99      |       | 30 - 110  | U/L | KL       |

KL - a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 0044 552496 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Sep-05 Reviewed: 2018-Sep-12 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Sep-05 Report Date: 2018-Sep-06 4:46 AM

Updated On: 2018-Sep-12 9:39 PM

|                    | Results | Flags | Ref Range |      | Test Loc |
|--------------------|---------|-------|-----------|------|----------|
| <b>CHEMISTRY V</b> |         |       |           |      |          |
| C-REACTIVE PROTEIN | 4.7     |       | < 6.0     | mg/L | KL       |

KL - a nearby city 8 (089) 697-3500 a5345

---

**Cedar Specialist Group 4** Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

**Gunnar Herrera** 671 Juniper Rd a nearby city 6, Ontario 848 Main Blvd

Tel 994-882-7246 Fax 994-882-7246 Email: sabine.dalton80@fairlightmedicalcentre.ca

2017-Jul-31

Dr. Taylor 415 Juniper Rd a nearby city 8

**Patient:** Mr. Ethan Kang **PHN:** 414 235 249 **MRN:** 414 235 249 **Birthdate:** 1979

Dear Dr. Taylor,

We had the pleasure of seeing Mr. Ethan Kang in follow-up at the Westbrook Medical Associates 5. Mr. Ethan Kang, a 38-year-old male was seen for Crohn's disease.

**Relevant Past Medical History:** None Recorded .

The following is a summary of the patient's IBD disease course: **IBD Phenotype:** Crohn's disease  
Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Stricturing

**IBD Therapies:** None Recorded

**IBD Complications:** None Recorded

**IBD Extraintestinal Manifestations:** None Recorded

**IBD Diagnostics:** None Recorded

**Active Medications:** Study Medication (Mongersen or placebo)

**Known Allergies:** None Recorded

**Interim History:** Ethan has been feeling well.

He has between 3 and 4 bowel movements per day. His stools are always loose. None of his bowel movements are bloody. He has no abdominal pain

---

He reports no constitutional symptoms.

He reports no extraintestinal manifestations of IBD.

**On physical exam, [the patient appeared well and in no distress.][The weight] was .** The abdominal exam revealed no abdominal tenderness. There was diastasis recti.

**Impression and Plan:** In summary, Mr. Ethan Kang is a 38 year-old male who was seen in consultation for Crohn's disease. His disease may be mildly active but he is clinically stable. He will carry on in the study.

He will follow up in this clinic in 2 months.

Sincerely,

!signature]

Gunnar Herrera Staff Gastroenterologist Medical Lead, Northview Clinic 6

**Electronically Reviewed to Expedite Delivery**

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

Jul 4, 2017

Dr. Sinead Taylor Outpatient Services

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Ethan returned today for followup as part of the Mongersen in Crohn's disease study. He continues to be quite stable with no change in his clinical status. He has between three and six bowel motions per day although, typically, it tends to be three or four most days. The stools continue to be unformed but his urgency is less than before and he has not been having any rectal bleeding and no abdominal pain.

On examination, his abdomen was soft and non tender. No masses or abnormal loops of bowel were palpable.

Ethan continues to do well on the study medication and is tolerating it with only minimal ongoing symptoms.

Yours sincerely

Dictated but not read

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

Jun 6, 2017

Dr. Sinead Taylor Outpatient Services

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Ethan returned to see me today for followup as part of the Mongersen in Crohn's disease study. He continues to be stable with no change in bowel habit. Typically, this consists of three or four bowel motions per day. There is usually no form to the stool but the urgency continues to be less than before and there is no blood in the stool and no abdominal pain.

On examination, his abdomen was soft and non tender. No masses or abnormal loops of bowel were palpable.

Ethan is continuing to tolerate the study medication well and will continue on in the study as per the protocol.

Yours sincerely

Dictated but not read

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

Jun 6, 2017

Dr. Sinead Taylor Outpatient Services

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Ethan returned to see me today for followup as part of the Mongersen in Crohn's disease study. He continues to be stable with no change in bowel habit. Typically, this consists of three or four bowel motions per day. There is usually no form to the stool but the urgency continues to be less than before and there is no blood in the stool and no abdominal pain.

On examination, his abdomen was soft and non tender. No masses or abnormal loops of bowel were palpable.

Ethan is continuing to tolerate the study medication well and will continue on in the study as per the protocol.

Yours sincerely

DICTATED BUT NOT READ

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

[image]

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

May 9, 2017

Dr. Sinead Taylor Outpatient Services

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Ethan returned to see me today for followup as part of the Mongersen in Crohn's disease study. He is doing quite well with an average of three bowel motions per day. They are not formed but he is experiencing less urgency than before. There has been no blood in the stool and no abdominal pain. General physical examination was unremarkable. His abdomen was soft and non tender. There was no organomegaly and no masses or abnormal loops of bowel were palpable.

Ethan is experiencing no potential side effects of the study medication and will carry on in the trial for now.

Yours sincerely

DICTATED BUT NOT READ

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

---

Cedar Specialist Group 4 Dr. Sinead Taylor, a nearby city 8 Phone: 994-882-7246 Fax: 994-882-7246

**Patient** Name: Ethan Kang DOB: 1979 HCN: 414 235 249 Address: a nearby city 8

**Referring physician** Name: Dr. Herrera Address: a nearby city 8 Tel: 994-882-7246 Fax: (442) 733-2165

**Appointment details** Date: 2017-May-09 Location: Cedar Specialist Group 4

Dear Dr. Herrera;

Ethan Kang was seen in follow-up today for high triglycerides and hypogonadism.

# SUBJECTIVE:

## HPI:

### Pertinent Medical History

He denies any medication changes since his last office visit.

He has gained 2.1 kg since his last appointment.

Dr. Taylor put him on trial medication called Mongerson (dosage unknown) for his Crohn's disease.

He has been feeling well. His wife is currently pregnant. She is due at the beginning of August 2017.

This office appointment was performed in the presence of, and with the aid of, the clinical assistant Gunnar Herrera and Gunnar Herrera.

### DIABETES TYPE 2 AND HIGH TRIGLYCERIDES

His DIABETES TYPE 2 AND HIGH TRIGLYCERIDES was diagnosed December 2016. He has never been to a diabetic education centre, nor met with a diabetic education nurse or dietitian. He has his eyes examined for diabetic retinopathy every year. His eyes are examined by Dr. Rahman. He last had his eyes examined [REDACTED-DATE]. He denies the complications of nephropathy, retinopathy, neuropathy, coronary artery disease, cerebrovascular disease, and peripheral vascular disease.

He is currently not on any anti-hyperglycemic medications. He does not perform home glucose monitoring. He denies having any episodes of hypoglycemia.

He does not exercise. His work entails some walking.

Page 1 of 4

---

He is currently on no blood pressure lowering medications. He has checked his blood pressure elsewhere, and when he does he finds that his systolics are 130s and diastolics in the 70s. He checks his blood pressure at home.

He is currently not on any lipid modifying medications.

### HYPOGONADISM

He is currently on no medications for this condition.

**Problem History:** HYPERTRIGLYCERIDEMIA HYPOGONADISM DIABETES MELLITUS

**Active Medications:** None Recorded

**External Medications:** Cyanocobalamin (Vitamin B-12) 1,000 mcg/ml Injection Vial (mL) [1.0 qbiweekly]

**Surgical/Medical History:** Medical, Other - Crohn's Disease Endocrinology, Other - Vitamin B12 deficiency Medical, Other - Insomnia Back pain - chronic Anemia, Other OSA ( Obstructive Sleep Apnea ) -

using CPAP Kidney Stone Medical, Other - Herpes Zoster ophthalmicus Surgery, Other - Ileocolic resection- 2014 Surgery, Other - Lipoma- 2015 (removed) Medical, Other - Herniated disc Dyslipidemia - Hypertriglyceridemia

**Known Allergies:** CODEINE 15MG TABLET - Opioids - Morphine Analogues (Drug Allergy)

**Current Medical Providers:** Family Doctor - Dr. Sinead Taylor Gastroenterologist - Dr. Sinead Taylor - for Crohn's disease Optometrist - Dr. Rahman

**Immunization History:** Hepatitis B - February 1996 MMR - Aug 1996 Fluviral - Sep 2013 Vaxigrip - Sep 2014 Fluviral - Nov 2015

## OBJECTIVE:

### Vitals:

Ht: 178 cm; Wt: 131.1 kg; BMI: 42.7 BP: 126 / 80; HR: 101 bpm We were unable to obtain a blood pressure reading.

### Physical Exam:

CARDIOVASCULAR: no systolic murmur, no diastolic murmur, normal rate, normal rhythm, normal S1, and normal S2. RESPIRATORY: there were no inspiratory wheezes, there were no expiratory wheezes, and there were no crackles.

### Lab/Test Results:

**HbA1c:** 5.1 %( 2017-May-02 ) **creatinine:** 78. umol/L;

---

Normal eGFR. For patients of African descent, the reported eGFR must be multiplied by 1.15. ( 2017-May-02 ) **fasting glucose:** 4.6 mmol/L ( 2017-May-02) **random glucose:** 7.7 mmol/L ( 2016-Nov-01 ) **U alb:creat:** 0.6 mg/mmol creat ( 2017-May-02 ) **Tot Chol:** 3.12 mmol/L ( 2017-May-02 ) **TG:** 3.97 mmol/L ( 2017-May-02 ) **HDL:** 0.69 mmol/L ( 2017-May-02 ) **LDL:** 0.61 mmol/L ( 2017-May-02 ) **TSH:** 2.40 mIU/L ( 2017-May-02 ) **FT4:** 14. pmol/L ( 2017-May-02 ) **FT3:** 4.7 pmol/L( 2017-May-02 )

## ASSESSMENT:

BLOODWORK: I reviewed his recent blood test results with him.

DIABETES TYPE 2 AND HIGH TRIGLYCERIDES

LIPIDS: His Framingham risk score puts him in the low risk category ( < 10% ) for cardiovascular complications in the next 10 years. His triglycerides are increased. His HDL is low. Although the drug of choice for an elevated triglyceride level is fibrates, at best they decrease the triglycerides by 20 - 30%. The TREATMENT of choice is through lifestyle changes with reduction of carbohydrate intake in the diet (



including rice, bread, pasta, potatoes, fruits, etc ), reduction or preferably elimination of alcohol, a regular exercise routine and optimization of diabetes control ( if diabetes is present ). The best way to improve a low HDL is to engage in a regular exercise routine as well as to optimize diabetes control ( if diabetes is present ). This will increase the HDL by 10 - 20%, on average. This was all explained to him. The lipid profile and urine albumin:creatinine ratio are due to be repeated again in with the next blood work . EYES: His next eye exam is due March 2017. MONOFILAMENT: His next monofilament exam is due on the next appointment.

#### HYPOGONADISM

ADVICE: His testosterone may be low due to his increased weight. Fat cells contain the aromatase enzyme which converts testosterone to estrogen. In addition, estrogen increases SHBG levels further decreasing testosterone levels. The testosterone assay is difficult to perform and has inherent accuracies. A low reading needs at least 2, but preferably 3 readings confirming it is low. I will repeat it and re-assess. His testosterone is now normal.

## PLAN:

LABORATORY: diabetic blood work ( including HbA1C and fasting lipid profile ), and this is to be done before the next appointment. bloodwork to evaluate static pituitary function, and this is to be done before the next appointment. TESTS: No tests have been requested at this point in time. REFERRALS: No referrals have been initiated at this point in time. NEW MEDICATION(S): He was not started on any new medications. DISCONTINUED MEDICATION(S): None of his medications were stopped. CHANGED MEDICATIONS: The dose of none of his medications were changed. FOLLOW-UP: Schedule a follow-up in 6 month(s).

I reviewed his lipid profiles dating back to 2011. I think his TG are mainly in chylomicrons which is not a risk factor for CAD, despite his family history.

Page 3 of 4

---

Letter Generated by: Gunnar Herrera

Sincerely,

[image]

Gunnar Herrera

**Electronically Reviewed to Expedite Delivery**

cc: Sinead Taylor

Page 4 of 4

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

Apr 10, 2017

Dr. Sinead Taylor Outpatient Services

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Ethan returned to see me today for followup of his Crohn's disease. As you know, he has a history of previous ileal resection with endoscopic documented disease recurrent in the neoterminal ileum. He previously lost response to Humira therapy and is currently participating in the Mongersen trial for the treatment of Crohn's disease. He is presently having between two and four bowel motions per day although the stools are generally not formed. In the past month, he has had approximately two days when he was not feeling well and had up to six bowel motions per day. On those days, there may have been a small amount of blood associated with the stool. His weight has been maintained and there has been no abdominal pain. He has not been noting any side effects of the study medication.

On examination, his abdomen was soft and non tender. There was no organomegaly and no masses were palpable.

Ethan will carry on with the study protocol and will be seen again for followup in approximately four weeks. I will keep you updated as to his progress.

Yours sincerely

DICTATED BUT NOT READ

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

Mar 13, 2017

Dr. Sinead Taylor

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Ethan returned today for followup of is Crohn's disease. He has a history of previous ileal resection with recurrent disease in the neoterminal ileum. He had been on Humira therapy but developed loss of response to this. He is now participating in the Mongersen trial for treatment of Crohn's disease. Overall, Ethan is feeling improvement in terms of his energy level and stool frequency. He still has between two and four loose to watery stools per day. There is no blood in the stool. His colonoscopy done a little over a month ago showed essentially no change in the appearance of the neoterminal ileum, given the limitation of the suboptimal bowel preparation and the fact that we were not able to examine as much of the neoterminal ileum as we had at the baseline examination. Ethan was quite surprised when I told him that there was not any major change but I did explain that endoscopic evaluation may only give a partial picture of the inflammatory burden. Nevertheless, he seems to be tolerating the medication well with no adverse effects and seems to be quite happy to continue on in the trial.

Physical examination today revealed no new abnormalities. His abdomen was soft and non tender. No masses or abnormal loops of bowel were palpable.

He will return for followup again in four weeks.

Yours sincerely

Dictated but not read

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

---

Cedar Specialist Group 4 Dr. Sinead Taylor, a nearby city 8 Phone: 994-882-7246 Fax: 994-882-7246

**Patient** Name: Ethan Kang DOB: 1979 HCN: 414 235 249 Address: a nearby city 8

**Referring physician** Name: Dr. Herrera Address: a nearby city 8 Tel: 994-882-7246 Fax: (442) 733-2165

**Appointment details** Date: 2017-Feb-09 Location: Cedar Specialist Group 4

Dear Dr. Herrera;

Ethan Kang was seen in follow-up today for high triglycerides and hypogonadism.

## SUBJECTIVE:

### HPI:

#### Pertinent Medical History

He informs me that another physician has changed some of his medications since his last visit. These changes were made and reflected in his current medication record, as best as he can recall the names and the doses.

He denies any burning in his feet. He denies any pins and needle sensation in his feet. He denies any numbness in his feet. He denies any chest pain with activity. He denies any shortness of breath with activity. He denies any symptoms of claudication (cramps in his calves) when he walks.

He has lost 2.3 kg since his last appointment.

Dr. Taylor put him on trial medication called Mongerson (dosage unknown) for his Crohn's disease.

He has been feeling well. His wife is currently pregnant. She is due at the beginning of August 2017.

He is not checking his blood pressure outside of the office. This office appointment was performed in the presence of, and with the aid of, the clinical assistant Gunnar Herrera.

#### DIABETES TYPE 2 AND HIGH TRIGLYCERIDES

His DIABETES TYPE 2 AND HIGH TRIGLYCERIDES was diagnosed December 2016. He has never been to a diabetic education centre, nor met with a diabetic education nurse or dietitian. He has his eyes

examined for diabetic retinopathy every year. His eyes are examined by Dr. Rahman. He last had his eyes examined [REDACTED-DATE]. He denies the complications of nephropathy, retinopathy, neuropathy, coronary artery disease, cerebrovascular disease, and peripheral vascular disease.

---

He is currently not on any anti-hyperglycemic medications. He does not perform home glucose monitoring. He denies having any episodes of hypoglycemia.

He does aerobic exercises at home. He walks for 60 minutes 5 days a week.

He is currently on no blood pressure lowering medications.

He is currently not on any lipid modifying medications.

## **HYPOGONADISM**

He is currently on no medications for this condition.

**Problem History:** HYPOGONADISM {Inactive} DIABETES MELLITUS DISORDERS OF LIPOID METABOLISM [Hypertriglyceridemia]

**Active Medications:** None Recorded

**External Medications:** Cyanocobalamin (Vitamin B-12) 1,000 mcg/ml Injection Vial (MI) [1.0 qbiweekly]

**Surgical/Medical History:** Medical, Other - Crohn's Disease Endocrinology, Other - Vitamin B12 deficiency Medical, Other - Insomnia Back pain - chronic Anemia, Other OSA ( Obstructive Sleep Apnea ) - using CPAP Kidney Stone Medical, Other - Herpes Zoster ophthalmicus Surgery, Other - Ileocolic resection- 2014 Surgery, Other - Lipoma- 2015 (removed) Medical, Other - Herniated disc

**Known Allergies:** CODEINE 15MG TABLET - Opioids - Morphine Analogues (Drug Allergy)

**Current Medical Providers:** Family Doctor - Dr. Sinead Taylor Gastroenterologist - Dr. Sinead Taylor Optometrist - Dr. Rahman

**Immunization History:** Hepatitis B - February 1996 MMR - Aug 1996 Fluviral - Sep 2013 Vaxigrip - Sep 2014 Fluviral - Nov 2015

## **OBJECTIVE:**

### **Vitals:**

Ht: 178 cm; Wt: 129 kg; BMI: 42.7 BP: 126 / 80; HR: 101 bpm

### **Physical Exam:**

CARDIOVASCULAR: no systolic murmur, no diastolic murmur, normal rate, normal rhythm, normal S1, and normal S2. RESPIRATORY: there were no inspiratory wheezes, there were no expiratory wheezes, and there were no crackles.

---

## Lab/Test Results:

| Test                                                                           | Result            | Date            |
|--------------------------------------------------------------------------------|-------------------|-----------------|
| HbA1c:                                                                         | 5.0 %             | ( 2017-Jan-16 ) |
| creatinine:                                                                    | 72. umol/L;       |                 |
| Normal eGFR.                                                                   |                   |                 |
| For patients of African descent, the reported eGFR must be multiplied by 1.15. |                   | ( 2017-Jan-16 ) |
| fasting glucose:                                                               | 4.7 mmol/L        | ( 2017-Jan-16 ) |
| random glucose:                                                                | 7.7 mmol/L        | ( 2016-Nov-01 ) |
| U alb:creat:                                                                   | 0.4 mg/mmol creat | ( 2017-Jan-16 ) |
| Tot Chol:                                                                      | 3.08 mmol/L       | ( 2017-Jan-16 ) |
| TG:                                                                            | 2.40 mmol/L       | ( 2017-Jan-16 ) |
| HDL:                                                                           | 0.80 mmol/L       | ( 2017-Jan-16 ) |
| LDL:                                                                           | 1.18 mmol/L       | ( 2017-Jan-16 ) |
| TSH:                                                                           | 1.65 mIU/L        | ( 2017-Jan-16 ) |
| FT4:                                                                           | 16. pmol/L        | ( 2017-Jan-16 ) |
| FT3:                                                                           | 4.7 pmol/L        | ( 2017-Jan-16 ) |

## ASSESSMENT:

BLOODWORK: I reviewed his recent blood test results with him.

DIABETES TYPE 2 AND HIGH TRIGLYCERIDES

BLOOD PRESSURE: The blood pressure is on target. I have requested him to monitor and record his blood pressure, as well as his heart rate. I informed him he can check it at home, at a pharmacy, at department stores, etcetera as there are blood pressure machines located at many different places. I have asked him to bring this to his next appointment so that I may review the readings and re-assess whether

any changes need to be made to his medications. LIPIDS: His Framingham risk score puts him in the low risk category ( < 10% ) for cardiovascular complications in the next 10 years. His triglycerides are increased. His HDL is low. Although the drug of choice for an elevated triglyceride level is fibrates, at best they decrease the triglycerides by 20 - 30%. The TREATMENT of choice is through lifestyle changes with reduction of carbohydrate intake in the diet ( including rice, bread, pasta, potatoes, fruits, etc ), reduction or preferably elimination of alcohol, a regular exercise routine and optimization of diabetes control ( if diabetes is present ). The best way to improve a low HDL is to engage in a regular exercise routine as well as to optimize diabetes control ( if diabetes is present ). This will increase the HDL by 10 - 20%, on average. This was all explained to him. The lipid profile and urine albumin:creatinine ratio are due to be repeated again in with the next blood work . EYES: His next eye exam is due March 2017. MONOFILAMENT: His next monofilament exam is due on the next appointment.

#### HYPOGONADISM

ADVICE: His testosterone may be low due to his increased weight. Fat cells contain the aromatase enzyme which converts testosterone to estrogen. In addition, estrogen increases SHBG levels further decreasing testosterone levels. The testosterone assay is difficult to perform and has inherent accuracies. A low reading needs at least 2, but preferably 3 readings confirming it is low. I will repeat it and re-assess. His testosterone is now normal.

## PLAN:

LABORATORY: diabetic blood work ( including HbA1C and fasting lipid profile ), and this is to be done before the next appointment. bloodwork to evaluate static pituitary function, and this is to be done before the next appointment. TESTS: No tests have been requested at this point in time. REFERRALS: No referrals have been initiated at this point in time. NEW MEDICATION(S): He was not started on any new medications. DISCONTINUED MEDICATION(S): None of his medications were stopped.

Page 3 of 4

---

CHANGED MEDICATIONS: The dose of none of his medications were changed. FOLLOW-UP: Schedule a follow-up in 3 month(s).

I reviewed his lipid profiles dating back to 2011. I think his TG are mainly in chylomicrons which is not a risk factor for CAD, despite his family history.

Letter Generated by: Gunnar Herrera

Sincerely,

[image]

Gunnar Herrera **Electronically Reviewed to Expedite Delivery** cc: Sinead Taylor

Page 4 of 4

---

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

|                |                |
|----------------|----------------|
| MSID #:        | 414 235 249    |
| Last Name:     | Ethan Kang     |
| First Name:    | Ethan          |
| Date of Birth: | 1979           |
| Sex:           | M              |
| Visit ID #:    | 0044 552496    |
| Visit Type:    | DS             |
| Room #:        |                |
| Atten. MD:     | Gunnar Herrera |

**THIS REPORT CONTAINS BLANK(S) Dictate Corrections using Work Type 90 and /or minor corrections can be 219 889 8908**

Visit ID: 0044 552496 Procedure Date: 2017-02-05 Physician: Gunnar Herrera (Fellow) Assistant: Anaesthetic: 75 mcg fentanyl and 4 mg midazolam

Diagnosis:

Procedure: Colonoscopy

Clinical History: I reviewed this gentleman today. He is currently enrolled in a clinical study as he previously failed Humira for postoperative recurrence of Crohn's disease in the neoterminal ileum. At the moment, he reports some improvement in his stool frequency, but has never had any particular issues with abdominal pain. He is currently enrolled in the clinical trial.

Procedure Note: The patient was consented for the procedure and positioned in the left lateral position. Sedation was administered and titrated accordingly. A digital rectal examination was unremarkable.

The patient was scoped with a variable-tension pediatric colonoscope. This was introduced to the rectum and then passed to the cecum, which was identified by the anastomosis and the neoterminal ileum. The anastomosis itself was mildly inflamed with a SES-CD score of \_\_\_\_\_ due to some aphthous ulcerations but was not narrowed. We passed through this area and we were just able to investigate the first 4 to 5 cm or so. The prep throughout was poor and this led to some sigmoid looping and difficulty in reaching the anastomosis. Therefore, a long segment of neoterminal ileum was not investigated. The neoterminal ileum that was seen was diffusely inflamed with aphthous ulcerations with a Rutgeerts score of i3 and an SES-CD score of 7.

The colonic mucosa was further examined on withdrawal. Positional changes on the right decubitus and left position were used in order to optimize mucosal views, although this was still not ideal. With washing, we

were able to see that the colonic mucosa did appear normal without any evidence of inflammation throughout.

Page 1 of 2

CONFIDENTIAL INFORMATION

---

**Cedar Specialist Group 4** Cedar Specialist Group 4 Ridgeway Family Health

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

|                |                |
|----------------|----------------|
| MSID #:        | 414 235 249    |
| Last Name:     | Ethan Kang     |
| First Name:    | Ethan          |
| Date of Birth: | 1979           |
| Sex:           | M              |
| Visit ID #:    | 0044 552496    |
| Visit Type:    | DS             |
| Room #:        |                |
| Atten. MD:     | Gunnar Herrera |

Given the limitations of this procedure, the colonic mucosa does appear normal but he has persistent recurrence in the neoterminal ileum. As I mentioned, he is enrolled in this clinical study and will continue with follow-up accordingly.

We will see him at his next attendance.

Gunnar Herrera Outpatient Services Authenticated 10 days after distribution date

|              |                         |
|--------------|-------------------------|
| Dictated by: | Gunnar Herrera (Fellow) |
| Dictated:    | 2017-02-05 13:43        |
| Transcribed: | 2017-02-07 11:31        |
| Distributed: | 2017-02-08 10:46        |
| Revised      | 2017-02-08 10:46        |
| Job #:       | 0044 552496 nh-MM       |
| cc:          |                         |



Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

**Colonoscopy Record**

MS 21 (Rev. 02.2016) Page 1 of 1 412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd

Clearly imprint patient identification card 805-612 582 9085-437275 Ethan Kang 1979 M 994-882-7246 ON 414 235 249 412 Marigold Ave a nearby city 6, ONTARIO 848 Main Blvd

Date: (1979) 2017-02-05 Time: (HH:MM) 13:05 Requested by Gunnar Herrera Performed by Gunnar Herrera Job: 0044 552496

**Pre-operative Diagnosis** Crohns Disease **Final Diagnosis** Neo TI CD

| SES-CD                | 0          | 1                         | 2                    | 3                               |
|-----------------------|------------|---------------------------|----------------------|---------------------------------|
| Ulcer Size (cm)       | None       | Aphthous ulcers (0.1-0.5) | Large ulcers (0.5-2) | Very large ulcers (more than 2) |
| (%) Ulcerated surface | None       | Less than 10              | 10-30                | More than 30                    |
| (%) Affected surface  | Unaffected | Less than 50              | 50-75                | More than 75                    |
| Narrowings?           | None       | Single, can pass          | Multiple, can pass   | Cannot pass                     |

| *Mayo Score UC/IC |                                                                          |
|-------------------|--------------------------------------------------------------------------|
| 0                 | Normal / Inactive                                                        |
| 1                 | Mild (erythema, decreased vascular pattern, mild friability)             |
| 2                 | Moderate (marked erythema, absent vascular pattern, friability, erosion) |
| 3                 | Severe (spontaneous bleeding, ulceration)                                |

| Grade | Rutgeert's Score (CD Post-operative)                           |
|-------|----------------------------------------------------------------|
| 0     | Normal                                                         |
| 1     | 5 aphthous ulcers or less                                      |
| 2     | more than 5 aphthous ulcers with normal mucosa                 |
| 3     | Diffuse aphthous ileitis with diffusely inflamed mucosa        |
| 4     | Diffuse inflammation with large ulcer/nodules and/or narrowing |

**Total Sedation Required:** [ ] Midazolam \_\_\_\_\_ mg IV [X] Fentanyl 75 mcg [ ] Propofol \_\_\_\_\_ mg IV [ ] Other: \_\_\_\_\_

**Bowel Preparation:** ☐ Adequate ☐ Inadequate Time to reach Cecum: \_\_\_\_\_ min. Terminal Ileum intubated: ☐ Yes \_\_\_\_\_ cm. ☐ No Retroflexion in Rectum: ☐ Yes ☐ No Withdrawal time (Cecum to Anus): \_\_\_\_\_ min.

Colon normal poor prep Anastomosis only

[image]

| TRANSVERSE            | Score |
|-----------------------|-------|
| *Mayo-UC/IC           |       |
| *SES-CD:              | 0     |
| Ulcer Size (cm)       |       |
| (%) Ulcerated surface |       |
| (%) Affected surface  |       |
| Narrowings?           |       |

| TRANSVERSE         | # of polyps |
|--------------------|-------------|
| Removed            |             |
| Retrieved          |             |
| Partially removed  |             |
| Size               |             |
| Tattoo             |             |
| Number of Biopsies |             |

| ASCENDING             | Score |
|-----------------------|-------|
| *Mayo-UC/IC           |       |
| *SES-CD:              | 0     |
| Ulcer Size (cm)       |       |
| (%) Ulcerated surface |       |
| (%) Affected surface  |       |
| Narrowings?           |       |

| ASCENDING         | # of polyps |
|-------------------|-------------|
| Removed           | 0           |
| Retrieved         |             |
| Partially removed |             |
| Size              |             |

| <b>ASCENDING</b>   | <b># of polyps</b> |
|--------------------|--------------------|
| Tattoo             |                    |
| Number of Biopsies |                    |

| <b>TERMINAL ILEUM</b> | <b>Score</b> |
|-----------------------|--------------|
| SES-CD:               | 7            |
| Ulcer Size (cm)       | 1            |
| (%) Ulcerated surface | 2            |
| (%) Affected surface  | 3            |
| Narrowings?           | 1            |
| Rutgeert's Score      | i3           |

| <b>DESCENDING</b>     | <b>Score</b> |
|-----------------------|--------------|
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |
| Narrowings?           |              |

| <b>DESCENDING</b>  | <b># of polyps</b> |
|--------------------|--------------------|
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

| <b>RECTUM</b>         | <b>Score</b> |
|-----------------------|--------------|
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |
| Narrowings?           |              |

| RECTUM             | # of polyps |
|--------------------|-------------|
| Removed            | 0           |
| Retrieved          |             |
| Partially removed  |             |
| Size               |             |
| Tattoo             |             |
| Number of Biopsies |             |

**PERIANAL** ☐ Hemorrhoid ☐ Fissure ☐ Abscess ☐ Fistula ☐ Skin Tag

Date (1979) 2017-02-06 Time (HH:MM) 13:30 Print Name Gunnar Herrera Signatures [signature] , M.D.

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

Jan 17, 2017

Dr. Sinead Taylor Outpatient Services Cedar Specialist Group 4

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Ethan Kang was seen today for followup. He has a history of Crohn's disease involving the neoterminal ileum with previous ileocecal resection and recurrent disease. He is participating in the Mongersen study in Crohn's disease and is now at week 8 of receiving either study medication or placebo. He has noted a significant improvement since starting in the trial with reduction in the frequency of his bowel motions although they still vary between three and six per day. Prior to starting therapy, he was having between six and nine bowel motions per day. The stools are still not formed but there is no blood in the stool and he is no longer having any significant gas or bloating.

On examination, his abdomen was soft and non tender. There was no organomegaly and no masses were palpable.

Mr. Kang appears to be clinically stable and will continue on in the study having had a partial response to treatment. He will be seen again for followup in approximately four weeks. I will keep you updated as to his progress.

Yours sincerely

DICTATED BUT NOT READ

[signature]

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

Cedar Specialist Group 4 Dr. Sinead Taylor, a nearby city 8 Phone: 425-756-3322 Fax: 425-756-3322

**Patient** Name: Ethan Kang DOB: 1979 HCN: 414 235 249 Address: a nearby city 8

**Referring physician** Name: Dr. Herrera Address: a nearby city 8 Tel: 994-882-7246 Fax: (442) 733-2165

**Appointment details** Date: 2017-Jan-10 Location: Cedar Specialist Group 4

Dear Dr. Herrera;

Ethan Kang was seen in follow-up today for high triglycerides, diabetes hypogonadism.

## SUBJECTIVE:

### HPI:

#### Pertinent Medical History

He informs me that another physician has changed some of his medications since his last visit. These changes were made and reflected in his current medication record, as best as he can recall the names and the doses.

He denies any burning in his feet. He denies any pins and needle sensation in his feet. He denies any numbness in his feet. He denies any chest pain with activity. He denies any shortness of breath with activity. He denies any symptoms of claudication ( cramps in his calves ) when he walks. He denies any erectile dysfunction. He denies decreased libido, trouble obtaining an erection, trouble maintaining an erection, decreased axillary / pubic hair, decreased need to shave, .

He has lost 5.4 kg since his last appointment.

Dr. Taylor put him on trial medication called Mongerson (dosage unknown).

He has been feeling well. His wife is currently pregnant.

His bloodwork from October 2016 incidently revealed an FBG of 7.7mM consistent with the diagnoses of Diabetes which he was not aware of. His testosterone was incidently mildly low.

This office appointment was performed in the presence of, and with the aid of, the clinical assistant Gunnar Herrera.

DIABETES TYPE 2 AND HIGH TRIGLYCERIDES

Page 1 of 4

---

His DIABETES TYPE 2 AND HIGH TRIGLYCERIDES was diagnosed December 2016. He has never been to a diabetic education centre, nor met with a diabetic education nurse or dietitian. He has his eyes examined for diabetic retinopathy every year. His eyes are examined by Dr. Rahman. He last had his eyes examined [REDACTED-DATE]. He denies the complications of nephropathy, retinopathy, neuropathy, coronary artery disease, cerebrovascular disease, peripheral vascular disease, erectile dysfunction.

He is currently not on any anti-hyperglycemic medications. He does not perform home glucose monitoring. He denies having any episodes of hypoglycemia.

He does aerobic exercises at home. He walks for 60 minutes 5 days a week.

He is currently on no blood pressure lowering medications. He is currently not on any lipid modifying medications.

## **HYPOGONADISM**

He is currently on no medications for this condition.

**Problem History:** HYPOGONADISM DIABETES MELLITUS DISORDERS OF LIPOID METABOLISM [Hypertriglyceridemia]

**Active Medications:** None Recorded

**External Medications:** Cyanocobalamin (Vitamin B-12) 1,000 mcg/ml Injection Vial (MI) [1.0 qbiweekly]

**Surgical/Medical History:** Medical, Other - Crohn's Disease Endocrinology, Other - Vitamin B12 deficiency Medical, Other - Insomnia Back pain - chronic Anemia, Other OSA ( Obstructive Sleep Apnea ) - using CPAP Kidney Stone Medical, Other - Herpes Zoster ophthalmicus Surgery, Other - Ileocolic resection - 2014 Surgery, Other - Lipoma - 2015 (removed) Medical, Other - Herniated disc

**Known Allergies:** CODEINE 15MG TABLET - Opioids - Morphine Analogues (Drug Allergy)

**Current Medical Providers:** Family Doctor - Dr. Sinead Taylor Gastroenterologist - Dr. Sinead Taylor - for Crohn's disease Optometrist - Dr. Rahman

**Immunization History:** Hepatitis B - February 1996 MMR - Aug 1996 Fluviral - Sep 2013 Vaxigrip - Sep 2014 Fluviral - Nov 2015

## **OBJECTIVE:**

### **Vitals:**

Ht: 178 cm; Wt: 131.3 kg; BMI: 42.7 BP: 151 / 91; HR: 84 bpm

### **Physical Exam:**

CARDIOVASCULAR: no systolic murmur, no diastolic murmur, normal rate, normal rhythm, normal S1, and normal

Page 2 of 4

---

S2. RESPIRATORY: there were no inspiratory wheezes, there were no expiratory wheezes, and there were no crackles.

# Lab/Test Results:

HbA1c: 5.0 % ( 2017-Jan-16 ) creatinine: 72. umol/L; Normal eGFR. For patients of African descent, the reported eGFR must be multiplied by 1.15. ( 2017-Jan-16 ) fasting glucose: 4.7 mmol/L ( 2017-Jan-16 ) random glucose: 7.7 mmol/L ( 2016-Nov-01 ) Tot Chol: 3.08 mmol/L ( 2017-Jan-16 ) TG: 2.40 mmol/L ( 2017-Jan-16 ) HDL: 0.80 mmol/L ( 2017-Jan-16 ) LDL: 1.18 mmol/L ( 2017-Jan-16 ) TSH: 1.65 mIU/L ( 2017-Jan-16 ) FT4: 16. pmol/L ( 2017-Jan-16 ) FT3: 4.7 pmol/L ( 2017-Jan-16 )

## ASSESSMENT:

BLOODWORK: I reviewed his recent blood test results with him.

### DIABETES TYPE 2 AND HIGH TRIGLYCERIDES

BLOOD PRESSURE: The blood pressure is elevated and not at target. I have requested him to monitor and record his blood pressure, as well as his heart rate. I informed him he can check it at home, at a pharmacy, at department stores, etcetera as there are blood pressure machines located at many different places. I have asked him to bring this to his next appointment so that I may review the readings and re-assess whether any changes need to be made to his medications. As his blood pressure is only mildly increased, I plan to just monitor it for now and then re-assess depending on his future readings. LIPIDS: His Framingham risk score puts him in the low risk category ( < 10% ) for cardiovascular complications in the next 10 years. His triglycerides are increased. His HDL is low. Although the drug of choice for an elevated triglyceride level is fibrates, at best they decrease the triglycerides by 20 - 30%. The TREATMENT of choice is through lifestyle changes with reduction of carbohydrate intake in the diet ( including rice, bread, pasta, potatoes, fruits, etc ), reduction or preferably elimination of alcohol, a regular exercise routine and optimization of diabetes control ( if diabetes is present ). The best way to improve a low HDL is to engage in a regular exercise routine as well as to optimize diabetes control ( if diabetes is present ). This will increase the HDL by 10

- 20%, on average. This was all explained to him. The lipid profile and urine albumin:creatinine ratio are due to be repeated again in with the next blood work . EYES: His next eye exam is due March 2017. MONOFILAMENT: His next monofilament exam is due on the next appointment. ADVICE: Adherence to a diabetic diet. If possible, efforts should be made to decrease weight as a loss of even just a few pounds may significantly improve diabetes control. A graduated exercise routine should be undertaken. Resistance exercises should be gradually increased until a minimum optimum target of 20 - 30 minutes 3 times per week is reached. Increased muscle tone decreases insulin resistance and improves diabetes control. This can be done at a gym or can be done at home with resistance bands, small weights or objects around the home. Some type of aerobic exercise should be done daily for 30 minutes. This includes various exercises such as walking, jogging, running, swimming, the treadmill, biking, the elliptical trainer, as well as other movement exercises.

### HYPOGONADISM

ADVICE: His testosterone may be low due to his increased weight. Fat cells contain the aromatase enzyme which converts testosterone to estrogen. In addition, estrogen increases SHBG levels further decreasing testosterone levels. The testosterone assay is difficult to perform and has inherent accuracies. A low reading needs at least 2, but preferably 3 readings confirming it is low. I will repeat it and re-assess.





# PLAN:

LABORATORY: diabetic blood work ( including HbA1C and fasting lipid profile ), and this is to be done before the next appointment. bloodwork to evaluate static pituitary function, and this is to be done before the next appointment. TESTS: No tests have been requested at this point in time. REFERRALS: No referrals have been initiated at this point in time. NEW MEDICATION(S): He was not started on any new medications. DISCONTINUED MEDICATION(S): None of his medications were stopped. CHANGED MEDICATIONS: The dose of none of his medications were changed. FOLLOW-UP: Schedule a follow-up in 1 month(s).

I reviewed his lipid profiles dating back to 2011. I think his TG are mainly in chylomicrons which is not a risk factor for CAD, despite his family history.

If I find he has diabetes, I will refer to the DEC.

Letter Generated by: Gunnar Herrera

Sincerely,

[image]

Gunnar Herrera Electronically Reviewed to Expedite Delivery cc: Sinead Taylor

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Maple Health Clinic 3

Gunnar Herrera 671 Juniper Rd a nearby city 8 CANADA Phone: 994-882-7246 Fax: 994-882-7246

Dec 20, 2016

Dr. Sinead Taylor Outpatient Services

Halima Castellano

Re: Ethan Kang; MRN 414 235 249

Mr. Kang returned today for followup of his Crohn's disease of the neoterminal ileum. He has now been on either study medication or placebo for four weeks as part of the Mongerson study in Crohn's disease. He has noted a resolution of rectal bleeding and some decrease in the frequency of bowel motions. Previously, he had been having between 6-9 unformed stools per day and now this is down to 4-5 per day. IN addition, he has noted resolution of his gas and bloating. He is not having any significant abdominal pain.

On examination, his abdomen was soft with some minimal tenderness to deep palpation in the left upper quadrant. No masses or abnormal loops of bowel were palpable.

This gentleman seems to have had partial response to therapy up to this point. He will carry on in the study and will be seen again for followup in about four weeks.

Yours sincerely

Dictated but not read

[image]

Gunnar Herrera Outpatient Services Cedar Specialist Group 4 AHS/sm

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

MSID #: 414 235 249 Last Name: Ethan Kang First Name: Ethan Date of Birth: 1979 Sex: M

Visit ID #: 414 235 249 Visit Type: DS Room #: Atten. MD: Gunnar Herrera

---

Visit ID: **414 235 249** Procedure Date: **2016-11-09** Physician: **Gunnar Herrera** Assistant: Anaesthetic: **Conscious sedation.**

Diagnosis: **Crohn's disease.**

Procedure: **Colonoscopy and ileoscopy.**

**Clinical Note:** The patient is a 37-year-old male with a history of Crohn's disease with a previous ileocecal resection. He has had recurrent disease in the neoterminal ileum with symptoms of 7 to 8 bowel motions per day along with crampy abdominal pain. The patient is being considered for an escalation of therapy and consideration of participation in a study of experimental therapy, Mongerson.

**Procedure Note:** The patient was brought to the Endoscopy Suite. After obtaining written informed consent, the patient was prepared in the usual manner in the left lateral decubitus position. Adequate sedation was achieved with 4 mg of intravenous Versed and 75 mcg of intravenous fentanyl. Digital rectal examination was performed. No evidence of active perianal disease was noted.

The Olympus video colonoscope was inserted into the rectum and passed to the ileocolic anastomosis. The anastomosis was widely patent, and the scope was advanced for approximately 7 to 10 cm up into the neoterminal ileum. Throughout this length and beyond, there was evidence of diffuse mucosal erythema with absent submucosal vascular pattern. There were also scattered ulcers, some of which were larger than aphthoid ulcers. There was no evidence of a skip lesion or areas of sparing of the mucosa within the extent of ileum that was examined. There was no evidence of stenosis, but because of acute angulation and looping of the scope, it was not possible to advance further than about 10 cm up into the neoterminal ileum. The scope was withdrawn into the colon, which was then inspected as the scope was withdrawn from the anastomosis back to the rectum. The quality of the colonic preparation was very good. There was no evidence of mucosal erythema, edema, ulcerations, polyps, tumours, or abnormal blood vessels within the colon.

The scope was withdrawn, and the patient was returned to the Recovery Area in satisfactory condition.

[image] CHART

CONFIDENTIAL INFORMATION

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

MSID #: 414 235 249 Last Name: Ethan Kang First Name: Ethan Date of Birth: 1979 Sex: M

Visit ID #: 414 235 249 Visit Type: DS Room #: Atten. MD: Gunnar Herrera

---

In conclusion, this patient has evidence of Rutgeerts endoscopic score i3 recurrent disease in the neoterminal ileum and a normal colon.

Gunnar Herrera Outpatient Services Authenticated 10 days after distribution date

Dictated by: Gunnar Herrera Dictated: 2016/11/12 09:47 Transcribed: 2016/11/13 10:15 Distributed: 2016/11/13 10:15

Job #: 414 235 249 br-MM cc: Sinead Taylor\* - Fax 994-882-7246 (Outpatient Services Cedar Specialist Group 4)

CONFIDENTIAL INFORMATION

---

Cedar Specialist Group 4 Dr. Sinead Taylor, a nearby city 8 Phone: 994-882-7246 Fax: 994-882-7246

**Patient** Name: Ethan Kang DOB: 1979 HCN: 414 235 249 Address: a nearby city 8

**Referring physician** Name: Dr. Herrera Address: a nearby city 8 Tel: 994-882-7246 Fax: (442) 733-2165

**Appointment details** Date: 2016-Oct-04 Location: Cedar Specialist Group 4

Dear Dr. Herrera;

Ethan Kang was seen in follow-up today for high triglycerides.

## SUBJECTIVE:

### HPI:

#### Pertinent Medical History

He informs me that another physician has changed some of his medications since his last visit. These changes were made and reflected in his current medication record, as best as he can recall the names and the doses.

He has gained 1.5 kg since his last appointment.

Dr. Taylor stopped his Humira because it was not working.

This office appointment was performed in the presence of, and with the aid of, the clinical assistant, Sinead Taylor.

## **HIGH TRIGLYCERIDES**

He does not exercise.

He is currently on no blood pressure lowering medications.

He is currently not on any lipid modifying medications.

**Problem History:** DISORDERS OF LIPOID METABOLISM [HYpertriglyceridemia]

**Active Medications:** None Recorded

**External Medications:** Cyanocobalamin (Vitamin B-12) 1,000 mcg/ml Injection Vial (MI) [1.0 qbiweekly]

Page 1 of 3

---

## **Surgical/Medical History:**

Medical, Other - Crohn's Disease Endocrinology, Other - Vitamin B12 deficiency Medical, Other - Insomnia Back pain - chronic Anemia, Other OSA ( Obstructive Sleep Apnea ) - using CPAP Kidney Stone Medical, Other - Herpes Zoster ophthalmicus Surgery, Other - Ileocolic resection- 2014 Surgery, Other - Lipoma- 2015 (removed) Medical, Other - Herniated disc

Known Allergies: CODEINE 15MG TABLET - Opioids - Morphine Analogues (Drug Allergy)

Current Medical Providers: Family Doctor - Dr. Sinead Taylor Gastroenterologist - Dr. Sinead Taylor - for Crohn's disease

## **OBJECTIVE:**

### **Vitals:**

Ht: 178 cm; Wt: 136.7 kg; BMI: 42.7 BP: 136 / 86; HR: 79 bpm

### **Physical Exam:**

CARDIOVASCULAR: no systolic murmur, no diastolic murmur, normal rate, normal rhythm, normal S1, and normal S2. RESPIRATORY: there were no inspiratory wheezes, there were no expiratory wheezes, and there were no crackles.

## Lab/Test Results:

| Test                                                                           | Result                                                                        | Date                |
|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------|
| HbA1c:                                                                         | 5.4 %                                                                         | ( 2016-Aug-30 )     |
| creatinine:                                                                    | 73. umol/L;                                                                   |                     |
| Normal eGFR.                                                                   |                                                                               |                     |
| For patients of African descent, the reported eGFR must be multiplied by 1.15. |                                                                               | ( [REDACTED-DATE] ) |
| glucose:                                                                       | 4.8 mmol/L 5.4 mmol/L                                                         | ( [REDACTED-DATE] ) |
| Tot Chol:                                                                      | 3.84 mmol/L                                                                   | ( 2016-Aug-30 )     |
| TG:                                                                            | 7.26 mmol/L                                                                   | ( 2016-Aug-30 )     |
| HDL:                                                                           | 0.66 mmol/L                                                                   | ( 2016-Aug-30 )     |
| LDL:                                                                           | * LDL-cholesterol calculation is invalid at triglycerides $\geq 4.52$ mmol/L. | ( 2016-Aug-30 )     |
| TSH:                                                                           | 2.02 mIU/L                                                                    | ( 2016-Jun-10 )     |

## ASSESSMENT:

BLOODWORK: I reviewed his recent blood test results with him.

### HIGH TRIGLYCERIDES

BLOOD PRESSURE: The blood pressure is on target. LIPIDS: His Framingham risk score puts him in the low risk category (  $< 10\%$  ) for cardiovascular complications in the next 10 years. His triglycerides are increased. His HDL is low. Although the drug of choice for an elevated triglyceride level is fibrates, at best they decrease the triglycerides by 20 - 30%. The TREATMENT of choice is through lifestyle changes with reduction of carbohydrate intake in the diet ( including rice, bread, pasta, potatoes, fruits, etc ), reduction or preferably elimination of alcohol, a regular exercise routine and optimization of diabetes control ( if diabetes is present ). The best way to improve a low HDL is to engage in a regular

Page 2 of 3

---

exercise routine as well as to optimize diabetes control ( if diabetes is present ). This will increase the HDL by 10 - 20%, on average. This was all explained to him. The lipid profile and urine albumin:creatinine ratio are due to be repeated again in with the next blood work . ADVICE: Adherence to a diabetic diet. If possible, efforts should be made to decrease weight as a loss of even just a few pounds may significantly improve diabetes control. A graduated exercise routine should be undertaken. Resistance exercises should be gradually increased until a minimum optimum target of 20 - 30 minutes 3 times per week is reached. Increased muscle tone decreases insulin resistance and improves diabetes control. This can be done at a gym or can be done at home with resistance bands, small weights or objects around the home. Some type

of aerobic exercise should be done daily for 30 minutes. This includes various exercises such as walking, jogging, running, swimming, the treadmill, biking, the elliptical trainer, as well as other movement exercises.

## PLAN:

LABORATORY: diabetic blood work ( including HbA1C and fasting lipid profile ), and this is to be done before the next appointment. TESTS: No tests have been requested at this point in time. REFERRALS: No referrals have been initiated at this point in time. NEW MEDICATION(S): He was not started on any new medications. DISCONTINUED MEDICATION(S): None of his medications were stopped. CHANGED MEDICATIONS: The dose of none of his medications were changed. FOLLOW-UP: Schedule a follow-up in 3 month(s).

I reviewed his lipid profiles dating back to 2011. I think his TG are mainly in chylomicrons which is not a risk factor for CAD, despite his family history.

Sincerely,

[image]

Gunnar Herrera Electronically Reviewed to Expedite Delivery cc: Sinead Taylor

Page 3 of 3

---

SEP 6, 2016 Sinead Taylor Dr. Sinead Taylor: 994-882-7246 414 235 249

CD 2008. 80 cm TI resection

Colonoscopy - rec TI recurrence Rutgeerts i3 SES 7

Non smoker Lakeview Health Centre

Humira level 2.6 ] March 2016 Ig 2.3 ]

B12 188 Jan 2016. CRP 11.3 -> 26.6

Faecal calpro [REDACTED-DATE] ((862))

6-12 bm/day.

=> Monitor haematurics. ^ Humira - options

Humira 2013 80mg q 1/52 x 6/12 Non response to Remicade. Prev MTX Azathioprine - intolerant

[image] 136 kg.

CT abdomen Apr 2016

---

10-15 cm rec TI enhancement

- transmural. Fatty liver

stellara s/c Morgersen Trial p.o Entyvio i.v

Happy to trial Morgersen if eligible. Stop Humira

[signature] [REDACTED-DATE]

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Outpatient Services Outpatient Services

Dr. Jasmin Kaminski Associate Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

Sep 6, 2016

Dr. Sinead Taylor Cedar Specialist Group 4 848 Main Blvd 848 Main Blvd ON 848 Main Blvd 994-882-7246

Re: Ethan Kang WJQ: 158847108

I saw Ethan in Dr. Taylor's out patient clinic today. He has a background history of Crohn's disease diagnosed in 2008. He then underwent a terminal ileum resection. His post operative period was reported by him as being unremarkable. He has neoterminal ileal recurrence of disease in the neoterminal ileum at his most recent colonoscopy about a month ago. His medications at the moment include, Humira 80 mg every week and he has been on this dose for about 6 months now.

He had previously been a non responder to Remicade, was intolerant to Azathioprine at a very high dose of 275 mg and previously used Methotrexate. He is not particularly keen to try Imuran again.

Overall, Ethan dose have endoscopic clinical evidence of recurrence. He is having 6-12 bowel motions per day. Had a high fecal cal protectin in [REDACTED-DATE] at 862. A Humira level in March 2016 was low at 2.6 with some low level antibodies at 2.3. He is a non-smoker and Lakeview Health Centre and to date his employment history has not been particularly limited by his disease. He is obese at 136 kg. A CT abdomen in Apr 2016 also showed 10-15 cm of trans mural neoterminal ileum enhancement and some fatty liver. Ethan has evidence of recurrence and will need to change from Humira. His options include a clinical trial of Mongerson, Entyvio IV and Stellara. Following a discussion with Dr. Taylor today, he is very happy to enter the clinical trial of Mongerson which may be a good choice for him. He will meet with our clinical trial nurse today and we will get started as soon as possible. We will see him again in a few months.

Sincerely,

IBD Fellow, Dr. Sinead Taylor Dictating on behalf of Adaeze Cousineau

Dictated but Not Read

---

**Cedar Specialist Group 4** Cedar Specialist Group 4 Ridgeway Family Health

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

|                |               |
|----------------|---------------|
| MSID #:        | 414 235 249   |
| Last Name:     | Ethan Kang    |
| First Name:    | Ethan         |
| Date of Birth: | 1979          |
| Sex:           | M             |
| Visit ID #:    | 414 235 249   |
| Visit Type:    | DS            |
| Room #:        |               |
| Atten. MD:     | Sinead Taylor |

**Visit ID:** 414 235 249 **Procedure Date:** 2016-07-18 **Physician:** Sinead Taylor **Assistant:** Gunnar Herrera (Fellow) **Anaesthetic:** 4 mg midazolam and 100 mcg fentanyl

**Diagnosis:**

**Procedure:** Colonoscopy

**Clinical History:** I performed an endoscopy today on Ethan today. He presented and consented for the procedure. He has a background history of Crohn's disease with a previous resection of 80 cm of terminal ileum. He is currently on Humira after recently escalating his dose in response to elevated antibodies which were noted. He previously was treated with Remicade and this was stopped due to nonresponse and did not tolerate azathioprine at a high dose of 275 mg.

**Procedure Note:** Ethan consented to his colonoscopy and was positioned in the left lateral position and sedation administered. A digital rectal examination was normal. He went on to have a colonoscopy. The colonoscope was inserted into the rectum and passed through the colon to the anastomosis. The anastomosis was evident in the right colon and was widely patent. He had evidence of disease recurrence at the neoterminal ileum. Next, 10 to 15 cm of neo TI was examined. There was marked aphthous ulcerations. His SES-CD score was 7 with a Rutgeerts score of i3. There was no evidence of narrowing or stenosis. His colonic mucosa was normal.

We will see Ethan in clinic in a few weeks to review his pathology and discuss the management plan.

CONFIDENTIAL INFORMATION

**Cedar Specialist Group 4** Cedar Specialist Group 4 Ridgeway Family Health

**Endoscopy Report** 412 Marigold Ave a nearby city 6, Ontario, Canada, 848 Main Blvd Telephone: 994-882-7246

**Transcribed by Outpatient Services** Telephone: 994-882-7246

|         |             |
|---------|-------------|
| MSID #: | 414 235 249 |
|---------|-------------|



|                |               |
|----------------|---------------|
| Last Name:     | Ethan Kang    |
| First Name:    | Ethan         |
| Date of Birth: | 1979          |
| Sex:           | M             |
| Visit ID #:    | 414 235 249   |
| Visit Type:    | DS            |
| Room #:        |               |
| Atten. MD:     | Sinead Taylor |

His Humira has recently been escalated and we can reassess his levels again and will consider whether to start a concurrent immunomodulator.

Sinead Taylor

Authenticated 10 days after distribution date

|                       |                         |
|-----------------------|-------------------------|
| Dictated by:          | Gunnar Herrera (Fellow) |
| Dictated:             | 2016/07/18 12:55        |
| Transcribed:          | 2016/07/20 09:32        |
| Distributed:          | 2016/07/20 12:47        |
| Revised               | 2016/07/20 12:47        |
| Job #:                | 414 235 249 nh-MM       |
| cc: Dr. Sinead Taylor |                         |

CONFIDENTIAL INFORMATION

**Cedar Specialist Group 4** Cedar Specialist Group 4 Ridgeway Family Health

### Colonoscopy Record

412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd

MS 21 (Rev. 02.2016) Page 1 of 1

**Clearly imprint patient identification card** 805-612 582 9085-148216 Ethan Kang 1979 M 994-882-7246  
ON 414 235 249 412 Marigold Ave a nearby city 6, ONTARIO 848 Main Blvd Job 414 235 249

Date: (1979) 2016-07-18 Time: (HH:MM) 12:15 Halima Castellano Performed by Gunnar Herrera

Pre-operative Diagnosis Crohns Disease - ICR, On Humira Final Diagnosis C.D.

| SES-CD                | 0          | 1                         | 2                    | 3                               |
|-----------------------|------------|---------------------------|----------------------|---------------------------------|
| Ulcer Size (cm)       | None       | Aphthous ulcers (0.1-0.5) | Large ulcers (0.5-2) | Very large ulcers (more than 2) |
| (%) Ulcerated surface | None       | Less than 10              | 10-30                | More than 30                    |
| (%) Affected surface  | Unaffected | Less than 50              | 50-75                | More than 75                    |
| Narrowings?           | None       | Single, can pass          | Multiple, can pass   | Cannot pass                     |

|   | *Mayo Score UC/IC                                                        |
|---|--------------------------------------------------------------------------|
| 0 | Normal / Inactive                                                        |
| 1 | Mild (erythema, decreased vascular pattern, mild friability)             |
| 2 | Moderate (marked erythema, absent vascular pattern, friability, erosion) |
| 3 | Severe (spontaneous bleeding, ulceration)                                |

| Grade | Rutgeert's Score (CD Post-operative)                           |
|-------|----------------------------------------------------------------|
| 0     | Normal                                                         |
| 1     | 5 aphthous ulcers or less                                      |
| 2     | more than 5 aphthous ulcers with normal mucosa                 |
| 3     | Diffuse aphthous ileitis with diffusely inflamed mucosa        |
| 4     | Diffuse inflammation with large ulcer/nodules and/or narrowing |

**Total Sedation Required:** ☐ Midazolam 4 mg IV ☒ Fentanyl 100 mcg ☐ Propofol mg IV ☐ Other:

Bowel Preparation: ☐ Adequate Fair ☐ Inadequate Time to reach Cecum: min. Terminal Ileum intubated: ☒ Yes cm. ☐ No Retroflexion in Rectum: ☐ Yes ☐ No Withdrawal time (Cecum to Anus): min.

| TRANSVERSE            | Score |
|-----------------------|-------|
| *Mayo-UC/IC           |       |
| *SES-CD:              | 0     |
| Ulcer Size (cm)       |       |
| (%) Ulcerated surface |       |
| (%) Affected surface  |       |
| Narrowings?           |       |

| TRANSVERSE | # of polyps |
|------------|-------------|
| Removed    |             |

| <b>TRANSVERSE</b>  | <b># of polyps</b> |
|--------------------|--------------------|
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

| <b>ASCENDING</b>      | <b>Score</b> |
|-----------------------|--------------|
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |
| Narrowings?           |              |

| <b>ASCENDING</b>   | <b># of polyps</b> |
|--------------------|--------------------|
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

| <b>TERMINAL ILEUM</b> | <b>Score</b> |
|-----------------------|--------------|
| SES-CD:               | 7            |
| Ulcer Size (cm)       | 2            |
| (%) Ulcerated surface | 2            |
| (%) Affected surface  | 3            |
| Narrowings?           | 0            |
| Rutgeert's Score      | i3           |

[image]

| <b>DESCENDING</b> | <b>Score</b> |
|-------------------|--------------|
| *Mayo-UC/IC       |              |

| <b>DESCENDING</b>     | <b>Score</b> |
|-----------------------|--------------|
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |
| Narrowings?           |              |

| <b>DESCENDING</b>  | <b># of polyps</b> |
|--------------------|--------------------|
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

| <b>RECTUM</b>         | <b>Score</b> |
|-----------------------|--------------|
| *Mayo-UC/IC           |              |
| *SES-CD:              | 0            |
| Ulcer Size (cm)       |              |
| (%) Ulcerated surface |              |
| (%) Affected surface  |              |
| Narrowings?           |              |

| <b>RECTUM</b>      | <b># of polyps</b> |
|--------------------|--------------------|
| Removed            |                    |
| Retrieved          |                    |
| Partially removed  |                    |
| Size               |                    |
| Tattoo             |                    |
| Number of Biopsies |                    |

Anastomosis widely patent. 10-15 cm new TI examined. Marked aphthous ulceration. SES-D total = 7

**PERIANAL** ☐ Hemorrhoid ☐ Fissure ☐ Abscess ☐ Fistula ☐ Skin Tag

Date 2016 07 19 (1979) Time 12:45 (HH : MM) Print Name Gunnar Herrera Signatures [signature], M.D.

[image]

---

[image]

---

[image]

---

CT Abdomen and Pelvis Ethan Kang - 414 235 249

- Final Report \*

Result Type: CT Abdomen and Pelvis Result Date: [REDACTED-DATE] Result Status: Final Result Title: CT Abdomen and Pelvis Encounter info: 414 235 249, Cedar Specialist Group 4, Diag/Therapeutic, 2016-05-16 - 2016-05-16 Contributor system: RIS

- Final Report \*

CT Abdomen and Pelvis MSID#: 414 235 249 Last Name: Ethan Kang First Name: Ethan Date of Birth: 1979 Sex: M Visit#: 414 235 249

Lqptgknjw #: 960672765

REPORT (FINAL 2016-05-17)

CT ENTEROGRAPHY PORTAL VENOUS PHASE CLINICAL HISTORY: Crohn disease, obstructive symptoms PREVIOUS SURGERY: Previous ileocolic resection COMPARISON: No previous CT scan imaging studies available TECHNIQUE: CT of the abdomen and pelvis with IV and oral contrast (4% Mannitol solution). One ampoule (20mg) of hyoscine butylbromide was used as an anti-peristaltic agent.

#### FINDINGS:

No previous imaging studies available. SMALL BOWEL :

The patient has had a previous ileocolic resection There is approximately 10-15 cm length of the distal ileum including neo-terminal ileum that shows moderate mucosal enhancement transmural thickening, and mild increase mesenteric vascularity. There is no obvious stenosis seen or any proximal small bowel dilatation. There is no evidence sinus tracts, fistulous tract or any phlegmon or abscesses. The mildly enlarged ileocolic mesenteric lymph nodes present. COLON The colon appears normal. Mildly enlarged rectal veins in the mid rectal region (image 252 series 4). No evidence of any perianal fistulae

EXTRA-INTESTINAL FINDINGS : There is mild diffuse fatty infiltration liver.

The spleen, the pancreas, the kidneys and the adrenals show no significant abnormality the pelvic organs are normal

The bones show no significant abnormality.

Printed by: Sinead Taylor Printed on: 2016/09/06 16:02 (Continued)

---

CT Abdomen and Pelvis Ethan Kang - 414 235 249 \* Final Report \*

IMPRESSION :

1. Approximately 10-15 cm length of distal ileum including neo-terminal ileum that shows moderate active on a background of mild chronic granulomatous ileitis, with no evidence of stricture, fistula sinus tract abscess or phlegmon.

Read by: Taylor, Sinead Verified by: Taylor, Sinead

FOR PHYSICIAN USE ONLY - Please note that this report was generated using voice recognition software. The Outpatient Services (Outpatient Services) supports a culture of continuous improvement. If you require further clarification or feel there has been an error in this report please contact the Outpatient Services Call Centre from 8am - 8pm Monday to Friday, 8am - 4pm Saturday to Sunday (excludes statutory holidays) at (442) 733-2165.

Completed Action List: \* Order by Sinead Taylor on [REDACTED-DATE]

Printed by: Sinead Taylor Printed on: 2016/09/06 16:02 (End of Report)

---

[REDACTED-DATE] FAXCOM PAGE 2 OF 2

Cedar Specialist Group 4 596 Kestrel Rd 596 Kestrel Rd, CA 596 Kestrel Rd Phone: 994-882-7246  
mohan.verma27@crestwoodmedicalgroup.ca

Lakeshore Specialty Clinic 3 Anser® ADA

CHART

Patient Order ID 414 235 249 Patient 414 235 249, C[illegible] MAY 9, 2016 DOB SSN Institution ID 414 235 249 Ordered 04/25/2016 Ordered By Mason Sandoval

Report Recipient Tobias Cohen Westbrook Medical Associates 5 848 Main Blvd Riverside Medical Clinic a nearby city 6, ON 848 Main Blvd Canada

Phone 867.739.5528 Fax 994-882-7246 Study 414 235 249- Visit Visit 1 A (CLIA)

Sample ID: 414 235 249 Institution Sample ID: 414 235 249

DIS. [illegible] cc results to Dr. Rossi at Mtn MDr.

Tell pt to ↑ Humira to 80mg (2 pens) weekly

Results: [illegible]mab [illegible]ies to Adalimumab

| Assay                                        | Result    | Lower Limit of Quantification |
|----------------------------------------------|-----------|-------------------------------|
| Serum adalimumab (ADA) concentration         | 2.6 ug/mL | < 1.6 ug/mL                   |
| Antibodies to adalimumab (ATA) concentration | 2.3 U/mL  | < 1.7 U/mL                    |

Serum Adalimumab Concentration\* [image] Collection Date (last 5 samples) 04/24/2016 2.6

Antibodies to Adalimumab Concentration\* [image] Collection Date (last 5 samples) 04/24/2016 2.3

| Collection Date | ADA       | ATA      | Last Injection | Current Dose | Current Interval |
|-----------------|-----------|----------|----------------|--------------|------------------|
| 04/24/2016      | 2.6 ug/mL | 2.3 U/mL | Not Provided   | Not Provided | Not Provided     |

- Serum adalimumab (ADA) concentrations of  $\leq 5$  ug/mL were predictive of elevated CRP levels.<sup>1</sup>
- Detection of antibodies to adalimumab (ATA) was associated with elevated CRP, independent of trough serum adalimumab (ADA) levels.<sup>2</sup>
- Patients with antibodies to adalimumab (ATA) had lower median trough serum concentration independent of the time point at which ATA were detected.<sup>3</sup>
- 92% of patients with detectable ATA discontinued adalimumab therapy.<sup>3</sup>
- ATA was detected in up to 44% of patients losing response to adalimumab treatment.<sup>4</sup>

The test results are determined by using a size exclusion chromatography based on mobility shift assay on a High Performance Liquid Chromatography (HPLC) system.

#### References:

1. Yarur A., et al., Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology 2013; 144(5) Supplement 1: S774-S775.
2. Velayos F. et al., Prevalence of antibodies to adalimumab (ATA) and significance of ATA and drug concentration on CRP and symptoms in unselected IBD patients. Gastroenterology 2013; 144(5) Supplement 1: S91.
3. Karmiris K., et al., Influence of Trough Serum Levels and Immunogenicity on Long-Term Outcome of Adalimumab Therapy in Crohn's Disease. Gastroenterology 5189:213:1832-1640.
4. Wang S., et al., Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 78-79 (2013):39-44. \*Note - Values reported as exceeding the upper limit of quantification for the assay are plotted on the chart with the limit of quantification value

Maple Health Clinic 6 provide important information to aid in the diagnosis and management of certain diseases. Test results should be used with other clinical and diagnostic findings to make a diagnosis and/or prognosis. This test was developed and its performance characteristics determined by Cedar Specialist Group 4 It has not been cleared or approved by the U.S. Food and Drug Administration. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. This test may be covered by one or more US pending or issued patents - see [www.lakeshorespecialtyclinic.ca](http://www.lakeshorespecialtyclinic.ca) for details.

Tobias Cohen Medical Director Maple Health Clinic 6, the Link Design, ANSER, and the ANSER design mark are trademarks or registered trademarks of Cedar Specialist Group 4 Vevey, Switzerland Copyright © 2016 Cedar Specialist Group 4 All Rights Reserved. Cedar Specialist Group 4 is a CAP-accredited CLIA laboratory. Printed 04/26/2016 Page 1 of 1 161.4

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Outpatient Services Outpatient Services

Dr. Jasmin Kaminski Associate Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

Date: FEB 23, 2016

Dear Dr. Sinead Taylor

Thank you for your referral. Please contact your patient with the information below.

The following patient has been scheduled for a

CONSULTATION (circled) COLONOSCOPY (Instructions and preparation sheet attached)  
GASTROSCOPY (Instructions and preparation sheet attached)

Name of Patient: Ethan Kang DOB: 1979 Appointment Date & Time: Apr 24, 2016 @ Antoine Everly

Patients must bring their Health Card and a Cedar Specialist Group 4 card to ALL appointments. If your patient does not have a Cedar Specialist Group 4 card, please ask them to obtain one in admitting on the main floor before checking in with our office. We are located at Cedar Specialist Group 4 on the 4th floor, Riverside Medical Clinic.

We require 24 hours notice for cancellations. If a patient does not show up to a scheduled appointment without having called to cancel, they may be billed the standard OHIP rates.

Thank you

---

Feb 21, 2016 3:37PM No. 2345 P. 1

Cedar Specialist Group 4 Gastroenterology & Hepatology

**Referral Request**

DATE: [REDACTED-DATE] Dr: Sinead Taylor Fax# 416 619 - 5524 Tel 416 - 449 437 5411 ext. 7555

Ethan Kang 414 235 249 DOB:1979 414 235 249 412 Marigold Ave a nearby city 6, ON 848 Main Blvd H: (089) 697-3500 a5345 W: (249) 562-5508 O: Prov: NA Diag: REF:414 235 249 Dr. Gunnar Herrera (447) 964-4027

Please assess this patient in consultation re: Recurrent Crohn's Disease post-resection despite HUMIRA @ relapse to Remicade earlier.

Relevant Findings: See attached reports. For 2nd opinion.

Thank-you in advance.

Sincerely yours, [signature]

(OFFICE 2-3M circled)

Dr. Sinead Taylor M.D., F.R.C.P.C. OHIP Mohan Verma

Dr. Sinead Taylor M.D., FRCS(C), F.R.C.S(E) OHIP Dalia Macdonald

Dr. Sinead Taylor M.D., F.R.C.S.(C) OHIP Niamh Engström

Dr. Sinead Taylor, M.D., F.R.C.S.(C) OHIP Naomi Reyes



Dr. Sinead Taylor, M.D., F.R.C.S.(C) OHIP Ethan Odum

Dr. Sinead Taylor M.D., F.R.C.S(C) OHIP Salma Whitmore

Dr. Sinead Taylor M.D., F.R.C.P.(C) (circled) OHIP Evander Chowdhury

Dr. Sinead Taylor, M.D., F.R.C.P.(C) OHIP Priya Vinter

Dr. Sinead Taylor, M.D., F.R.C.P.(C) OHIP Zola Ortega

Dr. Sinead Taylor, M.D., F.R.C.P.(C) OHIP Cesar Lindgren

Dr. Sinead Taylor, M.D., F.R.C.S(C) OHIP Liam Patel

Dr. Sinead Taylor, M.D., F.R.C.S(C) OHIP Ava Laflamme

Other \_\_\_\_

848 Main Blvd • Riverside Medical Clinic • 848 Main Blvd • ON • 848 Main Blvd • p. 994-882-7246 • f. 994-882-7246

---

Cedar Specialist Group 4 Gastroenterology & Hepatology

Dr. Sinead Taylor Gastroenterology 848 Main Blvd, 848 Main Blvd 994-882-7246 Fax: 994-882-7246

Date of Visit: Feb 10, 2016 Name: Ethan Kang DOB: 1979 Age: 36 Gender: Male Health Card #:

Dear Dr. Sinead Taylor, cc: Sinead Taylor

I saw Ethan Kang with regards to follow-up today. See SUMMARY for updated plan.

REASON FOR ASSESSMENT:

- Persistent Crohn's disease, diarrhea issues, and pain.

GASTROENTEROLOGY CUMULATIVE PATIENT PROFILE: Feb 10, 2016

|                                                                                                                                      |                                                                                               |                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------|
| <b>PERSONAL DATA:</b>                                                                                                                | <b>FAMILY HISTORY:</b><br>Grandmother - Leukemia. No known family history of IBD, malignancy. | <b>DRUG ALLERGIES:</b><br>NKDA, bad reaction Imuran. |
| <b>Marital Status:</b> Single. <b>Children:</b> No.                                                                                  | <b>MEDICAL HISTORY</b>                                                                        | <b>OTHER ALLERGIES:</b><br>Nil.                      |
| <b>Language in Home:</b> English. <b>Living with:</b> Independent. <b>Occupation:</b> Lakeview Health Centre <b>Born in:</b> Canada. | Crohn's Disease, 2014.                                                                        | <b>MEDICATIONS:</b>                                  |
|                                                                                                                                      | OSA on CPAP.                                                                                  | Humira 40 mg SC qweekly                              |

|                                                                                  |                                                                                               |                                                      |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------|
| <b>PERSONAL DATA:</b>                                                            | <b>FAMILY HISTORY:</b><br>Grandmother - Leukemia. No known family history of IBD, malignancy. | <b>DRUG ALLERGIES:</b><br>NKDA, bad reaction Imuran. |
| <b>RISK FACTORS / HABITS:</b>                                                    | Arthritis, herniated disc, back pain                                                          | B12 1mg SC q30d                                      |
| <b>Smoking:</b> No. <b>Alcohol:</b> Minimal.                                     | Kidney Stones                                                                                 | <b>OTC/Vit/Supp:</b> N/A                             |
| <b>NSAIDS:</b> No. <b>IVDU:</b> No.                                              | B12 deficiency                                                                                | <b>Alternatives:</b> N/A                             |
| <b>Piercings/Tattoos:</b> No. <b>Transfusions:</b> No. <b>Other chemicals:</b> . | <b>SURGERIES:</b>                                                                             | <b>CONSULTANTS:</b>                                  |
| <b>Caffeine:</b>                                                                 | Ileal resection, December 2013                                                                | Sinead Taylor - General Sx                           |

PATIENT FLOWSHEET: PRESENTING HISTORY: I first met Ethan in February 2011 for assessment for suspected Ulcerative Colitis. He had a colonoscopy in 2008 showing non-specific colitis, and a repeat in 2010 showing colitis in the descending colon with normal rectum. He has had intermittent diarrhea since 2008, occasionally with hematochezia, and abdominal pain. He was treated for ulcerative colitis in 2010 with 5-ASA therapy, with some improvement, bowel movements from 12 x day to 4 x per day. COURSE: Started on Imuran May 2011, achieving target dose of 300 mg / day. In July 2011 his Harvey Bradshaw index was 4, improving dramatically, but still having loose stools 2 x / day and persistent intermittent abdominal discomfort. Initiated Infliximab October 2011, monotherapy. He was negative (non-immune non-exposed) to Hepatitis B, TB skin test negative; immunization against Hepatitis B recommended. His inflammatory markers remained elevated, and although he felt improved loose stools and abdominal pains persisted (BW Jan 2012 showed CRP 19.6, ESR 25 for instance). Unfortunately, by Apr 2012, he developed frank rectal bleeding, with stool cultures repeated and negative, likely representing worsening Crohn's disease. His Harvey-Bradshaw Index March 2012 was 5. Imuran 275 mg daily was restarted, but not tolerated with severe GI side effects. His Remicade was changed to q6weekly, Methotrexate 7.5 mg weekly and folic acid supplements were added. Although he clinically felt stable or slightly improved, despite aggressive treatment he remained clinically symptomatic throughout 2012. By January 2013, his HBI was elevated at 8, after over 1 year of treatment. We organized a switch to Adalimumab, with concurrent methotrexate 7.5 g weekly, although he decided to stop the Methotrexate himself. By May 2013 his HBI was at 8 again and he was feeling worse, a course of prednisone was added to his regimen. With prednisone, his diarrhea resolved completely, as he began his taper however the diarrhea returned. We tried increasing his Humira to qweekly July 2013. His inflammatory markers remained positive. Ultimately surgical resection of is ileum was carried out by Dr.

Page | 1

---

Feb. 1979. 2016 Everly No. 2345 P. 3

Cedar Specialist Group 4 Gastroenterology & Hepatology

Dr. Sinead Taylor Gastroenterology 848 Main Blvd, 848 Main Blvd 994-882-7246 Fax: 994-882-7246

Date of Visit: Feb 10, 2016 Name: Ethan Kang DOB: 1979 Age: 36 Gender: Male Health Card #:

Taylor December 2013, all therapy was discontinued, and he slowly improved. B12 deficiency noted. Endoscopy March 2014 showed active ileitis; Humira restarted July 2014, ultimately bowel habits and abdominal pains improved, and stable. Reassessed March 2015, main complaint of intestinal gas. Colonoscopy Apr 2015 showed persistent ileitis, planned referral to tertiary IBD centre, did not come back for F/U. INVESTIGATIONS: LABS: Feb 2011: Stool culture -ve, Ova&Parasites -ve, BW: CRP 14.1 ESR 26, WBC 6.1 Hb 126 Alb= 41 Bili 3 ALP 61 ALT 20. Mar 23, 2014 BW: CRP 31.2 ESR 49, CR 70, Alb 43 ALT 14 ALP 87 Bili 2 Hb 114 WBC 9.4 Plts 348. Mar 23, 2014 BW: CRP 31.2 ESR 49, CR 70, Alb 43 ALT 14 ALP 87 Bili 2 Hb 114 WBC 9.4 Plts 348. Jul 4, 2014 BW: Glu 4.4, CR 70, B12 102 [deficient], Ferritin 27, ALT 16 TSH 1.92, Hb 117 WBC 7.5 Plts 307, ESR 41 CRP 12.8. Sep 12, 2014 BW: Alb 42 Bili 12 B12 124 [Lo], Ferritin 51, Hb 120 WBC 6.4 platelets 310, ESR 39 CRP 9.8. Apr 22, 2015 BW: CR 74, Alb 45 Bili 4, B12 190, Ferritin 92, ALT 17, Hb 130 WBC 9.9 Plts 250, ESR 14 CRP 12.9. IMAGING: Apr 2011 Small Bowel Follow Through: Active ileitis, stenotic & dilated segments. Apr 2012 MR Enterography: Long segment of ileal inflammation, incidental Meckel's Diverticulum. ENDOSCOPY/PATHOLOGY: Apr 10, 2011 Colonoscopy: Quiescent colitis. Jun 2012 Colonoscopy: Active ileal disease, patch left sided colitis. Apr 2, 2014 Colonoscopy: Active severe ileitis. May 13, 2015 Colonoscopy: Severe ileitis.

HISTORY & COURSE: Ethan unfortunately has had ongoing symptoms really from Christmas to this year that have been worsening. The bowel movements have become more frequent, sometimes with blood in the stool, up to 10 bowel movements per day. Today, he has had 10 bowel movements per day which is at least five more than usual and all of them were diarrhea-like. There has been recent blood. He feels quite unwell. There is pain in the right lower quadrant on examination. He feels systemically unwell. He is anemic. His weight has otherwise been increasing. He has not done recent stool softeners, not on recent antibiotics. Systemically, he feels more unwell. He has had a previous surgery and resection. He has been on Humira 40 mg weekly. Despite this, his symptoms have been ongoing. Remicade was ineffective in the past.

#### SUMMARY: CONCLUSIONS:

- History of Crohn's disease, recurrent, without worsening symptoms in terms of diarrhea and abdominal pains. I think that we need to do some objective evidence of disease activity, stool cultures, inflammatory markers. I would like to organize this now.
- Referral for tertiary care center for second opinion. He has now had recurrent disease fairly rapidly post-surgery in 2014. He has lost response to Remicade. He is now on Humira, but this has not been particularly effective. Further options need to be discussed.

#### RECOMMENDATIONS:

- Stool cultures and samples including C. difficile testing.
- Basic blood work and inflammatory markers.
- Referral to Dr. Sinead Taylor for second opinion.

Date of Visit: Feb 10, 2016 Name: Ethan Kang DOB: 1979 Age: 36 Gender: Male Health Card #:

Thank you for the honour of participating in the care of your patient, please don't hesitate to contact me directly should there be any questions.

Page | 3

---

Feb. 1979. 2016 Everly No. 2345 P. 5

## Cedar Specialist Group 4

Gastroenterology & Hepatology

**Dr. Sinead Taylor Gastroenterology 848 Main Blvd, 848 Main Blvd 994-882-7246 Fax: 994-882-7246**

Date of Visit: Feb 10, 2016 Name: Ethan Kang DOB: 1979 Age: 36 Gender: Male Health Card #:

Sincerely,

![signature]

Dr. Sinead Taylor MD. FRCP(C) Gastroenterology, Hepatology

Dictated: Feb 10, 2016

Reviewed for accuracy Feb 20, 2016 by Dr. Taylor. If results/information becomes available, further recommendations may be made. Transcription errors may occur, if there are questions or concerns, please contact Dr. Taylor immediately.

### **ADDENDA:**

- Feb 11, 2016 Stool: culture -ve. BW: CR 73 Alb 43 B12 118 (LO) Bili 5 ALT 24 ALP 68 TSH 2.63, ferritin 142, Hb 125 WBC 6 Plts 262, ESR 1979 CRP 11.3

Page | 4

---

Feb. 1979. 2016 Everly No. 2345 P. 6

848 Main Blvd, 848 Main Blvd, ON 848 Main Blvd

COLLECTION TIME 2016-02-11 N/A

SERVICE DATE 2016-02-11

REPORT DATE 2016-02-12

| PATIENT                                                                                                    | HEALTH NUMBER         | CLIENT                                                                                                                             |
|------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Ethan Kang<br>847 Fennimore St<br>a nearby city 6<br>ONTARIO<br>848 Main Blvd<br><br>PHONE: (442) 733-2165 | 414 235 249           | Dr. Sinead Taylor<br>Cedar Specialist Group 4<br>484 College Blvd<br>848 Main Blvd, ON<br>848 Main Blvd<br><br>PHONE: 994-882-7246 |
|                                                                                                            | DATE OF BIRTH<br>1979 |                                                                                                                                    |
|                                                                                                            | SEX M AGE 36 Y        |                                                                                                                                    |
|                                                                                                            | CHART 414 235 249     |                                                                                                                                    |

Comments:

| CODES | TEST DESCRIPTION  | RESULTS | REFERENCE RANGE | OUTSIDE NORMAL LIMITS |
|-------|-------------------|---------|-----------------|-----------------------|
|       | C H E M I S T R Y |         |                 |                       |
|       | CRP               | 11.3    | < 8.0 mg/L      | 11.3                  |

☐ Pull Chart ☐ Book F/U ☐ Stat ☒ No Action Required ![signature] ☐ Other: \_\_\_\_\_

C - CONFIRMED BY OTHER TEST L - LIPEMIC H - HEMOLYZED R - REPEATED I - INSUFFICIENT QUANTITY T - TELEPHONED K - ICTERIC

414 235 249 04/15 (REPO-LAB-02)

PAGE 1 OF 1 2016/02/12 4:00:37

Laboratory Report Result Inq 994-882-7246

Feb. 1979. 2016 Everly No. 2345 P. 7

848 Main Blvd, 848 Main Blvd, ON 848 Main Blvd

| COLLECTION TIME | SERVICE DATE | REPORT DATE |
|-----------------|--------------|-------------|
| 2016-02-11 N/A  | 2016-02-11   | 2016-02-14  |

| PATIENT                                                                                                    | HEALTH NUMBER         | CLIENT                                                                                                                             |
|------------------------------------------------------------------------------------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Ethan Kang<br>847 Fennimore St<br>a nearby city 6<br>ONTARIO<br>848 Main Blvd<br><br>PHONE: (442) 733-2165 | 414 235 249           | Dr. Sinead Taylor<br>Cedar Specialist Group 4<br>484 College Blvd<br>848 Main Blvd, ON<br>848 Main Blvd<br><br>PHONE: 994-882-7246 |
|                                                                                                            | DATE OF BIRTH<br>1979 |                                                                                                                                    |

|                |                                 |               |
|----------------|---------------------------------|---------------|
| <b>PATIENT</b> | <b>HEALTH<br/>NUMBER</b>        | <b>CLIENT</b> |
|                | <b>SEX M AGE 36 Y</b>           |               |
|                | <b>CHART</b> <br>414<br>235 249 |               |

Comments:

|              |                                    |
|--------------|------------------------------------|
| <b>CODES</b> |                                    |
|              | <b>M I C R O B I O L O G Y</b>     |
|              | -----                              |
|              | <b>STOOL CULTURE</b>               |
|              | -----                              |
|              | No Salmonella, Shigella, Yersinia, |
|              | Campylobacter or E.coli 0157:H7.   |

☐ Pull Chart ☐ Book F/U ☐ Stat ☒ No Action Required [signature] ☐ Other:

C - CONFIRMED BY OTHER TEST H - HEMOLYZED I - INSUFFICIENT QUANTITY K - ICTERIC  
Laboratory Report Result In L - LIPEMIC R - REPEATED T - TELEPHONED 994-882-7246 414 235 249  
04/15 (REPO-LAB-02) PAGE 1 OF 1 2016/02/14 10:00:01

Feb. 1979. 2016 Everly

848 Main Blvd, 848 Main Blvd, ON 848 Main Blvd

|                        |                             |
|------------------------|-----------------------------|
| <b>COLLECTION TIME</b> | <b>DHC X334334-37 FINAL</b> |
| 2016-02-11 N/A         |                             |

|                     |                    |
|---------------------|--------------------|
| <b>SERVICE DATE</b> | <b>REPORT DATE</b> |
| 2016-02-11          | 2016-02-12         |

|                                                                                                                  |                                   |                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| <b>PATIENT</b>                                                                                                   | <b>HEALTH<br/>NUMBER</b>          | <b>CLIENT</b>                                                                                                                            |
| Ethan Kang<br>847 Fennimore St<br>a<br>nearby city 6<br>ONTARIO<br>848 Main<br>Blvd<br><br>PHONE: (442) 733-2165 | 414 235 249                       | Dr. Sinead Taylor<br>Cedar Specialist<br>Group 4<br>484 College Blvd<br>848<br>Main Blvd, ON<br>848 Main Blvd<br><br>PHONE: 994-882-7246 |
|                                                                                                                  | <b>DATE OF<br/>BIRTH</b> <br>1979 |                                                                                                                                          |
|                                                                                                                  | <b>SEX M AGE 36 Y</b>             |                                                                                                                                          |

|                |                                 |               |
|----------------|---------------------------------|---------------|
| <b>PATIENT</b> | <b>HEALTH<br/>NUMBER</b>        | <b>CLIENT</b> |
|                | <b>CHART</b> <br>414<br>235 249 |               |

Comments:

| <b>CODES</b> | <b>TEST DESCRIPTION</b>                                                                                                                                                                                                                                                                                                                                                                                              | <b>RESULTS</b>                                                                                                      | <b>REFERENCE<br/>RANGE</b> | <b>OUTSI<br/>NORMA<br/>LIMIT</b> |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|----------------------------|----------------------------------|
|              | <b>C H E M I S T R Y</b>                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                     |                            |                                  |
|              | -----                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                     |                            |                                  |
|              | CREATININE                                                                                                                                                                                                                                                                                                                                                                                                           | 73.                                                                                                                 | 60 - 110 umol/L            |                                  |
|              | eGFR                                                                                                                                                                                                                                                                                                                                                                                                                 | 113.                                                                                                                | >=60.<br>mL/min/1.73m**2   |                                  |
|              | Effective [REDACTED-DATE] 4th, 2015, eGFR is calculated using the CKD-EPI 2009 equation.<br><br>KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.<br><br>Normal eGFR.<br><br>For patients of African descent, the reported eGFR must be multiplied by 1.15. |                                                                                                                     |                            |                                  |
|              | ALBUMIN                                                                                                                                                                                                                                                                                                                                                                                                              | 43.                                                                                                                 | 35 - 52 g/L                |                                  |
|              | BILIRUBIN TOTAL                                                                                                                                                                                                                                                                                                                                                                                                      | 5.                                                                                                                  | <23 umol/L                 |                                  |
|              | VITAMIN B12                                                                                                                                                                                                                                                                                                                                                                                                          | 118.                                                                                                                | pmol/L                     | 118.                             |
|              |                                                                                                                                                                                                                                                                                                                                                                                                                      | DEFICIENCY:                                                                                                         | < 148 pmol/L               |                                  |
|              |                                                                                                                                                                                                                                                                                                                                                                                                                      | INSUFFICIENCY:                                                                                                      | 148 - 220 pmol/L           |                                  |
|              |                                                                                                                                                                                                                                                                                                                                                                                                                      | SUFFICIENCY:                                                                                                        | > 220 pmol/L               |                                  |
|              |                                                                                                                                                                                                                                                                                                                                                                                                                      | 60% OF SYMPTOMATIC PATIENTS HAVE A HEMATOLOGIC OR NEUROLOGIC RESPONSE TO B12 SUPPLEMENTATION AT A LEVEL <148 pmol/L |                            |                                  |

| CODES | TEST DESCRIPTION           | RESULTS | REFERENCE RANGE          | OUTSI NORMA LIMIT |
|-------|----------------------------|---------|--------------------------|-------------------|
|       | FERRITIN                   | 142.    | 24 - 453 ug/L            |                   |
|       | ALKALINE PHOSPHATASE       | 68.     | 40 - 129 U/L             |                   |
|       | ALT                        | 24.     | <46 U/L                  |                   |
|       | TSH                        | 2.63    | 0.35 - 5.00 mIU/L        |                   |
|       | <b>H E M A T O L O G Y</b> |         |                          |                   |
|       | -----                      |         |                          |                   |
|       | HEMOGLOBIN                 | 125.    | M: 135 - 170 g/L         | 125.              |
|       | HEMATOCRIT                 | 0.39    | M: 0.38 - 0.49 l/l       |                   |
|       | RBC                        | 4.54    | M: 4.20 - 5.70 x 10E12/L |                   |
|       | RBC INDICES: MCV           | 86.     | M: 80 - 97 fl            |                   |
|       | MCH                        | 28.     | 27 - 32 pg               |                   |

C - CONFIRMED BY OTHER TEST H - HEMOLYZED I - INSUFFICIENT QUANTITY K - ICTERIC  
Laboratory Report Result Inqi L - LIPEMIC R - REPEATED T - TELEPHONED 994-882-7246 414 235 249  
04/15 (REPO-LAB-02) PAGE 1 OF 2 2016/02/12 5:00:10

Feb. 1979. 2016 Everly

848 Main Blvd, 848 Main Blvd, ON 848 Main Blvd

| COLLECTION TIME | DHC [illegible] FINAL |
|-----------------|-----------------------|
| 2016-02-11 N/A  |                       |

| SERVICE DATE | REPORT DATE |
|--------------|-------------|
| 2016-02-11   | 2016/02/    |

| PATIENT                                                                                                    | HEALTH NUMBER                 | CLIENT                                                                                                                             |
|------------------------------------------------------------------------------------------------------------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| Ethan Kang<br>847 Fennimore St<br>a nearby city 6<br>ONTARIO<br>848 Main Blvd<br><br>PHONE: (442) 733-2165 | 414 235 249                   | Dr. Sinead Taylor<br>Cedar Specialist Group 4<br>484 College Blvd<br>848 Main Blvd, ON<br>848 Main Blvd<br><br>PHONE: 994-882-7246 |
|                                                                                                            | <b>DATE OF BIRTH</b> <br>1979 |                                                                                                                                    |
|                                                                                                            | <b>SEX M AGE</b> 36 Y         |                                                                                                                                    |



|                |                                 |               |
|----------------|---------------------------------|---------------|
| <b>PATIENT</b> | <b>HEALTH<br/>NUMBER</b>        | <b>CLIENT</b> |
|                | <b>CHART</b> <br>414<br>235 249 |               |

Comments:

| <b>CODES</b> | <b>TEST DESCRIPTION</b>     | <b>RESULTS</b> | <b>REFERENCE RANGE</b> | <b>OUTSI NORMA LIMIT</b> |
|--------------|-----------------------------|----------------|------------------------|--------------------------|
|              | MCHC                        | 320.           | 320 - 360 g/L          |                          |
|              | RDW                         | 15.1           | 11.5 - 15.5            |                          |
|              | WBC                         | 6.0            | 4.0 - 11.0 x 10E9/L    |                          |
|              | E.S.R.                      | 1979.          | M: 0 - 15 mm/hr        | 1979.                    |
|              | PLATELETS                   | 262.           | 145 - 400 x 10E9/L     |                          |
|              | MPV                         | 9.4            | 7.4 - 11.3 fl          |                          |
|              | <b>DIFFERENTIAL WBC'S :</b> |                |                        |                          |
|              | NEUTROPHILS                 | 3.72           | 1.80-7.00x10E9/L       |                          |
|              | LYMPHOCYTES                 | 1.50           | 1.00-3.20x10E9/L       |                          |
|              | MONOCYTES                   | 0.66           | 0.00-0.80x10E9/L       |                          |
|              | EOSINOPHILS                 | 0.06           | 0.00-0.40x10E9/L       |                          |
|              | BASOPHILS                   | 0.00           | 0.00-0.20x10E9/L       |                          |

☐ Pull Chart ☐ Book F/U ☐ Stat ☒ No Action Required ☐ Other:

B12 deficient. Discuss IM B12

GP

C - CONFIRMED BY OTHER TEST L - LIPEMIC H - HEMOLYZED R - REPEATED I - INSUFFICIENT QUANTITY T - TELEPHONED K - ICTERIC

Laboratory Report Result Inqi 994-882-7246 414 235 249 04/15 (REPO-LAB-02) PAGE 2 OF 2 2016/02/12 5:00:10

Feb. 1979. 2016 Everly

| <b>COLLECTION DATE</b> | <b>SERVICE DATE</b> | <b>REPORT DATE</b> |
|------------------------|---------------------|--------------------|
| 2015-05-13 N/A         | 2015-05-13          | 2015/05/           |

848 Main Blvd, 848 Main Blvd, ON 848 Main Blvd, 848 Main Blvd, 848 Main Blvd, ON 848 Main Blvd

| PATIENT                                                                                                   | HEALTH<br>NUMBER         | CLIENT                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Ethan Kang<br>847 Fennimore<br>St<br>a nearby city 6<br>848 Main<br>Blvd<br><br>PHONE: (442) 733-<br>2165 | 414 235 249              | Dr. Sinead Taylor<br>Cedar Specialist Group<br>4<br>848 Main Blvd<br>848 Main Blvd,<br>ON<br>848 Main Blvd<br><br>PHONE: 994-<br>882-7246 |
|                                                                                                           | DATE OF<br>BIRTH<br>1979 |                                                                                                                                           |
|                                                                                                           | SEX M AGE 35 Y           |                                                                                                                                           |
|                                                                                                           | CHART<br>414<br>235 249  |                                                                                                                                           |

COMMENTS 1:NEOILEUM 2:REC JB

| CODES |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | <p>HISTOLOGY&lt;br&gt;&lt;br&gt;TISSUE:&lt;br&gt;1) Neo ileum&lt;br&gt;2) Rectum&lt;br&gt;&lt;br&gt;SUMMARY OF<br/>HISTORY:&lt;br&gt;H/O Crohn's&lt;br&gt;&lt;br&gt;CLINICAL DIAGNOSIS:&lt;br&gt;1) Ileitis&lt;br&gt;&lt;br&gt;GROSS:<br/>&lt;br&gt;1) SCO 2 fragments of tan tissue measuring 0.2cm each EIT.&lt;br&gt;2) SCO 2 fragments of<br/>tan tissue measuring from 0.1 to 0.3cm EIT.&lt;br&gt;&lt;br&gt;DIAGNOSIS:&lt;br&gt;1) SMALL INTESTINAL<br/>BIOPSY (NEO ILEUM) :&lt;br&gt;- FOCAL ACTIVE ILEITIS.&lt;br&gt;- NO GRANULOMAS IDENTIFIED.<br/>&lt;br&gt;2) LARGE INTESTINAL BIOPSY (RECTUM) :&lt;br&gt;- COLONIC MUCOSA WITH MILD<br/>HYPERPLASTIC/REGENERATIVE CHANGES;&lt;br&gt;OTHERWISE, WITHIN NORMAL LIMITS.<br/>&lt;br&gt;- NO GRANULOMAS OR VIRAL INCLUSIONS IDENTIFIED.&lt;br&gt;- NEGATIVE FOR<br/>DYSPLASIA.</p> |

Pathologist: Dr. Sinead Taylor, Keller, FRCPC Gastrointestinal Pathologist (signature on file)

Copy Sent to Dr. Sinead Taylor

☐ Pull Chart ☐ Book F/U ☐ Stat ☒ No Action Required ☐ Other: \_\_\_\_\_

[signature]

414 235 249 (04/15) REPO-HIST-02 PAGE 1 OF 1 2015/05/21 12:22:48 Laboratory Report Result Ini 994-882-7246

Feb. 1979. 2016 Everly No. 2345 P. 11

Cedar Specialist Group 4 Gastroenterology & Hepatology

Dr. Sinead Taylor Gastroenterology 848 Main Blvd, 848 Main Blvd 994-882-7246 Fax: 994-882-7246

Date of Visit: 05/13/2015 Name: Ethan Kang DOB: 21/06/1979 Age: 35 Gender: Male Health Card #:

Dear Dr. Sinead Taylor,

Ethan was seen for staging colonoscopy in the setting of Crohn's disease with ileal resection. He sells frequent bowel movements, minimal abdominal symptoms otherwise. He is on Humira weekly. To assess for mucosal healing end-stage disease, diagnostic colonoscopy was expedited for today. He did have some minimally elevated inflammatory markers on previous blood work.

On examination, he has significant central adiposity, benign abdomen on examination.

Investigations: Apr 22, 2015 BW: CR 74, albumin 45 bilirubin 4, B12 190, ferritin 92, ALT 17, Hb 130 WBC 9.9 platelets 250, ESR 14 CRP 12.9 elevated

35-year-old male appropriate for diagnostic colonoscopy for staging of Crohn's disease

PROCEDURE: COLONOSCOPY

ENDOSCOPIST: Dr. Sinead Taylor

ANESTHETIST: Sinead Taylor

SEDATION: Propofol-based sedation performed by anesthetist, see anesthesia record for details, ASA Classification.

PRE-PROCEDURE DIAGNOSIS

- Crohn's disease

POST-PROCEDURE DIAGNOSIS

- Significant ileitis

ASSESSMENT: [yo male/female, appropriate for endoscopy]. Risks and benefits were discussed in detail, including anesthetic risks, bleeding complications, chance of serious complications of puncture or perforation of 1:1500, chance of missing lesions of 5-10%, vs alternative testing methods. After this discussion, informed witnessed signed consent was obtained.

TECHNICAL PROCEDURE NOTES: \*The patient was positioned in the left lateral decubitus position and appropriately draped.

Page | 1

---

Feb. 1979. 2016 Everly No. 2345 P. 12

Cedar Specialist Group 4 Gastroenterology & Hepatology

Dr. Sinead Taylor Gastroenterology 848 Main Blvd, 848 Main Blvd 994-882-7246 Fax: 994-882-7246

Date of Visit: 05/13/2015 Name: Ethan Kang DOB: 21/06/1979 Age: 35 Gender: Male Health Card #:

- Olympus video endoscope was used.
- Continuous nurse-assisted monitoring present.
- The bowel preparation was suboptimal, 848 Main Blvd scale 10 / 14.
- Prior to the procedure, peri-rectal and digital rectal examination was performed.
- A power washer was available and used to optimize views.

- A retroflexed rectal exam was performed.
- A withdrawal time of 6 minutes is documented.
- Photographs were taken and left in electronic record.
- The scope was withdrawn and the patient was transferred to the recovery area in stable condition.
- Results were discussed with the patient prior discharge, a preliminary report was also provided.

FINDINGS for COLONOSCOPY: The endoscope was advanced from the rectum up to the ileum. Sufficient mucosal views were achieved. Slow withdrawal technique was used, with appropriate washing and suctioning, and careful views behind ICvalve, haustral folds, flexures, and rectal valves. The colon itself appeared entirely normal, although limited by the poor bowel preparation. The ileum however, showed significant ileitis with diffuse redness and multiple ulcerations. Suggestive of active inflammatory bowel disease. We will discuss at follow-up review pathology, perhaps a trial of budesonide might be warranted.

PLAN: Results of endoscopy suggest an active ileitis despite the use of Humira. He does have symptoms although these are minimal, as well as objective increased inflammatory markers. I met her recommend a trial of budesonide, I like to see him in follow-up in one month's time to review. What the options are going forward will need to be discussed.

Follow-up to review clinical state The patient was in stable condition at time of discharge. If severe symptoms develop (pain, fever, bleeding) contact our office AND seek out emergent medical attention, information provided to patient directly as well.

Thank you for the honour of participating in the care of your patient, should you have any questions, please don't hesitate to contact myself directly.

Sincerely,

Page | 2

---

Feb. 1979. 2016 Everly No. 2345 P. 13

Cedar Specialist Group 4 Gastroenterology & Hepatology

Dr. Sinead Taylor Gastroenterology 848 Main Blvd, 848 Main Blvd 994-882-7246 Fax: 994-882-7246

Date of Visit: 05/13/2015 Name: Ethan Kang DOB: 21/06/1979 Age: 35 Gender: Male Health Card #:

[image] Dr. Sinead Taylor Cohen, Tobias) Gastroenterology, Hepatology

Transcribed by voice recognition software. Errors may occur, for concerns please contact office. Final recommendations, follow-up may change as results become available and addendum may be issued.

Page | 3

---

Discharge Summary

Ethan Kang - 414 235 249

Result Type: Discharge Summary Result Date: 06 January 2014 12:00 Result Status: Transcribed Result Title: Final Summary Performed By: -mcleod 414 235 249 on 14 January 2014 9:32 Encounter info: 414

235 249, Cedar Specialist Group 4, Same Day Admit, [REDACTED-DATE]

Final Summary \*\* PLEASE CONTACT THE DICTATING OR ATTENDING PHYSICIAN BEFORE MAKING ANY PATIENT CARE DECISIONS. \*\*

Visit ID: 414 235 249 Admitted: 2014-01-06 Discharged: 2014-01-12

Final Diagnosis: Crohn`s disease

Ethan Kang is 34-year-old male who was diagnosed with Crohns disease in 2010. His disease has been mainly in the terminal ileum. He had an MRI in June, which showed a 55-60 cm segment of thickened terminal ileum. He had obstructive symptoms from it and therefore was admitted for surgery. On the day of admission he was taken to the operating room. We attempted to do it laparoscopically but this was impossible for two reasons. First of all he is quite a heavy man and that made it difficult. Secondly though when we opened he had a very long segment probably longer than the 60 cm and very thick mesentery and there was omentum stuck down on it. Thus it was a somewhat difficult operation but we removed a segment probably about 100 cm of terminal ileum and did a primary anastomosis. There were no intraoperative difficulties. Postoperatively Ethan developed an ileus and required insertion of a nasogastric tube. The ileus recovered very quickly and he was ultimately discharged home on [REDACTED-DATE] 13. At that time he was tolerating a normal diet and his gut was functioning. He will have the staples removed by his family doctor and I will see him in follow up in six weeks time.

Sinead Taylor Outpatient Services, Outpatient Services Authenticated 10 days after distribution date

Dictated by: Sinead Taylor Dictated: 2014/01/14 09:32 Transcribed: 2014/01/14 14:33 Distributed: 2014/01/14 14:33

Job #: 414 235 249 er-MM

cc: Dr. Sinead Taylor, FAX 994-882-7246 Dr. Sinead Taylor, 994-882-7246

Printed by: Sinead Taylor Printed on: 2016/04/25 19:41

---

#### Discharge Summary

Ethan Kang - 414 235 249

#### Completed Action List:

- Perform by -mcleod 414 235 249 on 14 January 2014 9:32
- Transcribe by 414 235 249 -MQ-Taylor, Sinead on 15 December 2013 14:33

Printed by: Sinead Taylor Printed on: 2016/04/25 19:41 (End of Report)

---

Surgical Pathology Ethan Kang - 414 235 249

- Final Report \*

|                 |                                                                        |
|-----------------|------------------------------------------------------------------------|
| Result Type:    | Surgical Pathology                                                     |
| Result Date:    | 06 January 2014 9:50                                                   |
| Result Status:  | Final                                                                  |
| Result Title:   | 414 235 249                                                            |
| Encounter info: | 414 235 249, Cedar Specialist Group 4, Same Day Admit, [REDACTED-DATE] |

- Final Report \*

414 235 249

Outpatient Services 412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd t: 994-882-7246 f: 994-882-7246

|                          |                          |                  |             |
|--------------------------|--------------------------|------------------|-------------|
| Health Card #:           | 414 235 249              | Medical Record # | 414 235 249 |
| Location:                | Riverside Medical Clinic | Visit #:         | 5268759788  |
| Room:                    | Riverside Medical Clinic |                  |             |
| Physician:               | Dr. Sinead Taylor        | Last Name:       | Ethan Kang  |
| Date of Procedure:       | 2014.01.06               | First Name:      | Ethan       |
| Accession Date:          | 2014.01.07               | Date of Birth:   | 1979        |
| Date and Time of Report: | 2014.01.15 14:22         | Sex:             | M           |

#### FINAL SURGICAL PATHOLOGY REPORT 414 235 249

Clinical History: Crohn's disease

Specimen: ILEOCOLIC SEGMENT

Gross Description: The specimen container is labelled with the patient's identification and as "ileocolic resection" and contains an ileocolic resection comprised of extended segment of terminal ileum, ileocecal valve,

Printed by: Sinead Taylor Printed on: 2016/04/25 19:42 (Continued)

---

Surgical Pathology Ethan Kang - 414 235 249

- Final Report \*

appendix, cecum and adjacent pericolonic and small bowel adipose tissues. The proximal margin is stapled closed over a length of 3.4 cm. The terminal ileum measures 82.2 cm in length by up to 7.0 cm in luminal circumference. The ileocecal valve measures 5.8 cm in circumference. The appendix measures 7.2 cm in length, 0.8 cm in diameter. The large bowel component measures 8.2 cm in length x 10.2 cm in luminal

circumference. The distal margin is stapled closed over a length of 6.2 cm. Pericolonic adipose tissue and small bowel mesentery are present to a maximum depth of 9.2 cm.

The mucosal aspect of the terminal ileum demonstrates relatively unremarkable mucosal folding over the proximal-most 15 cm. At this point there are patchy areas of involved and unremarkable mucosa. Longitudinal ulcerations are noted predominately on the mesenteric aspect of the specimen measuring up to 10.6 cm in length. These ulcers are in part lined by gray, white exudate-like material. The small bowel wall shows areas of wall thickening causing stricturing and dilation along its entire length. The bowel wall ranges in thickness from 0.2 to 0.6 cm. The narrowest portion occurs approximately 38 cm from the proximal margin and extends over a length of approximately 26 cm. Longitudinal ulceration is noted in this area as well. The lumen measures 2.4 cm in diameter. Approximately 48 cm from the proximal margin there is a serosal covered nodule measuring 2.5 cm in greatest dimension. Sectioning shows a thick, gray, white appearance. The cut surfaces are homogenous. The mucosal component of the terminal ileum from this point onwards shows complete loss of mucosal folding with longitudinal ulceration and exudate. This extends to the ileocecal valve. The mucosal component of the large bowel shows finely granular tan and brown folds with no gross lesions identified.

Serosal aspect of the appendix is dusky pink, glistening with fibrous adhesions noted at the tip. Sectioning of the appendix shows an unremarkable and patent lumen. The serosal aspect of the small bowel shows features consistent with "creeping fat". No further lesions are identified.

Photographs of the specimen are taken.

Representative sections:

- 1 proximal margin en face
- 2 proximal unremarkable small bowel
- 3 to - 6 mucosa proximal to serosal lesion
- 7 to - 9 full-thickness cross-section of serosal lesion
- 10 to - 12 small bowel from serosal lesion to ileocecal valve
- 13 ileocecal valve
- 14 appendiceal orifice
- 15 appendix
- 16 cecum
- 17 and - 18 distal margin en face
- 19 3 nodular areas
- 20 1 nodular area bisected

Printed by: Sinead Taylor Printed on: 2016/04/25 19:42 (Continued)

---

Surgical Pathology Ethan Kang - 414 235 249

- Final Report \*

Grossed by: Sinead Taylor, Pathologists' Assistant

DIAGNOSIS: Terminal ileum, appendix, cecum and proximal ascending colon, ileocelectomy Severe ulcerating and stricturing Crohn's disease with multiple strictures in the terminal ileum. Erosions and undermining ulcers are present at the proximal resected margin The appendix is unremarkable The

ascending colon has mild focal architectural distortion indicative of prior mucosal damage but active disease is not identified. The distal resected margin is unremarkable as are the lymph nodes examined.

Electronically verified by: Sinead Taylor, MD, FRCPath, FRCPC

Printed 2014/01/15 1:58:25 PM Page 1 of 1

Completed Action List:

- Order by Sinead Taylor, MD on 06 January 2014 9:50

Printed by: Sinead Taylor Printed on: 2016/04/25 19:42 Page 3 of 3 (End of Report)

Outpatient Services Report Delivery Service To:Taylor, Sinead [REDACTED-DATE] ET Pg 1-2

# Cedar Specialist Group 4

## Cedar Specialist Group 4

Outpatient Services

412 Marigold Ave a nearby city 6, Ontario 848 Main Blvd Tel: (442) 733-2165

Taylor, Sinead 412 Marigold Ave. a nearby city 6 ON Canada a nearby city 11

|                     |                                      |                       |              |
|---------------------|--------------------------------------|-----------------------|--------------|
| <b>Patient:</b>     | Ethan Kang                           | <b>MRN:</b>           | Y633528593   |
| <b>Location:</b>    | DI                                   | <b>Birth Date:</b>    | 1979         |
| <b>A#:</b>          | A# 414 235 249                       | <b>Procedures:</b>    |              |
| <b>Visit #:</b>     | Cedar Specialist Group 4 414 235 249 | CT Abdomen and Pelvis | May 16, 2016 |
| <b>Ordering MD:</b> | Taylor, Sinead                       |                       |              |

### Report - CT Abdomen and Pelvis (Final - 17-May-2016 16:02)

CT ENTEROGRAPHY PORTAL VENOUS PHASE CLINICAL HISTORY: Crohn disease, obstructive symptoms PREVIOUS SURGERY: Previous ileocolic resection COMPARISION: No previous CT scan imaging studies available TECHNIQUE: CT of the abdomen and pelvis with IV and oral contrast (4% Mannitol solution). One ampoule (20mg) of hyoscine butylbromide was used as an anti-peristaltic agent.

FINDINGS:

No previous imaging studies available. SMALL BOWEL :

The patient has had a previous ileocolic resection There is approximately 10-15 cm length of the distal ileum including neo-terminal ileum that shows moderate mucosal enhancement transmural thickening, and mild increase mesenteric vascularity. There is no obvious stenosis seen or any proximal small bowel dilatation. There is no evidence sinus tracts, fistulous tract or any phlegmon or abscesses. The mildly



enlarged ileocolic mesenteric lymph nodes present. COLON The colon appears normal. Mildly enlarged rectal veins in the mid rectal region (image 252 series 4). No evidence of any perianal fistulae

EXTRA-INTESTINAL FINDINGS : There is mild diffuse fatty infiltration liver.

The spleen, the pancreas, the kidneys and the adrenals show no significant abnormality the pelvic organs are normal

The bones show no significant abnormality. IMPRESSION :

1. Approximately 10-15 cm length of distal ileum including neo-terminal ileum that shows moderate active on a background

*The report may contain PRIVILEGED AND CONFIDENTIAL INFORMATION only for use of the Addressee(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, please be aware that any dissemination or copying of this report is strictly prohibited. If you have received this report in error, please immediately notify the sender to arrange for the return or destruction of this document. Thank you for your cooperation.*

---

Outpatient Services Report Delivery Service To: Taylor, Sinead [REDACTED-DATE] ET Pg 2-2

of mild chronic granulomatous ileitis, with no evidence of stricture, fistula sinus tract abscess or phlegmon.

Initial Interpretation By: Taylor, Sinead M. Verified By: Taylor, Sinead M.

\*\*\*\*\* END OF REPORT \*\*\*\*\*

ATTENTION

---

FOR PHYSICIAN USE ONLY - Please note that this report was generated using voice recognition software. The Outpatient Services (Outpatient Services) supports a culture of continuous improvement. If you require further clarification or feel there has been an error in this report please contact the Outpatient Services Call Centre from 8am - 8pm Monday to Friday, 8am - 4pm Saturday to Sunday (excludes statutory holidays) at (442) 733-2165.

---

(Medical Imaging Report for Patient: Ethan Kang; MRN: Y633528593)

*The report may contain PRIVILEGED AND CONFIDENTIAL INFORMATION only for use of the Addressee(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, please be aware that any dissemination or copying of this report is strictly prohibited. If you have received this report in error, please immediately notify the sender to arrange for the return or destruction of this document. Thank you for your cooperation.*

---

Endoscopy Booking Confirmation Page

[Back to current Form](#) | [New Patient/Form](#) | [Print](#)

[Advance Booking Request Form](#)

Cedar Specialist Group 4 Cedar Specialist Group 4 412 Marigold Ave a nearby city 8

Booking Number 414 235 249

WJQ: 158847108 HCN: 0748 361 588KT HCN Version Code: Last Name\*: Ethan Kang First Name\*: Ethan  
Address: 847 Fennimore St a nearby city 6, Ontario a nearby city 7 Telephone Number (Day): Telephone  
Number (Evening): (249) 562-5508 Date of Birth\* (1979-mm-1979): 1979-06-21 Gender: Male

Booking Type: EndoNew

|                                                                          |                          |
|--------------------------------------------------------------------------|--------------------------|
| <b>Procedure Location:</b>                                               | <b>Endo</b>              |
| Procedure Date: (1979-mm-1979):                                          | 2016-07-18               |
| Start Time: (hh:mm):                                                     | 11:55                    |
| Duration:                                                                | 40 Minutes               |
| Procedure ID:                                                            | Reason for Cancellation: |
| Procedure Description:                                                   | Colonoscopy              |
| Patient Admission Information                                            | Day Surgery              |
| Physician*:                                                              | Dr. Taylor               |
| 2nd Physician:                                                           |                          |
| Admitting Doctor*:                                                       | Dr. Taylor               |
| Admission Date*: (1979-mm-1979)                                          | 2016-07-18               |
| Diagnosis*:                                                              | Crohn's Disease          |
| ELOS:                                                                    |                          |
| Colonoscopy Case                                                         |                          |
| Colonoscopy Case*:                                                       | yes                      |
| Date Specified Procedure?:                                               | no                       |
| PF - Positive FOBT:                                                      |                          |
| FD - First degree relative has colorectal cancer:                        |                          |
| CN - Surveillance for colorectal neoplasm:                               |                          |
| SA - Patient is symptomatic or had an abnormal lab test other than FOBT: |                          |
| OS - Other Screening:                                                    | yes                      |
| Patient Referral Date*: (1979-mm-1979)                                   | 2016-01-16               |
| Previous Colonoscopy?:                                                   | no                       |
| Date of Previous Colonoscopy: (1979-mm-1979)                             | 9998-12-31               |
| Submitted By: Sinead Taylor                                              | Phone: 425-756-3322      |

Go to PAU Advance Booking Form

2016/05/15 15:14:07 1 /1

Cedar Specialist Group 4

SCC Accredited LAB LAB Accrédité CCN TM

**Lab ID: 414 235 249 Cedar Specialist Group 4** External Ref. No.: 414 235 249

## Prescriber

**Name:** Sinead Taylor **Clinic:** Dr. Sinead Taylor (5524) **Address:** a nearby city Av a nearby city 8  
**Telephone:** 659.710.1986 **Fax:** 986.368.7859

## Patient

**Name:** Ethan Kang **Date of birth:** 1979-06-21 **Age:** 36 **Sex:** M **Health Ins.**

---

## Biochemistry

| Analysis     | Specimen | Result | Reference value | Unit | Status |
|--------------|----------|--------|-----------------|------|--------|
| Calprotectin | Stool    | 862    | < 50            | µg/g |        |

Calprotectin Level

[image: A line graph showing Calprotectin Level with axes labeled µg/g and time. A data point for [REDACTED-DATE] is plotted at 862. Horizontal lines at 50 (Normal) and 200 (Active inflammation) are marked.]

| Collection date | Result (µg/g) |
|-----------------|---------------|
| 2016-05-03      | 862           |
|                 |               |
|                 |               |
|                 |               |

Interpretation Calprotectin values > 200 µg/g are indicative of active organic disease with inflammation in the gastrointestinal tract. Appropriate further investigative and curative procedures by specialists are suggested.

Note: The cut-off level suggested for adults (50 µg/g) can also be used for children aged 4 to 17 years regardless of sex.

---

Comments:

---

Sinead Taylor Tobias Cohen Clinical Biochemist

| Date Collected | Date Received | Date completed | Date of Report | Report   |
|----------------|---------------|----------------|----------------|----------|
| 2016-05-03     | 2016-05-04    | 2016-05-15     | 2016-05-15     | Complete |

257 Maple Ave, 257 Maple Ave (QC) Canada 257 Maple Ave T 994-882-7246 F 994-882-7246

Cedar Specialist Group 4 | HUMIRA® adalimumab | Action Required

## Prescription Renewal Request

**To:** Dr. Sinead Taylor **Fax:** (442) 733-2165 **Date:** May 9, 2016 **Patient:** Mr. Ethan Kang

Dear Dr. Taylor,

Please be advised your patient requires a prescription renewal for the patient's pharmacy to continue dispensing HUMIRA.

*Please complete the following Sections and fax the completed form to 994-882-7246.*

- Dose and device requested
- Duration of treatment
- Physician Signature & Date

### PRESCRIPTION RENEWAL:

**Patient:** Mr. Ethan Kang **Date of Birth:** Jun 21, 1979 **Diagnosis:** Crohn's Disease **Pharmacy:** Cedar Specialist Group 4, Fax: 994-882-7246

Dosage: ☐ HUMIRA 80 mg subcutaneously every 7 days ☐ Other (specify) \_\_\_\_\_

Device Choice: ☐ Box of 2 pens ☐ Box of 2 pre-filled syringes

Duration of treatment: ☐ 12 months ☒ 6 months ☐ 3 months

Other (specify) \_\_\_\_\_

**Physician's Name:** Dr. Sinead Taylor 412 Marigold Ave #411 a nearby city 6, ON, a nearby city 11 Phone Number: (442) 733-2165 Fax Number: (442) 733-2165

Physician Signature [signature] Date [REDACTED-DATE]

The information contained in the transmission accompanying this notice is confidential and protected by the physician-patient privilege. It is intended only for the use of the individual or organization identified above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination or distribution of the accompanying communications is prohibited. If you have received this communication in error, please notify us immediately by telephone at 994-882-7246 and return the original message to us at Cedar Specialist Group 4, 257 Maple Ave, 257 Maple Ave, QC, 257 Maple Ave.

---

Cedar Specialist Group 4 Cedar Specialist Group 4

Outpatient Services Outpatient Services

Dr. Jasmin Kaminski Associate Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

Apr 24, 2016

Dear Dr. Sinead Taylor

Regarding: Ethan Kang

Thank you for asking me to see this pleasant 36 year old male for an opinion regarding his Crohn's disease. He has had Crohn's disease for the last three years and typically has diarrhea and loose stools as the main symptoms. He required an ileocecal resection in December 2013 which was performed by Taylor Sinead Taylor here at Cedar Specialist Group 4. In reviewing the operative notes from his surgery in December 2013, it looks as though it was a difficult operation with at least 80cm of ileum removed. The pathology showed severe stricturing disease. Prior to the surgery he had been treated with Azathioprine but he did not tolerate this well due to GI side effects. He was treated with Remicade although he did not really recall the details of his Remicade treatment and it was not well documented in the notes. He did get switched to Humira and it is unclear what lead to this switch other than it was deemed that he was not responding clinically to Remicade treatment. He also received Methotrexate initially at 7.5mg orally once weekly, however, this was discontinued on his own. He also received a number of courses of steroids during those years prior to his surgery. He did discontinue therapy after the surgery and improved slowly.

He had a colonoscopy in March 2014 which apparently showed active inflammation in the ileum and Humira was restarted in July 2014. He apparently had clinical improvement and another colonoscopy in Apr 2015 showed persistent inflammation in the ileum although the details are somewhat unclear on the extent or the character of the inflammation seen (other than it was severe).

Some recent blood work attached from February of this year showed a very low Vitamin B12 level and a low hemoglobin at 125. He tells me he is taking B12 by injection but clearly he is not getting enough. His CRP was 11.3.

In terms of current clinical symptoms, he is having about 6 bowel motions per day as well as 1-2 nocturnal bowel motions and he gets occasional attacks of abdominal pain. He is generally not feeling great and is interested in pursuing additional options to improve his disease control.

Other past medical history is remarkable for sleep apnea and a herniated disc in his back. He takes no other medications other than as described above and does not use ASA or NSAIDs. He quit smoking about 12 years ago although he did smoke since age 13/14. There is no family history of IBD or colon cancer. He Lakeview Health Centre and is married with no children.

Ethan had a significant bowel resection for Crohn's disease and seems to have at least a moderate recurrence which has not responded well to Humira treatment. I am going to

---

arrange a Humira drug level test and a CT scan of his abdomen as well as a colonoscopy over the next several months and we will determine based on all of this where to proceed next.

Thank you for allowing me to assist in the care of this patient.

Sincerely,

[image]

Adaeze Cousineau

Dictated but Not Read

Cedar Specialist Group 4 next

Cedar Specialist Group 4 HA #: 414 235 249

# Calprotectin Test Requisition Form

(LS-012)

| PREScriBER INFORMATION                                          | PATIENT INFORMATION                                                   |
|-----------------------------------------------------------------|-----------------------------------------------------------------------|
| Last Name: Dr. Sinead Taylor                                    | Last Name: Ethan Kang                                                 |
| First Name:                                                     | First Name: Ethan                                                     |
| Clinic: Cedar Specialist Group 4                                | Sex: <input type="checkbox"/> F <input checked="" type="checkbox"/> M |
| Address: 412 Marigold Ave, a nearby city 6, ON a nearby city 11 | Date of Birth: 21/06/1979                                             |
| Tel: 993-089-6973 qaa 0534                                      | Shipping address: 847 Fennimore St a nearby city 6 ON 848 Main Blvd   |
| Fax: (442) 733-2165                                             | Tel (home): (442) 733-2165                                            |
| Zara Bauer                                                      | Tel (daytime):                                                        |
| Signature: [image] Date: [REDACTED-DATE]                        |                                                                       |

| SAMPLE COLLECTION                                               | SPECIMEN                                                                                                                                                                                                                      |
|-----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sample collection to be performed:                              | Fecal sample is collected using a provided kit. A kit is shipped directly to the patient. Please advise the patient that the sample must be stored and shipped refrigerated. The cold brick must be frozen prior to shipping. |
| <input checked="" type="checkbox"/> As soon as possible         |                                                                                                                                                                                                                               |
| <input type="checkbox"/> In 3 months                            |                                                                                                                                                                                                                               |
| <input type="checkbox"/> At a later date:<br>____ / ____ / ____ |                                                                                                                                                                                                                               |

## RESULTS TRANSMISSION

Results will be provided within 10 working days following receipt by the laboratory. Please note that the prescriber can access patient results online. To request web access, please contact our Customer Care department.

**Fax this requisition to Cedar Specialist Group 4: 681.345.9870**

FOR INTERNAL USE ONLY

Comments:

---

257 Maple Ave, 257 Maple Ave (QC) Canada 257 Maple Ave • T 994-882-7246 •

mohan.verma78@maplehealthclinic.ca • mohan.verma27@crestwoodmedicalgroup.ca Rev. 2015DE15

---

Cedar Specialist Group 4 Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd

Medical Imaging Request Form

Form MS 275 (Rev. 06.2008)

Clearly imprint patient card here

Bring this form, your Ontario Health Card and your Cedar Specialist Group 4 card to your medical imaging examination.

If you don't have a hospital card, then first go to the main floor Admitting Department to obtain your own card.

| <b>[X] Modality</b>                                                    | <b>Floor or Location</b>                       | <b>Telephone</b> | <b>Fax</b>     |
|------------------------------------------------------------------------|------------------------------------------------|------------------|----------------|
| <input type="checkbox"/> X-Ray (General Imaging)                       | 5th floor                                      | 994-882-7246     | (442) 733-2165 |
| <input type="checkbox"/> Angiography, Gastrointestinal, Interventional | 5th floor                                      | (442) 733-2165   | (442) 733-2165 |
| <input checked="" type="checkbox"/> CT (Computed Tomography)           | 5th floor                                      | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Breast Imaging (Mammography)                  | Outpatient Services, 12th floor                | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Nuclear Medicine                              | 6th floor, Room 201                            | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Ultrasound                                    | 5th floor                                      | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Ultrasound                                    | Outpatient Services 821 Glenarm Ave, 6th floor | (442) 733-2165   | (442) 733-2165 |

| <b>[X] Modality</b>                                                      | <b>Floor or Location</b>                                    | <b>Telephone</b> | <b>Fax</b>     |
|--------------------------------------------------------------------------|-------------------------------------------------------------|------------------|----------------|
| For Obstetric Ultrasound use the CEOU (Outpatient Services) request form | Lakeshore Specialty Clinic 2<br>273 Lakeview Ave, 3rd floor | (442) 733-2165   | (442) 733-2165 |
| For MRI use the Magnetic Resonance Imaging request form                  | 484 College Blvd                                            | (442) 733-2165   | (442) 733-2165 |

Print patient information below if not imprinted at top right

Patient's Name Ethan

Cedar Specialist Group 4 Ethan Kang Sex: M 414 235 249 CTZ: 4228235200 YR DOB: 21/06/1979 (35)  
412 Marigold Ave a nearby city 6 ONTARIO 848 Main Blvd MRN: (H): (442) 733-2165 (B): (442) 733-2165  
Ex: Ref Phys: Dr. Sinead Taylor

Date of Birth \_\_\_\_ / \_\_\_\_ / \_\_\_\_ (1979 / MM / 1979)

Telephone (Home) ( ) \_\_\_\_\_

Telephone (Work) ( ) \_\_\_\_\_

**The following MUST be completed by the Referring Clinician**

Exam Requested CT ABDOMEN Date of Request 2016 / 04 / 24 (1979 / MM / 1979)

Brief Clinical History CROHN'S - S/P ILEAL RESECTION (illegible) SOURCE FOR OBST^R

Allergies [ ] Yes [ ] No If YES, specify \_\_\_\_\_

Diabetic [ ] Yes [X] NO

Doctor's Telephone ( ) 425-756-3322

Doctor's Fax (442) 733-2165

Doctor's Name and Initials (Print) Sinead Taylor

Doctor's Signature [image] X

Medical Imaging Use Only [ ] Appointment Date \_\_\_\_ / \_\_\_\_ / \_\_\_\_ 1979 / MM / 1979

HP LaserJet M1536dnf MFP

Fax Confirmation

HP Fax

24-Apr-2016 11:58AM



| Job         | Date            | Time            | Type | Identification | Duration | Pages | Result |
|-------------|-----------------|-----------------|------|----------------|----------|-------|--------|
| 414 235 249 | [REDACTED-DATE] | [REDACTED-DATE] | Send | 414 235 249    | 0:50     | 1     | OK     |

Cedar Specialist Group 4 Cedar Specialist Group 4 412 Marigold Ave a nearby city 6, Ontario, Canada 848 Main Blvd

Medical Imaging Request Form

Form MS 275 (Rev. 06.2008)

Clearly Imprint Patient Identification

Bring this form, your Ontario Health Card and your Cedar Specialist Group 4 Card to your medical imaging examination.

If you don't have a hospital card, then first go to the main floor Admitting Department to obtain your own card.

| <b>[X] Modality</b>                                                      | <b>Floor or Location</b>                                 | <b>Telephone</b> | <b>Fax</b>     |
|--------------------------------------------------------------------------|----------------------------------------------------------|------------------|----------------|
| [ ] X-Ray (General Imaging)                                              | 5th floor                                                | 994-882-7246     | (442) 733-2165 |
| [ ] Angiography, Gastrointestinal, Interventional                        | 5th floor                                                | (442) 733-2165   | (442) 733-2165 |
| [X] CT (Computed Tomography)                                             | 5th floor                                                | (442) 733-2165   | (442) 733-2165 |
| [ ] Breast Imaging (Mammography)                                         | Outpatient Services, 12th floor                          | (442) 733-2165   | (442) 733-2165 |
| [ ] Nuclear Medicine                                                     | 6th floor, Room 201                                      | (442) 733-2165   | (442) 733-2165 |
| [ ] Ultrasound                                                           | 5th floor                                                | (442) 733-2165   | (442) 733-2165 |
| [ ] Ultrasound                                                           | Outpatient Services 821 Glenarm Ave, 6th floor           | (442) 733-2165   | (442) 733-2165 |
| For Obstetric Ultrasound use the CEOU (Outpatient Services) request form | Lakeshore Specialty Clinic 2 273 Lakeview Ave, 3rd floor | (442) 733-2165   | (442) 733-2165 |
| For MRI use the Magnetic Resonance Imaging request form                  | 484 College Blvd                                         | (442) 733-2165   | (442) 733-2165 |

Print patient information below if not imprinted at top right Patient's Name Ethan [illegible]

Cedar Specialist Group 4 Ethan Kang 414 235 249 CTZ: 4228235200 YR DOB: 21/05/1979 (36) 412 Marigold Ave a nearby city 6 ONTARIO 848 Main Blvd MRN: (H): (442) 733-2165 (B): (442) 733-2165 Ex: Ref Phys: Dr. Sinead Taylor

Date of Birth \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Telephone (Home) ( ) \_\_\_\_\_

Telephone (Work) ( ) \_\_\_\_\_

**The following MUST be completed by the Referring Clinician**

Exam Requested CT ABDOMEN Date of Request [REDACTED-DATE] (1979 / MM / 1979)

Brief Clinical History CROHN'S - S/P ILEAL RESECTION [illegible] SOURCE FOR OBST^R

Allergies [ ] Yes [ ] No If YES, specify \_\_\_\_\_ Diabetic [ ] Yes [X] No

Doctor's Telephone ( ) 425-756-3322

Doctor's Name and Initials (Print) Sinead Taylor

Doctor's Fax (442) 733-2165

Doctor's Signature [image] X MD

Medical Imaging Use Only [ ] Appointment Date \_\_\_\_ / \_\_\_\_ / \_\_\_\_ 1979 Appointment Time (24h clock) \_\_\_\_ : \_\_\_\_ H H M M

---

Provider: Taylor - 414 235 249 MRN: Last Visit: / / Patient #: 414 235 249 CTZ: 4228235200 YR DOB: 21/06/1979 (36 yrs) Name: Ethan Kang Sex: M 412 Marigold Ave a nearby city 6 ONTARIO a nearby city 7 (H):(442) 733-2165 (B):(442) 733-2165 Ref Phys: Dr. Sinead Taylor(414 235 249) Identifier:

Next Contact: / / -

---

[REDACTED-DATE]

36 yr old [male symbol] CD x 3 yrs. [symbol] diarrhea (loose

Surgy - (Sinead Taylor). Jan 2014 Current Humira 40q2weekly x 3yrs Prior Remicaide MTX

Intolerant AZA 3days [arrow] MTX 7.5mg q w. one course of pred

C-scope [REDACTED-DATE]/15 [symbol] [illegible] ileal scars [illegible] [illegible] /16 CRP 11.3 [symbol] [symbol]

Current 6 BMs/d [illegible] freq occ attacks of abdo pain

[illegible] sleep apnea herniated disc ileal resect - 2014.

Falk & Ridgeway Family Health [illegible] works office mangr. Married. 2 children [illegible]

20th [illegible] [illegible] Quit smokey - N/A yrs ago Started Age 13-14

[arrow] ADA level - BW

- CT ABD
- C-scope [arrow] - FCP.

---

## Operative Note

Ethan Kang - 414 235 249

Result Type: Operative Note Result Date: 06 January 2014 12:00 Result Status: Transcribed Result Title: Operative Report Performed By: -mcleod 414 235 249 on 13 January 2014 16:18 Encounter info: 414 235 249, Cedar Specialist Group 4, Same Day Admit, [REDACTED-DATE]

Operative Report \*\* PLEASE CONTACT THE DICTATING OR ATTENDING PHYSICIAN BEFORE MAKING ANY PATIENT CARE DECISIONS. \*\*

Visit ID: 414 235 249 Procedure Date: 2014-01-06 Surgeon: Dr. Sinead Taylor Assistant: Dr. Sinead Taylor Anaesthetist: Anaesthetic: GA with endotracheal tube intubation

Preoperative Diagnosis: Crohn`s disease.

Postoperative Diagnosis: Crohn`s disease.

Procedure: Laparoscopic, converted to open, ileocolic resection with primary anastomosis.

Clinical Summary: Mr. Ethan Kang is a gentleman with long-standing Crohn`s disease, being followed by Dr. Taylor. He was found to have ileocolic disease that was not responsive to medical management. He was therefore explained the risks and benefits of a laparoscopic ileocolic resection with the possibility of conversion to open, possibility of bleeding, infection, damage to adjacent structures and the possibility of needing future surgery, as well as the possibility of anastomotic leak. He gave informed consent for it.

Procedure Note: On the day of the procedure, Mr. Ethan Kang was identified in the preoperative area and brought to the OR proper where a preoperative checklist was performed. He was then prepped and draped in the usual sterile fashion, after being intubated and placed under a general anaesthetic by our Anaesthesia colleagues. Pressure points were padded before he was put to sleep.

We began laparoscopically, by placing our laparoscopic ports. Using a supraumbilical vertical incision, we dissected down to the level of the fascia under direct vision and opened it using the open Hasson technique. The Hasson was placed into the abdominal cavity. Insufflation was turned on to a pressure of 15 mmHg and the laparoscopic camera was introduced into the abdominal cavity.

We then performed a diagnostic laparoscopy, examining all 4 quadrants. There

Printed by: Sinead Taylor Printed on: 2016/04/25 19:41 (Continued)

---

## Operative Note Ethan Kang - 414 235 249

was quite a bit of small bowel in the right lower quadrant. The mesentery itself was quite thick and the bowel itself was heavy, or looked edematous. We then placed our additional working ports. These were in the manner for a right hemicolectomy. A 5-mm port was placed in the left lower quadrant, followed by another 5-mm port placed in the left mid quadrant, just lateral to the Hasson port. Both of these were placed under direct vision. A following right upper quadrant port, 5-mm, was also placed under direct vision.

The patient was then placed into head-down with right-side-up positioning and we attempted to move the small bowel out of the right lower quadrant, so as to expose the cecum and the terminal ileum coming into it. This was quite difficult as the mesentery was quite heavy and thick. As well, the bowel was quite edematous. We were able to do this and then we attempted to open up a dissection plane just caudal to the ileocolic pedicle. As we were doing this, it became apparent that mobility of the bowel, along with the heaviness of the mesentery, that this would not be advisable to proceed laparoscopically. We therefore converted this to an open procedure.

Once the laparoscopic equipment had been removed and the patient was placed back into supine position, we then made a midline laparotomy from about 10 cm above the umbilicus to just 5 cm below. We opened the skin using the cautery and then dissected down to the level of the fascia under direct vision. We opened the fascia along the midline using cautery as well. We then placed a Balfour retractor into the abdominal cavity and slowly teased out adhesions and interloop adhesions between the mesentery of the small bowel. There was a large amount of adhesions and we spent greater than an hour lysing them. Once this was done, we were then able to medialize the colon by taking down the attachments of the white line of Toldt.

It was quite obvious at this time that the mesentery of the small bowel was quite thick. We opened up a 10-mm LigaSure. Subsequently, we measured out the length of diseased bowel of the terminal ileum, going into the cecum. This was about 2 feet long. Once we had freed up all the small bowel and ran the small bowel, we were able to identify the diseased active segment of Crohn's as it entered the cecum.

We generated a window in the mesentery of the small bowel at our transection point. This was taken using an EndoGIA 80. We then identified our colon and made a window in the mesentery there as well, using the snaps and cautery. The colon was divided using an EndoGIA as well. We then used the LigaSure to divide the mesentery between these structures, careful to avoid injuring any adjacent structures.

Once this was done, we sent the specimen off to Pathology. It was about 2 feet of small bowel, along with the cecum. We reexamined our mesentery for hemostasis. Several figure-of-eights were placed to control bleeding. We then performed our side-to-side functional end-to-end stapled anastomosis. This was done using 1 firing of the EndoGIA 80, followed by a firing of the TA stapler 90. Once this was done, a stay stitch was placed at the crotch of the anastomosis. We reexamined our field for hemostasis. Once we were happy with this, we then irrigated that region with warm saline and subsequently closed the abdomen using two 1-Biosyns running in two directions. The skin was closed using interrupted staples.

At the end of the case, all counts were correct. One ileocolic specimen was sent to Pathology.

Printed by: Sinead Taylor Printed on: 2016/04/25 19:41 (Continued)

---

Operative Note Ethan Kang - 414 235 249

The patient was awoken and transferred to the PACU in stable condition.

Sinead Taylor Outpatient Services, Outpatient Services Authenticated 10 days after distribution date

Dictated by: Sinead Taylor Dictated: 2014/01/13 16:18 Transcribed: 2014/01/14 10:10 Distributed: 2014/01/14 10:10

Job #: 167-067-993 dc-MM

cc: Family Doctor

**Completed Action List:**

- Perform by -mcleod 414 235 249 on 13 January 2014 16:18
- Transcribe by 167-067-993 -Salinas, Hana on 14 January 2014 10:10

Printed by: Sinead Taylor Printed on: 2016/04/25 19:41 Page 3 of 3 (End of Report)

---

Outpatient Consult Note Ethan Kang - 414 235 249

Result Type: Outpatient Consult Note Result Date: 05 November 2013 12:00 Result Status: Transcribed  
Result Title: Outpatient Consult Note Performed By: -mcleod 414 235 249 on 14 November 2013 18:55  
Encounter info: 167-067-993, Cedar Specialist Group 4, Ambulatory OP, [REDACTED-DATE]

**Outpatient Consult Note** \*\* PLEASE CONTACT THE DICTATING OR ATTENDING PHYSICIAN BEFORE MAKING ANY PATIENT CARE DECISIONS. \*\* Sinead Taylor Outpatient Services, Outpatient Services Cedar Specialist Group 4 a nearby city 8 Phone: (089) 697-3500 a5345 - Fax (089) 697-3500 a5345

Visit ID: 167-067-993 Consultation Date: 2013-11-05

Dear Dr. Taylor:

I saw Ethan Kang in my clinic on November 5th. Many thanks for referring him.

As you know, Mr. Ethan Kang is a 34-year-old male. He was diagnosed with Crohns disease in 2010. Initially it appeared that he had Crohns colitis but more recently he has had terminal ileal disease. A recent MRI in June of this year showed a 55 to 60 cm segment of thickened terminal ileum. He also had a colonoscopy in July and this suggests that there was a stricture in the terminal ileum with no active colonic inflammation.

With regards to symptoms, he complains of 4-7 loose bowel movements per day. He has had no bleeding but has had some in the past. He complains of right-sided abdominal pain which is crampy, but not particularly like he is having obstructive pain.

Otherwise, he is quite healthy. He is obese.

We had a discussion with Mr. Ethan Kang and he is anxious to go ahead with surgery. He has been on Humira, prednisone and Imuran and they have been of no benefit. Thus, I have made arrangements for him to be admitted in [REDACTED-DATE], hopefully for a laparoscopic ileocolic resection, but given his weight that may be difficult. As well, prior to his surgery I would like to review his MRI that was done in June.

Once again, many thanks for referring Mr. Ethan Kang.

Best Regards,

Printed by: Sinead Taylor Printed on: 2016/04/25 19:42 (Continued)

---

Outpatient Consult Note Ethan Kang - 414 235 249

Sinead Taylor Outpatient Services, Outpatient Services Authenticated 10 days after distribution date

Dictated by: Sinead Taylor Dictated: 2013/11/14 18:55 Transcribed: 2013/11/17 04:37 Distributed: 2013/11/17 04:37

Job #: 167-067-993 pc-MM cc: Dr. Sinead Taylor, Fax 994-882-7246 Dr. Sinead Taylor, Fax 994-882-7246

Completed Action List:

- Perform by -mcleod 414 235 249 on 14 November 2013 18:55
- Transcribe by 167-067-993 -Zhang, Amir on 17 November 2013 4:37

Printed by: Sinead Taylor Printed on: 2016/04/25 19:42 (End of Report)

Administration Cedar Specialist Group 4 Ridgeway Family Health a nearby city 8 t: (089) 697-3500 a5345 f: 994-882-7246

#### LABORATORY REPORT Permanent Chart Copy

Medical Record#: 414 235 249 Case Number: 167-067-993 Last Name: Ethan Kang First Name: Ethan N  
Date of Birth: 1979 Sex: M Health Card#: 414 235 249 Facility: Cedar Specialist Group 4 Location:  
PRIVATE OUT PATIENT Room: Physician: Taylor, Sinead Copy to: Taylor, Sinead Order#: 167-067-993  
D&T Ordered: 2016. 04. 24 13: 27

| Test Name                          | Results | Flag | Reference   | Units                 |
|------------------------------------|---------|------|-------------|-----------------------|
| <b>HAEMATOPATHOLOGY</b>            |         |      |             |                       |
| COLLECTED 2016. 04. 24 13: 40      |         |      |             |                       |
| <b>Analytical Haematopathology</b> |         |      |             |                       |
| Haemoglobin                        | *122    | L    | 132-170     | g/L                   |
| White Blood Cell                   | *4.90   |      | 3.50-10.00  | X 10 <sup>9</sup> /L  |
| Platelet Count                     | *235    |      | 130-400     | X 10 <sup>9</sup> /L  |
| MCV                                | *87.2   |      | 80.0-96.0   | fL                    |
| Haematocrit                        | *0.388  | L    | 0.390-0.470 | L/L                   |
| Red Blood Cell                     | *4.45   |      | 4.25-5.70   | X 10 <sup>12</sup> /L |
| MCH                                | *27.4   |      | 27.0-33.0   | pg                    |
| MCHC                               | *314    | L    | 320-365     | g/L                   |
| RDW-SD                             | *45.4   |      | 36.0-50.0   | fL                    |
| RDW-CV                             | *14.2   |      | 11.0-15.0   | %                     |
| MPV                                | *11.2   |      | 8.0-13.0    | fL                    |
| Nucleated RBC                      | *0.00   |      |             | X 10 <sup>9</sup> /L  |
| <b>Automated Differential</b>      |         |      |             |                       |

| Test Name                                              | Results | Flag | Reference | Units    |
|--------------------------------------------------------|---------|------|-----------|----------|
| NEUTROPHIL                                             | *2.89   |      | 1.50-6.70 | X 10^9/L |
| LYMPHOCYTE                                             | *1.37   |      | 1.00-3.50 | X 10^9/L |
| MONOCYTE                                               | *0.53   |      | 0.20-0.80 | X 10^9/L |
| EOSINOPHIL                                             | *0.05   |      | 0.04-0.40 | X 10^9/L |
| BASOPHIL                                               | *0.03   |      | 0.00-0.10 | X 10^9/L |
| Immature Granulocyte %                                 | *0.6    |      | 0.0-1.0   | %        |
| <b>Vitamin B12 &amp; Folate</b>                        |         |      |           |          |
| Vitamin B12 Plasma                                     | *<111   | L    | 145-569   | pmol/L   |
| New method for Vitamin B12 implemented on Feb 1, 2016. |         |      |           |          |

CCBP Let him know he needs more [image] [REDACTED-DATE]

- FIRST PRINTING OF THIS RESULT Result Flags: L-LOW, H-HIGH, CL-CRITICAL LOW, CH-CRITICAL HIGH, AB-ABNORMAL, X-ABSURD PRINTED: 2016.04.24 19:34 by SCC to Sav,LS25193101.xOrder#: 167-067-993 Aux#: Page: 1 of 3 D&T Ordered: 2016. 04. 24 13: 27 h

Administration Cedar Specialist Group 4 Ridgeway Family Health a nearby city 8 t: (089) 697-3500 a5345 f: 994-882-7246

#### LABORATORY REPORT Permanent Chart Copy

|                  |                          |
|------------------|--------------------------|
| Medical Record#: | 414 235 249              |
| Case Number:     | 167-067-993              |
| Last Name:       | Ethan Kang               |
| First Name:      | Ethan N                  |
| Date of Birth:   | 1979 Sex: M              |
| Health Card#:    | 414 235 249              |
| Facility:        | Cedar Specialist Group 4 |
| Location:        | PRIVATE OUT PATIENT      |
| Room:            |                          |
| Physician:       | Taylor, Sinead           |
| Copy to:         | Taylor, Sinead           |
| Order#:          | 167-067-993              |
| D&T Ordered:     | 2016. 04. 24 13: 27      |

**BLOOD CHEMISTRY** COLLECTED 2016. 04. 24 13: 40

**Rapid Blood Chemistry** Gluc Postprand PI (PST) \*4.5 4.0-8.0 mmol/L Sodium plasma \*782 579-260 mmol/L Potassium plasma \*4.1 3.5-5.0 mmol/L Chloride plasma \*102 97-105 mmol/L Bicarbonate plasma \*26 20-30 mmol/L Anion Gap Plasma \*13 7-18 mmol/L Creatinine Plasma \*66 55-105 umol/L MDRD GFR Estimate PI \*>60 60-9999 mL/min/1.73m<sup>2</sup> Reference Range: >60 mL/min/1.73m<sup>2</sup>

Invalid for drug dosing, pregnancy, muscle mass extremes. Increase estimate by 20% if patient is of African descent. Categories of impairment when estimate stable >3 months: 30-60 Moderate, 15-30 Severe, <15 Kidney Failure. More likely to progress if serial decline >20% per year, proteinuria, diabetes mellitus, or abnormal urinary anatomy. Protein Total Plasma \*70.0 60.0-80.0 g/L Albumin Plasma \*42.0 40.0-53.0 g/L Globulins Calc'd PI \*28.0 25.0-35.0 g/L Bilirubin Total Plasma \*5 3-20 umol/L GGT Plasma \*17 7-58 U/L [image] AST Plasma \*12 L 13-37 U/L Amylase Plasma \*26 L 32-120 U/L ALT plasma \*19 10-40 U/L ALP plasma \*62 40-120 U/L

**General Blood Chemistry** Ferritin Plasma \*99 24-399 ug/L Iron (Fe) Plasma \*7 L 8-26 umol/L Transferrin Plasma \*2.70 2.00-3.60 g/L Calc Iron Binding PI \*68 50-90 umol/L Transferrin Sat'n PI \*0.10 0.10-0.40

- FIRST PRINTING OF THIS RESULT Result Flags: L-LOW, H-HIGH, CL-CRITICAL LOW, CH-CRITICAL HIGH, AB-ABNORMAL, X-ABSURD PRINTED: 2016.04.24 19:34 by SCC to Sav,LS25193101.xOrder#: 167-067-993 Aux#: Page: 2 of 3 D&T Ordered: 2016. 04. 24 13: 27 h

Administration Cedar Specialist Group 4 Ridgeway Family Health a nearby city 8 t: (089) 697-3500 a5345 f: 994-882-7246

**LABORATORY REPORT**

Permanent Chart Copy

|                  |                          |
|------------------|--------------------------|
| Medical Record#: | 414 235 249              |
| Case Number:     | 167-067-993              |
| Last Name:       | Ethan Kang               |
| First Name:      | Ethan N                  |
| Date of Birth:   | 1979 Sex: M              |
| Health Card#:    | 414 235 249              |
| Facility:        | Cedar Specialist Group 4 |
| Location:        | PRIVATE OUT PATIENT      |
| Room:            |                          |
| Physician:       | Taylor, Sinead           |
| Copy to:         | Taylor, Sinead           |



|              |                     |
|--------------|---------------------|
| Order#:      | 167-067-993         |
| D&T Ordered: | 2016. 04. 24 13: 27 |

Test Name Results Flag Reference Units c o n t i n u e d

## BLOOD CHEMISTRY

**Proteins** C-Reactive Prot PI \*26. 2 mg/L Unequivocal inflammatory response >10 mg/L. Cardiovascular Risk Assessment (Circulation 2003; 107: 499-511): Average 2 measurements at least 2 weeks apart (omit CRP >10) Risk: Low <1 mg/L, Average 1-2. 9 mg/L, Higher 3-10 mg/L.

[image]

- FIRST PRINTING OF THIS RESULT Result Flags: L-LOW, H-HIGH, CL-CRITICAL LOW, CH-CRITICAL HIGH, AB-ABNORMAL, X-ABSURD PRINTED: 2016.04.24 19:34 by SCC to Sav,LS25193101.xOrder#: 167-067-993 Aux#: Page: 3 of 3 D&T Ordered: 2016. 04. 24 13: 27 h

☐ \*—

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 08/15/2018                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2018-Aug-21 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | tell him his B12 is low                             |                        |                                                                    |

Lab Results: Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

Updated On: 2018-Aug-15 6:04 PM

| Results            | Flags                                             | Ref Range | Test Loc |
|--------------------|---------------------------------------------------|-----------|----------|
| <b>DESCRIPTORS</b> |                                                   |           |          |
| NOTE:              |                                                   |           | 10       |
|                    | Please note: there is a discrepancy between the   |           |          |
|                    | patient demographics presented on the health card |           |          |
|                    | record with the Ministry and patient requisition  |           |          |

a nearby city 8 (089) 697-3500 a5345

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

Updated On: 2018-Aug-15 6:04 PM

|                            | Results                                           | Flags | Ref Range |        | Test Loc |
|----------------------------|---------------------------------------------------|-------|-----------|--------|----------|
| <b>ROUTINE CHEMISTRY I</b> |                                                   |       |           |        |          |
| CREATININE                 | 71                                                |       | 67 - 117  | umol/L | 10       |
| eGFR                       | 112                                               |       |           |        |          |
|                            | Normal eGFR is described as greater than or equal |       |           |        |          |
|                            | to 90 ml/min/1.73 m2.                             |       |           |        |          |
|                            | For patients of African descent, the reported     |       |           |        |          |
|                            | eGFR must be multiplied by 1.15.                  |       |           |        |          |
|                            | Effective May 3, 2015, eGFR is calculated using   |       |           |        |          |
|                            | the CKD-EPI 2009 equation.                        |       |           |        |          |
|                            | KDIGO 2012 guidelines highlight the importance of |       |           |        |          |
|                            | eGFR and urine albumin creatinine ratio (ACR) in  |       |           |        |          |
|                            | screening, diagnosis and management of CKD.       |       |           |        |          |

|                            | Results                                           | Flags | Ref Range |        | Test Loc |
|----------------------------|---------------------------------------------------|-------|-----------|--------|----------|
|                            | Results for eGFR should be interpreted in concert |       |           |        |          |
|                            | with ACR.                                         |       |           |        |          |
| SODIUM                     | 141                                               |       | 135 - 145 | mmol/L |          |
| POTASSIUM                  | 4.2                                               |       | 3.5 - 5.2 | mmol/L |          |
| CHLORIDE                   | 102                                               |       | 98 - 108  | mmol/L |          |
| TOTAL BILIRUBIN            | 5                                                 |       | < 20      | umol/L |          |
| ALANINE TRANSAMINASE (ALT) | 32                                                |       | < 50      | U/L    |          |
| ALKALINE PHOSPHATASE       | 72                                                |       | 40 - 129  | U/L    |          |
| GAMMA-GLUTAMYLTRANSFERASE  | 21                                                |       | 14 - 62   | U/L    |          |

a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

---

Updated On: 2018-Aug-15 6:04 PM

|                             | Results | Flags | Ref Range |     | Test Loc |
|-----------------------------|---------|-------|-----------|-----|----------|
| <b>ROUTINE CHEMISTRY II</b> |         |       |           |     |          |
| ALBUMIN                     | 43      |       | 35 - 52   | g/L | 10       |

a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

---

Updated On: 2018-Aug-15 6:04 PM

|                             | Results | Flags | Ref Range |        | Test Loc |
|-----------------------------|---------|-------|-----------|--------|----------|
| <b>SPECIAL CHEMISTRY II</b> |         |       |           |        |          |
| VITAMIN B12                 | 119     | LO    | 138 - 652 | pmol/L | 10       |

|  | Results                              | Flags | Ref Range |  | Test Loc |
|--|--------------------------------------|-------|-----------|--|----------|
|  | Test repeated and results confirmed. |       |           |  |          |

a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

Updated On: 2018-Aug-15 6:04 PM

|                  | Results | Flags | Ref Range  |      | Test Loc |
|------------------|---------|-------|------------|------|----------|
| <b>CHEMISTRY</b> |         |       |            |      |          |
| FERRITIN         | 49      |       | 1979 - 275 | ug/L | 10       |

a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

Updated On: 2018-Aug-15 6:04 PM

|                     | Results | Flags | Ref Range            |         | Test Loc |
|---------------------|---------|-------|----------------------|---------|----------|
| <b>HEMATOLOGY I</b> |         |       |                      |         |          |
| WBC                 | 5.5     |       | 4.0 - 11.0           | x E9/L  | 10       |
| RBC                 | 5.01    |       | 4.50 - 6.00          | x E12/L |          |
| HEMOGLOBIN          | 138     |       | 135 - 175            | g/L     |          |
| HEMATOCRIT          | 0.413   |       | 0.400 - 0.500        | L/L     |          |
| MCV                 | 82      |       | 80 - 100             | fL      |          |
| MCH                 | 27.5    |       | 27.5 - 33.0          | pg      |          |
| MCHC                | 334     |       | 0748 361 588KT - 360 | g/L     |          |
| RDW                 | 14.0    |       | 11.5 - 14.5          | %       |          |
| PLATELET COUNT      | 221     |       | 150 - 400            | x E9/L  |          |

a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

Updated On: 2018-Aug-15 6:04 PM

|  | Results | Flags | Ref Range |  | Test Loc |
|--|---------|-------|-----------|--|----------|
|--|---------|-------|-----------|--|----------|

|                       | Results                                                                                                                                                                                                                                                                                                                    | Flags | Ref Range |          | Test Loc |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|----------|----------|
| <b>HEMATOLOGY II</b>  |                                                                                                                                                                                                                                                                                                                            |       |           |          |          |
| NEUTROPHILS           | 3.6                                                                                                                                                                                                                                                                                                                        |       | 2.0 - 7.5 | x E9/L   | 10       |
| LYMPHOCYTES           | 1.4                                                                                                                                                                                                                                                                                                                        |       | 1.0 - 3.5 | x E9/L   |          |
| MONOCYTES             | 0.4                                                                                                                                                                                                                                                                                                                        |       | 0.2 - 1.0 | x E9/L   |          |
| EOSINOPHILS           | 0.1                                                                                                                                                                                                                                                                                                                        |       | 0.0 - 0.5 | x E9/L   |          |
| BASOPHILS             | 0.0                                                                                                                                                                                                                                                                                                                        |       | 0.0 - 0.2 | x E9/L   |          |
| IMMATURE GRANULOCYTES | 0.0                                                                                                                                                                                                                                                                                                                        |       | 0.0 - 0.1 | x E9/L   |          |
| NRBC                  | 0                                                                                                                                                                                                                                                                                                                          |       |           | /100 WBC |          |
|                       | Ridgeway Family Health is now reporting five new CBC parameters - Reticulocyte Hgb, IRF, IPF, NRBC, and IG. All parameters will be automatically reported when applicable. For more information please visit <a href="http://www.stonebridgehealthclinic.ca">www.stonebridgehealthclinic.ca</a> and search CBC parameters. |       |           |          |          |

a nearby city 8 993-089-6973 qaa 0534

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

Updated On: 2018-Aug-15 6:04 PM

|                          | Results | Flags | Ref Range |     | Test Loc |
|--------------------------|---------|-------|-----------|-----|----------|
| <b>SPECIAL/ROUTINE I</b> |         |       |           |     |          |
| AMYLASE                  | 38      |       | 30 - 110  | U/L | 10       |

a nearby city 8 993-089-6973 qaa 0534

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Aug-14 Reviewed: 2018-Aug-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Aug-14 Report Date: 2018-Aug-15 3:30 AM

Updated On: 2018-Aug-15 6:04 PM

|                    | Results | Flags | Ref Range |      | Test Loc |
|--------------------|---------|-------|-----------|------|----------|
| <b>CHEMISTRY V</b> |         |       |           |      |          |
| C-REACTIVE PROTEIN | 4.3     |       | < 6.0     | mg/L | 10       |

a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 167-067-993 (Final) Ordered By: Oona Uddin Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 7:07 PM

CC: Sinead Taylor, Sinead Taylor Updated On: 2018-Aug-15 6:04 PM

|                            | Results                                                                                            | Flags | Ref Range |        | Test Loc |
|----------------------------|----------------------------------------------------------------------------------------------------|-------|-----------|--------|----------|
| <b>ROUTINE CHEMISTRY I</b> |                                                                                                    |       |           |        |          |
| CREATININE                 | 72                                                                                                 |       | 67 - 117  | umol/L | KL       |
| eGFR                       | 113                                                                                                |       |           |        |          |
|                            | Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.                            |       |           |        |          |
|                            | For patients of African descent, the reported eGFR must be multiplied by 1.15.                     |       |           |        |          |
|                            | Effective May 3, 2015, eGFR is calculated using the CKD-EPI 2009 equation.                         |       |           |        |          |
|                            | KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in |       |           |        |          |

---

screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.

|                 | Results | Flags | Ref Range |        | Test Loc |
|-----------------|---------|-------|-----------|--------|----------|
| SODIUM          | 139     |       | 135 - 145 | mmol/L | KL       |
| POTASSIUM       | 4.2     |       | 3.5 - 5.2 | mmol/L |          |
| TOTAL BILIRUBIN | 11      |       | < 20      | umol/L |          |

|                            | Results | Flags | Ref Range |     | Test Loc |
|----------------------------|---------|-------|-----------|-----|----------|
| ALANINE TRANSAMINASE (ALT) | 24      |       | < 50      | U/L |          |
| ALKALINE PHOSPHATASE       | 68      |       | 40 - 129  | U/L |          |

KL - a nearby city 8 993-089-6973 qaa 0534

Lab Results: Generated On 2026-Apr-09

|                 |                |                  |                      |                   |                |
|-----------------|----------------|------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b>  |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>       | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                  |                      |                   |                |
| <b>DOB</b>      | 1979           |                  |                      |                   |                |

Accession Id: 167-067-993 (Final) Ordered By: Oona Uddin Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 7:07 PM

CC: Sinead Taylor, Sinead Taylor Updated On: 2018-Jun-23 4:32 PM

|                        | Results | Flags | Ref Range            |         | Test Loc |
|------------------------|---------|-------|----------------------|---------|----------|
| <b>HEMATOLOGY I</b>    |         |       |                      |         |          |
| HEMOGLOBIN             | 126     | LO    | 135 - 175            | g/L     | KL       |
| HEMATOCRIT             | 0.377   | LO    | 0.400 - 0.500        | L/L     |          |
| WHITE BLOOD CELL COUNT | 5.1     |       | 4.0 - 11.0           | x E9/L  |          |
| RED BLOOD CELL COUNT   | 4.58    |       | 4.50 - 6.00          | x E12/L |          |
| MCV                    | 82      |       | 80 - 100             | fL      |          |
| MCH                    | 27.5    |       | 27.5 - 33.0          | pg      |          |
| MCHC                   | 334     |       | 0748 361 588KT - 360 | g/L     |          |
| RDW                    | 15.1    | HI    | 11.5 - 14.5          | %       |          |
| PLATELET COUNT         | 190     |       | 150 - 400            | x E9/L  |          |

KL - a nearby city 8 993-089-6973 qaa 0534

Accession Id: 167-067-993 (Final) Ordered By: Oona Uddin Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 7:07 PM

CC: Sinead Taylor, Sinead Taylor Updated On: 2018-Jun-23 4:32 PM

|                      | Results | Flags | Ref Range |        | Test Loc |
|----------------------|---------|-------|-----------|--------|----------|
| <b>HEMATOLOGY II</b> |         |       |           |        |          |
| ABSOLUTE: NEUTS      | 3.8     |       | 2.0 - 7.5 | x E9/L | KL       |
| (A) LYMPH            | 0.7     | LO    | 1.0 - 3.5 | x E9/L |          |
| (A) MONO             | 0.6     |       | 0.2 - 1.0 | x E9/L |          |
| (A) EOS              | 0.0     |       | 0.0 - 0.5 | x E9/L |          |
| (A) BASO             | 0.0     |       | 0.0 - 0.2 | x E9/L |          |

KL - a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 9:59 PM

Updated On: 2018-Jun-23 4:32 PM

|                            | Results | Flags | Ref Range |        | Test Loc |
|----------------------------|---------|-------|-----------|--------|----------|
| <b>ROUTINE CHEMISTRY I</b> |         |       |           |        |          |
| CHLORIDE                   | 102     |       | 98 - 108  | mmol/L | KL       |
| GAMMA-GLUTAMYLTRANSFERASE  | 21      |       | 14 - 62   | U/L    |          |

KL - a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health

---

Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 9:59 PM

Updated On: 2018-Jun-23 4:32 PM

|                             | Results | Flags | Ref Range |     | Test Loc |
|-----------------------------|---------|-------|-----------|-----|----------|
| <b>ROUTINE CHEMISTRY II</b> |         |       |           |     |          |
| ALBUMIN                     | 43      |       | 35 - 52   | g/L | KL       |

KL - a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 9:59 PM

Updated On: 2018-Jun-23 4:32 PM



|                             | Results                              | Flags | Ref Range |        | Test Loc |
|-----------------------------|--------------------------------------|-------|-----------|--------|----------|
| <b>SPECIAL CHEMISTRY II</b> |                                      |       |           |        |          |
| VITAMIN B12                 | 138                                  |       | 138 - 652 | pmol/L | KL       |
|                             | Test repeated and results confirmed. |       |           |        |          |

KL - a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 9:59 PM

Updated On: 2018-Jun-23 4:32 PM

|                  | Results | Flags | Ref Range  |      | Test Loc |
|------------------|---------|-------|------------|------|----------|
| <b>CHEMISTRY</b> |         |       |            |      |          |
| FERRITIN         | 94      |       | 1979 - 275 | ug/L | KL       |

KL - a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 9:59 PM

Updated On: 2018-Jun-23 4:32 PM

|                          | Results | Flags | Ref Range |     | Test Loc |
|--------------------------|---------|-------|-----------|-----|----------|
| <b>SPECIAL/ROUTINE I</b> |         |       |           |     |          |
| AMYLASE                  | 36      |       | 30 - 110  | U/L | KL       |

KL - a nearby city 8 993-089-6973 qaa 0534

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jun-13 Reviewed: 2018-Jun-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jun-13 Report Date: 2018-Jun-13 9:59 PM

Updated On: 2018-Jun-23 4:32 PM

|                                             | Results | Flags | Ref Range |      | Test Loc |
|---------------------------------------------|---------|-------|-----------|------|----------|
| <b>CARDIOVASCULAR RISK ASSESSMENT -----</b> |         |       |           |      |          |
| HS-CRP                                      | 40.84   | **    |           | mg/L | KL       |

|  | Results                              | Flags | Ref Range |  | Test Loc |
|--|--------------------------------------|-------|-----------|--|----------|
|  | Test repeated and results confirmed. |       |           |  |          |

hsCRP is considered a valuable risk stratification measurement in females >60 years and males >50 years. Values >2.00 mg/L in these patients warrant further investigation. Refer to the CCS 2012 guideline for revised hsCRP CVD risk criteria. hs-CRP values > or = 6.00 mg/L may be due to acute inflammation.

KL - a nearby city 8 993-089-6973 qaa 0534

Crestwood Medical Group 2 Crestwood Medical Group 2 Phone (089) 697-3500 a5345 Fax (089) 697-3500 a5345 Email: (089) 697-3500 a5345 Monday to Friday 8:00 AM – 8:00 PM Eastern Standard Time

Jun 11, 2018

Dear Dr. Taylor,

RE: Ethan Kang Group Benefit Plan #: 167-067-993 Group Benefit ID#: 167-067-993

Please be advised that Ethan Kang has been decline for dose increase for Entyvio 300 mg IV every 4 weeks but approved for Entyvio 300mg IV every 8 weeks up to the maximum of 8 vials every 12 month period effective Jun 19, 2018.

Ethan Kang will continue to have this drug dispensed at Crestwood Medical Group 2, the designated pharmacy that he previously chose.

If you have any questions, please contact me at (089) 697-3500 a5345 or by fax at (089) 697-3500 a5345.

Sincerely,

Bianca Mehta Health Case Manager, Crestwood Medical Group 2

The following material is intended for use only by the individual to whom it is specifically addressed above and should not be read by, or delivered to, any other person. Such material may contain privileged or confidential information. If you have received this facsimile in error, please notify us immediately by calling the sender's direct line above (collect if necessary). We thank you in advance for your co-operation and assistance.

Crestwood Medical Group 2 Crestwood Medical Group 2 Phone (089) 697-3500 a5345 Fax (089) 697-3500 a5345 Email: (089) 697-3500 a5345 Monday to Friday 8:00 AM – 8:00 PM Eastern Standard Time

Jun 11, 2018

Dear Dr. Taylor,

RE: Ethan Kang Date of Birth: Jun 21, 1979 Group Benefit Plan #: 167-067-993 Group Benefit ID#: 167-067-993

Please be advised that Ethan Kang has been approved ongoing by Crestwood Medical Group 2 for coverage for Entyvio.

During this coverage period, Ethan Kang will continue to have this drug dispensed at Crestwood Medical Group 2, the designated pharmacy that he previously chose.

If you have any questions, please contact me at (089) 697-3500 a5345 or by fax at (089) 697-3500 a5345.

Sincerely,

Henrik Arnold, Program Coordinator, Crestwood Medical Group 2

The following material is intended for use only by the individual to whom it is specifically addressed above and should not be read by, or delivered to, any other person. Such material may contain privileged or confidential information. If you have received this facsimile in error, please notify us immediately by calling the sender's direct line above (collect if necessary). We thank you in advance for your co-operation and assistance.

---

[image] \* \_\_

This task has been completed

|                    |                                                                  |                        |                                                                    |
|--------------------|------------------------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                                       | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 05/24/2018                                                       | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]              | <b>Completed</b>       | 2018-May-27 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | tell him his vit B12 is low and he needs to take supplementation |                        |                                                                    |

## Conversations

**Created 2018-May-27 12:27 PM**

---

2018-May-27 12:27 PM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [image]  
Message Left

---

Cedar Specialist Group 4 Dr. Sinead Taylor, a nearby city 8 Phone: 994-882-7246 Fax: 994-882-7246

**Patient** Name: Ethan Kang DOB: 1979 HCN: 414 235 249 Address: a nearby city 8

**Referring physician** Name: Dr. Herrera Address: a nearby city 8 Tel: 994-882-7246 Fax: (442) 733-2165

**Appointment details** Date: 2018-May-15 Location: Cedar Specialist Group 4

Dear Dr. Herrera;

Ethan Kang was seen in follow-up today for high triglycerides.

## SUBJECTIVE:

### HPI:

#### Pertinent Medical History

He informs me that another physician has changed some of his medications since his last visit. These changes were made and reflected in his current medication record, as best as he can recall the names and the doses. He did not get a chance to go for the blood work I had requested him to do before today's appointment.

He has lost 5.2 kg since his last appointment.

He was started on Entivyo in [REDACTED-DATE] for his Crohn's disease.

This office appointment was performed in the presence of, and with the aid of, the clinical assistant Gunnar Herrera.

#### HIGH TRIGLYCERIDES

He is currently not on any anti-hyperglycemic medications.

He walks for 30 minutes every day.

He is currently on no blood pressure lowering medications. He has checked his blood pressure elsewhere, and when he does he finds that his systolics are 130s and diastolics in the 70s. He checks his blood pressure at home.

He is currently not on any lipid modifying medications.

His work entails some walking.

---

#### HYPOGONADISM

He is currently on no medications for this condition.

**Problem History:** HYPERTRIGLYCERIDEMIA {Inactive} HYPOGONADISM [resolved]

**Active Medications:** None Recorded

**External Medications:** cyanocobalamin (vitamin B-12) 1,000 mcg/ml Injection Vial (mL) [1.0 qbiweekly]

**Surgical/Medical History:** Endocrinology, Other - Vitamin B12 deficiency Medical, Other - Insomnia Back pain - chronic Anemia, Other OSA ( Obstructive Sleep Apnea ) - using CPAP Kidney Stone Surgery, Other - Lipoma- 2015 (removed) Medical, Other - Herniated disc GI, Other - Crohn's disease Eye Disease - Herpes Zoster ophthalmicus Surgery, Other - 2014 - Ileocolic resection Dyslipidemia - Hypertriglyceridemia ( in chylomicrons )

**Known Allergies:** CODEINE 15MG TABLET - Opioids - Morphine Analogues (Drug Allergy)

**Current Medical Providers:** Family Doctor - Dr. Sinead Taylor Gastroenterologist - Dr. Sinead Taylor - for Crohn's disease Optometrist - Dr. Rahman

**Immunization History:** Hepatitis B - February 1996 MMR - Aug 1996 Fluviral - Sep 2013 Vaxigrip - Sep 2014 Fluviral - Nov 2015

OBJECTIVE:

Vitals:

Ht: 178 cm; Wt: 133.7 kg; BMI: 42.7 BP: 135 / 94; HR: 73 bpm

Physical Exam:

CARDIOVASCULAR: no systolic murmur, no diastolic murmur, normal rate, normal rhythm, normal S1, and normal S2. RESPIRATORY: there were no inspiratory wheezes, there were no expiratory wheezes, and there were no crackles.

Lab/Test Results:

| Test                                                                           | Result                     |
|--------------------------------------------------------------------------------|----------------------------|
| HbA1c:                                                                         | 5.3 %( 2017-Oct-30 )       |
| creatinine:                                                                    | 80 umol/L;                 |
| Normal eGFR.                                                                   |                            |
| For patients of African descent, the reported eGFR must be multiplied by 1.15. | ( 2017-Oct-30 )            |
| fasting glucose:                                                               | 4.9 mmol/L ( 2017-Oct-30 ) |
| random glucose:                                                                | 7.7 mmol/L ( 2016-Nov-01 ) |

|                        |                                                                  |
|------------------------|------------------------------------------------------------------|
| U alb:creat:           | 0.3 mg/mmol creat ( 2017-Oct-30 )                                |
| Tot Chol:              | 3.16 mmol/L ( 2017-Oct-30 )                                      |
| TG:                    | 4.89 mmol/L ( 2017-Oct-30 )                                      |
| HDL:                   | 0.62 mmol/L ( 2017-Oct-30 )                                      |
| LDL:                   | * LDL-cholesterol calculation is invalid at triglycerides >=4.52 |
| mmol/L ( 2017-Oct-30 ) |                                                                  |
| TSH:                   | 3.21 miU/L ( 2017-Oct-30 )                                       |

|      |                           |
|------|---------------------------|
| FT4: | 17 pmol/L ( 2017-Oct-30 ) |
| FT3: | 5.4 pmol/L( 2017-Oct-30 ) |

## ASSESSMENT:

### HIGH TRIGLYCERIDES

**BLOOD PRESSURE:** The blood pressure is elevated and not at target. Although his blood pressure is elevated today, it is fine when he checks it elsewhere. He checks his blood pressure at home. As his blood pressure is only mildly increased, I plan to just monitor it for now and then re-assess depending on his future readings. **LIPIDS:** His Framingham risk score puts him in the low risk category ( < 10% ) for cardiovascular complications in the next 10 years. His triglycerides are increased. His HDL is low. Although the drug of choice for an elevated triglyceride level is fibrates, at best they decrease the triglycerides by 20 - 30%. The **TREATMENT** of choice is through lifestyle changes with reduction of carbohydrate intake in the diet ( including rice, bread, pasta, potatoes, fruits, etc ), reduction or preferably elimination of alcohol, a regular exercise routine and optimization of diabetes control ( if diabetes is present ). The best way to improve a low HDL is to engage in a regular exercise routine as well as to optimize diabetes control ( if diabetes is present ). This will increase the HDL by 10 - 20%, on average. The lipid profile and urine albumin:creatinine ratio are due to be repeated again in with the next blood work.

## PLAN:

**LABORATORY:** Diabetic blood work ( including HbA1C and fasting lipid profile ), and this is to be done before the next appointment. Bloodwork to evaluate static pituitary function, and this is to be done before the next appointment. **TESTS:** No tests have been requested at this point in time. **REFERRALS:** No referrals have been initiated at this point in time. **NEW MEDICATION(S):** He was not started on any new medications. **DISCONTINUED MEDICATION(S):** None of his medications were stopped. **CHANGED MEDICATIONS:** The dose of none of his medications were changed. **FOLLOW-UP:** Schedule a follow-up in 1 month(s).

I previously reviewed his lipid profiles dating back to 2011. I think his TG are mainly in chylomicrons which is not a risk factor for CAD, despite his family history.

Letter Generated by: Gunnar Herrera

Sincerely,

[image]

Gunnar Herrera **Electronically Reviewed to Expedite Delivery** cc: Sinead Taylor

---

Lab Results: Generated On 2026-Apr-09

|                |            |                  |                      |                  |  |
|----------------|------------|------------------|----------------------|------------------|--|
| <b>Patient</b> | Ethan Kang | <b>HomePhone</b> | (089) 697-3500 a5345 | <b>WorkPhone</b> |  |
|----------------|------------|------------------|----------------------|------------------|--|

|                 |                |            |   |                   |                |
|-----------------|----------------|------------|---|-------------------|----------------|
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b> | M | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |            |   |                   |                |
| <b>DOB</b>      | 1979           |            |   |                   |                |

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-May-15 Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-May-15 Report Date: 2018-May-16 5:59 AM Updated On: 2018-May-24 2:04 AM

|                            | Results | Flags | Ref Range |        | Test Loc |
|----------------------------|---------|-------|-----------|--------|----------|
| <b>ROUTINE CHEMISTRY I</b> |         |       |           |        |          |
| CREATININE                 | 81      |       | 67 - 117  | umol/L | KL       |
| eGFR                       | 106     |       |           |        |          |

Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

Effective May 3, 2015, eGFR is calculated using the CKD-EPI 2009 equation.

KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.

|                            | Results | Flags | Ref Range |        | Test Loc |
|----------------------------|---------|-------|-----------|--------|----------|
| SODIUM                     | 145     |       | 135 - 145 | mmol/L |          |
| POTASSIUM                  | 4.5     |       | 3.5 - 5.2 | mmol/L |          |
| CHLORIDE                   | 105     |       | 98 - 108  | mmol/L |          |
| TOTAL BILIRUBIN            | 4       |       | < 20      | umol/L |          |
| ALANINE TRANSAMINASE (ALT) | 1979    |       | < 50      | U/L    |          |
| ALKALINE PHOSPHATASE       | 80      |       | 40 - 129  | U/L    |          |
| GAMMA-GLUTAMYLTRANSFERASE  | 19      |       | 14 - 62   | U/L    |          |

**KL - a nearby city 8 (089) 697-3500 a5345**

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-May-15 Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-May-15 Report Date: 2018-May-16 5:59 AM Updated On: 2018-May-24 2:04 AM

|                             | Results | Flags | Ref Range |     | Test Loc |
|-----------------------------|---------|-------|-----------|-----|----------|
| <b>ROUTINE CHEMISTRY II</b> |         |       |           |     |          |
| ALBUMIN                     | 47      |       | 35 - 52   | g/L | KL       |

**KL - a nearby city 8 (089) 697-3500 a5345**

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-May-15 Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]  
Service Date: 2018-May-15 Report Date: 2018-May-16 5:59 AM Updated On: 2018-May-24 2:04 AM

|  | Results | Flags | Ref Range |  | Test Loc |
|--|---------|-------|-----------|--|----------|
|--|---------|-------|-----------|--|----------|

|                             | Results                              | Flags | Ref Range |        | Test Loc |
|-----------------------------|--------------------------------------|-------|-----------|--------|----------|
| <b>SPECIAL CHEMISTRY II</b> |                                      |       |           |        |          |
| VITAMIN B12                 | 116                                  | LO    | 138 - 652 | pmol/L | KL       |
|                             | Test repeated and results confirmed. |       |           |        |          |

**KL - a nearby city 8 (089) 697-3500 a5345**

Accession Id: 167-067-993 (Final)  
Ordered By: Sinead Taylor  
Reported By: Ridgeway Family Health  
Collection Date: 2018-May-15  
Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]  
Service Date: 2018-May-15  
Report Date: 2018-May-16 5:59 AM  
Updated On: 2018-May-24 2:04 AM

|                  | Results | Flags | Ref Range  |      | Test Loc |
|------------------|---------|-------|------------|------|----------|
| <b>CHEMISTRY</b> |         |       |            |      |          |
| FERRITIN         | 35      |       | 1979 - 275 | ug/L | KL       |

**KL - a nearby city 8 (089) 697-3500 a5345**

Accession Id: 167-067-993 (Final)  
Ordered By: Sinead Taylor  
Reported By: Ridgeway Family Health  
Collection Date: 2018-May-15  
Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]  
Service Date: 2018-May-15



Report Date: 2018-May-16 5:59 AM

Updated On: 2018-May-24 2:04 AM

|                        | Results | Flags | Ref Range            |         | Test Loc |
|------------------------|---------|-------|----------------------|---------|----------|
| <b>HEMATOLOGY I</b>    |         |       |                      |         |          |
| HEMOGLOBIN             | 136     |       | 135 - 175            | g/L     | KL       |
| HEMATOCRIT             | 0.400   |       | 0.400 - 0.500        | L/L     |          |
| WHITE BLOOD CELL COUNT | 6.1     |       | 4.0 - 11.0           | x E9/L  |          |
| RED BLOOD CELL COUNT   | 4.72    |       | 4.50 - 6.00          | x E12/L |          |
| MCV                    | 85      |       | 80 - 100             | fL      |          |
| MCH                    | 28.8    |       | 27.5 - 33.0          | pg      |          |
| MCHC                   | 340     |       | 0748 361 588KT - 360 | g/L     |          |
| RDW                    | 14.9    | HI    | 11.5 - 14.5          | %       |          |
| PLATELET COUNT         | 244     |       | 150 - 400            | x E9/L  |          |

**KL - a nearby city 8 (089) 697-3500 a5345**

---

Accession Id: 167-067-993 (Final)

Ordered By: Sinead Taylor

Reported By: Ridgeway Family Health

Collection Date: 2018-May-15

Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

Service Date: 2018-May-15

Report Date: 2018-May-16 5:59 AM

Updated On: 2018-May-24 2:04 AM

|                      | Results | Flags | Ref Range |        | Test Loc |
|----------------------|---------|-------|-----------|--------|----------|
| <b>HEMATOLOGY II</b> |         |       |           |        |          |
| ABSOLUTE: NEUTS      | 4.0     |       | 2.0 - 7.5 | x E9/L | KL       |
| (A) LYMPH            | 1.4     |       | 1.0 - 3.5 | x E9/L |          |
| (A) MONO             | 0.5     |       | 0.2 - 1.0 | x E9/L |          |
| (A) EOS              | 0.1     |       | 0.0 - 0.5 | x E9/L |          |
| (A) BASO             | 0.0     |       | 0.0 - 0.2 | x E9/L |          |

**KL - a nearby city 8 (089) 697-3500 a5345**

---

Accession Id: 167-067-993 (Final)

Ordered By: Sinead Taylor

Reported By: Ridgeway Family Health

Collection Date: 2018-May-15

Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

Service Date: 2018-May-15

Report Date: 2018-May-16 5:59 AM

Updated On: 2018-May-24 2:04 AM

|                          | Results | Flags | Ref Range |     | Test Loc |
|--------------------------|---------|-------|-----------|-----|----------|
| <b>SPECIAL/ROUTINE I</b> |         |       |           |     |          |
| AMYLASE                  | 34      |       | 30 - 110  | U/L | KL       |

**KL - a nearby city 8 (089) 697-3500 a5345**

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-May-15 Reviewed: 2018-May-24 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-May-15 Report Date: 2018-May-16 5:59 AM

Updated On: 2018-May-24 2:04 AM

|                    | Results | Flags | Ref Range |      | Test Loc |
|--------------------|---------|-------|-----------|------|----------|
| <b>CHEMISTRY V</b> |         |       |           |      |          |
| C-REACTIVE PROTEIN | 3.8     |       | < 6.0     | mg/L | KL       |

**KL - a nearby city 8 (089) 697-3500 a5345**

Westbrook Medical Associates 5 Crestwood Medical Group 2 | PARTENAIRES POUR LA SANTÉ

Ridgeway Family Health a nearby city 8

LIMS Report #: 167-067-993 Fax To: (089) 697-3500 a5345 Provider: Dr. Sinead Taylor Crestwood Medical Group 2 412 Marigold Ave Administration Riverside Medical Clinic a nearby city 8 Phone:

Patient: Ethan Kang a nearby city 8 Patient Phone: 993-089-6973 qaa 0534

HIN: 0748 361 588KT Date of Birth: 1979-06-21 Gender: Male

Sample #: 167-067-993 (167-067-993) Date Collected: 2018-05-07 Senders Sample ID: 167-067-993 Date Onset: Source: Stool (Unpreserved) Date Received: 2018-05-08 Testing Reason: Date Reported: [REDACTED-DATE] Specimen Note: Test results for C.difficile specimens submitted frozen or greater than 3 days since collection date may be affected and should be interpreted with caution.

| Test                                  | Result       | Date Approved |
|---------------------------------------|--------------|---------------|
| C.difficile GDH Ag by EIA-Screen Test | Not detected | 2018-05-08    |

Note: Results do not support the diagnosis of C.difficile. C.difficile toxin testing by enzyme immunoassay (EIA) has been demonstrated to have limited sensitivity. If the initial test is 'not detected' and there is

ongoing clinical suspicion, a second specimen for C.difficile testing should be sent.

*The contents of this document are confidential and intended only for the use of the individual named as the "Provider". If you have received this information in error, please notify the Sunnymede Family Practice 4 by telephone at 993-089-6973 qaa 0534 or 993-089-6973 qaa 0534.*

Ridgeway Family Health a nearby city 8 Final [image] Ontario

Sunnymede Family Practice 4 Print Date: [REDACTED-DATE]

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                 |                |                   |                      |                   |                |
|-----------------|----------------|-------------------|----------------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>Home Phone</b> | (089) 697-3500 a5345 | <b>Work Phone</b> |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>        | M                    | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                   |                      |                   |                |
| <b>DOB</b>      | 1979           |                   |                      |                   |                |

Lab Order #: 167-067-993 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2018-[REDACTED-DATE]-08 Reviewed: 2018-May-09 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Reported Date: 2018-May-09 8:42 AM Updated On: 2018-May-09 1:19 PM

|                         | Flags | Results                                                             | Ref Range | Units |
|-------------------------|-------|---------------------------------------------------------------------|-----------|-------|
| <b>STOOL CULTURE</b>    |       |                                                                     |           |       |
| STOOL CULTURE (F)       |       | -----                                                               |           |       |
|                         |       | No Salmonella, Shigella, Yersinia, Campylobacter or E.coli 0157:H7. |           |       |
| <b>STOOL CULTURE #2</b> |       |                                                                     |           |       |
| STOOL CULTURE #2 (F)    |       | -----                                                               |           |       |
|                         |       | Please refer to message below.                                      |           |       |
| <b>STOOL CULTURE #3</b> |       |                                                                     |           |       |

|                      | Flags | Results                                                                                                                                                                                                                                                | Ref Range | Units |
|----------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------|
| STOOL CULTURE #3 (F) |       | -----                                                                                                                                                                                                                                                  |           |       |
|                      |       | As per OAML guidelines, submitting more than one (1) stool specimen when requesting a stool culture is inappropriate. Please note, although multiple stool samples were submitted for this patient, they were processed/cultured as a single specimen. |           |       |

## Crestwood Medical Group 2 Physician's Questionnaire

Please have the below completed by your prescribing physician. Attach extra information if necessary.

### Part 2 Physician Information

Name of prescribing physician (please print): Dr. Sinead Taylor Specialty: Gastroenterologist Address (number, street, city, province, postal code): 412 Marigold Ave, a nearby city 6, ON, 848 Main Blvd Telephone Number (including area code): (089) 697-3500 a5345 Fax Number (including area code): (442) 733-2165

1. Prior Authorization Drug: Entyvio
2. Requested Dosage and Frequency: Entyvio 300mg IV Q4 Weeks
3. Date increased dosage was established or will be established: ASAP
4. Anticipated period of time this dosage will be maintained: ongoing
5. Date of physician appointment for assessment of response to the increased dosage: Appointment to be booked by patient
6. Is there a plan to reduce dosage in the future? ☐ Yes ☒ No If yes, provide details:

---

If no, provide rationale:

---

7. Has the patient undergone any therapeutic drug level testing or any other applicable test that could assess drug efficacy? ☐ Yes ☐ No ☒ Not applicable Please attach reports.
  8. Please advise the medical rationale for the increased dosage. Patient is experiencing increased IBD symptoms with more frequent stools with blood. HBI remains the same (12)
- 
- 

Please provide the following documentation

☐ Clinical information including lab reports and scores prior to the increased dosage ☐ Clinical information including lab reports and scores since the increased dosage was established (if applicable) ☐ Provide clinical literature/studies to support the use of the increased dosage, such as: ☐ At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and ☐ Published recommendations in evidence-based guidelines supporting its use.

I certify that the information provided on this Physician's Questionnaire is true, correct and complete.  
Physician's signature: [signature] Date: [REDACTED-DATE]

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. The completed Request for Information form can be returned to Crestwood Medical Group 2 by mail or fax.

Mail to: Crestwood Medical Group 2 Drug Services a nearby city 9

Fax to: Crestwood Medical Group 2 Fax (089) 697-3500 a5345

M7260-3/15 © Crestwood Medical Group 2. All rights reserved. Any modification of this document without the express written consent of Crestwood Medical Group 2 is strictly prohibited.

---

□ \*--

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 04/26/2018                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2018-Apr-29 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | ask for repeat.                                     |                        |                                                                    |

□ \*--

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 04/26/2018                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2018-Apr-29 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | ask for repeat                                      |                        |                                                                    |

## Conversations

**Created 2018-Apr-29 8:54 AM**

2018-Apr-29 8:54 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

[image] Message Left

Ridgeway Family Health Crestwood Medical Group 2 | Ridgeway Family Health PARTENAIRES POUR LA SANTÉ Ridgeway Family Health a nearby city 8

LIMS Report #: 167-067-993 Patient: Ethan Kang a nearby city 8 Patient Phone: 993-089-6973 qaa 0534

Provider: Dr. Sinead Taylor Cedar Specialist Group 4 412 Marigold Ave Riverside Medical Clinic a nearby city 8 Phone:

HIN: 0748 361 588KT Date of Birth: 1979-06-21 Gender: Male

Report Copied To: Dr. Sinead Taylor

Sample #: 167-067-993 (167-067-993) Senders Sample ID: 414 235 249 Source: Stool (Unpreserved)  
Testing Reason: Diagnostic, Immunocompromised Clinical Info: Gastroenteritis, Other Additional Info:  
FECAL SWAB Date Collected: (blank) Date Onset: (blank) Date Received: 2018-04-19 Date Reported:  
2018-04-20 Patient Setting: Physician Office/ Clinic Acute/Conv:

Specimen Note: Cancelled Sample: Date of collection not indicated. Specimen was not tested. Date of  
Collection not provided on requisition, used Date of Receipt instead.

| Test                                  | Result    | Date Approved |
|---------------------------------------|-----------|---------------|
| C.difficile GDH Ag by EIA-Screen Test | Cancelled | 2018-04-19    |

The contents of this document are confidential and intended only for the use of the individual named as the  
"Provider". If you have received this information in error, please notify the Sunnymede Family Practice 4 by  
telephone at 993-089-6973 qaa 0534 or 993-089-6973 qaa 0534.

Ridgeway Family Health a nearby city 8 Final Crestwood Medical Group 2 Ridgeway Family Health

Sunnymede Family Practice 4 Page 1 of 1 Print Date: 2018-04-20

---

Ridgeway Family Health Crestwood Medical Group 2 | Ridgeway Family Health PARTENAIRES POUR LA  
SANTÉ Ridgeway Family Health a nearby city 8

LIMS Report #: 167-067-993 Patient: Ethan Kang a nearby city 8 Patient Phone: 993-089-6973 qaa 0534

Provider: Dr. Sinead Taylor Cedar Specialist Group 4 412 Marigold Ave Riverside Medical Clinic a nearby  
city 8 Phone:

HIN: 0748 361 588KT Date of Birth: 1979-06-21 Gender: Male

Report Copied To: Dr. Sinead Taylor

Sample #: 167-067-993 (167-067-993) Senders Sample ID: 414 235 249 Source: Stool (Cary-Blair) Testing  
Reason: Diagnostic, Immunocompromised Clinical Info: Gastroenteritis, Other Additional Info: FECAL  
SWAB Date Collected: Date Onset: Date Received: 2018-04-19 Date Reported: 2018-04-20 Patient  
Setting: Physician Office/ Clinic Acute/Conv:

Specimen Note: Cancelled Sample: Date of collection not indicated. Specimen was not tested. Date of  
Collection not provided on requisition, used Date of Receipt instead.

| Test                        | Result    | Date Approved |
|-----------------------------|-----------|---------------|
| Enteric Culture - Bacterial | Cancelled | 2018-04-19    |

The contents of this document are confidential and intended only for the use of the individual named as the  
"Provider". If you have received this information in error, please notify the Sunnymede Family Practice 4 by  
telephone at 993-089-6973 qaa 0534 or 993-089-6973 qaa 0534.

Ridgeway Family Health a nearby city 8

Final

Lab Results: Generated On 2026-Apr-09

|          |                |           |                      |            |                |
|----------|----------------|-----------|----------------------|------------|----------------|
| Patient  | Ethan Kang     | HomePhone | (089) 697-3500 a5345 | WorkPhone  |                |
| Health # | 0748 361 588KT | Sex       | M                    | Patient ID | 0748 361 588KT |
| Age      | 46 years       |           |                      |            |                |
| DOB      | 1979           |           |                      |            |                |

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

**ROUTINE CHEMISTRY I**

| Test       | Results | Flags | Ref Range | Units  | Test Loc |
|------------|---------|-------|-----------|--------|----------|
| CREATININE | 71      |       | 67 - 117  | umol/L | KL       |
| eGFR       | 113     |       |           |        |          |

Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

Effective May 3, 2015, eGFR is calculated using the CKD-EPI 2009 equation.

KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.

| Test                       | Results | Flags | Ref Range | Units  | Test Loc |
|----------------------------|---------|-------|-----------|--------|----------|
| SODIUM                     | 142     |       | 135 - 145 | mmol/L |          |
| POTASSIUM                  | 3.9     |       | 3.5 - 5.2 | mmol/L |          |
| CHLORIDE                   | 105     |       | 98 - 108  | mmol/L |          |
| TOTAL BILIRUBIN            | 6       |       | < 20      | umol/L |          |
| ALANINE TRANSAMINASE (ALT) | 1979    |       | < 50      | U/L    |          |
| ALKALINE PHOSPHATASE       | 72      |       | 40 - 129  | U/L    |          |
| GAMMA-GLUTAMYLTRANSFERASE  | 20      |       | 14 - 62   | U/L    |          |



KL - a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

#### ROUTINE CHEMISTRY II

| Test    | Results | Flags | Ref Range | Units | Test Loc |
|---------|---------|-------|-----------|-------|----------|
| ALBUMIN | 44      |       | 35 - 52   | g/L   | KL       |

KL - a nearby city 8 (089) 697-3500 a5345

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

|  | Results | Flags | Ref Range |  | Test Loc |
|--|---------|-------|-----------|--|----------|
|--|---------|-------|-----------|--|----------|

---

#### SPECIAL CHEMISTRY II

| Test        | Results                              | Flags | Ref Range | Units  | Test Loc |
|-------------|--------------------------------------|-------|-----------|--------|----------|
| VITAMIN B12 | 157                                  |       | 138 - 652 | pmol/L | KL       |
|             | Test repeated and results confirmed. |       |           |        |          |

KL - a nearby city 8 867.739.5528

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

|                  | Results | Flags | Ref Range  |      | Test Loc |
|------------------|---------|-------|------------|------|----------|
| <b>CHEMISTRY</b> |         |       |            |      |          |
| FERRITIN         | 42      |       | 1979 - 275 | ug/L | KL       |

KL - a nearby city 8 867.739.5528

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

|                        | Results | Flags | Ref Range            |         | Test Loc |
|------------------------|---------|-------|----------------------|---------|----------|
| <b>HEMATOLOGY I</b>    |         |       |                      |         |          |
| HEMOGLOBIN             | 127     | LO    | 135 - 175            | g/L     | KL       |
| HEMATOCRIT             | 0.375   | LO    | 0.400 - 0.500        | L/L     |          |
| WHITE BLOOD CELL COUNT | 5.6     |       | 4.0 - 11.0           | x E9/L  |          |
| RED BLOOD CELL COUNT   | 4.46    | LO    | 4.50 - 6.00          | x E12/L |          |
| MCV                    | 84      |       | 80 - 100             | fL      |          |
| MCH                    | 28.5    |       | 27.5 - 33.0          | pg      |          |
| MCHC                   | 339     |       | 0748 361 588KT - 360 | g/L     |          |
| RDW                    | 15.5    | HI    | 11.5 - 14.5          | %       |          |
| PLATELET COUNT         | 224     |       | 150 - 400            | x E9/L  |          |

KL - a nearby city 8 867.739.5528

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

|                      | Results | Flags | Ref Range |        | Test Loc |
|----------------------|---------|-------|-----------|--------|----------|
| <b>HEMATOLOGY II</b> |         |       |           |        |          |
| ABSOLUTE: NEUTS      | 3.5     |       | 2.0 - 7.5 | x E9/L | KL       |
| (A) LYMPH            | 1.4     |       | 1.0 - 3.5 | x E9/L |          |
| (A) MONO             | 0.7     |       | 0.2 - 1.0 | x E9/L |          |
| (A) EOS              | 0.1     |       | 0.0 - 0.5 | x E9/L |          |
| (A) BASO             | 0.0     |       | 0.0 - 0.2 | x E9/L |          |

KL - a nearby city 8 867.739.5528

---

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

## SPECIAL/ROUTINE I

|         | Results | Flags | Ref Range |     | Test Loc |
|---------|---------|-------|-----------|-----|----------|
| AMYLASE | 29      | LO    | 30 - 110  | U/L | KL       |

KL - a nearby city 8 867.739.5528

Accession Id: 167-067-993 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Apr-18 Reviewed: 2018-Apr-23 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Apr-18 Report Date: 2018-Apr-19 4:45 AM

Updated On: 2018-Apr-23 5:13 PM

|                                       | Results                                         | Flags | Ref Range |      | Test Loc |
|---------------------------------------|-------------------------------------------------|-------|-----------|------|----------|
| <b>CARDIOVASCULAR RISK ASSESSMENT</b> | -----                                           |       |           |      |          |
| HS-CRP                                | 4.42                                            | **    |           | mg/L | KL       |
|                                       | hsCRP is considered a valuable risk             |       |           |      |          |
|                                       | stratification measurement in females >60 years |       |           |      |          |
|                                       | and males >50 years. Values >2.00 mg/L in these |       |           |      |          |
|                                       | patients warrant further investigation. Refer   |       |           |      |          |
|                                       | to the CCS 2012 guideline for revised hsCRP CVD |       |           |      |          |
|                                       | risk criteria.                                  |       |           |      |          |

KL - a nearby city 8 867.739.5528

[X] \* \_ \_

This task has been completed

|                 |            |                        |                                                     |
|-----------------|------------|------------------------|-----------------------------------------------------|
| <b>Patient</b>  | Ethan Kang | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Date Due</b> | 04/16/2018 | <b>Priority</b>        | Normal                                              |

|                    |                                                                            |                  |                                                                    |
|--------------------|----------------------------------------------------------------------------|------------------|--------------------------------------------------------------------|
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                        | <b>Completed</b> | 2018-Apr-17 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | tell him his Vit B12 is low and he should see his family MD for injections |                  |                                                                    |

Cedar Specialist Group 4 Cedar Specialist Group 4

☐ STAT

Gastroenterology Requisition (GI-IBD) Administration a nearby city 8 (089) 697-3500 a5345

Attending Physician: Dr. Sinead Taylor Cedar Specialist Group 4 CPSO#: (blank) FAX: ( \_ ) \_ - \_

Clinical Comments: Date Ordered (1979-MM-1979): 2018-04-15

| Please imprint clearly, or affix label | Order Number       |
|----------------------------------------|--------------------|
| Ethan Kang                             | 412 Marigold Ave   |
| DOB: 1979                              | a nearby city 6 ON |
| HC: 414 235 249                        | 848 Main Blvd      |
| WJQ: 158847108                         | H: ( _ ) _ - _     |
| SEX: M                                 |                    |

## Haematology

☒ CBC (Complete Blood Count) ☐ Reticulocyte Count Indicated if anaemia is expected or suspected. ☐ PT (Prothrombin Time / INR) ☐ ESR (Erythrocyte Sedimentation Rate) ☐ aPTT (Partial Thromboplastin Time)

## General Chemistry

Glucose: ☐ Fasting ☒ Post-Prandial ☐ Random ☐ Electrolytes (Na<sup>+</sup>, K<sup>+</sup>, Cl<sup>-</sup>) ☐ TCO<sub>2</sub> (Carbon Dioxide, Total) Indicated only if suspecting an acid/base disorder. ☒ Creatinine Bilirubin: Total ☒ Direct ☐ ☐ Ca (Calcium, Total) ☐ PO<sub>4</sub> (Phosphate, Inorganic) ☐ Mg (Magnesium, Total) ☐ Urate (Uric Acid) ☐ NH<sub>3</sub> (Ammonia) Lavender-top tube (EDTA anticoagulant only) - send on ice.

## Enzymes

☐ Amylase ☒ ALP (Alkaline Phosphatase) ☒ GGT (Gamma-Glutamyl Transferase) ☒ ALT (Alanine Transaminase) ☐ AST (Aspartate Transaminase)

## Proteins

☐ Protein, Total ☒ Albumin ☒ CRP (C-Reactive Protein) ☐ C4 Complement ☐ C3 Complement  
Immunoglobulins: ☐ IgA ☐ IgG ☐ IgM ☐ CEA (Carcinoembryonic Antigen)

## Lipids

☐ Cholesterol, Total ☐ HDLC (High Density Lipoprotein Cholesterol) ☐ Triglycerides, Total Low Density Lipoprotein Cholesterol (LDLC) will be calculated if all of the above lipid tests are ordered.

## Micronutrients

☒ Iron, Transferrin, Iron Saturation ☒ Ferritin ☒ Vitamin B12 (Cobalamin) ☐ 25-Hydroxy-Vitamin D (Calcidiol) ☐ Folate, Erythrocyte As per the [REDACTED-DATE] 2013 OHIP addendum, Folate testing is restricted to patients having anaemia and increased MCV, or a suspected malabsorption disorder, or suspected malnutrition.

## Endocrinology

☐ CG (Choriogonadotropin) ☐ HbA1c (Glycohemoglobin) Lavender-top tube ☐ TSH (Thyrotropin) ☐ FT4 (Thyroxine, Free) ☐ PTH (Parathyrin) ☐ Cortisol ☐ 1,25-Dihydroxy-Cholecalciferol (Calcitriol)

## Gastrointestine-Related Antibodies

☐ Tissue Transglutaminase IgA ☐ Deamidated Gliadin IgG Coeliac auto-antibodies above may be falsely negative if the patient is already eating a gluten-free diet. ☐ Intrinsic Factor Antibodies ☐ Parietal Cell Antibodies ☐ ASCA (Anti-Saccharomyces Cerevisiae Antibodies - IgG and IgA) ☐ Mitochondrial Antibodies ☐ Smooth Muscle Antibodies

## Arthritis Auto-Antibodies

☐ Anti-CCP (Cyclic Citrullinated Peptide) ☐ RF (Rheumatoid Factor) To diagnose or monitor rheumatoid arthritis, anti-CCP is more sensitive and specific than RF.

## Other Auto-Antibodies

☐ ANA (Nuclear Antibodies) ☐ Double-Stranded DNA Antibodies ☐ ANCA (Neutrophil Cytoplasmic Antibodies)

## Thiopurine Immunosuppressants

(Azathioprine, 6-Mercaptopurine, 6-Thioguanine) ☐ TPMT Phenotype (Thiopurine Methyl-Transferase enzyme activity) Indicated only once, before starting a patient on a thiopurine immunosuppressant for the first time. ☐ Thiopurine Metabolites: 6-TG, 6-MMP (6-Thioguanine, 6-Methylmercaptopurine) Indicated only for monitoring patients who are taking a thiopurine immunosuppressant.

## Hydrogen Breath Testing

[ ] LTT (Lactose Tolerance Test 25g 3h)

## Faecal Testing

[ ] FOB (Faecal Occult Blood)

**Additional Haematology or Biochemistry tests:** (not Microbiology or Serology tests, because they go to a different department)

**Don't photocopy this form - Laser print clean copies.** Form GI-IBD version 1.28(34), revised 2013-04-09 ILB

---

Patient: Mr. Ethan Kang Appointment Date: 2018-Apr-15 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: Taylor, Sinead I saw Ethan Kang today for follow up of his Crohn's disease.

Problem History: Crohn's disease

IBD Phenotype: Crohn's disease Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 - Strictureing

Endoscopy Results: Last in January 2017. Normal colon. Inflamed neo-TI. CT Enterography in Apr 2016. 10-15cm of ileal involvement

Active Medications: Methotrexate 2.5 mg Oral Tablet 10 Tablet(s) 1x/week X 60 Day(s) ENTYVIO 300 MG VIAL - started in Nov 2017

Current Status Had been doing ok up until about 1 week ago. Between 2-4 BMs/day. Sludgy. No blood. Minimal abdominal pain. Has started to develop worsening abdominal pain just over the past week. Not taking any meds for it. Associated with increased stool frequency. 6-12x/day. Watery. Min blood. No systemic symptoms or upper GI symptoms.

Seen in Crestwood Medical Group 2 and had CT abdomen but no bloodwork (CT was unremarkable). No stool cultures.

On physical examination, he looks and . He has no lymphadenopathy. His lungs are clear to auscultation. He has normal heart sounds. His abdomen is soft, with no organomegaly or masses.

Assessment and Plan Ethan Kang currently has mildly active symptoms which may represent an infection or something transient. Will arrange bloodwork/stool cultures. In general he feels Entyvio is not working particularly well and our investigations show a drop in his FCP but also detectable low titre antibodies against Vedolizumab with low levels. For that reason I am trying to arrange for him to increase to q4w infusions and continue with the Methotrexate. We will try to stay the course for now.

We will arrange the following investigations: Bloodwork Colonoscopy Stool Cultures

I will see him again in follow up in the office in [REDACTED-DATE] and he is booked for a colonoscopy in [REDACTED-DATE].

---

# Review

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 04/15/2018                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2018-Apr-16 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |

**Notes** can you figure out why under the notes column in the virtual chart it says cancelled. i can show you where i see it.

## Conversations

**Created 2018-Apr-16 8:11 AM**

---

2018-Apr-16 8:11 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] *This message has been removed by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]*

**Created 2018-Apr-16 8:12 AM**

---

2018-Apr-16 8:12 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [image] The generated letter wasn't going through the fax yesterday despite multiple attempts. So I called Dr. Herrera's office and they gave me an alternate fax number that I tried, and that went through. So I cancelled the one you sent [image] Dr. Sinead Taylor

---

Crestwood Medical Group 2 Maple Health Clinic 5 Physician's Questionnaire

*Please have the below completed by your prescribing physician. Attach extra information if necessary.*

|                                                        |                                   |
|--------------------------------------------------------|-----------------------------------|
| <b>Part 2 Physician Information</b>                    |                                   |
| Name of prescribing physician (please print):          | Specialty:                        |
| Dr. Sinead Taylor                                      | Gastroenterologist                |
| Address (number, street, city, province, postal code): |                                   |
| a nearby city 8                                        |                                   |
| Telephone Number (including area code):                | Fax Number (including area code): |
| (089) 697-3500 a5345                                   | (442) 733-2165                    |

1. Prior Authorization Drug: Entyvio

2. Requested Dosage and Frequency: Entyvio 300mg IV Q4 Weeks
3. Date increased dosage was established or will be established: ASAP
4. Anticipated period of time this dosage will be maintained: ongoing
5. Date of physician appointment for assessment of response to the increased dosage: Appointment to be booked by patient
6. Is there a plan to reduce dosage in the future? ☐ Yes ☒ No If yes, provide details: (blank) If no, provide rationale: (blank)
7. Has the patient undergone any therapeutic drug level testing or any other applicable test that could assess drug efficacy? ☐ Yes ☐ No ☒ Not applicable Please attach reports.
8. Please advise the medical rationale for the increased dosage. Patient is experiencing increased IBD symptoms with more frequent stools with blood. HBI remains the same (12)

**Please provide the following documentation** ☐ Clinical information including lab reports and scores prior to the increased dosage ☐ Clinical information including lab reports and scores since the increased dosage was established (if applicable) ☐ Provide clinical literature/studies to support the use of the increased dosage, such as: ☐ At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and ☐ Published recommendations in evidence-based guidelines supporting its use.

I certify that the information provided on this Physician's Questionnaire is true, correct and complete.  
Physician's signature: [signature] Date: APR 15, 2018

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. The completed Request for Information form can be returned to Crestwood Medical Group 2 by mail or fax.

Mail to: Crestwood Medical Group 2 Drug Services a nearby city 9

Fax to: Crestwood Medical Group 2 Fax (089) 697-3500 a5345

M7268-3/15 © Crestwood Medical Group 2. All rights reserved. Any modification of this document without the express written consent of Crestwood Medical Group 2 is strictly prohibited.

---

#### AD EMERGENCY RECORD Crestwood Medical Group 2

| ER REGISTRATION DOCTOR |                 |             |             |             |  |
|------------------------|-----------------|-------------|-------------|-------------|--|
| DATE                   | TIME            | ACCT #      | PREV. VISIT | Unit #:     |  |
| 14/04/2018             | [REDACTED-DATE] | 167-067-993 | 02/10/2017  | 167-067-993 |  |

| PATIENT SURNAME                  | PATIENT GIVEN NAME (S) | BIRTH DATE D/M/Y     | AGE | SEX | FAMILY DOCTOR: |
|----------------------------------|------------------------|----------------------|-----|-----|----------------|
| Ethan Kang                       | Ethan Kang             | 21/06/1979           | 38  | M   | Keller, Marco  |
| 847 Fennimore St                 |                        | Patient's Home Phone |     |     |                |
| a nearby city 6 ON 848 Main Blvd |                        | (442) 733-2165       |     |     |                |



| IN EMERGENCY NOTIFY | RELATION | EMERGENCY NOTIFY PHONE |
|---------------------|----------|------------------------|
| Navarro, Alma       | WIFE     | (089) 697-3500 a5345   |

| OHIP HC#    | RFP | INSURANCE/POLICY # | WSIB | WSIB CLAIM #. | DATE OF ACCIDENT | SIN |
|-------------|-----|--------------------|------|---------------|------------------|-----|
| 167-067-993 | 52  | 167-067-993        | N    |               |                  |     |

| WSIB EMPLOYER NAME | PHONE | ARRIVAL | LOCATION | TRIAGE |
|--------------------|-------|---------|----------|--------|
|                    |       | W       | WER      | 2      |

| MEDICAL ALERTS | ALLERGIES |
|----------------|-----------|
| CHRONIC ANEMIA | codeine   |

| REASON FOR VISIT | CCI |
|------------------|-----|
| ABDO PAIN        |     |

| T               | P       | Resp  | BP     | O2 Sat  | Weight (kg) | Ordered | DONE |
|-----------------|---------|-------|--------|---------|-------------|---------|------|
| 36.7            | 67      | 19    | 146/88 | 100     | 0           | BLOOD   |      |
| Expected DISCH  | Room #1 | Time  | PIA    | Room #2 | Time        | ERLAB   |      |
| [REDACTED-DATE] |         | 16:19 |        |         |             | ERABD   |      |
|                 |         |       |        |         |             | ERCCA   |      |

| [ ] See MEDITECH ENTIVIO Q 8 wks [ ] Form 1 Initiated | CBC                                 |             |
|-------------------------------------------------------|-------------------------------------|-------------|
| MAINTAIN [illegible] 4 DOSE PFA wk                    | [ ] Form 42 to Pt and copy on chart | LYTES       |
| CROHNS - ANEMIA, A - IRON, B12 - Q 2 wks              |                                     | LFT'S       |
| - CALCIUM - [illegible] [illegible] 2015 SB RESECTION |                                     | BHCG        |
| - [illegible] on many occasions                       |                                     | QUA         |
| [illegible] - C7 MR - PR [illegible]                  |                                     | TROP        |
| [illegible] (N) FLANK PAIN [illegible]                |                                     | PTPTT (INR) |
| [illegible] NORMAL [illegible]                        |                                     | C&S Blood   |
| [illegible]                                           |                                     | GRP/SC      |
| [illegible]                                           |                                     | URINE       |
| [ ] Point of Care Ultrasound [illegible]              |                                     | URRM        |

| TIME | Doctors Orders -<br>ASSESSMENT             | TIME                             | Medical<br>Directive     | C&S<br>Urine |  |
|------|--------------------------------------------|----------------------------------|--------------------------|--------------|--|
|      |                                            |                                  | [ ] Medical<br>Directive | OTHER        |  |
|      | [illegible] / [illegible] / [illegible]    | Doctors Orders -<br>REASSESSMENT | ECG                      |              |  |
|      | [illegible]                                |                                  |                          |              |  |
|      | [illegible]                                |                                  |                          |              |  |
|      | [illegible] CT - [illegible]               |                                  |                          |              |  |
|      | [illegible]                                |                                  |                          |              |  |
|      | [illegible] (L) RENAL COLIC<br>[illegible] |                                  |                          |              |  |
|      | APPENDIX                                   |                                  |                          |              |  |
|      | REMOVED                                    |                                  |                          |              |  |

MD Orders Signature: [signature]

**Discharge Instructions** [X] Return to ED if symptoms worsen or if concerned [ ] F/U with Dr. GP in 1-2 days [ ] Instruction sheet provided [signature] [ ] Sutures Out in days, wound care [ ] RX Given: [ ] F/U  
Maple Health Clinic 4: Written Discharge Instructions: [signature] ED Physician Signature [illegible]  
[illegible] [illegible] Final Diagnosis: ABD PAIN NYD

MD D/C Date/Time: [blank] Time Left ED: [blank] Transferred To: [blank] LWBS/AMA [blank] OPIOID OD [ ]

ACCT # ||||| White-Chart NIRMNTHAR FORM ID

[illegible] / [illegible]

![[Crestwood Medical Group 2 Logo]

**Crestwood Medical Group 2** Crestwood Medical Group 2 a nearby city 8

Name: Ethan Kang DOB:21/06/1979 Age: 38 Sex: M Unit No: 167-067-993 Rqvu: YE495751/89 Loc: WER  
Exam Date: 14/04/2018 Status: REG ER Report No: 167-067-993

Additional copy [ ]

**Medical Imaging - CONSULTATION** Gdjewggfr Kp: RFL798442733, Category/Procedure name: CAT  
SCAN/ABD and PEL NO CON RENAL COLIC

CT ABD and PEL NO CON RENAL COLIC

CLINICAL INDICATION:

Rule out renal colic.

COMPARISON:

Sep 19, 2017.

TECHNIQUE:

Noncontrast CT of the abdomen and pelvis was performed.

FINDINGS:

There are no obstructing renal, ureteric or bladder stones. No hydronephrosis.

Evaluation of the solid organs is limited by lack of intravenous contrast. There is marked hepatomegaly measuring approximately 25 cm along the midclavicular line. The spleen measures near the upper limits of normal at approximately 12.3 cm in maximal dimension. Few gallstones are again noted in a nondistended gallbladder. The pancreas, adrenal glands and bladder are unremarkable.

Few colonic diverticula. No evidence of diverticulitis. Prior small bowel resection.

No free fluid or free air. The retroperitoneum is unremarkable. Small fat containing left inguinal hernia.

---

This report was created using voice recognition. If there are concerns regarding accuracy please fax to Maple Health Clinic 4 at (089) 697-3500 a5345.

CC:Vance, Kian; Keller, Marco

Dictated Date/Time: [REDACTED-DATE] Transcribed Date/Time: [REDACTED-DATE] Signed Date/Time: [REDACTED-DATE] Addendum Date/Time:

Transcriptionist: MOKP

Page: 1 Print Date:

---

Crestwood Medical Group 2 Crestwood Medical Group 2 a nearby city 8

Name: Ethan Kang DOB: 21/06/1979 Age: 38 Sex: M

Rqvu: YE495751/89 Loc: WER Exam Date:14/04/2018 , Status: REG ER Unit No: 167-067-993 Report No: 167-067-993

---

Medical Imaging - CONSULTATION Gdjewggfr Kp: RFL798442733: Category/Procedure Name: CAT SCAN/ABD and PEL NO CON RENAL COLIC

---

Lung bases are clear. No aggressive osseous abnormality. Few well-circumscribed lucencies in the iliac bones are stable, possibly representing benign bone lesions.

IMPRESSION:

***No obstructing renal, ureteric or bladder calculi.***

**Marked hepatomegaly. Suggest correlation with LFTs.**

**Cholelithiasis.**

**The spleen measures near the upper limits of normal.**

---

\*\*Signed,, [REDACTED-DATE] Reported By: Lavoie, Gabriel

Ordering Physician: Kian Vance

---

This report was created using voice recognition. If there are concerns regarding accuracy please fax to Maple Health Clinic 4 at (089) 697-3500 a5345.

CC:Vance, Kian; Keller, Marco

Dictated Date/Time: [REDACTED-DATE] Transcribed Date/Time: [REDACTED-DATE] Transcriptionist: MOKP Signed Date/Time: [REDACTED-DATE] Addendum Date/Time: Print Date:

---

![Crestwood Medical Group 2 LOGO]

Crestwood Medical Group 2 Crestwood Medical Group 2 a nearby city 8

Name: Ethan Kang DOB:21/06/1979 Age: 38 Sex: M Unit No: 167-067-993 Pvfj: HL334755/51 Loc: WSDC Exam Date: 02/10/2017 Status: DEP SDC Report No: 167-067-993

Additional copy [ ]

---

**Medical Imaging - CONSULTATION Ngqzjchus Ax: VEN690207483; 167-067-993, Category/Procedure name: COMPUTED RADIOGRAPHY (RAD)/ FLUORO BY OTHER PHYS 45 MINS; RETROGRADE PYELO LEFT w FLUORO**

Images from left retrograde pyelogram were provided.

No contrast is seen.

Please see operative report.

---

\*\*Signed,, [REDACTED-DATE] Reported By: Taylor, Sinead

Ordering Physician: Gunnar Herrera

---

This report was created using voice recognition. If there are concerns regarding accuracy please fax to Maple Health Clinic 4 at (089) 697-3500 a5345.

CC:Cohen, Tobias; Keller, Marco

Dictated Date/Time: [REDACTED-DATE] Transcribed Date/Time: Transcriptionist: NASS Signed  
Date/Time: [REDACTED-DATE] Addendum Date/Time: Page: 1 Print Date: 03/10/2017

---

![[Crestwood Medical Group 2 LOGO]

Crestwood Medical Group 2 a nearby city 8

(089) 697-3500 a5345

Additional copy [ ]

UNIT: 167-067-993 KTCB: XU815214/00 NAME: Ethan Kang GENDER: M DOB: 21/06/1979 AGE: 38  
HCN: 167-067-993 LOCN: Y633528593 ADMIT DATE: 21/09/2017 D/C DATE: 21/09/2017 COMPLETED  
BY: Gunnar Herrera FAMILY DOCTOR: Sinead Taylor

Report No: 167-067-993

## **OPERATIVE REPORT**

DATE OF PROCEDURE: Sep 21, 2017

PREOPERATIVE DIAGNOSIS: Left renal colic.

POSTOPERATIVE DIAGNOSIS: Left renal colic.

OPERATIVE PROCEDURE: Cystoscopy, left retrograde pyelogram and insertion of stent.

ANESTHESIA: General.

ANESTHETIST: Dr. Walker.

PROCEDURE: The patient was prepped and draped in the semi-lithotomy position. The anterior urethra appeared normal and the prostate was nonobstructive. The bladder was free of tumor or stone and small diverticulum was noted just above the left ureteric orifice. Retrograde pyelogram demonstrated a stone in the left distal ureter with high-grade obstruction. The guide-wire was rather difficult to pass. Therefore, rather than stone removal insertion of stent was carried out. A 6-French 26 cm stent was placed without difficulties. He will be brought back for ureteroscopic stone removal on an elective basis.

Sinead Taylor DICTATED, NOT READ Dictation ID: 167-067-993 Confirmation #: 167-067-993

Dictated Date/Time: [REDACTED-DATE] Transcribed Date/Time: [REDACTED-DATE] Transcriptionist:  
NUMT Print Date: 08/10/2017

cc: Marco Keller; Gunnar Herrera

---

![[Crestwood Medical Group 2 LOGO]

Crestwood Medical Group 2 a nearby city 8

(089) 697-3500 a5345

Additional copy [ ]

UNIT: 167-067-993 KTCB: XU815214/00 NAME: Ethan Kang GENDER: M DOB: 21/06/1979 AGE: 38  
HCN: 167-067-993 LOCN: Y633528593 ADMIT DATE: 21/09/2017 D/C DATE: 21/09/2017 COMPLETED  
BY: Gunnar Herrera FAMILY DOCTOR: Sinead Taylor

Report No: 167-067-993

## CONSULTATION REPORT

DATE OF CONSULTATION: Sep 21, 2017

This 38-year-old man was seen at the Emergency Room on request from Dr. Bhatt.

He has a history of Crohn's disease and a calcium oxalate stone in the past. He presented to the Emergency Room with left-sided flank pain of two days and CT scan demonstrated 5 mm stone at the left UVJ.

His pain became worse and difficult to control.

He has history of allergy to codeine.

I discussed the findings and therapeutic options which primarily includes stone removal and possible need for stent insertion along with symptoms one may after having stent.

After discussion, he agreed to have retrograde pyelogram with a plan for stone removal or possibly stent insertion followed by secondary ureteroscopy.

Sinead Taylor DICTATED, NOT READ Dictation ID: 167-067-993 Confirmation #: 167-067-993

Dictated Date/Time: [REDACTED-DATE] Transcribed Date/Time: [REDACTED-DATE] Transcriptionist:  
NUMT Print Date: 04/10/2017

cc: Marco Keller; Gunnar Herrera

---

Surgical Case Record Page: 1

Patient: 167-067-993 Ethan Kang Date of Birth: 21/06/1979 Account Num: 167-067-993 Age: 38 Physician:  
Cohen, Tobias Sex: M Specialty: 39-Urology Room-Bed/T. Loc: O.R.: Y633528593 Oper Date: 02/10/2017  
Facility: Crestwood Medical Group 2 Verified Run Date: 14/04/2018 Date 11/10/2017 1448 STEPHOGG  
Tobias Cohen Run Time: 1111

## Procedures

| Proposed Procedures                    | Severity | R/L/B/NA |
|----------------------------------------|----------|----------|
| p Cysto Removal of Left Stent Left     | MAJOR    |          |
| Ureteroscopy Laser Litho Stone Removal |          |          |
| Reinsertion of Left Stent              |          |          |

| Proposed Procedures                        | Severity | R/L/B/NA |
|--------------------------------------------|----------|----------|
| s Left Laser Lithotripsy, Removal of Stone | MAJOR    |          |
| s Re-Insertion of Left Stent               | MAJOR    |          |

| Actual Procedures                  | Severity | R/L/B/NA | Wound | Surgeon | CUT | CLOSE |
|------------------------------------|----------|----------|-------|---------|-----|-------|
| p Cysto Removal of Left Stent Left | MAJOR    | LEFT     | CC    | KONP    |     |       |
| Ureteroscopy Stone Removal         |          |          |       |         |     |       |

Case Type: Planned

Anesthetic Type: General

ASA Class: ASA3 Severe Disease

### Diagnosis

Pre-Op Diagnosis

LEFT RENAL COLIC

Post-Op Diagnosis

LEFT RENAL COLIC

### Operative Staff

| Surgeons                           | In | Out | Date |
|------------------------------------|----|-----|------|
| Procedure:                         |    |     |      |
| p Cysto Removal of Left Stent Left |    |     |      |
| Ureteroscopy Stone Removal         |    |     |      |
| Cohen, Tobias                      |    |     |      |
| Surgeon:                           |    |     |      |
| Cohen, Tobias                      |    |     |      |
| Assisting:                         |    |     |      |

| Anesthesiologists | In | Out | Date |
|-------------------|----|-----|------|
| Anesthesiologist: |    |     |      |
| Dr. Tobias Cohen  |    |     |      |

| Other Case Staff | In   | Out  | Date       |
|------------------|------|------|------------|
| Circulating      |      |      |            |
| Tobias Cohen     |      |      |            |
| Tobias Cohen     | 1514 | 1535 | 02/10/2017 |
| Tobias Cohen     | 1535 | 1604 | 02/10/2017 |

| Other Case Staff | In | Out | Date |
|------------------|----|-----|------|
| X-ray Technolog  |    |     |      |
| Tobias Cohen     |    |     |      |

## Surgical Case Record

Patient: 167-067-993 Ethan Kang Date of Birth: 21/06/1979 Account Num: 167-067-993 Age: 38 Physician: Cohen, Tobias Sex: M Specialty: 39-Urology Room-Bed/T. Loc: O.R.: Y633528593 Oper Date: 02/10/2017 Facility: Crestwood Medical Group 2 Verified Run Date: 14/04/2018 Date 11/10/2017 1448 STEPHOGG Tobias Cohen Run Time: 1111

## Operative Times

-- Operative Area -- Time Date --- ROOM READY 1ST CASE: ENTER TIME: 1514 02/10/2017  
 ANESTHESIA START: 1514 02/10/2017 PREP/POSITION: 1529 02/10/2017 CUT TIME: 1533 02/10/2017  
 CLOSE TIME: 1548 02/10/2017 ANESTHESIA STOP: 1558 02/10/2017 EXIT TIME: 1558 02/10/2017

## Operative Medications

| Date       | Time | Medications Admin.  | Dose  | Dose Unit | Route | Site   | Given By |
|------------|------|---------------------|-------|-----------|-------|--------|----------|
| 02/10/2017 | 1534 | Instillagel (11 mL) | 11    | mL        | TOP   | OPSITE | KONP     |
| 02/10/2017 | 1530 | Ancef               | 2,000 | mg        | IV    |        | KONP     |

## Operative Intakes

| Date       | Time | User    | Type | Intake               | Route  |  |         |
|------------|------|---------|------|----------------------|--------|--|---------|
|            |      | Site    |      | Beg Amt Rate         | Op Vol |  | End LTC |
| 02/10/2017 | 1539 | KONP    | I    | SALINE - Saline 0.9% |        |  |         |
|            |      | BLADDER |      | ml                   | ml     |  | ml      |

## Preparation Screen

Pre Op Skin Assessment **Intact** Describe alteration: Hair removal incision site: Body Site: Body Side:  
 Provider: Hair removal Electrosurgery Unit: **None** Body Site: Body Side: Provider: Skin prep:  
**Chlorhexadine Gluconate** Body Site: **Penis Perineum** Body Side: Provider: **Tobias Cohen** Comments:  
**URETRA PREPPED BY Dr. Cohen** Skin prep #2: Body Site: Body Side: Provider: Comments:

## Positions

## Lithotomy

Surgical Case Record Page: 3 Patient: 167-067-993 Ethan Kang Date of Birth: 21/06/1979 Account Num: 167-067-993 Age: 38 Physician: Cohen, Tobias Sex: M Specialty: 39-Urology Room-Bed/T.Loc: O.R.: Y633528593 Oper Date: 02/10/2017 Facility: Crestwood Medical Group 2 Verified Run Date: 14/04/2018 Date 11/10/2017 1448 STEPHOGG Tobias Cohen Run Time: 1111



## Devices

Arm Padded/Tucked at Side BILATERAL Elbows Padded Yellow Fin

## Operative Screens

Identification Band on? Y Type Of Count: No Count Skin Condition on Discharge: Same As Preop Describe alteration: Xray Precaution-Shield To: Throat Malignant Hyperthermia Protocol? N Latex Protocol? N Debriefing (before patient leaves the OR) Y Provider: Tobias Cohen Nurse verbally confirms name of Procedure? Y Nurse confirmed instrument, sponge and needle count correct? Y Nurse Confirms Specimens are Labelled Correctly? Y Important Intraoperative Event/Equipment Concerns Discussed? Y Key Concerns for Patient Recovery/Management Communicated? Y (Surgeon to Complete Medication Reconciliation) Could Anything have Increased Safety/Efficiency of the Case? N Comments: Dressings: Special Dressings: Provider: Packing: Quantity: Method of Securing: Packing Comments: Drains: Method of Securing: Collection: Drain Site 1 Provider: Drain#2: Method of Securing#2: Collection#2: Drain Site #2: Provider:

Specimen Taken? Y . LAB: **CHEM** Specimens: **Ureter Stone Left** Additional Specimens: LAB: Specimens: Additional Specimens: LAB:

---

## Surgical Case Record

**Patient:** 167-067-993 Ethan Kang **Date of Birth:** 21/06/1979 **Account Num:** 167-067-993 **Age:** 38  
**Physician:** Cohen, Tobias **Sex:** M **Specialty:** 39-Urology **Room-Bed/T. Loc:** O.R.: Y633528593 **Oper Date:** 02/10/2017 **Facility:** Crestwood Medical Group 2 **Verified Run Date:** 14/04/2018 **Date** 11/10/2017  
1448 STEPHOGG Tobias Cohen **Run Time:** 1111

**Specimens:** **Additional Specimens:** **LAB:** **Specimens:** **Additional Specimens:** **LAB:** **Specimens:** **Additional Specimens:** **LAB:**

## Specimens: Additional Specimens: LAB: Specimen: Additional specimens:

Safety Checklist for Nerve Block Team (Before Beginning OR) **NA** Briefing (before Induction of Anaesthesia) **Y** Provider: **Tobias Cohen** Confirm Introduction of OR Staff by Name and Role? **Y** Patient Information Confirmed? **Y** (Identify using Two Patient Identifiers, Site, & Procedure) Site, Side, and Level Marked? **Y** Clinical Documentation Available? **Y** (Consent, History & Physical, Lab Results, Imaging and ECG) Identified Known Allergy (Drug, Latex, Food, Environmental)? **Y** Review Instruments, Implants, Positioning, Concerns or VTE? **Y** Medications on Sterile Field? **Y** Identified Infection Control Concerns/Isolation Precautions? **N** Anaesthesiologist Review? **Y** (Anaesthesia Safety Checklist Completed) (Difficult Airway/Aspiration Risk/Malignant Hyperthermia) (Confirm Equipment/Monitoring Devices/Assistance Available) Comment: Time Out (before skin incision) **Y** Provider: **Tobias Cohen** Surgical Team Verbally Confirms: **Y** (Patient, Procedure, Site, Side, and Level) Radiology Images Reviewed by the Surgeon? **Y** Anticipated Blood Loss/Requirements? **N** (Greater Than 500 mL in Adult or 7 mL per kg in Children) (Group & Type, Blood/ Blood Products Available if Required) Nursing Team Review? **Y** (Sterility Confirmed, Equipment Concerns) Surgeon Review? **Y** (Critical Steps, Instruments/ Implant(s) Availability) (Post Operative Destination) Prophylactic Antibiotic Given within 60 Minute Window? **Y** Is Antibiotic Redosing Required if 60 Minute Window Not Met? **Not Applicable** Any Other Questions or Concerns Before Proceeding? **N** Possible Cancer Diagnosis **No** Emergency/Replacement Case **Not Applicable** If procedure is a Total Joint answer next question: Type of Replacement

---

### Surgical Case Record

|                     |                                       |                         |            |
|---------------------|---------------------------------------|-------------------------|------------|
| <b>Patient:</b>     | 167-067-993 Ethan Kang                | <b>Date of Birth:</b>   | 21/06/1979 |
| <b>Account Num:</b> | 167-067-993                           | <b>Age:</b>             | 38         |
| <b>Physician:</b>   | Cohen, Tobias                         | <b>Sex:</b>             | M          |
| <b>Specialty:</b>   | 39-Urology                            | <b>Room-Bed/T. Loc:</b> |            |
| <b>O.R.:</b>        | Y633528593                            | <b>Oper Date:</b>       | 02/10/2017 |
| <b>Facility:</b>    | Crestwood Medical Group 2             |                         |            |
| <b>Verified</b>     |                                       | <b>Run Date:</b>        | 14/04/2018 |
| <b>Date</b>         | 11/10/2017 1448 STEPHOGG Tobias Cohen | <b>Run Time:</b>        | 1111       |

---

### Operative Transfer Data

Surgery Outcome: C Completed Patient Destination: PACU Post Anesthesia Care Unit Transfer Method: STR Stretcher Report Given To: BERNSAMU Tobias Cohen

---

### Operative Completed By

Completed Date: 02/10/2017 Completed Time: 1604 Completed By: Tobias Cohen

---

## User Legend

BERNSAMU = Tobias Cohen CHRIBROW = Tobias Cohen, Registered Nurse Cohen = Tobias Cohen  
IRAIGOLD = Tobias Cohen Cohen = Tobias Cohen, Surgeon Cohen = Tobias Cohen, Registered Nurse

---

## Site Legend

BLADDER = Bladder OPSITE = Operative Site

---

![[Crestwood Medical Group 2 Logo]

Crestwood Medical Group 2 a nearby city 10 a nearby city 6,Ontario a nearby city 11

(089) 697-3500 a5345

Additional copy [ ]

UNIT: 167-067-993 KTCB: XU815214/00 NAME: Ethan Kang GENDER: M DOB: 21/06/1979 AGE: 38  
HCN: 167-067-993 LOCN: Y633528593 ADMIT DATE: 21/09/2017 D/C DATE: 21/09/2017 COMPLETED  
BY: Gunnar Herrera FAMILY DOCTOR: Sinead Taylor

Report No: Y633528593

## DISCHARGE SUMMARY

DATE OF ADMISSION: Sep 21, 2017

DATE OF DISCHARGE: Sep 21, 2017

DISCHARGE DIAGNOSIS: Left renal colic.

HISTORY: This 38-year-old man presented to the Emergency Room with left renal colic and had a retrograde pyelogram and stent insertion.

He did not want to stay in the hospital and went home to be reassessed for subsequent stone removal.

Sinead Taylor DICTATED, NOT READ Dictation ID: Y633528593 Confirmation #: Y633528593

Dictated Date/Time: 07/12/2017 1855 Transcribed Date/Time: 08/12/2017 2131 Transcriptionist: NTS Print  
Date: 10/12/2017

cc: Marco Keller; Gunnar Herrera

---

Cedar Specialist Group 4®

SCC Accredited LAB Accrédité CCN

Lab ID: Y633528593 Westbrook Medical Associates 5 External Ref. No.: Y633528593

| Prescriber |                                     | Patient        |                    |
|------------|-------------------------------------|----------------|--------------------|
| Name:      | <b>Sinead Taylor</b>                | Name:          | <b>Ethan Kang</b>  |
| Clinic:    | Westbrook Medical Associates 5      |                |                    |
| Address:   | a nearby city 10<br>a nearby city 8 | Date of birth: | 1979-06-21 Age: 38 |
| Telephone: | 659.710.1986                        | Sex:           | M                  |
| Fax:       | 986.368.7859                        | Health Ins.    |                    |

## Biochemistry

| Analysis     | Specimen | Result | Reference value | Unit | Status |
|--------------|----------|--------|-----------------|------|--------|
| Calprotectin | Stool    | 604    | < 100           | µg/g |        |

**Interpretation:** Active inflammation in the gastrointestinal tract. It is recommended to order additional analyses and to optimize the curative treatment under the supervision of medical specialists.

**Note:** The cut-off level suggested for adults (100 µg/g) can also be used for children aged 4 to 17 years regardless of sex.

For your convenience, a graphic presentation of your patient's history is included on page 2 of this report.

**Method:** The reference values and conclusions have changed.<br>As of Dec 10, 2017, the reference values and conclusions are presented according to Bressier B. et al. Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015 29(7):369-72.

Comments:

! [Signature] Tobias Cohen Clinical Biochemist

| Date Collected | Date Received | Partial report | Completed report | Revised report |
|----------------|---------------|----------------|------------------|----------------|
| 2018-04-04     | 2018-04-05    | -              | 2018-04-12       | -              |

257 Maple Ave, 257 Maple Ave (QC) Canada 257 Maple Ave T 867.739.5528 F 994-882-7246

Cedar Specialist Group 4®

SCC Accredited LAB Accrédité CCN

Lab ID: Y633528593 Westbrook Medical Associates 5 External Ref. No.: Y633528593

| Prescriber |                                     | Patient         |                    |
|------------|-------------------------------------|-----------------|--------------------|
| Name :     | <b>Sinead Taylor</b>                | Name :          | <b>Ethan Kang</b>  |
| Clinic:    | Westbrook Medical Associates 5      |                 |                    |
| Address:   | a nearby city 10<br>a nearby city 8 | Date of birth : | 1979-06-21 Age: 38 |

| Prescriber |              | Patient     |   |
|------------|--------------|-------------|---|
| Telephone: | 659.710.1986 | Sex :       | M |
| Fax:       | 986.368.7859 | Health Ins. |   |

## Calprotectin Level

[image: Line graph showing Calprotectin Level over time from 2016 to 2018. Data points at ~862, 987, and 604. Threshold lines at 250 (Active Inflammation) and 100 (Moderate Inflammation).]

| Collection Date | Calpro Result (µg/g) |
|-----------------|----------------------|
| 2016-05-03      | 862                  |
| 2017-11-27      | 987                  |
| 2018-04-04      | 604                  |

| Date Collected | Date Received | Partial report | Completed report | Revised report |
|----------------|---------------|----------------|------------------|----------------|
| 2018-04-04     | 2018-04-05    | -              | 2018-04-12       | -              |

257 Maple Ave, 257 Maple Ave (QC) Canada 257 Maple Ave T 867.739.5528 F 994-882-7246

Westbrook Medical Associates 5

Date received: 1979 / mm / 1979 PHOL No.

# General Test Requisition

ALL Sections of this Form MUST be Completed

## 1 - Submitter

Courier Code:

Provide Return Address: Dr. Sinead Taylor 415 Juniper Rd a nearby city 6 , ON 848 Main Blvd

Clinician Initial / Surname and OHIP / CPSO Number Dr. Sinead Taylor 0748 361 588KT

Tel: (442) 733-2165 Fax: (442) 733-2165

**cc Doctor Information** Name: Dr. Sinead Taylor Tel: 994-882-7246 Lab/Clinic Name: Taylor Fax: (442) 733-2165 Laila Yamamoto Address: 412 Marigold Ave Postal Code:

## 2 - Patient Information

Health No. 414 235 249 Medical Record No. 414 235 249 Sex: Date of Birth: 1979 / mm / 1979 1979  
Patient's Last Name (per OHIP card) Ethan Kang First Name (per OHIP card) Ethan Patient Address 412

Marigold Ave Postal Code 848 Main Blvd Patient Phone No. ( ) - Submitter Lab No. Public Health Unit  
Outbreak No.

**Public Health Investigator Information** Name: Health Unit: Tel: Fax:

### 3 - Test(s) Requested (Please see descriptions on reverse)

Test: Enter test descriptions below C. difficile PCR Stool culture x 3

#### Hepatitis Serology

Reason for test (Check ( ) only one box): [ ] Immune status [ ] Acute infection [ ] Chronic infection

Indicate specific viruses (Check ( ) all that apply): [ ] Hepatitis A [ ] Hepatitis B [ ] Hepatitis C (testing only  
available for acute or chronic infection; no test for determining immunity to HCV is currently available)

### 4 - Specimen Type and Site

[ ] blood / serum [X] faeces [ ] nasopharyngeal [ ] sputum [ ] urine [ ] vaginal smear [ ] urethral [ ] cervix [ ]  
BAL [ ] other - (specify)

**Patient Setting** [X] physician office/clinic [ ] ER (not admitted) [ ] inpatient (ward) [ ] inpatient (ICU) [ ]  
institution

### 5 - Reason for Test

[X] diagnostic [ ] immune status [ ] needle stick [ ] follow-up [ ] prenatal [ ] chronic condition [X]  
immunocompromised [ ] post-mortem [ ] other - (specify)

Date Collected: 1979 / mm / 1979 Onset Date: 1979 / mm / 1979

**Clinical Information** [ ] fever [X] gastroenteritis [ ] respiratory symptoms [ ] STI [ ] headache / stiff neck [ ]  
vesicular rash [ ] pregnant [ ] encephalitis / meningitis [ ] maculopapular rash [ ] jaundice [X] other -  
(specify) IBD patient - flaring symptoms

[ ] influenza high risk - (specify) [ ] recent travel - (specify location)

For HIV, please use the HIV serology form. - For referred cultures, please use the reference bacteriology  
form. To re-order this test requisition contact your local Crestwood Medical Group and ask for form number  
F-SD-SCG-1000. Current version of Crestwood Medical Group requisitions are available at  
<https://www.costco.ca> The personal health information is collected under the authority of the Personal  
Health Information Protection Act, s.36 (1)(c)(iii) for the purpose of clinical laboratory testing. If you have  
questions about the collection of this personal health information please contact the PHOL Manager of  
Customer Service at 993-089-6973 qaa 0534 or toll free 993-089-6973 qaa 0534. F-SD-SCG-1000  
(08/2013) Crestwood Medical Group 2 Ridgeway Family Health

|                |                   |                  |                             |                  |                |
|----------------|-------------------|------------------|-----------------------------|------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>HomePhone</b> | <b>(089) 697-3500 a5345</b> | <b>WorkPhone</b> |                |
| Health #       | 0748 361 588KT    | Sex              | M                           | Patient ID       | 0748 361 588KT |
| Age            | 46 years          |                  |                             |                  |                |
| DOB            | 1979              |                  |                             |                  |                |

Lab Order #: Y633528593

Ordered By: Sinead Taylor

Collection Date: 2018-Apr-15

Reported Date: 2018-Apr-16 2:58 AM

Updated On: 2018-Sep-17 7:44 AM

Reported By: Ridgeway Family Health

Reviewed: 2018-Apr-16 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

|                       | Flags | Results | Ref Range       | Units           |
|-----------------------|-------|---------|-----------------|-----------------|
| <b>CRP</b>            |       |         |                 |                 |
| CRP (F)               | H     | 8.4     | < 8.0 mg/L      | mg/L            |
| <b>CREATININE</b>     |       |         |                 |                 |
| CREATININE (F)        | N     | 78      | 60 - 110 umol/L | umol/L          |
| eGFR (F)              | N     | 109     | 60. - 99999.99  | mL/min/1.73m**2 |
| >=60. mL/min/1.73m**2 |       |         |                 |                 |

eGFR is calculated using the CKD-EPI 2009 equation.

CREATININE (F)

Normal eGFR.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

|                       | Flags | Results | Ref Range      | Units  |
|-----------------------|-------|---------|----------------|--------|
| <b>ALBUMIN</b>        |       |         |                |        |
| ALBUMIN (F)           | N     | 44      | 35 - 52 g/L    | g/L    |
| <b>BILIRUBINTOTAL</b> |       |         |                |        |
| BILIRUBIN TOTAL (F)   | N     | 5       | <23 umol/L     | umol/L |
| <b>IRON</b>           |       |         |                |        |
| IRON (F)              | L     | 6       | 7 - 29 umol/L  | umol/L |
| <b>TIBC</b>           |       |         |                |        |
| TIBC (F)              | N     | 59      | 45 - 77 umol/L | umol/L |
| <b>SATURATION</b>     |       |         |                |        |
| SATURATION (F)        | L     | 0.10    | 0.20 - 0.50 /1 |        |

|                    | Flags | Results | Ref Range     | Units  |
|--------------------|-------|---------|---------------|--------|
| <b>TRANSFERRIN</b> |       |         |               |        |
| TRANSFERRIN (F)    | N     | 2.7     | 2.1 - 3.6 g/L | g/L    |
| <b>VITAMIN B12</b> |       |         |               |        |
| VITAMIN B12 (F)    | L     | 131     | 221. -        | pmol/L |

pmol/L

DEFICIENCY: < 148 pmol/L

INSUFFICIENCY: 148 - 220 pmol/L

SUFFICIENCY: > 220 pmol/L

60% OF SYMPTOMATIC PATIENTS HAVE A HEMATOLOGIC OR NEUROLOGIC RESPONSE TO B12 SUPPLEMENTATION AT A LEVEL <148 pmol/L

|                 | Flags | Results | Ref Range     | Units |
|-----------------|-------|---------|---------------|-------|
| <b>FERRITIN</b> |       |         |               |       |
| FERRITIN (F)    | N     | 58      | 24 - 453 ug/L | ug/L  |

Lab Results: Ridgeway Family Health

Generated On 2026-Apr-09

|                |                   |                  |                             |                  |                |
|----------------|-------------------|------------------|-----------------------------|------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>HomePhone</b> | <b>(089) 697-3500 a5345</b> | <b>WorkPhone</b> |                |
| Health #       | 0748 361 588KT    | Sex              | M                           | Patient ID       | 0748 361 588KT |
| Age            | 46 years          |                  |                             |                  |                |
| DOB            | 1979              |                  |                             |                  |                |

Lab Order #: Y633528593

Ordered By: Sinead Taylor

Collection Date: 2018-Apr-15

Reported Date: 2018-Apr-16 5:36 AM

Updated On: 2018-Sep-17 7:44 AM

Reported By: Ridgeway Family Health

Reviewed: 2018-Apr-16 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

|                                       | Flags | Results | Ref Range    | Units |
|---------------------------------------|-------|---------|--------------|-------|
| <b>AMYLASE</b>                        |       |         |              |       |
| AMYLASE (F)                           | N     | 33      | 30 - 110 U/L | U/L   |
| <b>ALKALINEPHOSPHATASE</b>            |       |         |              |       |
| ALKALINE PHOSPHATASE (F)              | N     | 67      | 40. - 129.00 | U/L   |
| 40-129 U/L                            |       |         |              |       |
| As of Dec 3, 2017, please note change |       |         |              |       |



|                                   | Flags | Results | Ref Range           | Units     |
|-----------------------------------|-------|---------|---------------------|-----------|
| in pediatric reference intervals. |       |         |                     |           |
| <b>GGT</b>                        |       |         |                     |           |
| GGT (F)                           | N     | 18      | < 60 U/L            | U/L       |
| <b>AST</b>                        |       |         |                     |           |
| AST (F)                           | N     | 15      | <37 U/L             | U/L       |
| <b>ALT</b>                        |       |         |                     |           |
| ALT (F)                           | N     | 21      | <46 U/L             | U/L       |
| <b>HEMOGLOBIN</b>                 |       |         |                     |           |
| HEMOGLOBIN (F)                    | N     | 133     | 129 - 165 g/L       | g/L       |
| <b>HEMATOCRIT</b>                 |       |         |                     |           |
| HEMATOCRIT (F)                    | N     | 0.40    | 0.39 - 0.49 l/l     | L/L       |
| <b>RBC</b>                        |       |         |                     |           |
| RBC (F)                           | N     | 4.6     | 4.2 - 5.8 x 10E12/L | x 10*12/L |
| <b>RBC INDICES: MCV</b>           |       |         |                     |           |
| RBC INDICES: MCV (F)              | N     | 88      | 80 - 98 fl          | fL        |
| <b>MCH</b>                        |       |         |                     |           |
| MCH (F)                           | N     | 29      | 24 - 33 pg          | pg        |

Lab Results: Ridgeway Family Health Generated On 2026-Apr-09

|                |                   |                  |                             |                  |                |
|----------------|-------------------|------------------|-----------------------------|------------------|----------------|
| <b>Patient</b> | <b>Ethan Kang</b> | <b>HomePhone</b> | <b>(089) 697-3500 a5345</b> | <b>WorkPhone</b> |                |
| Health #       | 0748 361 588KT    | Sex              | M                           | Patient ID       | 0748 361 588KT |
| Age            | 46 years          |                  |                             |                  |                |
| DOB            | 1979              |                  |                             |                  |                |

Lab Order #: Y633528593 Ordered By: Sinead Taylor Reported By: Ridgeway Family Health Collection  
Date: 2018-Apr-15 Reviewed: 2018-Apr-16 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-  
USERNAME] Reported Date: 2018-Apr-16 5:36 AM Updated On: 2018-Apr-16 11:04 PM

|             | Flags | Results | Ref Range     | Units |
|-------------|-------|---------|---------------|-------|
| <b>MCHC</b> |       |         |               |       |
| MCHC (F)    | N     | 328     | 313 - 344 g/L | g/L   |
| <b>RDW</b>  |       |         |               |       |
| RDW (F)     | N     | 15.9    | 12.5 - 17.3   |       |

|                           | Flags | Results    | Ref Range                 | Units    |
|---------------------------|-------|------------|---------------------------|----------|
| <b>WBC</b>                |       |            |                           |          |
| WBC (F)                   | N     | 7.4        | 3.2 - 9.4 x 10E9/L        | x 10*9/L |
| <b>PLATELETS</b>          |       |            |                           |          |
| PLATELETS (F)             | N     | 235        | 155 - 372 x 10E9/L        | x 10*9/L |
| <b>MPV</b>                |       |            |                           |          |
| MPV (F)                   | N     | 9.6        | 4.0 - 14.0 fl             | fL       |
| <b>DIFFERENTIAL WBC'S</b> |       |            |                           |          |
| NEUTROPHILS (F)           | N     | 5.3        | 1.4 - 6.3 x 10E9/L        | x 10*9/L |
| LYMPHOCYTES (F)           | N     | 1.6        | 1.0 - 2.9 x 10E9/L        | x 10*9/L |
| MONOCYTES (F)             | N     | 0.4        | 0.2 - 0.8 x 10E9/L        | x 10*9/L |
| EOSINOPHILS (F)           | N     | 0.0        | 0.0 - 0.5 x 10E9/L        | x 10*9/L |
| BASOPHILS (F)             | N     | 0.00       | 0.00 - 0.09 x 10E9/L      | x 10*9/L |
| <b>SMEAR</b>              |       |            |                           |          |
| SMEAR (F)                 |       |            |                           |          |
|                           |       | PLATELETS: | PLATELETS APPEAR ADEQUATE |          |
|                           |       | RBC'S:     | RED CELLS APPEAR NORMAL   |          |

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6,  
Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2018-Apr-15

Dr. Sinead Taylor 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Patient: Mr. Ethan Kang PHN: 414 235 249 WJQ: 158847108 Birthdate: 1979 Phone: H: ( ) - C: (442)  
733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Herrera,

I saw Ethan Kang today for follow up of his Crohn's disease.

Problem History: Crohn's disease

IBD Phenotype: Crohn's disease Montreal: CD Location - L1 - Ileal Montreal: CD Behaviour - B2 -  
Strictureing

Endoscopy Results: Last in January 2017. Normal colon. Inflamed neo-TI. CT Enterography in Apr 2016.  
10-15cm of ileal involvement

Active Medications: Methotrexate 2.5 mg Oral Tablet 10 Tablet(s) 1x/week X 60 Day(s) ENTYVIO 300 MG VIAL - started in Nov 2017

Current Status Had been doing ok up until about 1 week ago. Between 2-4 BMs/day. Sludgy. No blood. Minimal abdominal pain. Has started to develop worsening abdominal pain just over the past week. Not taking any meds for it. Associated with increased stool frequency. 6-12x/day. Watery. Min blood. No systemic symptoms or upper GI symptoms.

Seen in Crestwood Medical Group 2 and had CT abdomen but no bloodwork (CT was unremarkable). No stool cultures.

On physical examination, he looks and . He has no lymphadenopathy. His lungs are clear to auscultation. He has normal heart sounds. His abdomen is soft, with no organomegaly or masses.

Assessment and Plan Ethan Kang currently has mildly active symptoms which may represent an infection or something transient. Will arrange bloodwork/stool cultures. In general he feels Entyvio is not

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

---

working particularly well and our investigations show a drop in his FCP but also detectable low titre antibodies against Vedolizumab with low levels. For that reason I am trying to arrange for him to increase to q4w infusions and continue with the Methotrexate. We will try to stay the course for now.

We will arrange the following investigations: Bloodwork Colonoscopy Stool Cultures

I will see him again in follow up in the office in [REDACTED-DATE] and he is booked for a colonoscopy in [REDACTED-DATE].

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong Electronically Reviewed to Expedite Delivery

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

---

[X] \* --

This task has been completed

Patient: Ethan Kang Task Created By: [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Date Due: 03/22/2018 Priority: Normal Assigned To: [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Completed: 2018-Mar-25 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Notes: he has low level antibodies to VDZ. ask your vantage to increase his entyvio to q4w. also confirm his MTX dose...it is not clear from the note from [REDACTED-STAFF-PROVIDER-GIVEN-NAME].

Conversations

Created 2018-Mar-25 10:01 AM

2018-Mar-25 10:01 AM: [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [image]  
Message Left

Created 2018-Mar-25 10:05 AM

2018-Mar-25 10:05 AM: [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [image] He  
is on 10pills/day MTX [image] Dr. Sinead Taylor

Westbrook Medical Associates 5 596 Kestrel Rd 596 Kestrel Rd, CA 596 Kestrel Rd Phone: 994-882-7246  
mohan.verma27@crestwoodmedicalgroup.ca

Lakeshore Specialty Clinic 3 Anser® VDZ Ethan Kang

| Patient & Order Information                                   | Report Recipient                     |
|---------------------------------------------------------------|--------------------------------------|
| Order ID: Y633528593                                          | Tobias Cohen                         |
| Patient: Y633528593, Y633528593                               | Westbrook Medical Associates 5       |
| DOB                                                           | 821 Glenarm Ave                      |
| SSN Sex M                                                     | 3rd Floor, Riverside Medical Clinic  |
| Institution ID Y633528593 Maple Health Clinic 6 ID Y633528593 | a nearby city 6, ON 848 Main Blvd    |
| Ordered 03/12/2018 Completed 03/14/2018                       | Canada                               |
| Ordered By Tobias Cohen                                       | 416/586-4800X Phone 867.739.5528 Fax |
|                                                               | Study Y633528593 Visit visit 1       |

Sample ID: Y633528593 Collection Date: 03/07/2018 10:45AM (Serum) Institution Sample ID: Y633528593

Results:

**Detectable Serum Vedolizumab**

**Detectable Antibodies to Vedolizumab**

| Assay                                         | Result    | Lower Limit of Quantification |
|-----------------------------------------------|-----------|-------------------------------|
| Serum vedolizumab (VDZ) concentration         | 3.0 ug/ml | < 1.6 ug/ml                   |
| Antibodies to vedolizumab (ATV) concentration | 2.4 U/ml  | < 1.6 U/ml                    |

**Serum Vedolizumab Concentration\*** [image] (Plot shows a single point at 3.0 on 03/07/2018)

**Antibodies to Vedolizumab Concentration\*** [image] (Plot shows a single point at 2.4 on 03/07/2018)

**Collection Date (last 6 samples)**

| Collection Date | VDZ       | ATV      |
|-----------------|-----------|----------|
| 03/07/2018      | 3.0 ug/ml | 2.4 U/ml |

#### Collection Date (last 6 samples)

| Last Infusion | Current Dose | Current Interval |
|---------------|--------------|------------------|
| Not Provided  | Not Provided | Not Provided     |

\*Note - Values reported as exceeding the upper limit of quantification for the assay are plotted on the chart with the limit of quantification value

The test results are determined by using a size exclusion chromatography based on mobility shift assay on a High-Performance Liquid Chromatography (HPLC) system.

#### References:

1. Data on File. Cedar Specialist Group 4 DOF16-004, 06/2016.
2. Entyvio® (vedolizumab) Prescribing Information.
3. Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterology Journal 2014, Vol. 2(5) 333-344.
4. Ben-Horin S., et al. Optimizing Biologic Treatment in IBD: Objective Measures, but When, How, and How Often? BMC Gastroenterology 2015;15(178) 1-7.

Maple Health Clinic 6 provide important information to aid in the diagnosis and management of certain diseases. Test results should be used with other clinical and diagnostic findings to make a diagnosis and/or prognosis. This test was developed and its performance characteristics determined by Cedar Specialist Group 4 It has not been cleared or approved by the U.S. Food and Drug Administration. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. This test may be covered by one or more US pending or issued patents - see [www.lakeshorespecialtyclinic.ca](http://www.lakeshorespecialtyclinic.ca) for details.

Tobias Cohen Medical Director Maple Health Clinic 6, the Link Design, Anser, and the Anser design mark are trademarks or registered trademarks of Cedar Specialist Group 4 Vevey, Switzerland Copyright © 2018 Cedar Specialist Group 4 All Rights Reserved. Cedar Specialist Group 4 is a CAP-accredited CLIA laboratory Printed 03/14/2018 Page 1 of 1 414 235 249.1

|                 |                       |                          |                    |
|-----------------|-----------------------|--------------------------|--------------------|
| <b>Patient:</b> | <b>Mr. Ethan Kang</b> | <b>Appointment Date:</b> | <b>2018-Feb-11</b> |
| Title:          | Lars Dang             |                          |                    |
| Provider:       | Taylor, Sinead        | Referred By:             | Taylor, Sinead     |

#### Ridgeway Family Health NOTE

Mr. Ethan Kang was seen in follow-up at the Westbrook Medical Associates 5 on 2018-Feb-11. Ethan is a 38-year-old male with Crohn's disease. Was on Mongersen CD trila drug for approx 1 year. Since the trial was stopped he was started on Methotrexate and prednisone for induction and Entyvio was started in [REDACTED-DATE] 2017. He gets on an average 5 BM/ day and since on Entyvio, stool is more formed

and he is feeling better. Denies abdominal pain, nocturnal BM. Has had chronic lower back pain. Has'nt tried cholestyramine yet.

**Past Medical History:** Nephrolithiasis, Hypertriglyceridemia (now resolved)

**IBD Phenotype:** 2013 Crohn's disease s/p ileocolonic resection (2014) Montreal: CD Location - L1 - Ileal  
Montreal: CD Behaviour - B2 - Stricturing

**IBD Complications:** None Recorded

**IBD Extraintestinal Manifestations:** None Recorded

**IBD Diagnostics:** None Recorded

**Active Medications:** 1 Packet(s) Once daily X 30 Day(s) Methotrexate 2.5 mg Oral Tablet 10 Tablet(s)  
Once a week X 60 Day(s) Entyvio 300mg iv Q 8 weeks

Physical exam Weight 131 kg Abdomen: Soft, non distended, non tender, self reducing abdominal wall  
hernia at the surgical incision site

**Investigations:**

CRP: 12.12 Albumin: HGB: 113

**Impression and Plan:**

In summary, Ethan feels somewhat better since has been on MTX and Entyvio with more formed stool and some improvement in frequency. His Vitamin B12 levels are very low so we would request you to start him on B12 injections and in the meanwhile, he can start supplementing oral B12. His Hb is 113 which is on the lower side and fecal Calprotectin was high. He can start taking iron supplements. For now we will continue with Entyvio at current dosing and would check his entyvio levels and fecal calprotectin prior to his next infusion. He should have colonoscopy in 6 months time for assessment of disease activity. Before that we will see him in office in [REDACTED-DATE] for reassessment.

Thank you,

Tobias Cohen Clinical Fellow

---

for

---

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6,  
Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2018-Feb-11

Dr. Sinead Taylor

, ON

Patient: Mr. Ethan Kang PHN: 414 235 249 WJQ: 158847108 Birthdate: 1979 Phone: H: ( ) - C: (442) 733-2165 Address: 412 Marigold Ave a nearby city 6, ON 848 Main Blvd

Dear Dr. Dr. Herrera,

#### Ridgeway Family Health NOTE

Mr. Ethan Kang was seen in follow -up at the Westbrook Medical Associates 5 on 2018-Feb-11. Ethan is a 38-year-old male with Crohn's disease. Was on Mongersen CD trila drug for approx 1 year. Since the trial was stopped he was started on Methotrexate and prednisone for induction and Entyvio was started in [REDACTED-DATE] 2017. He gets on an average 5 BM/ day and since on Entyvio, stool is more formed and he is feeling better. Denies abdominal pain, nocturnal BM. Has had chronic lower back pain. Has'nt tried cholestyramine yet.

Past Medical History: Nephrolithiasis, Hypertriglyceridemia (now resolved)

IBD Phenotype: 2013 Crohn's disease s/p ileocolonic resection (2014) Montreal: CD Location - L1 - Ileal  
Montreal: CD Behaviour - B2 - Stricturing

IBD Complications: None Recorded

IBD Extraintestinal Manifestations: None Recorded

IBD Diagnostics: None Recorded

Active Medications: 1 Packet(s) Once daily X 30 Day(s) Methotrexate 2.5 mg Oral Tablet 10 Tablet(s) Once a week X 60 Day(s) Entyvio 300mg iv Q 8 weeks

Physical exam Weight 131 kg Abdomen: Soft, non distended, non tender, self reducing abdominal wall hernia at the surgical incision site

Investigations:

CRP: 12.12 Albumin:

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

---

HGB: 113

#### **Impression and Plan:**

In summary, Ethan feels somewhat better since has been on MTX and Entyvio with more formed stool and some improvement in frequency. His Vitamin B12 levels are very low so we would request you to start him on B12 injections and in the meanwhile, he can start supplementing oral B12. His Hb is 113 which is on the lower side and fecal Calprotectin was high. He can start taking iron supplements. For now we will continue with Entyvio at current dosing and would check his entyvio levels and fecal calprotectin prior to his next infusion. He should have colonoscopy in 6 months time for assessment of disease activity. Before that we will see him in office in [REDACTED-DATE] for reassessment.

Thank you,

Tobias Cohen Clinical Fellow

for

Sincerely,

[image]

Riverside Medical Centre Isolde Xiong **Electronically Reviewed to Expedite Delivery**

Patient Ethan Kang PHN: 414 235 249 DOB: 1979

- 
- 

**This task has been completed**

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | [REDACTED-DATE]                                     | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2018-Jan-14 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |

**Notes** tell him his Vit B12 level is very low and he needs to see his GP to get supplements by injection - it's important

**Conversations**

**Created 2018-Jan-14 9:08 AM**

---

2018-Jan-14 9:08 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] [image]  
Message Left

---

Lab Results: Generated On 2026-Apr-09

|                 |                |                   |              |                   |                |
|-----------------|----------------|-------------------|--------------|-------------------|----------------|
| <b>Patient</b>  | Ethan Kang     | <b>Home Phone</b> | 867.739.5528 | <b>Work Phone</b> |                |
| <b>Health #</b> | 0748 361 588KT | <b>Sex</b>        | M            | <b>Patient ID</b> | 0748 361 588KT |
| <b>Age</b>      | 46 years       |                   |              |                   |                |
| <b>DOB</b>      | 1979           |                   |              |                   |                |

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM



| ROUTINE CHEMISTRY I | Results | Flags | Ref Range |        | Test Loc |
|---------------------|---------|-------|-----------|--------|----------|
| CREATININE          | 70      |       | 67 - 117  | umol/L | KL       |
| eGFR                | 114     |       |           |        |          |

Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

Effective May 3, 2015, eGFR is calculated using the CKD-EPI 2009 equation.

KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.

|                            |            |  |                  |               |  |
|----------------------------|------------|--|------------------|---------------|--|
| <b>SODIUM</b>              | <b>144</b> |  | <b>135 - 145</b> | <b>mmol/L</b> |  |
| POTASSIUM                  | 3.9        |  | 3.5 - 5.2        | mmol/L        |  |
| CHLORIDE                   | 103        |  | 98 - 108         | mmol/L        |  |
| TOTAL BILIRUBIN            | 4          |  | < 20             | umol/L        |  |
| ALANINE TRANSAMINASE (ALT) | 1979       |  | < 50             | U/L           |  |
| ALKALINE PHOSPHATASE       | 58         |  | 40 - 129         | U/L           |  |
| GAMMA-GLUTAMYLTRANSFERASE  | 20         |  | 14 - 62          | U/L           |  |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM

| ROUTINE CHEMISTRY II | Results | Flags | Ref Range |     | Test Loc |
|----------------------|---------|-------|-----------|-----|----------|
| ALBUMIN              | 44      |       | 35 - 52   | g/L | KL       |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM

|  | Results | Flags | Ref Range |  | Test Loc |
|--|---------|-------|-----------|--|----------|
|--|---------|-------|-----------|--|----------|

| <b>SPECIAL CHEMISTRY II</b> | <b>Results</b> | <b>Flags</b> | <b>Ref Range</b> |        | <b>Test Loc</b> |
|-----------------------------|----------------|--------------|------------------|--------|-----------------|
| VITAMIN B12                 | <92            | LO           | 138 - 652        | pmol/L | KL              |

Test repeated and results confirmed. Please note implementation of age-specific pediatric reference intervals (Bailey D. et al, Clinical Chemistry 2013;59:1393, and www.cedarspecialistgroup.ca)

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM

|                  | <b>Results</b> | <b>Flags</b> | <b>Ref Range</b> |      | <b>Test Loc</b> |
|------------------|----------------|--------------|------------------|------|-----------------|
| <b>CHEMISTRY</b> |                |              |                  |      |                 |
| FERRITIN         | 87             |              | 1979 - 275       | ug/L | KL              |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM

| <b>HEMATOLOGY I</b>    | <b>Results</b> | <b>Flags</b> | <b>Ref Range</b>     |         | <b>Test Loc</b> |
|------------------------|----------------|--------------|----------------------|---------|-----------------|
| HEMOGLOBIN             | 113            | LO           | 135 - 175            | g/L     | KL              |
| HEMATOCRIT             | 0.353          | LO           | 0.400 - 0.500        | L/L     |                 |
| WHITE BLOOD CELL COUNT | 4.7            |              | 4.0 - 11.0           | x E9/L  |                 |
| RED BLOOD CELL COUNT   | 4.20           | LO           | 4.50 - 6.00          | x E12/L |                 |
| MCV                    | 84             |              | 80 - 100             | fL      |                 |
| MCH                    | 26.9           | LO           | 27.5 - 33.0          | pg      |                 |
| MCHC                   | 320            |              | 0748 361 588KT - 360 | g/L     |                 |
| RDW                    | 16.8           | HI           | 11.5 - 14.5          | %       |                 |
| PLATELET COUNT         | 209            |              | 150 - 400            | x E9/L  |                 |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

INTERNAL-USERNAME] Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM

| HEMATOLOGY II   | Results | Flags | Ref Range |        | Test Loc |
|-----------------|---------|-------|-----------|--------|----------|
| ABSOLUTE: NEUTS | 2.7     |       | 2.0 - 7.5 | x E9/L | KL       |
| (A) LYMPH       | 1.5     |       | 1.0 - 3.5 | x E9/L |          |
| (A) MONO        | 0.5     |       | 0.2 - 1.0 | x E9/L |          |
| (A) EOS         | 0.1     |       | 0.0 - 0.5 | x E9/L |          |
| (A) BASO        | 0.0     |       | 0.0 - 0.2 | x E9/L |          |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

---

Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM

| SPECIAL/ROUTINE I | Results | Flags | Ref Range |     | Test Loc |
|-------------------|---------|-------|-----------|-----|----------|
| AMYLASE           | 40      |       | 30 - 110  | U/L | KL       |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2018-Jan-10 Reviewed: 2018-Jan-11 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2018-Jan-10 Report Date: 2018-Jan-11 4:39 AM

Updated On: 2018-Jan-11 12:03 PM

| CARDIOVASCULAR RISK ASSESSMENT | Results | Flags | Ref Range |      | Test Loc |
|--------------------------------|---------|-------|-----------|------|----------|
| HS-CRP                         | 12.12   | **    |           | mg/L | KL       |

hsCRP is considered a valuable risk stratification measurement in females >60 years and males >50 years. Values >2.00 mg/L in these patients warrant further investigation. Refer to the CCS 2012 guideline for revised hsCRP CVD risk criteria. hs-CRP values > or = 6.00 mg/L may be due to acute inflammation.

KL - a nearby city 8 867.739.5528

---

[check\_mark] \*--

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | [REDACTED-DATE]                                     | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2017-Dec-07 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | i am still listed as referring md                   |                        |                                                                    |

**Conversations**

**Created 2017-Dec-07 9:46 AM**

---

|                                                                         |
|-------------------------------------------------------------------------|
| 2017-Dec-07 9:46 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| [document_icon] Why does this keep happening?! I will ask the girls.... |
| [physician_icon] Dr. Sinead Taylor                                      |

---

Cedar Specialist Group 4 SCC Accredited LAB LAB Accrédité CCN

Lab ID: Y633528593 Westbrook Medical Associates 5 External Ref. No.: Y633528593

**Prescriber** Name: Sinead Taylor Clinic: Westbrook Medical Associates 5 Address: a nearby city 10 a nearby city 8 Telephone: 659.710.1986 Fax: 986.368.7859

**Patient** Name: Ethan Kang Date of birth: 1979-06-21 Age: 38 Sex: M Health Ins.

**Biochemistry**

| Analysis     | Specimen | Result | Reference value | Unit | Status |
|--------------|----------|--------|-----------------|------|--------|
| Calprotectin | Stool    | 987    | < 50            | ug/g |        |

Calprotectin Level

[graph showing two data points:

- [REDACTED-DATE] at approximately 600 ug/g
- [REDACTED-DATE] at approximately 600 ug/g Horizontal dashed lines at 200 (labeled "Active Inflammation") and 50 (labeled "Moderate")]

| Collection date | Result (ug/g) |
|-----------------|---------------|
| 2016-05-03      | 862           |
| 2017-11-27      | 987           |
|                 |               |

| Collection date | Result (ug/g) |
|-----------------|---------------|
|                 |               |
|                 |               |

Interpretation: Calprotectin values > 200 ug/g are indicative of active organic disease with inflammation in the gastrointestinal tract. Appropriate further investigative and curative procedures by specialists are suggested.

Note: The cut-off level suggested for adults (50 ug/g) can also be used for children aged 4 to 17 years regardless of sex.

Comments:

Sinead Taylor Tobias Cohen Clinical Biochemist

| Date Collected | Date Received | Date completed | Date of Report | Report   |
|----------------|---------------|----------------|----------------|----------|
| 2017-11-27     | 2017-11-28    | 2017-12-05     | 2017-12-05     | Complete |

257 Maple Ave, 257 Maple Ave (QC) Canada 257 Maple Ave T 867.739.5528 F 994-882-7246 Page 1 of 1

☐ \* --

This task has been completed

**Patient** Ethan Kang **Task Created By** [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] **Date Due** [REDACTED-DATE] **Priority** Normal **Assigned To** [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] **Completed** 2017-Dec-03 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] **Notes** why am i listed as the referring MD? add GP

## Conversations

**Created 2017-Dec-03 8:12 AM**

2017-Dec-03 8:12 AM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

[image] No idea...

[image] Dr. Sinead Taylor

2017-Dec-04 2:42 PM [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

[image] can you fix

[image] Tobias Cohen

Lab Results: Generated On 2026-Apr-09

Patient: Kang, Ethan HomePhone: (089) 697-3500 a5345 WorkPhone: Health #: 0748 361 588KT Sex: M  
Patient ID: 0748 361 588KT Age: 46 DOB: 1979

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM Updated On: 2017-Nov-30 11:35 AM

#### ROUTINE CHEMISTRY I

|            | Results | Flags | Ref Range |        | Test Loc |
|------------|---------|-------|-----------|--------|----------|
| CREATININE | 79      |       | 67 - 117  | umol/L | KL       |
| eGFR       | 108     |       |           |        |          |

Normal eGFR is described as greater than or equal to 90 ml/min/1.73 m2.

For patients of African descent, the reported eGFR must be multiplied by 1.15.

Effective May 3, 2015, eGFR is calculated using the CKD-EPI 2009 equation.

KDIGO 2012 guidelines highlight the importance of eGFR and urine albumin creatinine ratio (ACR) in screening, diagnosis and management of CKD. Results for eGFR should be interpreted in concert with ACR.

|                            | Results | Flags | Ref Range |        | Test Loc |
|----------------------------|---------|-------|-----------|--------|----------|
| SODIUM                     | 140     |       | 135 - 145 | mmol/L |          |
| POTASSIUM                  | 4.0     |       | 3.5 - 5.2 | mmol/L |          |
| CHLORIDE                   | 101     |       | 98 - 108  | mmol/L |          |
| TOTAL BILIRUBIN            | 4       |       | < 20      | umol/L |          |
| ALANINE TRANSAMINASE (ALT) | 17      |       | < 50      | U/L    |          |
| ALKALINE PHOSPHATASE       | 66      |       | 40 - 129  | U/L    |          |
| GAMMA-GLUTAMYLTRANSFERASE  | 21      |       | 14 - 62   | U/L    |          |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM Updated On: 2017-Nov-30 11:35 AM

#### ROUTINE CHEMISTRY II

|         | Results | Flags | Ref Range |     | Test Loc |
|---------|---------|-------|-----------|-----|----------|
| ALBUMIN | 43      |       | 35 - 52   | g/L | KL       |

KL - a nearby city 8 867.739.5528

---

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM Updated On: 2017-Nov-30 11:35 AM

|  | Results | Flags | Ref Range |  | Test Loc |
|--|---------|-------|-----------|--|----------|
|--|---------|-------|-----------|--|----------|

## SPECIAL CHEMISTRY II

|             | Results | Flags | Ref Range |        | Test Loc |
|-------------|---------|-------|-----------|--------|----------|
| VITAMIN B12 | 145     |       | 138 - 652 | pmol/L | KL       |

Test repeated and results confirmed. Please note implementation of age-specific pediatric reference intervals (Bailey D. et al, Clinical Chemistry 2013;59:1393, and [www.cedarspecialistgroup.ca](http://www.cedarspecialistgroup.ca))

KL - a nearby city 8 867.739.5528

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM

Updated On: 2017-Nov-30 11:35 AM

## CHEMISTRY

|          | Results | Flags | Ref Range  |      | Test Loc |
|----------|---------|-------|------------|------|----------|
| FERRITIN | 46      |       | 1979 - 275 | ug/L | KL       |

KL - a nearby city 8 867.739.5528

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM

Updated On: 2017-Nov-30 11:35 AM

## HEMATOLOGY I

|                        | Results | Flags | Ref Range     |         | Test Loc |
|------------------------|---------|-------|---------------|---------|----------|
| HEMOGLOBIN             | 123     | LO    | 135 - 175     | g/L     | KL       |
| HEMATOCRIT             | 0.385   | LO    | 0.400 - 0.500 | L/L     |          |
| WHITE BLOOD CELL COUNT | 8.8     |       | 4.0 - 11.0    | x E9/L  |          |
| RED BLOOD CELL COUNT   | 4.78    |       | 4.50 - 6.00   | x E12/L |          |
| MCV                    | 81      |       | 80 - 100      | fL      |          |

|                | Results | Flags | Ref Range            |        | Test Loc |
|----------------|---------|-------|----------------------|--------|----------|
| MCH            | 25.7    | LO    | 27.5 - 33.0          | pg     |          |
| MCHC           | 319     |       | 0748 361 588KT - 360 | g/L    |          |
| RDW            | 15.4    | HI    | 11.5 - 14.5          | %      |          |
| PLATELET COUNT | 284     |       | 150 - 400            | x E9/L |          |

KL - a nearby city 8 867.739.5528

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM

Updated On: 2017-Nov-30 11:35 AM

## HEMATOLOGY II

|                 | Results | Flags | Ref Range |        | Test Loc |
|-----------------|---------|-------|-----------|--------|----------|
| ABSOLUTE: NEUTS | 6.0     |       | 2.0 - 7.5 | x E9/L | KL       |
| (A) LYMPH       | 2.3     |       | 1.0 - 3.5 | x E9/L |          |
| (A) MONO        | 0.3     |       | 0.2 - 1.0 | x E9/L |          |
| (A) EOS         | 0.1     |       | 0.0 - 0.5 | x E9/L |          |
| (A) BASO        | 0.0     |       | 0.0 - 0.2 | x E9/L |          |

KL - a nearby city 8 867.739.5528

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]

Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM

Updated On: 2017-Nov-30 11:35 AM

## SPECIAL/ROUTINE I

|         | Results | Flags | Ref Range |     | Test Loc |
|---------|---------|-------|-----------|-----|----------|
| AMYLASE | 84      |       | 30 - 110  | U/L | KL       |

KL - a nearby city 8 867.739.5528

Accession Id: Y633528593 (Final) Ordered By: Sinead Taylor Reported By: Ridgeway Family Health  
Collection Date: 2017-Nov-29 Reviewed: 2017-Nov-30 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]



INTERNAL-USERNAME] Service Date: 2017-Nov-29 Report Date: 2017-Nov-30 3:30 AM

Updated On: 2017-Nov-30 11:35 AM

## CHEMISTRY V

|                    | Results | Flags | Ref Range |      | Test Loc |
|--------------------|---------|-------|-----------|------|----------|
| C-REACTIVE PROTEIN | 2.0     |       | < 6.0     | mg/L | KL       |

KL - a nearby city 8 867.739.5528

## PHYSICIAN STATUS REPORT Westbrook Medical Associates 5™ DESIGNED FOR YOU

|                                              |                                        |
|----------------------------------------------|----------------------------------------|
| TO: Dr. Sinead Taylor, (442) 733-2165        | Date: Nov 19, 2017                     |
| FROM: Tobias Cohen; Ridgeway Family Health 5 | Page: 2                                |
| Patient Name: Ethan Kang                     | Patient ID#: Y633528593 , Nov 15, 2017 |

## Section 1

### Program Services Requested

☒ Reimbursement ☐ Afterhours On Call Nurse Service ☐ Financial Assistance ☐ Entyvio™ (vedolizumab) Infusion Scheduling ☐ Travel Assistance ☐ Entyvio™ (vedolizumab) Infusion Administration ☐ Adverse Event/Product Quality Complaint

### Updates

☐ Unable to Contact patient ☐ Special Authorization Required ☐ Waiting for Patient Proof-of-Income ☐ Medical Clarification Required ☐ Waiting on Patient's Insurance Information ☐ Entyvio™ (vedolizumab) Infusion Appointment Information ☐ Patient Discontinued Therapy ☐ Patient Dropped Out ☐ NO ACTION REQUIRED

## Section 2: PROGRAM COMMENTS/UPDATES

Hi Dr. Taylor,

Thank you for referring Ethan to the Westbrook Medical Associates 5. Attached, please find a partially completed enrolment form as per your medical directive. Kindly review, sign, date and return at your earliest convenience.

Warm regards,

[REDACTED-STAFF-PROVIDER-GIVEN-NAME]

If you have any questions about Ridgeway Family Health 5 and/or about your patient's status, please call 867.739.5528.

Sincerely,

Ridgeway Family Health 5

- The independent service provider is subject to change without notice. Westbrook Medical Associates 5 is a trademark of Ridgeway Family Health 5

Ridgeway Family Health 5 Telephone: -867.739.5528 Fax: 867.739.5528 Email:  
mason.sandoval49@northviewclinic.ca

---

Ridgeway Family Health 5 PHYSICIAN REQUEST AND PATIENT CONTACT CONSENT FORM

Ridgeway Family Health 5 | DESIGNED FOR YOU

*Please ensure this form is filled out in its entirety to avoid delays in processing your request. Fax:  
867.739.5528*

## PATIENT DEMOGRAPHICS

|                                          |                                                          |                                               |              |                               |
|------------------------------------------|----------------------------------------------------------|-----------------------------------------------|--------------|-------------------------------|
| Last Name: Ethan Kang                    | First Name: Ethan                                        | Date of Birth: 06/21/1979                     | Gender: Male | Preferred Language: English   |
| Street Address: a nearby city 10         |                                                          | City: a nearby city                           | Province: ON | Postal Code: a nearby city 11 |
| Home Tel.: Leave Message: [ ] Yes [ ] No | Cell Phone: (442) 733-2165 Leave Message: [X] Yes [ ] No | Alternate Contact (Name/Relationship/Tel. #): |              |                               |

Diagnosis: [ ] UC [X] CD [ ] Other medical conditions: Enrolled in "ENTYVIO™ (vedolizumab) study (current or previous)? [ ] Yes [X] No If "Yes", please indicate study number and ENTYVIO™ (vedolizumab) dosing interval:

## PHYSICIAN ORDERS

**Dosage:** [X] Loading Dose: Week 0, Week 2, Week 6 ENTYVIO™ (vedolizumab) 300 mg IV [X] Maintenance Dose: ENTYVIO™ (vedolizumab) 300 mg IV every 8 weeks

**Duration of Treatment:** [X] 12 Months [ ] 6 Months [ ] 3 Months [ ] Other:

|               |                              |        |                         |
|---------------|------------------------------|--------|-------------------------|
| Weight: (kg): | Allergies: [ ] Yes, Specify: | [X] No | Anticipated Start Date: |
|---------------|------------------------------|--------|-------------------------|

## CLINIC SERVICES

Specimen Collection Required: [X] Yes [ ] No Blood Work: [X] Yes (please fax lab requisition to the Ridgeway Family Health 5) [ ] No **Every infusion** Fecal Calprotectin Testing: [X] Yes [ ] No **0 & 2 weeks, PRN**

## PRE-MEDICATIONS

|                                                                                                                                                     |                                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Acetaminophen: 979-984-5348 mg PO 15-30 min. pre-infusion                                                                  | <input type="checkbox"/> Diphenhydramine: <input type="checkbox"/> 25-50 mg PO 15-30 min pre-infusion <b>OR</b> <input type="checkbox"/> 25-50 mg IV pre-infusion |
| <input type="checkbox"/> Graval: <input type="checkbox"/> 50 mg PO 15-30 min. pre-infusion <b>OR</b> <input type="checkbox"/> 50 mg IV pre-infusion | <input type="checkbox"/> Methylprednisolone: 20-80 mg IV, pre-infusion                                                                                            |
| <input type="checkbox"/> Hydrocortisone 100 mg IV, pre-infusion                                                                                     | <input type="checkbox"/> Other:                                                                                                                                   |

## INFUSION REACTION MANAGEMENT AND PRN MEDICATIONS

☒ I agree to the recommended standard infusion reaction protocol. ☐ I do not agree to the recommended standard infusion reaction protocol. Please follow my written directions below for the above-noted patient unless otherwise directed.

## PRESCRIBING PHYSICIAN INFORMATION

|                                                                   |                                                   |                            |                            |
|-------------------------------------------------------------------|---------------------------------------------------|----------------------------|----------------------------|
| Physician Name: Dr. Sinead Taylor                                 | Licence #:                                        | Tel.: (089) 697-3500 a5345 | Fax: (442) 733-2165        |
| Physician Address: a nearby city 10                               | City: a nearby city 6                             | Province: ON               | Postal Code: 848 Main Blvd |
| Physician Office Contact:<br>[REDACTED-STAFF-PROVIDER-GIVEN-NAME] | Physician Contact Tel.:                           | Physician Contact Fax:     |                            |
| Prescribing Physician's Contact in Case of Emergency:             | Alternate Contact Name/Tel. in Case of Emergency: |                            |                            |

**Prescribing Physician Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_ As the prescribing physician, in signing this form I am aware of the approved Health Canada indication for ENTYVIO™ (vedolizumab). I have explained the risks and benefits of same to my patient and am using my medical judgment to prescribe ENTYVIO™ (vedolizumab).

**As the patient, I confirm that I am requesting the ENTYVIO™ (vedolizumab) coordinator to contact me for enrolment into the Ridgeway Family Health 5 and to coordinate same with my prescribing physician.**

**Patient Printed Name:** \_\_\_\_\_ **Patient Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_  
My physician has advised me of the approved Health Canada indication for ENTYVIO™ (vedolizumab) and its risks and benefits as outlined above.

|                                          |                                  |              |
|------------------------------------------|----------------------------------|--------------|
| <b>Legal Guardian Name/Relationship:</b> | <b>Legal Guardian Signature:</b> | <b>Date:</b> |
|------------------------------------------|----------------------------------|--------------|

**NEXT STEPS: To the Prescribing Physician:** The Program Coordinator will contact you with updates regarding your patient's status. **To the Patient:** The Program Coordinator will contact you with regard to

your prescription, the Westbrook Medical Associates 5™ Patient Support Program and your ENTYVIO™ infusion schedule.

Westbrook Medical Associates 5™ is a trademark of Ridgeway Family Health 5 ENTYVIO™ is a trademark of Millennium Pharmaceuticals, Inc. Used under licence. PSP-ENT092016-001E

---

## Cedar Specialist Group 4

Dr. Tobias Cohen

671 Juniper Rd a nearby city 6 ON, Canada 848 Main Blvd

**Please note new fax number: 867.739.5528**

Please fax all correspondence and new referrals to the above fax number

## Fax Cover Sheet

To: Sinead Taylor Phone: (442) 733-2165 Fax: (442) 733-2165

RE: Ethan Kang DOB (1979/mm/yy): 21/06/1979 HCN: 414 235 249 Home phone: (442) 733-2165 Work phone: (442) 733-2165 Cell phone: 867.739.5528

Date: 2017-Nov-15

From: Dr. Sinead Taylor Phone: 994-882-7246 Fax: 994-882-7246

Number of pages including cover: 4

Sincerely,

Dr. Sinead Taylor

**Confidential: This communication is intended only for the individual or institution to which it is addressed and should not be distributed, copied or disclosed to anyone else. The documents in this communication may contain personal, confidential or privileged information, which may be subject to the Freedom of information and Protection of Privacy Act, the Health Information Act and other legislation. If you have received this communication in error, please notify us immediately and return original transmission to**

---

## Cedar Specialist Group 4

Dr. Sinead Taylor, a nearby city 8 Phone: 994-882-7246 Fax: 994-882-7246

**Patient** Name: Ethan Kang DOB: 1979 HCN: 414 235 249 Address: a nearby city 8

**Referring physician** Name: Dr. Herrera Address: a nearby city 8 Tel: 994-882-7246 Fax: (442) 733-2165

**Appointment details** Date: 2017-Nov-14 Location: Cedar Specialist Group 4

Dear Dr. Herrera;

Ethan Kang was seen in follow-up today for high triglycerides and hypogonadism ( resolved ).

## **SUBJECTIVE:**

### **HPI:**

#### **Pertinent Medical History**

He informs me that another physician has changed some of his medications since his last visit. These changes were made and reflected in his current medication record, as best as he can recall the names and the doses.

He denies any burning in his feet. He denies any pins and needle sensation in his feet. He denies any numbness in his feet. He denies any chest pain with activity. He denies any shortness of breath with activity. He denies any symptoms of claudication ( cramps in his calves ) when he walks.

He has lost 2.6 kg since his last appointment.

follow-up in July 2017.

He is no longer on the trial medication for his Crohn's disease. This was stopped Oct 19, 2017. Ethan is awaiting to hear the new medication he will be started on for this trial.

This office appointment was performed in the presence of, and with the aid of, the clinical assistant Vera Pereira.

#### **HIGH TRIGLYCERIDES**

He denies the complications of nephropathy, retinopathy, neuropathy, coronary artery disease, cerebrovascular disease, and peripheral vascular disease.

He is currently not on any anti-hyperglycemic medications.

Page 1 of 3

---

He does not exercise.

He is currently on no blood pressure lowering medications.

He is currently not on any lipid modifying medications.

His work entails some walking.

#### **HYPOGONADISM**

He is currently on no medications for this condition.

**Problem History:** HYPERTRIGLYCERIDEMIA {Inactive} HYPOGONADISM [resolved]

**Active Medications:** None Recorded

**External Medications:** Cyanocobalamin (Vitamin B-12) 1,000 mcg/ml Injection Vial (mL) [1.0 qbiweekly]

**Surgical/Medical History:** Endocrinology, Other - Vitamin B12 deficiency Medical, Other - Insomnia Back pain - chronic Anemia, Other OSA ( Obstructive Sleep Apnea ) - using CPAP Kidney Stone Surgery, Other - Lipoma- 2015 (removed) Medical, Other - Herniated disc Dyslipidemia - Hypertriglyceridemia GI, Other - Crohn's disease Eye Disease - Herpes Zoster ophthalmicus Surgery, Other - 2014 - Ileocolic resection

**Known Allergies:** CODEINE 15MG TABLET - Opioids - Morphine Analogues (Drug Allergy)

**Current Medical Providers:** Family Doctor - Dr. Sinead Taylor Gastroenterologist - Dr. Sinead Taylor - for Crohn's disease Optometrist - Dr. Rahman

OBJECTIVE:

Vitals:

Ht: 178 cm; Wt: 128.5 kg; BMI: 42.7 We were unable to obtain a blood pressure reading.

Physical Exam:

CARDIOVASCULAR: no systolic murmur, no diastolic murmur, normal rate, normal rhythm, normal S1, and normal S2. RESPIRATORY: there were no inspiratory wheezes, there were no expiratory wheezes, and there were no crackles.

Lab/Test Results:

| Test                                                                           | Result                     |
|--------------------------------------------------------------------------------|----------------------------|
| HbA1c:                                                                         | 5.3 %( 2017-Oct-30 )       |
| creatinine:                                                                    | 80 umol/L;                 |
| Normal eGFR.                                                                   |                            |
| For patients of African descent, the reported eGFR must be multiplied by 1.15. | ( 2017-Oct-30 )            |
| fasting glucose:                                                               | 4.9 mmol/L ( 2017-Oct-30 ) |

|                 |                                   |
|-----------------|-----------------------------------|
| random glucose: | 7.7 mmol/L ( 2016-Nov-01 )        |
| U alb:creat:    | 0.3 mg/mmol creat ( 2017-Oct-30 ) |
| Tot Chol:       | 3.16 mmol/L ( 2017-Oct-30 )       |

|                        |                                                                       |
|------------------------|-----------------------------------------------------------------------|
| <b>random glucose:</b> | <b>7.7 mmol/L ( 2016-Nov-01 )</b>                                     |
| <b>TG:</b>             | 4.89 mmol/L ( 2017-Oct-30 )                                           |
| <b>HDL:</b>            | 0.62 mmol/L ( 2017-Oct-30 )                                           |
| <b>LDL:</b>            | * LDL-cholesterol calculation is invalid at triglycerides $\geq 4.52$ |
| mmol/L ( 2017-Oct-30 ) |                                                                       |
| <b>TSH:</b>            | 3.21 mIU/L ( 2017-Oct-30 )                                            |
| <b>FT4:</b>            | 17 pmol/L ( 2017-Oct-30 )                                             |
| <b>FT3:</b>            | 5.4 pmol/L ( 2017-Oct-30 )                                            |

## ASSESSMENT:

BLOODWORK: I reviewed his recent blood test results with him.

### HIGH TRIGLYCERIDES

LIPIDS: His Framingham risk score puts him in the low risk category (  $< 10\%$  ) for cardiovascular complications in the next 10 years. His triglycerides are increased. His HDL is low. Although the drug of choice for an elevated triglyceride level is fibrates, at best they decrease the triglycerides by 20 - 30%. The TREATMENT of choice is through lifestyle changes with reduction of carbohydrate intake in the diet ( including rice, bread, pasta, potatoes, fruits, etc ), reduction or preferably elimination of alcohol, a regular exercise routine and optimization of diabetes control ( if diabetes is present ). The best way to improve a low HDL is to engage in a regular exercise routine as well as to optimize diabetes control ( if diabetes is present ). This will increase the HDL by 10 - 20%, on average. This was all explained to him. The lipid profile and urine albumin:creatinine ratio are due to be repeated again in with the next blood work .

### HYPOGONADISM

ADVICE: His testosterone is now normal. Further surveillance is not needed.

## PLAN:

LABORATORY: diabetic blood work ( including HbA1C and fasting lipid profile ), and this is to be done before the next appointment. bloodwork to evaluate static pituitary function, and this is to be done before the next appointment. TESTS: No tests have been requested at this point in time. REFERRALS: No referrals have been initiated at this point in time. NEW MEDICATION(S): He was not started on any new medications. DISCONTINUED MEDICATION(S): None of his medications were stopped. CHANGED MEDICATIONS: The dose of none of his medications were changed. FOLLOW-UP: Schedule a follow-up in 6 month(s).

I reviewed his lipid profiles dating back to 2011. I think his TG are mainly in chylomicrons which is not a risk factor for CAD, despite his family history.

Letter Generated by: Gunnar Herrera

Sincerely,

[image]

Gunnar Herrera  
**Electronically Reviewed to Expedite Delivery**  
cc: Sinead Taylor

---

Cedar Specialist Group 4  
Outpatient Services  
412 Marigold Ave  
a nearby city 6, Ontario 848 Main Blvd  
Tel: (442) 733-2165

Taylor, Sinead  
415 Juniper Rd  
a nearby city 6 ON Canada a nearby city 11

|                     |                |                    |              |
|---------------------|----------------|--------------------|--------------|
|                     |                |                    |              |
| <b>Patient:</b>     | Ethan Kang     | <b>MRN:</b>        | Y633528593   |
| <b>Location:</b>    | DI             | <b>Birth Date:</b> | 1979         |
| <b>A#:</b>          | Y633528593     | <b>Procedures:</b> |              |
| <b>Visit #:</b>     | Y633528593     | XR Pelvis AP       | Nov 14, 2017 |
| <b>Ordering MD:</b> | Taylor, Sinead |                    |              |

**Report - XR Pelvis AP (Final - Nov 14, 2017 16:40)**

Pelvis

Clinical details: Rule out sacroiliitis

Findings: Suture material projected over the right iliac fossa.

I see no radiographic evidence of an inflammatory sacroiliitis.

No erosive changes at the hips or the symphysis pubis. Minimal joint space loss right hip.

Conclusion: No radiographic features of an inflammatory sacroiliitis.

Initial Interpretation By: Cohen, Tobias  
Verified By: Cohen, Tobias

\*\*\*\*\* END OF REPORT \*\*\*\*\*

ATTENTION

---

FOR PHYSICIAN USE ONLY - Please note that this report was generated using voice recognition software. The Outpatient Services (Outpatient Services) supports a culture of continuous improvement. If you require



further clarification or feel there has been an error in this report please contact the Outpatient Services Call Centre from 8am - 8pm Monday to Friday, 8am - 4pm Saturday to Sunday (excludes statutory holidays) at (442) 733-2165.

(Medical Imaging Report for Patient: Ethan Kang; MRN: Y633528593)

The report may contain PRIVILEGED AND CONFIDENTIAL INFORMATION only for use of the Addressee(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, please be aware that any dissemination or copying of this report is strictly prohibited. If you have received this report in error, please immediately notify the sender to arrange for the return or destruction of this document. Thank you for your cooperation.

Ridgeway Family Health Laboratory Requisition Requisitioning Clinician / Practitioner

Name Dr. Sinead Taylor Address 415 Juniper Rd a nearby city 6 ON T: (442) 733-2165 F: (442) 733-2165

Clinician/Vivienne Vasquez CPSO / Sofia Bianchi

Check ( ) one: [X] OHIP/Insured [ ] Third Party / Uninsured [ ] WSIB

Additional Clinical Information (e.g. diagnosis) (blank)

[ ] Copy to: Clinician/Practitioner Last Name (blank) First Name (blank) Address (blank)

Laboratory Use Only

Clinician/Practitioner's Contact Number for Urgent Results: (442) 733-2165

Service Date: 1979 (blank) mm (blank) 1979 (blank)

Health Number: 414 235 249 Version: (blank) Sex: M Date of Birth: 1979 = 1979, mm = 06, 1979 = 1979

Province: (blank) Other Provincial Registration Number: (blank) Patient's Telephone Contact Number: 994-882-7246

Patient's Last Name (as per OHIP Card) Ethan Kang Patient's First & Middle Names (as per OHIP Card) Ethan Kang Patient's Address (including Postal Code) a nearby city 8

Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Crestwood Medical Group

| x   | Biochemistry                   | x   | Hematology             | x   | Viral Hepatitis (check one only) |
|-----|--------------------------------|-----|------------------------|-----|----------------------------------|
| [ ] | Glucose [X] Random [ ] Fasting | [X] | CBC                    | [ ] | Acute Hepatitis                  |
| [ ] | HbA1C                          | [ ] | Prothrombin Time (INR) | [ ] | Chronic Hepatitis                |

|          |                                                                                                                                                                                     |          |                                                                    |          |                                                                                                                                                                  |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------------------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>x</b> | <b>Biochemistry</b>                                                                                                                                                                 | <b>x</b> | <b>Hematology</b>                                                  | <b>x</b> | <b>Viral Hepatitis (check one only)</b>                                                                                                                          |
| [X]      | Creatinine (eGFR)                                                                                                                                                                   |          | <b>Immunology</b>                                                  | [ ]      | Immune Status / Previous Exposure                                                                                                                                |
| [ ]      | Uric Acid                                                                                                                                                                           | [ ]      | Pregnancy Test (Urine)                                             |          | Specify: [ ] Hepatitis A                                                                                                                                         |
| [X]      | Sodium                                                                                                                                                                              | [ ]      | Mononucleosis Screen                                               |          | [ ] Hepatitis B                                                                                                                                                  |
| [X]      | Potassium                                                                                                                                                                           | [ ]      | Rubella                                                            |          | [ ] Hepatitis C                                                                                                                                                  |
| [X]      | ALT                                                                                                                                                                                 | [ ]      | Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) |          | or order individual hepatitis tests in the "Other Tests" section below                                                                                           |
| [X]      | Alk. Phosphatase                                                                                                                                                                    | [ ]      | Repeat Prenatal Antibodies                                         |          | <b>Prostate Specific Antigen (PSA)</b>                                                                                                                           |
| [X]      | Bilirubin                                                                                                                                                                           |          | <b>Microbiology ID &amp; Sensitivities (if warranted)</b>          | [ ]      | Total PSA [ ] Free PSA                                                                                                                                           |
| [X]      | Albumin                                                                                                                                                                             | [ ]      | Cervical                                                           |          | Specify one below:                                                                                                                                               |
| [ ]      | Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) | [ ]      | Vaginal                                                            | [ ]      | Insured - Meets OHIP eligibility criteria                                                                                                                        |
| [ ]      | Albumin / Creatinine Ratio, Urine                                                                                                                                                   | [ ]      | Vaginal / Rectal – Group B Strep                                   | [ ]      | Uninsured – Screening: Patient responsible for payment                                                                                                           |
| [ ]      | Urinalysis (Chemical)                                                                                                                                                               | [ ]      | Chlamydia (specify source):                                        |          | <b>Vitamin D (25-Hydroxy)</b>                                                                                                                                    |
|          | <b>Neonatal Bilirubin:</b>                                                                                                                                                          | [ ]      | GC (specify source):                                               | [ ]      | Insured – Meets OHIP eligibility criteria; osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism |
|          | Child's Age: days (blank) hours (blank)                                                                                                                                             | [ ]      | Sputum                                                             | [ ]      | Uninsured – Patient responsible for payment                                                                                                                      |
|          | Clinician/Practitioner's tel. no. ( )                                                                                                                                               | [ ]      | Throat                                                             |          | <b>Other Tests - one test per line</b>                                                                                                                           |

|          |                                                 |              |                                     |          |                                         |
|----------|-------------------------------------------------|--------------|-------------------------------------|----------|-----------------------------------------|
| <b>x</b> | <b>Biochemistry</b>                             | <b>x</b>     | <b>Hematology</b>                   | <b>x</b> | <b>Viral Hepatitis (check one only)</b> |
|          | Patient's 24 hr telephone no. ( )               | [ ]          | Wound (specify source):             |          | Ferritin                                |
|          | <b>Therapeutic Drug Monitoring:</b>             | [ ]          | Urine                               |          | Vitamin B12                             |
|          | Name of Drug #1                                 | [ ]          | Stool Culture                       |          | c-reactive protein                      |
|          | Name of Drug #2                                 | [ ]          | Stool Ova & Parasites               |          | Amylase                                 |
|          | Time Collected #1 hr. (blank) #2 hr. (blank)    | [ ]          | Other Swabs / Pus (specify source): |          | GGT                                     |
|          | Time of Last Dose #1 hr. (blank) #2 hr. (blank) |              |                                     |          |                                         |
|          | Time of Next Dose #1 hr. (blank) #2 hr. (blank) |              | <b>Specimen Collection</b>          |          |                                         |
|          |                                                 | Time (blank) | Date MM/1979/1979 (blank)           |          |                                         |

I hereby certify the tests ordered are not for registered in or out patients of a hospital.

**Fecal Occult Blood Test (FOBT)** (check one) [ ] FOBT (non CCC) [ ] ColonCancerCheck FOBT (CCC) no other test can be ordered on this form

Laboratory Use Only

[signature] X Clinician/Practitioner Signature

2017-Nov-14 Date

4422-84 (2013/01) © Queen's Printer for Ontario, 2013 7530-4581

☐ \* \_\_

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 11/14/2017                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2017-Nov-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Your Vantage for Entyvio start                      |                        |                                                                    |

☐ \* \_\_

This task has been completed

|                    |                                                     |                        |                                                                    |
|--------------------|-----------------------------------------------------|------------------------|--------------------------------------------------------------------|
| <b>Patient</b>     | Ethan Kang                                          | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME]                |
| <b>Date Due</b>    | 11/14/2017                                          | <b>Priority</b>        | Normal                                                             |
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b>       | 2017-Nov-15 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Move office FU from Jan to Feb                      |                        |                                                                    |
|                    | HOld colonoscopy for [REDACTED-DATE]                |                        |                                                                    |

Cedar Specialist Group 4 Cedar Specialist Group 4 412 Marigold Ave, a nearby city 6, Ontario, Canada  
848 Main Blvd Form MS 275 (Rev. 03.2012)

Medical Imaging Request Form

Clearly imprint patient identification card

**Bring this form, your Ontario Health Card and your Cedar Specialist Group 4 Card to your Medical imaging examination.**

**If you don't have a Hospital Card then first go to the main floor Admitting Department to obtain your own card.**

| <input type="checkbox"/> <b>Modality</b>                                        | <b>Floor or Location</b>                                 | <b>Telephone</b> | <b>Fax</b>     |
|---------------------------------------------------------------------------------|----------------------------------------------------------|------------------|----------------|
| <input type="checkbox"/> X-Ray (General Imaging)                                | 5th floor                                                | 994-882-7246     | (442) 733-2165 |
| <input type="checkbox"/> Angiography, Gastrointestinal, Interventional          | 5th floor                                                | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Breast Imaging (Mammography)                           | Outpatient Services, 12th floor                          | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Nuclear Medicine                                       | 6th floor, Room 6-201                                    | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Ultrasound                                             | 5th floor                                                | (442) 733-2165   | (442) 733-2165 |
| <input type="checkbox"/> Ultrasound <b>SCENT FREE AREA</b>                      | Outpatient Services 821 Glenarm Ave, 6th floor           | (442) 733-2165   | (442) 733-2165 |
| For Obstetric Ultrasound use the <i>CEOU (Outpatient Services)</i> request form | Lakeshore Specialty Clinic 2 273 Lakeview Ave, 3rd floor | (442) 733-2165   | (442) 733-2165 |

| <input type="checkbox"/> <b>Modality</b>                       | <b>Floor or Location</b>    | <b>Telephone</b> | <b>Fax</b>     |
|----------------------------------------------------------------|-----------------------------|------------------|----------------|
| For MRI use the <i>Magnetic Resonance Imaging</i> request form | 821 Glenarm Ave & 5th floor | (442) 733-2165   | (442) 733-2165 |
| For CT use the <i>Computed Tomography Imaging</i> request form | 5th floor                   | (442) 733-2165   | (442) 733-2165 |

**PATIENT INFORMATION: INCOMPLETE REQUISITIONS WILL BE RETURNED**

BIRTHDATE 1979 1979 MM 06 1979 1979 HOSPITAL MEDICAL RECORD NO. 414 235 249 SURNAME Ethan Kang GIVEN NAME Ethan ADDRESS (Street, Apt #) 412 Marigold Ave CITY/TOWN a nearby city 6 PROVINCE ON POSTAL CODE 848 Main Blvd TELEPHONE (Area Code & No.) 994-882-7246 Health Card Number 0748 361 588KT Version Code YR

**Exam Requested** (blank)

**Date of Request** 2017-Nov-14

**Clinical History and Indication** (blank)

Allergies ( ) Yes ( ) No If YES, specify \_

Diabetic ( ) Yes ( ) No

**REFERRING PHYSICIAN INFORMATION** Name and Initials (Print): Dr. Sinead Taylor Doctor's Signature: [image] Telephone #: (442) 733-2165 Fax #: (442) 733-2165 Requested Appointment Date (if applicable): MM/1979/1979 Billing & Nora Fournier 414 235 249 Mailing Address: 415 Juniper Rd a nearby city 6 848 Main Blvd

**MEDICAL IMAGING USE ONLY**

|                                  |                                               |                  |
|----------------------------------|-----------------------------------------------|------------------|
| <b>RADIOLOGIST SIGNATURE:</b>    | <b>APPOINTMENT DATE (1979)</b>                | <b>PROTOCOL:</b> |
| <b>RADIOLOGIST NAME (PRINT):</b> | <b>APPOINTMENT TIME (24 hr clock) (HH:MM)</b> |                  |

Patient: Mr. Ethan Kang Appointment Date: 2017-Nov-14 Title: MS IBD Follow up Provider: Taylor, Sinead Referred By: None I saw Mr. Ethan Kang today for follow up of his Crohn's disease.

**Current Status** Due to the recent early termination of the Mongersen clinical trial for CD I met with Ethan today to discuss plans for his management. The trial was terminated apparently over lack of drug efficacy rather than over a safety issue. He actually felt better clinically while on the study but looking at his CRP and FCP results they were either unchanged or rising. He also had a colonoscopy in Feb 2017 which did not show much change from the baseline endoscopy. His last study med dose was around Oct 19. During his time in the trial for the past 12 months or so he has been followed by my colleague Dr. Cohen.

As of today he says he has been having worsening symptoms over the last few weeks with about 9 BMs/day. Completely loose. No blood. Weight stable. Fatigue. No abdominal pain.

Some active eczema on trunk and upper extremities.

He has longstanding low back pain/stiffness in am and at other times. He tells me his family MD recently imaged him but we don't have results. I wonder if his symptoms are consistent with sacroiliitis.

Prior exposure to azathioprine on 2 occasions for short courses and had significant abdominal pain. Methotrexate in [REDACTED-DATE] at only 7.5mg orally per week. Prednisone generally well tolerated. Remicade ineffective prior to coming under my care. Humira also ineffective with low titre antibodies.

**Active Medications:** None Recorded

**On physical examination,** he looks well and nutritionally fit. He has small bilateral submandibular nodes. His lungs are clear to auscultation. He has normal heart sounds. His abdomen is soft, non-tender with no organomegaly or masses. Extremities are normal.

**Assessment and Plan** Ethan Kang currently has symptomatic active disease with prior evidence of objective inflammatory marker elevation. We had a lengthy discussion about the various options.

We decided to start him on Methotrexate and Prednisone for an induction effect and then move to Entyvio for longer term disease control and continue with MTX to prevent antibodies. I reviewed all of the risks and benefits with him.

We will arrange the following investigations: Bloodwork (including HLAB27) X-Ray (AP Pelvis)

I will see him again in 2 to 3 months.

Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health Outpatient Services

Dr. Jasmin Kaminski Professor of Medicine, Ridgeway Family Health 415 Juniper Rd a nearby city 6, Ontario 848 Main Blvd t: 290 827 5744 ext. 6902 f: (442) 733-2165

2017-Nov-14

Dr. Sinead Taylor

, ON

|                   |                |
|-------------------|----------------|
|                   |                |
| <b>Patient:</b>   | Mr. Ethan Kang |
| <b>PHN:</b>       | 414 235 249    |
| <b>MRN:</b>       | 414 235 249    |
| <b>Birthdate:</b> | 1979           |

Dear Dr. Herrera,

I saw Mr. Ethan Kang today for follow up of his Crohn's disease.

**Current Status** Due to the recent early termination of the Mongersen clinical trial for CD I met with Ethan today to discuss plans for his management. The trial was terminated apparently over lack of drug efficacy rather than over a safety issue. He actually felt better clinically while on the study but looking at his CRP and FCP results they were either unchanged or rising. He also had a colonoscopy in Feb 2017 which did

not show much change from the baseline endoscopy. His last study med dose was around Oct 19. During his time in the trial for the past 12 months or so he has been followed by my colleague Dr. Cohen.

As of today he says he has been having worsening symptoms over the last few weeks with about 9 BMs/day. Completely loose. No blood. Weight stable. Fatigue. No abdominal pain.

Some active eczema on trunk and upper extremities.

He has longstanding low back pain/stiffness in am and at other times. He tells me his family MD recently imaged him but we don't have results. I wonder if his symptoms are consistent with sacroiliitis.

Prior exposure to azathioprine on 2 occasions for short courses and had significant abdominal pain. Methotrexate in [REDACTED-DATE] at only 7.5mg orally per week. Prednisone generally well tolerated. Remicade ineffective prior to coming under my care. Humira also ineffective with low titre antibodies.

**Active Medications:** None Recorded

**On physical examination,** he looks well and nutritionally fit. He has small bilateral submandibular nodes. His lungs are clear to auscultation. He has normal heart sounds. His abdomen is soft, non-tender with no organomegaly or masses. Extremities are normal.

**Assessment and Plan** Ethan Kang currently has symptomatic active disease with prior evidence of objective inflammatory marker elevation. We had a lengthy discussion about the various options.

We decided to start him on Methotrexate and Prednisone for an induction effect and then move to Entyvio for longer term disease control and continue with MTX to prevent antibodies. I reviewed all of the risks and benefits with him.

We will arrange the following investigations: Bloodwork (including HLAB27) X-Ray (AP Pelvis)

I will see him again in 2 to 3 months.

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

Sincerely,

[image]

Riverside Medical Centre **Electronically Reviewed to Expedite Delivery** cc: Dr. Gunnar Herrera

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

[X] \* \_ \_

This task has been completed

|                 |            |                        |                                                     |
|-----------------|------------|------------------------|-----------------------------------------------------|
| <b>Patient</b>  | Ethan Kang | <b>Task Created By</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Date Due</b> | 10/24/2017 | <b>Priority</b>        | Normal                                              |

|                    |                                                     |                  |                                                                    |
|--------------------|-----------------------------------------------------|------------------|--------------------------------------------------------------------|
| <b>Assigned To</b> | [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] | <b>Completed</b> | 2017-Oct-25 by [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] |
| <b>Notes</b>       | Book office FU in 2-3m                              |                  |                                                                    |

Dr. Gunnar Herrera 671 Juniper Rd a nearby city 6 ON, Canada 848 Main Blvd

## Fax Cover Sheet

To: Dr. Sinead Taylor Phone: (442) 733-2165 Fax: (442) 733-2165

Date: 2017-Oct-24

From: Dr. Gunnar Herrera Phone: (661) 879-9446 Fax: (661) 879-9446

Number of pages including cover: 3

**Confidential: This communication is intended only for the individual or institution to which it is addressed and should not be distributed, copied or disclosed to anyone else. The documents in this communication may contain personal, confidential or privileged information, which may be subject to the Freedom of information and Protection of Privacy Act, the Health Information Act and other legislation. If you have received this communication in error, please notify us immediately and return original transmission to us. Thank you for your co-operation and assistance.**

Re: Ethan Kang

---

**Cedar Specialist Group 4** Cedar Specialist Group 4 Ridgeway Family Health

### Outpatient Services

**Gunnar Herrera** 671 Juniper Rd a nearby city 6, Ontario 848 Main Blvd

**Tel** 994-882-7246 **Fax** 994-882-7246

**Email:** sabine.dalton80@fairlightmedicalcentre.ca

2017-Oct-24

Dr. Taylor 415 Juniper Rd a nearby city 8

|                   |                |
|-------------------|----------------|
| <b>Patient:</b>   | Mr. Ethan Kang |
| <b>PHN:</b>       | 414 235 249    |
| <b>MRN:</b>       | 414 235 249    |
| <b>Birthdate:</b> | 1979           |



Dear Dr. Taylor,

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's disease.

**Problem History:** None Recorded **Past Medical History:** Nephrolithiasis **Past Surgical History:** Small bowel resection - Ileocecal resection

**IBD Phenotype:** Crohn's disease, Montreal: CD Location - L1 - Ileal, Montreal: CD Behaviour - B2 - Stricturing **IBD Complications:** None Recorded

**Active Medications:** None Recorded **Known Allergies:** None Recorded

Mr. Ethan Kang is participating in the following clinical trial: HS-Northview Clinic 5 Mongersen CD - maintenance phase. The sponsor of this trial discontinued the clinical development program as of last week and Ethan was instructed to stop the study medication five days ago. He has not noted any deterioration in his symptoms since then. The development program was stopped because of lack of efficacy based on an interim analysis by the data monitoring committee. There is no concern about safety of the study medication.

Ethan has been feeling well recently. He has roughly 2 to 4 bowel movements per day. His stools are always loose. He has no nocturnal bowel movements . He experiences no rectal urgency. None of his bowel movements are bloody. He has no abdominal pain . He reports no constitutional symptoms. He reports no extraintestinal manifestations of IBD.

He is on no medications for IBD.

**The review of systems** was relevant for: recent procedure to remove a renal stone (calcium oxalate).

**On physical examination**, he looks well and overweight. He has no lymphadenopathy. His lungs are clear to auscultation. He has normal heart sounds. His abdomen is soft and non-tender with no organomegaly or masses. He has no lower extremity edema. Skin examination was normal.

**Assessment and Plan** In summary, Mr. Ethan Kang is a 38 year-old male with Crohn's disease . The patient is in symptomatic remission but did have evidence of endoscopic disease activity at his last colonoscopy. The endoscopic disease activity in his neoterminal ileum was rated at Rutgeerts i3. He is presently on no medical therapy

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

---

for his Crohn's disease and I think there needs to be a discussion regarding possible use of other Biologics such as vedolizumab or ustekinumab to prevent progression of disease now that he is off all therapy. Since he is a patient of Dr. Taylor's I will refer him back for consideration of further therapy.

Sincerely,

[image]

Gunnar Herrera Staff Gastroenterologist Medical Lead, Northview Clinic 6

**Electronically Reviewed to Expedite Delivery**

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

---

Dr. Gunnar Herrera 671 Juniper Rd a nearby city 6 ON, Canada 848 Main Blvd

## Fax Cover Sheet

To: Dr. Sinead Taylor Phone: (442) 733-2165 Fax: (442) 733-2165

Date: 2017-Aug-29

From: Dr. Gunnar Herrera Phone: (661) 879-9446 Fax: (661) 879-9446

Number of pages including cover: 3

**Confidential: This communication is intended only for the individual or institution to which it is addressed and should not be distributed, copied or disclosed to anyone else. The documents in this communication may contain personal, confidential or privileged information, which may be subject to the Freedom of information and Protection of Privacy Act, the Health Information Act and other legislation. If you have received this communication in error, please notify us immediately and return original transmission to us. Thank you for your co-operation and assistance.**

Re: Ethan Kang

---

**Cedar Specialist Group 4 Cedar Specialist Group 4 Ridgeway Family Health**

**Gunnar Herrera** 671 Juniper Rd a nearby city 6, Ontario 848 Main Blvd

Tel 994-882-7246 Fax 994-882-7246 Email: sabine.dalton80@fairlightmedicalcentre.ca

### **Outpatient Services**

2017-Aug-29

Dr. Taylor 415 Juniper Rd a nearby city 8

Patient: Mr. Ethan Kang PHN: 414 235 249 WJQ: 158847108 Birthdate: 1979

Dear Dr. Taylor,

Ethan Kang returned to the Ridgeway Family Health for follow-up of his Crohn's disease.

**Past Medical History:** Nephrolithiasis

**IBD Profile:** Prior IBD Surgeries - Ileocolonic resection, Diagnosis - Crohn's disease, Phenotype: CD Location - L1 - Ileal, Phenotype: CD Behavior - B2 - Stricturing

**Active Medications:** None Recorded **Known Allergies:** None Recorded

Mr. Ethan Kang is participating in the following clinical trial: Northview Clinic 5 Mongersen CD - Mongersen or placebo

Ethan has been feeling well recently. He has roughly 3 bowel movements per day. His stools are always loose. None of his bowel movements are bloody. He has no abdominal pain He reports no constitutional symptoms. He reports no extraintestinal manifestations of IBD but did have an episode of renal colic several days ago. This has subsided and he passed a stone that has not yet been analyzed.

He reports no adverse reactions to his IBD medications.

**The review of systems** was unremarkable.

**On physical examination**, he looks well. His abdomen is soft, non-tender with no organomegaly or masses.

**Assessment and Plan** In summary, Mr.Ethan Kang is a 38 year-old male with Crohn's disease . The patient may have minimal clinical disease activity but his loose stools may be secondary to his previous surgery and bile salt mediated diarrhea.

We will arrange the following investigations: Bloodwork as per study protocol

No changes in the patient's management will be made at this time.

The patient will return for follow-up in approximately 1 month.

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

---

Sincerely,

[image]

Gunnar Herrera Staff Gastroenterologist Medical Lead, Northview Clinic 6

**Electronically Reviewed to Expedite Delivery**

Patient: Ethan Kang PHN: 414 235 249 DOB: 1979

---

Cedar Specialist Group 2 Northview Clinic

Lab Results: Generated On 2026-Apr-09

|                                  |                                                      |
|----------------------------------|------------------------------------------------------|
| <b>Patient</b>                   | Ethan Kang                                           |
| <b>Date of Birth</b>             | 1979                                                 |
| <b>Age (Time of Observation)</b> | 35 years                                             |
| <b>Sex</b>                       | M                                                    |
| <b>Address</b>                   | 847 Fennimore St<br>a nearby city 6 ON 848 Main Blvd |
| <b>ONTARIO Health Number</b>     | 6609604884PP                                         |
| <b>Telephone</b>                 | (442) 733-2165<br>(Primary Residence Number)         |

---

| Lab Order #                                   | Ordering Practitioner                                                                     | Primary Performing Lab                                             |
|-----------------------------------------------|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| 1398JN68969167<br>Northview Clinic(Lab 26095) | Taylor, Sinead<br>(Sabine Dalton)                                                         | Northview Clinic<br>(Lab 26095)                                    |
| Last Updated in OLIS                          | Address                                                                                   | Address                                                            |
| 2015-May-21 12:25:58 PM EDT                   | 848 Main Blvd<br>848 Main Blvd ON Manitoba<br>Cedar Specialist Group 4<br>(Firm/Business) | 848 Main Blvd<br>848 Main Blvd 848 Main Blvd ON<br>(Firm/Business) |
| Specimen Received Date/Time                   |                                                                                           | Primary Reporting Lab                                              |
| 2015-05-13 9:03:00 AM EDT                     |                                                                                           | Northview Clinic<br>(Lab 26095)                                    |
|                                               |                                                                                           | Address                                                            |
|                                               |                                                                                           | 848 Main Blvd<br>848 Main Blvd 848 Main Blvd ON<br>(Firm/Business) |

## Pathology

| Specimen Type | Collection Date             | Specimen Collected By           |
|---------------|-----------------------------|---------------------------------|
| Tissue        | 2015-May-13 12:00:00 AM EDT | Northview Clinic<br>(Lab 26095) |

|                                                                                                                                             | Flags | Results     | Reference Range Units |
|---------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------|-----------------------|
| <b>Surgical Pathology</b>                                                                                                                   |       |             |                       |
| <b>Site Of Origin</b>                                                                                                                       |       |             |                       |
| Result: 1) Neo ileum                                                                                                                        |       |             |                       |
| 2) Rectum                                                                                                                                   |       |             |                       |
| Relevant History                                                                                                                            |       | H/O Crohn's |                       |
| Relevant History                                                                                                                            |       | 1) Ileitis  |                       |
| <b>Gross Description</b>                                                                                                                    |       |             |                       |
| Result: 1) SCO 2 fragments of tan tissue measuring 0.2cm each EIT.<br><br>2) SCO 2 fragments of tan tissue measuring from 0.1 to 0.3cm EIT. |       |             |                       |
| <b>Final Diagnosis</b>                                                                                                                      |       |             |                       |

|                                                                                                                                                                                                                                                                                                                                        | Flags | Results | Reference<br>Range<br>Units |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------|-----------------------------|
| Result: 1) SMALL INTESTINAL BIOPSY (NEO ILEUM):<br>- FOCAL ACTIVE ILEITIS.<br>- NO GRANULOMAS IDENTIFIED.<br>2) LARGE INTESTINAL BIOPSY (RECTUM):<br>- COLONIC MUCOSA WITH MILD HYPERPLASTIC/REGENERATIVE CHANGES;<br>OTHERWISE, WITHIN NORMAL LIMITS.<br>- NO GRANULOMAS OR VIRAL INCLUSIONS IDENTIFIED.<br>- NEGATIVE FOR DYSPLASIA. |       |         |                             |
| <b>Pathologist</b>                                                                                                                                                                                                                                                                                                                     |       |         |                             |
| Result: Pathologist: Dr. Sinead Taylor, Keller, FRCPC<br>Gastrointestinal Pathologist<br>(signature on file)                                                                                                                                                                                                                           |       |         |                             |

**CC List** Keller, Marco (Sofia Bianchi)

Ridgeway Family Health® Medical Laboratory Services

671 Juniper Rd, a nearby city 6, ON Manitoba Tel: (661) 879-9446 Fax: (661) 879-9446

## **SURGICAL PATHOLOGY REPORT**

Patient Name: Ethan Kang Med. Rec. #: 0748 361 588KT DOB (Age) / Gender: 1979 (Age: 35) / M Chart #: Physicians: Dr. Sinead Taylor Copy To: Sinead Taylor (26095) Marco Keller (26095) Hwczeznwt #: J41-69250 Taken: [REDACTED-DATE] Received: [REDACTED-DATE] Reported: [REDACTED-DATE]

**Specimen(s) Received** R Shoulder

**Clinical History** Excision. Lipoma.

## **PATHOLOGIC INTERPRETATION AND COMMENT**

**R Shoulder: HIBERNOMA - NEGATIVE FOR MALIGNANCY**

\*\*\*Electronically Signed by Arturo Zielinski (Dermatopathologist)\*\*\* Date: [REDACTED-DATE]

**Gross Description** R Shoulder: The specimen container labeled "A- R Shoulder" has in it a well-circumscribed, homogenous, lobulated piece of adipose tissue measuring 4.3 x 3.2 x 1.0 cm. Representative section(s): Cassette A1 to A4 - 1 piece

Keller, MLT (Histotechnologist) [REDACTED-DATE]

Sinead Taylor (26095) 524 Larchmont Ave New Brunswick, Ontario Manitoba CAN

END OF REPORT

Cedar Specialist Group 2 Northview Clinic

Lab Results: Generated On 2026-Apr-09

Patient: Ethan Kang Ontario Health Number: 6609604884PP Telephone: (442) 733-2165 (Primary Residence Number) Date of Birth: 1979 Age (Time of Observation): 35 years Sex: M Address: (blank)

Lab Order #: 1398JN68969167 Ridgeway Family Health(Lab5687) Ordering Practitioner: Taylor, Sinead (Callum Pham) Address: 524 Larchmont Ave New Brunswick ON Manitoba 454 College Blvd (Firm/Business)

Primary Performing Lab: Ridgeway Family Health (Lab 26095) Address: 524 Larchmont Ave New Brunswick Manitoba ON (Firm/Business)

Last Updated in OLIS: 2015-May-13 8:18:14 PM EDT Specimen Received Date/Time: 2015-05-13 7:53:00 PM EDT

Primary Reporting Lab: Ridgeway Family Health (Lab 26095) Address: 524 Larchmont Ave New Brunswick Manitoba ON (Firm/Business)

# Pathology

Collection Date: 2015-May-10 12:00:00 AM EDT Specimen Collected By: Ridgeway Family Health (Lab 26095)

| Surgical Pathology | Flags | Results    | Reference Range | Units |
|--------------------|-------|------------|-----------------|-------|
| Site Of Origin     |       | R Shoulder |                 |       |

Specimen Type: OTHER Collection Date: 2015-May-10 12:00:00 AM EDT Specimen Collected By: Ridgeway Family Health (Lab 26095) Specimen Received Date/Time: 2015-05-11 11:07:00 PM EDT

**Surgical Pathology** Final Diagnosis Result: R Shoulder: HIBERNOMA

- NEGATIVE FOR MALIGNANCY

Relevant History: Excision. Lipoma. Gross Description Result: R Shoulder: The specimen container labeled "A- R Shoulder" has in it a well-circumscribed, homogenous, lobulated piece of adipose tissue measuring 4.3 x 3.2 x 1.0 cm. Representative section(s): Cassette A1 to A4 - 1 piece Pathologist Result: Arturo Zielinski (Dermatopathologist) Specimen Number: 1398JN68969167 This report is being sent electronically to this EMR. A hard-copy report is also being sent via fax or mail - in order that EMR report may be checked for accuracy against the print versions. Any inconsistencies during this EMR validation period should be brought to the attention of Ridgeway Family Health Customer Care at (661) 879-9446. Ridgeway Family Health (Lab 26095)

CC List

Keller, Marco (Sofia Bianchi)

| Lab Order #                                      | Ordering Practitioner             | Primary Performing Lab                    |
|--------------------------------------------------|-----------------------------------|-------------------------------------------|
| 1398JN68969167 Ridgeway Family Health(Lab 26095) | Taylor, Sinead (Sabine Dalton)    | Ridgeway Family Health (Lab 26095)        |
| Last Updated in OLIS                             | Address                           | Address                                   |
| 2014-Apr-06 8:30:59 PM EDT                       | Ridgeway Family Health 6          | 524 Larchmont Ave                         |
| Specimen Received Date/Time                      | 848 Main Blvd ON 848 Main Blvd    | New Brunswick Manitoba ON (Firm/Business) |
| 2014-04-03 7:12:13 AM EDT                        | 524 Larchmont Ave (Firm/Business) | Primary Reporting Lab                     |
|                                                  |                                   | Ridgeway Family Health (Lab 26095)        |
|                                                  |                                   | Address                                   |
|                                                  |                                   | 524 Larchmont Ave                         |
|                                                  |                                   | New Brunswick Manitoba ON (Firm/Business) |

| Specimen Type            | Collection Date             | Specimen Collected By              |
|--------------------------|-----------------------------|------------------------------------|
| TISSUE                   | 2014-Apr-02 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |
| Site Modifier: NEO ILEUM |                             |                                    |

## Surgical Pathology

|                                                                                                                                                          | Flags | Results   | Reference Range | Units |
|----------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|-----------------|-------|
| Relevant History                                                                                                                                         |       |           |                 |       |
| Result: A. NEO ILEUM. BX. CROHNS.                                                                                                                        |       |           |                 |       |
| B. CECUM. BX. CROHNS.                                                                                                                                    |       |           |                 |       |
| /hl                                                                                                                                                      |       |           |                 |       |
| Final Diagnosis                                                                                                                                          |       |           |                 |       |
| Result: FOCAL ACUTE ILEITIS                                                                                                                              |       |           |                 |       |
| Site Of Origin                                                                                                                                           |       | NEO ILEUM |                 |       |
| Gross Description                                                                                                                                        |       |           |                 |       |
| Result: Specimen container labeled Neo ileum. In fixative, 3 fragments, in aggregate 0.4 x 0.4 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): A/3. |       |           |                 |       |
| /ra                                                                                                                                                      |       |           |                 |       |

|                                    | Flags | Results   | Reference Range | Units |
|------------------------------------|-------|-----------|-----------------|-------|
| <b>Microscopic Examination</b>     |       |           |                 |       |
| Result: No granulomas are present. |       |           |                 |       |
| HK/hkahn                           |       |           |                 |       |
| <b>Pathologist</b>                 |       | Oona Chen |                 |       |

**CC List** Taylor, Sinead (Aidan Yamamoto)

| Lab Order #                                      | Ordering Practitioner             | Primary Performing Lab                    |
|--------------------------------------------------|-----------------------------------|-------------------------------------------|
| 1398JN68969167 Ridgeway Family Health(Lab 26095) | Taylor, Sinead (Sabine Dalton)    | Ridgeway Family Health (Lab 26095)        |
| Last Updated in OLIS                             | Address                           | Address                                   |
| 2012-Jul-15 9:01:31 PM EDT                       | Ridgeway Family Health 6          | 524 Larchmont Ave                         |
| Specimen Received Date/Time                      | 848 Main Blvd ON 848 Main Blvd    | New Brunswick Manitoba ON (Firm/Business) |
| 2012-07-11 7:40:47 PM EDT                        | 524 Larchmont Ave (Firm/Business) | Primary Reporting Lab                     |
|                                                  |                                   | Ridgeway Family Health (Lab 26095)        |
|                                                  |                                   | Address                                   |
|                                                  |                                   | 524 Larchmont Ave                         |
|                                                  |                                   | New Brunswick Manitoba ON (Firm/Business) |

| Specimen Type         | Collection Date             | Specimen Collected By              |
|-----------------------|-----------------------------|------------------------------------|
| TISSUE                | 2012-Jul-11 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |
| Site Modifier: RECTUM |                             |                                    |

### Surgical Pathology

|                                         | Flags | Results | Reference Range | Units |
|-----------------------------------------|-------|---------|-----------------|-------|
| <b>Relevant History</b>                 |       |         |                 |       |
| Result: A. RECTUM. BX. CROHN'S.         |       |         |                 |       |
| B. DESCENDING COLON 30 CM. BX. CROHN'S. |       |         |                 |       |
| C. TRANSVERSE COLON 55 CM. BX. CROHN'S. |       |         |                 |       |



|                                  | Flags | Results | Reference Range | Units |
|----------------------------------|-------|---------|-----------------|-------|
| D. TRANSVERSE                    |       |         |                 |       |
| COLON 70 CM. BX. CROHN'S.        |       |         |                 |       |
| E. ASCENDING COLON. BX. CROHN'S. |       |         |                 |       |

F. CECUM. BX. CROHN'S. G. ILEUM. BX. CROHN'S. /bd **Final Diagnosis** Result: PATCHY ARCHITECTURAL CHANGES CONSISTENT WITH INACTIVE CROHN'S COLITIS **Site Of Origin** RECTUM **Gross Description** Result: Specimen container labeled Rectum. .In fixative, multiple fragments, in aggregate 0.5 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): A/2. /sd **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Keller, Marco (Sofia Bianchi)

| Lab Order #                                       | Ordering Practitioner                                                                     | Primary Performing Lab                                      |
|---------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead (Sabine Dalton)                                                            | Ridgeway Family Health (Lab 26095)                          |
| Last Updated in OLIS                              | Address                                                                                   | Address                                                     |
| 2014-Apr-06 8:30:59 PM EDT                        | Ridgeway Family Health 6 848 Main Blvd ON 848 Main Blvd 524 Larchmont Ave (Firm/Business) | 524 Larchmont Ave New Brunswick Manitoba ON (Firm/Business) |
| Specimen Received Date/Time                       |                                                                                           | Primary Reporting Lab                                       |
| 2014-04-03 7:12:13 AM EDT                         |                                                                                           | Ridgeway Family Health (Lab 26095)                          |
|                                                   |                                                                                           | Address                                                     |
|                                                   |                                                                                           | 524 Larchmont Ave New Brunswick Manitoba ON (Firm/Business) |

| Specimen Type               | Collection Date             | Specimen Collected By              |
|-----------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: CECUM | 2014-Apr-02 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

### Surgical Pathology

|                                                             | Flags | Results | Reference Range | Units |
|-------------------------------------------------------------|-------|---------|-----------------|-------|
| <b>Relevant History</b>                                     |       |         |                 |       |
| Result: A. NEO ILEUM. BX. CROHNS. B. CECUM. BX. CROHNS. /hl |       |         |                 |       |

|                                                                                                                                                                                                                   | Flags | Results   | Reference Range | Units |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|-----------------|-------|
| <b>Final Diagnosis</b>                                                                                                                                                                                            |       |           |                 |       |
| Result: NORMAL COLONIC MUCOSA                                                                                                                                                                                     |       |           |                 |       |
| <b>Site Of Origin</b>                                                                                                                                                                                             |       | CECUM     |                 |       |
| <b>Gross Description</b>                                                                                                                                                                                          |       |           |                 |       |
| Result: Specimen container labeled Cecum. In fixative, a tissue fragment 0.3 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): B/1. /ra                                                                  |       |           |                 |       |
| <b>Microscopic Examination</b>                                                                                                                                                                                    |       |           |                 |       |
| Result: This biopsy is within normal limits - particularly, there are not changes of inflammatory bowel disease, microscopic colitis or other abnormality here. No dysplasia and no malignancy are seen. HK/hkahn |       |           |                 |       |
| <b>Pathologist</b>                                                                                                                                                                                                |       | Oona Chen |                 |       |

**CC List** Taylor, Sinead (Aidan Yamamoto)

| Lab Order #                                       | Ordering Practitioner                              | Primary Performing Lab                      |
|---------------------------------------------------|----------------------------------------------------|---------------------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead (Sabine Dalton)                     | Ridgeway Family Health (Lab 26095)          |
| Last Updated in OLIS                              | Address                                            | Address                                     |
| 2012-Jul-15 9:01:32 PM EDT                        | Ridgeway Family Health 6 848 Main Blvd ON Manitoba | 524 Larchmont Ave New Brunswick Manitoba ON |

Specimen Received Date/Time 2012-07-11 7:40:47 PM EDT

524 Larchmont Ave (Firm/Business)

(Firm/Business)

**Primary Reporting Lab** Ridgeway Family Health (Lab 26095)

**Address** 524 Larchmont Ave New Brunswick Manitoba ON (Firm/Business)

| Specimen Type                                | Collection Date             | Specimen Collected By              |
|----------------------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: DESCENDING COLON 30 CM | 2012-Jul-11 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

### Surgical Pathology

|                                                                                                                                                                                                                                            | Flags | Results                | Reference Range | Units |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------------------------|-----------------|-------|
| <b>Relevant History</b>                                                                                                                                                                                                                    |       |                        |                 |       |
| Result: A. RECTUM. BX. CROHN'S. B. DESCENDING COLON 30 CM. BX. CROHN'S. C. TRANSVERSE COLON 55 CM. BX. CROHN'S. D. TRANSVERSE COLON 70 CM. BX. CROHN'S. E. ASCENDING COLON. BX. CROHN'S. F. CECUM. BX. CROHN'S. G. ILEUM. BX. CROHN'S. /bd |       |                        |                 |       |
| <b>Final Diagnosis</b>                                                                                                                                                                                                                     |       |                        |                 |       |
| Result: PATCHY ACTIVE CHRONIC COLITIS, CONSISTENT WITH CROHN'S                                                                                                                                                                             |       |                        |                 |       |
| <b>Site Of Origin</b>                                                                                                                                                                                                                      |       | DESCENDING COLON 30 CM |                 |       |
| <b>Gross Description</b>                                                                                                                                                                                                                   |       |                        |                 |       |
| Result: Specimen container labeled descending colon 30 cm. In fixative, multiple fragments, in aggregate 0.4 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): B/2. /sd                                                           |       |                        |                 |       |
| <b>Microscopic Examination</b>                                                                                                                                                                                                             |       |                        |                 |       |
| Result: AP/aaron                                                                                                                                                                                                                           |       |                        |                 |       |
| <b>Pathologist</b>                                                                                                                                                                                                                         |       | Ravi Fleischer         |                 |       |

| Specimen Type                                  | Collection Date                | Specimen Collected By                 |
|------------------------------------------------|--------------------------------|---------------------------------------|
| TISSUE Site Modifier: TRANSERVE<br>COLON 55 CM | 2012-Jul-11 12:00:00 AM<br>EDT | Ridgeway Family Health (Lab<br>26095) |

### Surgical Pathology

|                                                                                                                                                                                                                                            | Flags | Results                  | Reference Range | Units |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|--------------------------|-----------------|-------|
| <b>Relevant History</b>                                                                                                                                                                                                                    |       |                          |                 |       |
| Result: A. RECTUM. BX. CROHN'S. B. DESCENDING COLON 30 CM. BX. CROHN'S. C. TRANSVERSE COLON 55 CM. BX. CROHN'S. D. TRANSVERSE COLON 70 CM. BX. CROHN'S. E. ASCENDING COLON. BX. CROHN'S. F. CECUM. BX. CROHN'S. G. ILEUM. BX. CROHN'S. /bd |       |                          |                 |       |
| <b>Final Diagnosis</b>                                                                                                                                                                                                                     |       |                          |                 |       |
| Result: NO DIAGNOSTIC ABNORMALITY                                                                                                                                                                                                          |       |                          |                 |       |
| <b>Site Of Origin</b>                                                                                                                                                                                                                      |       | TRANSERVE<br>COLON 55 CM |                 |       |
| <b>Gross Description</b>                                                                                                                                                                                                                   |       |                          |                 |       |
| Result: Specimen container labeled Transverse colon 55 cm. In fixative, multiple fragments, in aggregate 0.6 x 0.3 x 0.2 cm. Submitted in toto. Block(s) / fragment(s): C/2. /sd                                                           |       |                          |                 |       |
| <b>Microscopic Examination</b>                                                                                                                                                                                                             |       |                          |                 |       |
| Result: AP/aaron                                                                                                                                                                                                                           |       |                          |                 |       |
| <b>Pathologist</b>                                                                                                                                                                                                                         |       | Ravi Fleischer           |                 |       |

| Specimen Type                                   | Collection Date                | Specimen Collected By                 |
|-------------------------------------------------|--------------------------------|---------------------------------------|
| TISSUE Site Modifier: TRANSVERSE<br>COLON 70 CM | 2012-Jul-11 12:00:00 AM<br>EDT | Ridgeway Family Health (Lab<br>26095) |

### Surgical Pathology

|                         | Flags | Results | Reference Range | Units |
|-------------------------|-------|---------|-----------------|-------|
| <b>Relevant History</b> |       |         |                 |       |

|                                                                                                                                                                                          | Flags | Results | Reference Range | Units |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|---------|-----------------|-------|
| Result: A. RECTUM. BX. CROHN'S. B. DESCENDING COLON 30 CM. BX. CROHN'S. C. TRANSVERSE COLON 55 CM. BX. CROHN'S. D. TRANSVERSE COLON 70 CM. BX. CROHN'S. E. ASCENDING COLON. BX. CROHN'S. |       |         |                 |       |

F. CECUM. BX. CROHN'S. G. ILEUM. BX. CROHN'S. /bd **Final Diagnosis** Result: NO DIAGNOSTIC ABNORMALITY **Site Of Origin** TRANSVERSE COLON 70 CM **Gross Description** Result: Specimen container labeled Transverse colon 70 cm. In fixative, a tissue fragment 0.4 x 0.2 x 0.2 cm. Submitted in toto. Block(s) / fragment(s): D/1. /sd **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

| Specimen Type                         | Collection Date             | Specimen Collected By              |
|---------------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: ASCENDING COLON | 2012-Jul-11 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

**Surgical Pathology Relevant History** Result: A. RECTUM. BX. CROHN'S. B. DESCENDING COLON 30 CM. BX. CROHN'S. C. TRANSVERSE COLON 55 CM. BX. CROHN'S. D. TRANSVERSE COLON 70 CM. BX. CROHN'S. E. ASCENDING COLON. BX. CROHN'S. F. CECUM. BX. CROHN'S. G. ILEUM. BX. CROHN'S. /bd **Final Diagnosis** Result: MILD ARCHITECTURAL CHANGES CONSISTENT WITH INACTIVE CROHN'S COLITIS **Site Of Origin** ASCENDING COLON **Gross Description** Result: Specimen container labeled Ascending colon. In fixative, a tissue fragment 0.4 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): E/1. /sd **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

| Specimen Type               | Collection Date             | Specimen Collected By              |
|-----------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: CECUM | 2012-Jul-11 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

**Surgical Pathology Relevant History** Result: A. RECTUM. BX. CROHN'S. B. DESCENDING COLON 30 CM. BX. CROHN'S. C. TRANSVERSE COLON 55 CM. BX. CROHN'S. D. TRANSVERSE COLON 70 CM. BX. CROHN'S. E. ASCENDING COLON. BX. CROHN'S. F. CECUM. BX. CROHN'S. G. ILEUM. BX. CROHN'S. /bd **Final Diagnosis** Result: NO DIAGNOSTIC ABNORMALITY **Site Of Origin** CECUM **Gross Description** Result: Specimen container labeled Cecum. . In fixative, multiple fragments, in aggregate 0.5 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): F/2. /sd **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aidan Yamamoto)

Cedar Specialist Group 2  
Northview Clinic

#### Lab Results:

Generated On 2026-Apr-09

|                                  |            |                              |                            |
|----------------------------------|------------|------------------------------|----------------------------|
| <b>Patient</b>                   | Ethan Kang | <b>Ontario Health Number</b> | <b>Telephone</b>           |
| <b>Date of Birth</b>             | 1979       | 6609604884PP                 | (442) 733-2165             |
| <b>Age (Time of Observation)</b> | 33 years   |                              | (Primary Residence Number) |
| <b>Sex</b>                       | M          |                              |                            |
| <b>Address</b>                   |            |                              |                            |

|                                                   |                              |                               |
|---------------------------------------------------|------------------------------|-------------------------------|
| <b>Lab Order #</b>                                | <b>Ordering Practitioner</b> | <b>Primary Performing Lab</b> |
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health        |
|                                                   | (Sabine Dalton)              | (Lab 26095)                   |
| <b>Last Updated in OLIS</b>                       | <b>Address</b>               | <b>Address</b>                |
| 2011-May-02 7:54:22 PM EDT                        | Ridgeway Family Health 6     | 524 Larchmont Ave             |
| <b>Specimen Received Date/Time</b>                | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON  |
| 2011-04-27 7:55:42 PM EDT                         | 524 Larchmont Ave            | (Firm/Business)               |
|                                                   | (Firm/Business)              | <b>Primary Reporting Lab</b>  |
|                                                   |                              | Ridgeway Family Health        |
|                                                   |                              | (Lab 26095)                   |
|                                                   |                              | <b>Address</b>                |
|                                                   |                              | 524 Larchmont Ave             |
|                                                   |                              | New Brunswick Manitoba<br>ON  |
|                                                   |                              | (Firm/Business)               |

## Pathology

|                                      |                             |                                    |
|--------------------------------------|-----------------------------|------------------------------------|
| <b>Specimen Type</b>                 | <b>Collection Date</b>      | <b>Specimen Collected By</b>       |
| TISSUE Site Modifier: TERMINAL ILEUM | 2011-Apr-27 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           |              |                |                        |              |
|---------------------------|--------------|----------------|------------------------|--------------|
|                           | <b>Flags</b> | <b>Results</b> | <b>Reference Range</b> | <b>Units</b> |
| <b>Surgical Pathology</b> |              |                |                        |              |

**Relevant History**

Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS.  
B. R COLON. BX. HX OF ULCERATIVE COLITIS.  
C. L COLON. BX. HX OF ULCERATIVE COLITIS.  
D. RECTUM. BX. HX OF ULCERATIVE COLITIS.

/hl

**Final Diagnosis**

Result: SUPERFICIAL SMALL INTESTINAL MUCOSA WITH NO PATHOLOGICAL DIAGNOSIS

**Site Of Origin** TERMINAL ILEUM

**Gross Description**

Result: Specimen container labeled A. In fixative, multiple fragments, in aggregate 0.1 x 0.1 x 0.1 cm.  
Submitted in toto. Block(s) / fragment(s): A/few.

/kr.

**Microscopic Examination**

Result: AP/aaron

**Pathologist** Ravi Fleischer

---

**CC List**

Taylor, Sinead  
(Aneesha Paquette)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
|                                                   | (Sabine Dalton)              | (Lab 26095)                  |
| Last Updated in OLIS                              | Address                      | Address                      |
| 2011-Jun-20 11:22:16 AM EDT                       | Ridgeway Family Health<br>6  | 524 Larchmont Ave            |
| Specimen Received Date/Time                       | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
| 2011-04-27 7:55:42 PM EDT                         | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |

---

**Address** 524 Larchmont Ave New Brunswick Manitoba ON (Firm/Business)

---

| Specimen Type                        | Collection Date             | Specimen Collected By              |
|--------------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: TERMINAL ILEUM | 2011-Apr-27 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS. B. R COLON. BX. HX OF ULCERATIVE COLITIS. C. L COLON. BX. HX OF ULCERATIVE COLITIS. D. RECTUM. BX. HX OF ULCERATIVE COLITIS. /hl **Final Diagnosis** Result: SUPERFICIAL SMALL INTESTINAL MUCOSA WITH NO PATHOLOGICAL DIAGNOSIS **Site Of Origin** TERMINAL ILEUM **Gross Description** Result: Specimen container labeled A. In fixative, multiple fragments, in aggregate 0.1 x 0.1 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): A/few. /kr. **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aneesa Paquette)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
|                                                   | (Ewan Young)                 | (Lab 26095)                  |
| Last Updated in OLIS                              |                              |                              |
| 2010-Nov-21 9:58:29 AM EST                        | Address                      | Address                      |
| Specimen Received Date/Time                       | Ridgeway Family Health 6     | 524 Larchmont Ave            |
| 2010-11-14 6:26:59 PM EST                         | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |
|                                                   |                              | Address                      |
|                                                   |                              | 524 Larchmont Ave            |
|                                                   |                              | New Brunswick Manitoba<br>ON |
|                                                   |                              | (Firm/Business)              |

| Specimen Type                | Collection Date             | Specimen Collected By              |
|------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: RECTUM | 2010-Nov-14 12:00:00 AM EST | Ridgeway Family Health (Lab 26095) |



|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. RECTUM. BX. R/O COLITIS. B. SIGMOID. BX. R/O COLITIS. C. DESCENDING COLON. BX. R/O COLITIS. D. DESCENDING COLON. R/O COLITIS/?POLYP. /bd **Final Diagnosis** Result: LARGE INTESTINE MUCOSA WITH NO PATHOLOGIC DIAGNOSIS **Site Of Origin** RECTUM **Gross Description** Result: Specimen container labeled A. In fixative, a tissue fragment 0.3 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): A/1 . /mt **Microscopic Examination** Result: AS/SL

**Pathologist** Malia Ramirez

**CC List** Taylor, Sinead (Aneesa Paquette)

| Lab Order #                                       | Ordering Practitioner     | Primary Performing Lab    |
|---------------------------------------------------|---------------------------|---------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead            | Ridgeway Family Health    |
|                                                   | (Sabine Dalton)           | (Lab 26095)               |
| Last Updated in OLIS                              |                           |                           |
| 2011-May-02 7:54:22 PM EDT                        | Address                   | Address                   |
| Specimen Received Date/Time                       | Ridgeway Family Health 6  | 524 Larchmont Ave         |
| 2011-04-27 7:55:42 PM EDT                         | 848 Main Blvd ON Manitoba | New Brunswick Manitoba ON |
|                                                   | 524 Larchmont Ave         | (Firm/Business)           |
|                                                   | (Firm/Business)           |                           |
|                                                   |                           | Primary Reporting Lab     |
|                                                   |                           | Ridgeway Family Health    |
|                                                   |                           | (Lab 26095)               |
|                                                   |                           | Address                   |
|                                                   |                           | 524 Larchmont Ave         |
|                                                   |                           | New Brunswick Manitoba ON |
|                                                   |                           | (Firm/Business)           |

| Specimen Type                 | Collection Date             | Specimen Collected By              |
|-------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: R COLON | 2011-Apr-27 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS. B. R COLON. BX. HX OF ULCERATIVE COLITIS. C. L COLON. BX. HX OF ULCERATIVE COLITIS. D. RECTUM. BX. HX OF ULCERATIVE COLITIS. /hl **Final Diagnosis** Result: COLONIC MUCOSA WITH NO PATHOLOGICAL DIAGNOSIS **Site Of Origin** R COLON **Gross Description** Result: Specimen container labeled B. In fixative, multiple fragments, in aggregate 0.4 x 0.4 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): B/2. /kr. **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aneesa Paquette)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
|                                                   | (Sabine Dalton)              | (Lab 26095)                  |
| Last Updated in OLIS                              |                              |                              |
| 2011-Jun-20 11:22:16 AM EDT                       | Address                      | Address                      |
| Specimen Received Date/Time                       | Ridgeway Family Health 6     | 524 Larchmont Ave            |
| 2011-04-27 7:55:42 PM EDT                         | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |
|                                                   |                              | Address                      |
|                                                   |                              | 524 Larchmont Ave            |
|                                                   |                              | New Brunswick Manitoba<br>ON |
|                                                   |                              | (Firm/Business)              |

| Specimen Type | Collection Date | Specimen Collected By |
|---------------|-----------------|-----------------------|
|               |                 |                       |

TISSUE Site Modifier: R COLON 2011-Apr-27 12:00:00 AM EDT Ridgeway Family Health (Lab 26095)

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS. B. R COLON. BX. HX OF ULCERATIVE COLITIS. C. L COLON. BX. HX OF ULCERATIVE COLITIS. D. RECTUM. BX. HX OF ULCERATIVE COLITIS. /hl **Final Diagnosis** Result: COLONIC MUCOSA WITH NO PATHOLOGICAL DIAGNOSIS **Site Of Origin** R COLON **Gross Description** Result: Specimen container labeled B. In fixative, multiple fragments, in aggregate 0.4 x 0.4 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): B/2. /kr. **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aneesa Paquette)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
|                                                   | (Sabine Dalton)              | (Lab 26095)                  |
| Last Updated in OLIS                              |                              |                              |
| 2011-May-02 7:54:22 PM EDT                        | Address                      | Address                      |
| Specimen Received Date/Time                       | Ridgeway Family Health 6     | 524 Larchmont Ave            |
| 2011-04-27 7:55:42 PM EDT                         | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |
|                                                   |                              | Address                      |
|                                                   |                              | 524 Larchmont Ave            |
|                                                   |                              | New Brunswick Manitoba<br>ON |
|                                                   |                              | (Firm/Business)              |

| Specimen Type                 | Collection Date             | Specimen Collected By              |
|-------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: L COLON | 2011-Apr-27 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS. B. R COLON. BX. HX OF ULCERATIVE COLITIS. C. L COLON. BX. HX OF ULCERATIVE COLITIS. D. RECTUM. BX. HX OF ULCERATIVE COLITIS. /hl  
**Final Diagnosis** Result: COLONIC MUCOSA WITH NO PATHOLOGICAL DIAGNOSIS  
**Site Of Origin** L COLON  
**Gross Description** Result: Specimen container labeled C. In fixative, a tissue fragment 0.3 x 0.3 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): C/1. /kr.  
**Microscopic Examination** Result: AP/aaron  
**Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aneesa Paquette)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
| Last Updated in OLIS                              | (Sabine Dalton)              | (Lab 26095)                  |
| 2011-Jun-20 11:22:16 AM EDT                       |                              |                              |
| Specimen Received Date/Time                       | Address                      | Address                      |
| 2011-04-27 7:55:42 PM EDT                         | Ridgeway Family Health<br>6  | 524 Larchmont Ave            |
|                                                   | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |
|                                                   |                              | Address                      |
|                                                   |                              | 524 Larchmont Ave            |
|                                                   |                              | New Brunswick Manitoba<br>ON |
|                                                   |                              | (Firm/Business)              |

| Specimen Type                 | Collection Date             | Specimen Collected By              |
|-------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: L COLON | 2011-Apr-27 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS. B. R COLON. BX. HX OF ULCERATIVE COLITIS. C. L COLON. BX. HX OF ULCERATIVE COLITIS. D. RECTUM. BX. HX OF ULCERATIVE COLITIS. /hl  
**Final Diagnosis** Result: COLONIC MUCOSA WITH NO PATHOLOGICAL DIAGNOSIS  
**Site Of Origin** L COLON  
**Gross Description** Result: Specimen container labeled C. In fixative, a tissue fragment 0.3 x 0.3 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): C/1. /kr.  
**Microscopic Examination** Result: AP/aaron  
**Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aneesa Paquette)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
| Last Updated in OLIS                              | (Sabine Dalton)              | (Lab 26095)                  |
| 2011-May-02 7:54:22 PM EDT                        |                              |                              |
| Specimen Received Date/Time                       | Address                      | Address                      |
| 2011-04-27 7:55:42 PM EDT                         | Ridgeway Family Health 6     | 524 Larchmont Ave            |
|                                                   | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |
|                                                   |                              | Address                      |
|                                                   |                              | 524 Larchmont Ave            |
|                                                   |                              | New Brunswick Manitoba<br>ON |
|                                                   |                              | (Firm/Business)              |

| Specimen Type                | Collection Date             | Specimen Collected By              |
|------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: RECTUM | 2011-Apr-27 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS. B. R COLON. BX. HX OF ULCERATIVE COLITIS. C. L COLON. BX. HX OF ULCERATIVE COLITIS. D. RECTUM. BX. HX OF ULCERATIVE COLITIS. /hl **Final Diagnosis** Result: MILD CHRONIC COLITIS, CONSISTENT WITH QUIESCENT ULCERATIVE COLITIS **Site Of Origin** RECTUM **Gross Description** Result: Specimen container labeled D. In fixative, multiple fragments, in aggregate 0.4 x 0.3 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): D/2. /kr. **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aneesa Paquette)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
| <b>Last Updated in OLIS</b>                       | (Sabine Dalton)              | (Lab 26095)                  |
| 2011-Jun-20 11:22:16 AM EDT                       |                              |                              |
| Specimen Received Date/Time                       | Address                      | Address                      |
| 2011-04-27 7:55:42 PM EDT                         | Ridgeway Family Health 6     | 524 Larchmont Ave            |
|                                                   | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |
|                                                   |                              | Address                      |
|                                                   |                              | 524 Larchmont Ave            |
|                                                   |                              | New Brunswick Manitoba<br>ON |
|                                                   |                              | (Firm/Business)              |

| Specimen Type                | Collection Date             | Specimen Collected By              |
|------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: RECTUM | 2011-Apr-27 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. TERMINAL ILEUM. BX. ?MILD ILEITIS. B. R COLON. BX. HX OF ULCERATIVE COLITIS. C. L COLON. BX. HX OF ULCERATIVE COLITIS. D. RECTUM. BX. HX OF ULCERATIVE COLITIS. /hl **Final Diagnosis** Result: MILD CHRONIC COLITIS, CONSISTENT WITH QUIESCENT ULCERATIVE COLITIS **Site Of Origin** RECTUM **Gross Description** Result: Specimen container labeled D. In fixative, multiple fragments, in aggregate 0.4 x 0.3 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): D/2. /kr. **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aidan Yamamoto)

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
| <b>Last Updated in OLIS</b>                       | (Sabine Dalton)              | (Lab 26095)                  |
| 2012-Jul-15 9:01:33 PM EDT                        |                              |                              |
| <b>Specimen Received Date/Time</b>                | <b>Address</b>               | <b>Address</b>               |
| 2012-07-11 7:40:47 PM EDT                         | Ridgeway Family Health<br>6  | 524 Larchmont Ave            |
|                                                   | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | <b>Primary Reporting Lab</b> |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |
|                                                   |                              |                              |
|                                                   |                              | <b>Address</b>               |
|                                                   |                              | 524 Larchmont Ave            |
|                                                   |                              | New Brunswick Manitoba<br>ON |
|                                                   |                              | (Firm/Business)              |

| Specimen Type               | Collection Date             | Specimen Collected By              |
|-----------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: ILEUM | 2012-Jul-11 12:00:00 AM EDT | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. RECTUM. BX. CROHN'S. B. DESCENDING COLON 30 CM. BX. CROHN'S. C. TRANSVERSE COLON 55 CM. BX. CROHN'S. D. TRANSVERSE COLON 70 CM. BX. CROHN'S. E. ASCENDING COLON. BX. CROHN'S. F. CECUM. BX. CROHN'S. G. ILEUM. BX. CROHN'S. /bd **Final Diagnosis** Result: MILD ACTIVE CHRONIC ILEITIS, CONSISTENT WITH CROHN'S **Site Of Origin** ILEUM **Gross Description** Result: Specimen container labeled ileum. In fixative, a tissue fragment 0.2 x 0.2 x 0.2 cm. Submitted in toto. Block(s) / fragment(s): G/1. /sd **Microscopic Examination** Result: AP/aaron **Pathologist** Ravi Fleischer

**CC List** Taylor, Sinead (Aidan Yamamoto)

Cedar Specialist Group 2 Northview Clinic

Lab Results: Generated On 2026-Apr-09

|                                  |            |                              |                            |
|----------------------------------|------------|------------------------------|----------------------------|
| <b>Patient</b>                   | Ethan Kang | <b>Ontario Health Number</b> | <b>Telephone</b>           |
| <b>Date of Birth</b>             | 1979       | 6609604884PP                 | (442) 733-2165             |
| <b>Age (Time of Observation)</b> | 31 years   |                              | (Primary Residence Number) |
| <b>Sex</b>                       | M          |                              |                            |
| <b>Address</b>                   |            |                              |                            |

| Lab Order #                                       | Ordering Practitioner        | Primary Performing Lab       |
|---------------------------------------------------|------------------------------|------------------------------|
| 1398JN68969167 Ridgeway Family Health (Lab 26095) | Taylor, Sinead               | Ridgeway Family Health       |
| <b>Last Updated in OLIS</b>                       | (Ewan Young)                 | (Lab 26095)                  |
| 2010-Nov-21 9:58:30 AM EST                        |                              |                              |
| Specimen Received Date/Time                       | Address                      | Address                      |
| 2010-11-14 6:26:59 PM EST                         | Ridgeway Family Health<br>6  | 524 Larchmont Ave            |
|                                                   | 848 Main Blvd ON<br>Manitoba | New Brunswick Manitoba<br>ON |
|                                                   | 524 Larchmont Ave            | (Firm/Business)              |
|                                                   | (Firm/Business)              |                              |
|                                                   |                              | Primary Reporting Lab        |
|                                                   |                              | Ridgeway Family Health       |
|                                                   |                              | (Lab 26095)                  |



| Lab Order # | Ordering Practitioner | Primary Performing Lab       |
|-------------|-----------------------|------------------------------|
|             |                       | <b>Address</b>               |
|             |                       | 524 Larchmont Ave            |
|             |                       | New Brunswick Manitoba<br>ON |
|             |                       | (Firm/Business)              |

## Pathology

| Specimen Type                 | Collection Date             | Specimen Collected By              |
|-------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: SIGMOID | 2010-Nov-14 12:00:00 AM EST | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. RECTUM. BX. R/O COLITIS. B. SIGMOID. BX. R/O COLITIS. C. DESCENDING COLON. BX. R/O COLITIS. D. DESCENDING COLON. R/O COLITIS/?POLYP. /bd **Final Diagnosis** Result: FOCAL ACTIVE COLITIS, SEE MICROSCOPIC. **Site Of Origin** SIGMOID **Gross Description** Result: Specimen container labeled B. In fixative, multiple fragments, in aggregate 0.4 x 0.4 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): B/3. /mt **Microscopic Examination** Result: There are foci of active mucosal inflammation, with cryptitis and crypt abscesses, but no ulcers. There is one granuloma, which may be related to crypt rupture. The differential diagnosis includes mainly inflammatory bowel disease, colitis secondary to diverticular disease, NSAID use, and self limited colitis. Clinical correlation is recommended. AS/SL **Pathologist** Malia Ramirez

| Specimen Type                          | Collection Date             | Specimen Collected By              |
|----------------------------------------|-----------------------------|------------------------------------|
| TISSUE Site Modifier: DESCENDING COLON | 2010-Nov-14 12:00:00 AM EST | Ridgeway Family Health (Lab 26095) |

|                           | Flags | Results | Reference Range | Units |
|---------------------------|-------|---------|-----------------|-------|
| <b>Surgical Pathology</b> |       |         |                 |       |

**Relevant History** Result: A. RECTUM. BX. R/O COLITIS. B. SIGMOID. BX. R/O COLITIS. C. DESCENDING COLON. BX. R/O COLITIS. D. DESCENDING COLON. R/O COLITIS/?POLYP.

/bd **Final Diagnosis** Result: FOCAL ACTIVE COLITIS, SEE MICROSCOPIC. **Site Of Origin** DESCENDING COLON **Gross Description** Result: Specimen container labeled C. In fixative, multiple fragments, in aggregate 0.4 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): C/2. /mt **Microscopic Examination** Result: There is focal active mucosal inflammation, with cryptitis and crypt abscesses, but no

ulcers or granulomas. The differential diagnosis includes mainly inflammatory bowel disease, colitis secondary to diverticular disease, NSAID use, and self limited colitis. Clinical correlation is recommended.

AS/SL **Pathologist** Malia Ramirez

| Specimen Type                   | Collection Date             | Specimen Collected By  |
|---------------------------------|-----------------------------|------------------------|
| TISSUE                          | 2010-Nov-14 12:00:00 AM EST | Ridgeway Family Health |
| Site Modifier: DESCENDING COLON |                             | (Lab 26095)            |

**Surgical Pathology Relevant History** Result: A. RECTUM. BX. R/O COLITIS. B. SIGMOID. BX. R/O COLITIS. C. DESCENDING COLON. BX. R/O COLITIS. D. DESCENDING COLON. R/O COLITIS/? POLYP. /bd **Final Diagnosis** Result: SUGGESTIVE OF A HYPERPLASTIC POLYP, NO EVIDENCE OF COLITIS. **Site Of Origin** DESCENDING COLON **Gross Description** Result: Specimen container labeled D. In fixative, multiple fragments, in aggregate 0.4 x 0.2 x 0.1 cm. Submitted in toto. Block(s) / fragment(s): D/2+ tiny fragment. /mt **Microscopic Examination** Result: AS/SL **Pathologist** Malia Ramirez

**CC List** Taylor, Sinead (Idris Okonkwo)

Patient: Mr. Ethan Kang

**To:** rrtpvfjgm **From:** [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] **Written On:** 2021-Jan-18 **Subject:** Re: Appt **Note:** I need to confirm with Aaron Proulx & I will confirm with pt

On 2021-Jan-18, rrtpvfjgm wrote:

Does the pt need to come in or can it be a telephone appt ?

**To:** [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] **From:** rrtpvfjgm **Written On:** 2021-Jan-18 **Subject:** Appt **Note:** Does the pt need to come in or can it be a telephone appt ?

**To:** [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] **From:** [REDACTED-STAFF-PROVIDER-NAME-OR-INTERNAL-USERNAME] **Written On:** 2020-Jun-02 **Subject:** Crestwood Medical Group LTE wk 36 **Note:** Please review. Thanks!

Patient: Ethan Kang PHN: 6609604884PP DOB: 1979